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General   Introduction 
 
 
 
 
Adapted from: 
 
Clinical and etiological heterogeneity in patients with tracheo-esophageal malformations 
and associated anomalies. Eur.J. Med. Genet. submitted 
Erwin Brosens, Mirjam Ploeg, Yolande van Bever, Anna E. Koopmans, Hanneke IJsselstijn, Robbert J. Rottier, 
 Rene Wijnen, Dick. Tibboel, Annelies de Klein
Abstract 
Esophageal Atresia (EA) is a severe developmental defect of the foregut that presents 
with or without a Tracheo-Esophageal Fistula (TEF). The prevalence of EA/TEF over time 
and around the world has been relatively stable. EA/TEF is manifested in a broad spectrum 
of anomalies: in some patients it manifests as an isolated atresia or fistula, but in over half it 
affects several organ systems. While the associated malformations are often those of the 
VACTERL spectrum (Vertebral, Anorectal, Cardiac, Tracheo-Esophageal, Renal and Limb), 
many patients are affected by other malformations, such as microcephaly, micrognathia, 
pyloric stenosis, duodenal atresia, a single umbilical artery, and anomalies of the 
genitourinary, respiratory and gastrointestinal systems. Though EA/TEF is a genetically 
heterogeneous condition, recurrent genes and loci are sometimes affected. Tracheo-
Esophageal (TE) defects are in fact a variable feature in several known single gene disorders 
and in patients with specific recurrent Copy Number Variations and structural chromosomal 
aberrations.  
At present, a causal genetic aberration can be identified in 11-12% of patients. In 
most, EA/TEF is a sporadic finding; the familial recurrence rate is low (1%). As this 
suggests that epigenetic and environmental factors also contribute to the disease, non-
syndromic EA/TEF is generally believed to be a multifactorial condition. Several 
population-based studies and case reports describe a wide range of associated risks, 
including age, diabetes, drug use, herbicides, smoking and fetal alcohol exposure. The 
phenotypical and genetic heterogeneity seen in EA/TEF patients indicates not one 
underlying cause, but several.  
Unraveling the complex multifactorial and heterogeneous etiology of EA/TEF and 
associated features will require large cohorts of patients. Combined statistical analysis of 
component findings, genome sequencing, and genome wide association studies will elucidate 
new causal genetic defects and predisposing loci in the etiology within specific sub-
populations. Improved knowledge of environmental risk factors, genetic predisposition and 
causal genetic syndromes may improve prediction and parental counseling, and prevent co-
morbidity.  
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Introduction 
Esophageal Atresia (EA) with or without Tracheo-Esophageal Fistula (TEF), is a 
developmental defect of the foregut characterized by the absence of continuity of the 
esophagus. EA/TEF (MIM 189960) can be classified in three ways: 1.) the Gross anatomical 
classification based on the presence and location of atresia and fistula; 2) a classification 
based on the association with other congenital anomalies (isolated or non-isolated); and 3.) a 
classification based on the presence of Tracheo-Esophageal anomalies (TE) in a known 
genetic syndrome (syndromal or non-syndromal).[1, 2] In the vast majority of patients 
(78.0-91.8%), the atresia is associated with a TEF, i.e., a distal connection of the esophagus 
to the trachea. A minority of patients have only an atresia (5.0-13.0%), a fistula (2.4-6.5%), an 
atresia with a proximal connection to the trachea (0.4-5.7%), or an atresia combined with 
both a proximal and distal fistula (0.1-2.6%).[3, 4] In approximately half of patients, TE 
anomalies are associated with other congenital defects.[5, 6] Non-syndromal EA/TEF is 
considered to be a multifactorial disease resulting from a variety of genetic and 
environmental influences.[5, 7, 8]  
Prevalence, diagnosis and treatment 
At ~ 2.5 per 10,000 births, the average prevalence of EA/TEF has been stable over 
time; regional prevalence ranges roughly between 1 and 4 per 10,000 births, including 
stillbirths and terminations of pregnancies.[9, 10] Contributing to these regional 
fluctuations are the quality of registries. While boys are affected more often than girls, with 
a sex ratio of 3:2[5, 11], this gender disparity can be confounded by genetic and 
environmental factors.[12-14] Although it is preferable to detect EA before birth—in order 
to schedule delivery at a pediatric surgery and perinatal center, and also to improve parental 
counseling—EA is usually not detected by ultrasound or MRI [15]. Prenatal clinical 
manifestations of EA are polyhydramnios combined with non-visualization of the fetal 
stomach during ultrasound, at least in the case of an absent TEF. However, these signs are 
not exclusive to EA; if a TEF is present, amniotic fluid may flow into the fetal stomach 
resulting in normal fetal stomach filling.  
Prenatal detection rates differ substantially between reference centers (10-50%) 
[10], and were recently enhanced by combining ultrasound and the so-called amniotic fluid 
EA index, a promising biochemical approach that measures amniotic fluid alpha-fetoprotein 
and gamma-glutamyl transpeptidase.[16]  
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After birth, EA can be suspected if newborns have excessive saliva and/or are in 
respiratory distress. The diagnosis is confirmed if a nasogastric tube cannot be passed to the 
stomach. In most cases, tracheo-esophageal defects are repaired using a right sided 
thoracotomy within 48 hours of birth. Ten percent of European centers nowadays use a 
thoracoscopic procedure [17]. 
Early tracheo-esophageal development 
Esophagus and respiratory structures develop from one common structure, the 
foregut. At the end of the third week of development of a human embryo, the endodermal 
layer folds to form a primitive gut tube. The primitive gut is regionalized and eventually 
differentiates into specific organs and derivatives of the gut tube, by a time dependent and 
localized expression and signaling actions of several growth factors (NODAL, FGF4), 
transcription factors (HEX, SOX2, FOXA2 and CDX2) and molecular pathways.[18] For 
example, high NODAL levels prime the endodermal layer to an anterior fate, and low levels 
of NODAL and high levels of FGF4 to a posterior fate.[19] The midgut is eventually 
formed—and the gut tube completed—by the inward-growing foregut, now expressing 
HEX, SOX2 and FOXA2, and the hindgut, expressing CDX2.[20] Homeobox transcription 
factors are important for regionalizing the gut tube, and eventually define regional gut 
identity and specification.[21]  
In the fourth week of development, the foregut is arranged in a ventral respiratory 
field marked by high NKX2.1, the absence of SOX2 expression, and a dorsal gastrointestinal 
tube marked by the reverse NKX2.1/SOX2 expression pattern. In mice, dorsal-ventral 
patterning of Sox2 and Nkx2.1 is essential for proper foregut morphogenesis.[22, 23] This 
developmental process is excellently reviewed by Jacobs et al and Morrisey et al.[23, 24] 
The separation site of the dorsal and ventral foregut is marked by Barx-1, which is 
expressed in the mesenchyme.[25] After this specification, the foregut separates into two 
sections: a ventral respiratory part with two lung buds, and a dorsal gastrointestinal 
structure. Key biological processes involved in this separation process are regulated by 
signals to the epithelium and from the surrounding mesenchyme (Wnt2, Wnt2b, Fgf10 and 
Bmp4) and notochord (Nog, Shh).[24] Abnormal foregut morphogenesis can lead to 
disturbances in dorso-ventral patterning, expression pattern, and the timing of signaling 
factors in key regulatory networks such as those in Bmp-signaling [26], Wnt-signaling, 
RA-signaling[27] and Sonic Hedgehog signaling.[28]  
12 
Chapter 1.1 
Animal models and affected genes in patients with foregut abnormalities provide 
clues about a number of important biological processes during foregut separation and 
morphogenesis, including cell differentiation, proliferation, apoptosis, polarity and 
cytoskeletal rearrangements and cell-to-cell adhesion.[24]  
Tracheo-esophageal defects and the VACTERL association 
A broad phenotypical spectrum of anomalies is associated with EA. In some cases 
there is an isolated atresia, but in many more cases, several organ systems are affected.[5, 
29] Certain malformations are associated with TE anomalies, more often than one would 
expect by chance; many are of the VACTERL kind (Vertebral, Anorectal, Cardiac, Tracheo-
esophageal, Renal or urinary tract and Limbs malformations). VACTERL association is 
diagnosed if three or more of the VACTERL component features are present and known 
genetic syndromes are excluded.[30] As the inclusion criteria for VACTERL-associated 
malformations differ between institutions, VACTERL incidence ranges between 1 in 10,000 
to 40,000 live born infants.[30, 31]  
From a developmental perspective, it is difficult to explain this co-occurrence of 
multiple congenital anomalies. For instance, the VACTERL-associated structures are 
formed at different points during development, with vertebral organogenesis starting at 
around day 23, and anorectal development around day 45.[32] Many theories attempt to 
explain why the development of various organ systems is impaired: they include 
environmental exposure before or during organogenesis, epigenetic factors, hemodynamic 
instability in a monochorionic conception, a malformation sequence after abnormal 
notochord development that is followed by subsequent vertebral malsegmentation; and 
disturbances in developmental processes or key regulatory genes and pathways such as 
Sonic Hedgehog signaling (SHH, GLI2, GLI3).[32, 33]  
Tracheo-esophageal defects and other associated malformations 
TE anomalies are often associated with other, non-VACTERL, malformations such 
as microcephaly, duodenal atresia [29], single umbilical artery, pyloric stenosis[34], 
malformations of the genitourinary, respiratory, gastrointestinal and central nervous 
system; and diaphragmatic hernia, micrognathia and other craniofacial anomalies.[5, 29] 
These malformations are often associated with TE anomalies and one or more of the 
VACTERL components.[5] Specific combinations of associated features may indicate a 
common etiology.  
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The Erasmus University MC-Sophia TE cohort 
From 1988 to 2014, 582 patients with TE have been included in our Erasmus 
University MC-Sophia TE cohort (EMC cohort). At present, 186 patients (32%) have 
isolated TE (no other major congenital anomalies); 67 (11%) have TE with other, non-
VACTERL component features; 149 (26%) have TE plus one other VACTERL component 
feature; and 131 (23%) patients have two or more VACTERL component features. Fifty-
three patients (9%) have a confirmed genetic syndrome, 12 of whom with three or more 
VACTERL component features. These fifty-three patients and their genetic diagnosis are 
depicted in figure 1.  
 
Figure 1. Genetic syndromes in Erasmus University MC-Sophia-Children’s Hospital cohort of TE 
anomalies. The first dark gray bar for each syndrome represents the total number of patients with this 
syndrome in the Erasmus MC-Sophia TE cohort. The second light gray bar indicates the number of patients 
whose medical records do not describe a genetic test; these patients’ diagnoses were based on phenotypical 
characteristics alone. The last dark gray bar represents the number of patients whose syndrome was diagnosed 
or confirmed on the basis of a genetic test. For instance, as karyotyping identified three patients with a triple X 
karyotype, the first bar for this syndrome represents the three patients in the cohort, and the second bar has a 
value of zero because the diagnosis was confirmed by a genetic test (karyotyping and micro-array, the value of 
three in the third bar). Abbreviations: CAKUT= congenital anomalies of the kidney and urinary tract, 
VACTERL-H: Vertebral, Anorectal, Cardiac, Tracheo-Esophageal, Renal and Limb anomalies with 
Hydrocephalus.  
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Four (0.7%) patients have a confirmed de novo non-syndromal Copy Number 
Variation, two (0.3%) have a chromosomal anomaly, four (0.6%) have a 15q11 micro 
deletion, and two (0.3%)  a 22q11 micro duplication. The remaining 121 patients (21%) with 
TE-anomalies and two or more additional VACTERL component features do not have a 
genetic diagnosis and are classified as VACTERL associated. An overview of the number of 
affected organ systems and genetic diagnosis is given in figure 2. 
Figure 2. Distribution of anomalies in the Erasmus University MC-Sophia-Children’s Hospital cohort 
of TE anomalies.  TE; Tracheo-esophageal anomalies, TE plus; Tracheo-esophageal anomalies and one or 
more non-VACTERL associated major anomalies, VACTERL; Vertebral, Anorectal, Cardiac, Tracheo-
Esophageal, Renal or Limb anomalies.  
 
Cluster analysis of VACTERL-associated features has produced several proposals for 
subdividing VACTERL patients. Kallen and co-workers suggest a subdivision into a lower 
and upper group of VACTERL anomalies with cardiac anomalies clustering largely in the 
upper group, and renal anomalies clustering largely in the lower group.[35] Comparison of 
the Erasmus MC-Sophia (VACTERL) TE cohort with the figures published by Jenetzky and 
co-workers for the (VACTERL)-ARM cohort [36] does indeed suggest that renal anomalies 
are more prevalent in VACTERL patients with anorectal malformations than in patients 
with TE anomalies. Solomon et al describe five major subgroups, the largest two groups of 
which contain either anorectal malformations and no TE anomalies, or vice versa.[37] 
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However, subdivisions depend greatly on inclusion criteria and study design, i.e., the 
influence of sampling bias and possible differences in the classification of a “major” 
anomaly.[36]  
 
 Esophageal atresia 
[1, 4, 10] 
(n>1200), % 
EMC-Esophageal 
atresia 
(n=582), % 
 
VACTERL / 
VATER [37] 
(n=79), % 
EMC- VACTERL  
(n=139), % 
Vertebral 6-21 21 59-82 60 
Anorectal  10-16 14 55-90 52 
Cardiac  13-34 27 38-80 60 
Tracheo-esophageal  100 100 52-82 100 
Renal  5-14 16 52-81 53 
Limb  5-19 12 39-52 38 
 
Table 1: Distribution of VACTERL features in EA/TEF patients and in VACTERL patients. EMC 
cohort; Erasmus University Medical Centre-Sophia Children’s hospital cohort of TE anomalies  n=582, 139 
patients with three or more VACTERL components, genetic syndrome patients not excluded.  
 
For instance, while the Rotterdam-Sophia cohort is based on patients with TE 
anomalies, anorectal malformations are the main inclusion criterion in the cohort described 
by Jenetzky and co-workers. Use of the χ2 and phi association tests in the Erasmus MC-
Sophia TE cohort only showed a significant (P<0.0001) but moderate (phi. 0.421) 
association between the C-TE-R components; no other combinations were significant. An 
overview of the Erasmus MC-Sophia TE cohort VACTERL component feature distribution 
is given in table 1. 
 
Table 2a and b Genetic syndromes and abnormalities affecting tracheo-esophageal (TE) development.  
EMC-cohort; Erasmus University Medical Centre-Sophia Children’s hospital cohort of tracheo-esophageal 
anomalies, TE: tracheo-esophageal anomaly, Rare = not a common feature but at least 2 case reports known. 
Table based on information obtained from a literature search using Pubmed 
(http://www.ncbi.nlm.nih.gov/pubmed/), the OMIM database (http://www.ncbi.nlm.nih.gov/omim) [38], 
MGD database (http://www.informatics.jax.org/)[39] and London Dysmorphology Database.[40] Incidental  
reports, e.g. 1 or 2 cases described in literature and syndromes in which TE is a variable feature without a 
known gene or locus are depicted in the complete table, available in the supplementary information (suppl. 
table 1) In some of the patients with syndrome TE the described inheritance pattern are not clear, these are 
marked with “Uncertain” in the inheritance column.
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Table 2a Genetic syndromes and abnormalities affecting tracheo-esophageal (TE) development 
Syndrome Clinical features Gene Locus Inheritance 
T
E
 frequency 
C
ases in 
E
M
C
-cohort 
R
eference 
Microphthalmia 
and esophageal 
atresia 
Anophthalmia/microphthalmia, esophageal atresia with or 
without tracheo-esophageal fistula, and urogenital anomalies—
most commonly cryptorchidism, hypospadias and micropenis 
SOX2 3q26.3-q27 
Uncertain; 
Autosomal 
dominant 
 
100% 0 [1, 41] 
VACTERL 
association 
Vertebral anomalies, anorectal malformations, cardiac 
malformations, esophageal atresia, tracheoesophageal fistula, 
renal anomalies and limb anomalies. 
unknown unknown 
Uncertain; 
Sporadic 
 
50-80% 121 [1, 31, 37] 
Feingold 
Microcephaly, limb malformations, esophageal and duodenal 
atresias, learning disability/mental retardation, hand and foot 
abnormalities, cardiac and renal malformations, vertebral 
anomalies and deafness 
MYCN 2p24.1 Autosomal dominant 25-40% 2 [1, 2, 6, 41, 42] 
Trisomy 18 
 
Congenital heart defects, kidney malformations, mental 
retardation, omphalocele, esophageal atresia, growth deficiency. multiple 18 
Autosomal 
dominant 25% 7 
[43] 
CHARGE 
 
Coloboma, heart anomaly, choanal atresia, retardation, genital 
and ear anomalies/deafness, facial palsy, cleft palate, and 
dysphagia 
CHD7, SEMA3E 8q12; 7q21 
Autosomal 
Dominant; 
Microdeletion 
10-20% 9 [1, 2, 6, 41, 44] 
Fanconi Anaemia 
 
Developmental abnormalities in major organ systems, early 
onset bone-marrow failure, and a high predisposition towards 
cancer. VACTERL-associated defects and hydrocephalus. 
FANC 
A,B,C,D1,G 
16q, 9q22, 
13q12,3p25, 
9p13,Xp22 
- 1-14% 1 [1, 2, 6, 45] 
Hemifacial 
microsomia 
Craniofacial, cardiac, vertebral, and central nervous system 
defects. Incomplete development of the ear, nose, soft palate, lip, 
and mandible. 
BAPX1?; 
TCOF1? 
14q32; 5pter?, 
22q11.2 
Autosomal 
dominant 5% 2 [1, 46] 
Down 
 
Mental retardation, delayed physical growth, facial 
characteristics, congenital heart diseases, thyroid, 
gastrointestinal, eye and hearing disorders. 
multiple 21 Autosomal dominant 0.5-1.0% 11 [43, 47] 
Opitz GBBB 
 
Hypertelorism, hypospadias, cleft lip/palate, 
laryngotracheoesophageal abnormalities, imperforate anus, 
developmental delay, and cardiac defects 
MID1 Xp22 X-linked recessive rare 6 [1, 2, 8, 41] 
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Table 2b Genetic syndromes and abnormalities affecting tracheo-esophageal (TE) development.
Syndrome Clinical features Gene Locus Inheritance 
T
E
 frequency 
C
ases in 
E
M
C
-cohort 
R
eference 
Triple X 
Variable, ranging from  absence of symptoms to mental 
retardation and developmental defects such as  limb and gastro-
intestinal anomalies 
multiple X Uncertain rare 3 [48, 49] 
15q11 deletion Mental retardation, movement and behavior disorders, facial dysmorphisms, genital anomalies and developmental delay 
UBE3A, NDN, 
SNRPN 15q11 
Uncertain; 
Autosomal 
dominant 
rare 5 [50] 
22q11.2 del/ dup. 
Parathyroid hypoplasia, thymic hypoplasia, outflow-tract defects 
of the heart, cleft palate, facial dysmorphism, hypocalcaemia, 
hypertelorism, and midline defects. 
TBX1 22q11.2 
Uncertain; 
Autosomal 
dominant 
rare 2 [51] 
Renal adysplasia; 
Potter; CAKUT 
 
Kidney anomalies (renal dysplasia, duplex kidney, and 
hydronephrosis) and ureter anomalies (vesicoureteral reflux, 
megaureter, and ureterovesical junction (UVJ) vesicoureteral 
reflux obstruction) 
PAX2, HNF1B, 
DSTYK, UPK3A, 
ROBO2, TRAP1 
10q24.31, 
17q12, 1q32, 
3p12.3, 
8q11.23, 
16p13.3 
- rare 2 [52, 53] 
Alveolar capillary 
dysplasia 
Alveolar Capillary Dysplasia, VACTERL-associated defects, 
urinary tract obstruction FOXF1 16q24.1 - rare 2 [54] 
Klippel-Feil 
 
Fused cervical vertebrae, short neck, low posterior hairline, 
limited neck movement, Cardiac defects, craniofacial anomalies, 
skeletal and ocular anomalies, malformation of the larynx 
GDF6, GDF3, 
MEOX2 
8q22, 
12p13.3, 
17q21 
- rare 1 [55, 56] 
Trisomy 13 
Mental retardation, microcephaly, structural eye defects, 
meningo-myelocele, polydactyly, cleft palate, genital, kidney and 
heart defects. 
multiple 13 Autosomal dominant rare 1 
[43] 
Pallister-Hall 
Hypothalamic hamartoma, pituitary dysfunction, central 
polydactyly and visceral malformations, anal atresia and 
occasionally laryngotracheo-esophageal cleft. 
GLI3 7p13 - rare 0 [41, 57] 
Mandibulofacial 
dysostosis with 
microcephaly 
Microcephaly, midface and malar hypoplasia, micrognathia, 
microtia, dysplastic ears, preauricular skin tags, significant 
developmental delay, and speech delay. 
EFTUD2 17q21 - rare 0 [58] 
Thrombocytopenia-
absent radius 
Platelet number reduction, limb malformations, cardiac and 
renal abnormalities RBM8A 1q21 
Autosomal 
recessive; 
Microdeletion 
rare 0 [59-61] 
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Heritability of tracheo-esophageal anomalies and associated malformations 
Several lines of evidence suggest that TE has a genetic background: 1.) in 72 twins, 
the concordance rate is higher in monozygotic twins with isolated EA (67%) than in 
dizygotic twins (42%)[62]; 2.) murine knockout models indicate candidate genes in humans; 
3.) TE defects are a variable feature in several known single-gene disorders, and 4.) TE can 
be present in patients with specific mutations, Copy Number Variations, structural 
chromosomal aberrations or whole chromosome duplications.[2, 43, 63, 64] Finally, 
although TE and VACTERL association are usually sporadic findings, familial TE does 
exist [65, 66]: in the EMC-Sophia TE cohort we have ten familial TE patients in 5 families.  
(1.7%) (data not shown), and other studies indicate a comparable number of familial 
cases.[67]  
VACTERL-association heritability 
In 69 twins with VACTERL association there does not seem to be a higher 
concordance rate in monozygotic twins (27%) than in dizygotic twins (31%).[68] Familial 
recurrence of VACTERL association component features has also been reported in patients 
with EA .[69] McMullen et al describe that 1.4% of sibs of patients in their TE cohort 
(n=140) have one VACTERL component feature or more.[70] Two of the children (n=41) 
of these patients also were affected, one of them with TE anomalies, indicative of a 
recurrence risk of 2-3%. Similarly, Solomon found one or more component feature in 5% of 
first-degree relatives of VACTERL patients, with 9% of the probands having affected 
relatives.[71] However, Bartels and co-workers did not find a higher prevelance of 
component features in first-degree relatives of patients with VACTERL association.[72] 
TE and genetic syndromes  
TE can be present as a variable feature in several known genetic syndromes. 
EA/TEF is a fairly common finding in syndromes such as Anophthalmia-esophageal-genital 
(AEG) syndrome, Feingold syndrome, CHARGE syndrome (i.e., Coloboma, Heart anomaly, 
choanal Atresia, Retardation, Genital and Ear anomalies) and trisomy 13. TE defects in 
other syndromes or conditions are more incidental (table 2). AEG syndrome also known as 
Microphthalmia and esophageal atresia syndrome (OMIM #206900) is a rare autosomal 
dominant disorder caused by mutations and deletions in the SOX2 gene.[73] Clinical 
characteristics are specific eye anomalies (anophthalmia and microphthalmia), esophageal 
atresia (100%), genital abnormalities, and brain and neurodevelopmental anomalies.[74, 75] 
Feingold syndrome(OMIM #164280)  is an autosomal dominant disorder whose clinical 
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manifestations include microcephaly, brachy-mesophalanangy, learning disabilities, and 
gastrointestinal atresia. The frequency of TE-anomalies in Feingold syndrome range around 
30-40%. Feingold syndrome is caused by heterozygous mutations and deletions in the 
MYCN gene, a SHH signaling target gene.[76] Although heterozygous mycn mutated mice 
are healthy, homozygous knockout mice die around embryonic day 11; defects include those 
in the esophageal epithelium.[77] CHARGE syndrome (OMIM #214800)is caused by 
heterozygous mutations in the chromodomain CHD7 gene, and is characterized not only by 
anomalies of the eye (coloboma) and ear (semicircular canal anomalies), but also by heart and 
genital anomalies, choanal atresia, and cranial nerve defects. Cleft palate, esophageal atresia 
(10-20%) and dysphagia are also commonly associated with this syndrome.[78, 79] 
In the extended version of table 2 in the online supplementary information several 
other syndromes/conditions that have been reported as single case-reports; these still have 
to be confirmed in other EA/TEF patients. For instance, EA/TEF, duodenal atresia and 
hearing loss were observed in one of two monozygotic male siblings with a de novo deletion 
of the WHSC1 gene, one of the genes suspected in Wolf-Hirschorn syndrome (Erasmus MC-
Sophia cohort unpublished data). A second example is a female EA patient with a 15q11 
deletion, who had mild cardiac anomalies and pectus excavatum.[72] Wong and co-workers 
suggest that the phenotypical spectrum of 15q11 deletions should be expanded to contain 
these more severe congenital defects. In our database we also found four additional 15q11 
deletion patients, all with EA and cardiac anomalies (table 2 and figure 1A).  
As well as Klippel-Feil in a male patient with TE, macrocephaly and infantile 
hypertrophic pyloric stenosis, other syndromal diagnoses in our cohort include Townes 
Brocks syndrome in a male patient with TE, cardiac anomalies, anorectal malformation, 
macrocephaly, micrognathia and ear anomalies; a ZIC3 mutation in a patient with X-linked 
heterotaxy[80]; and, more recently, a compound heterozygous TRAP1 mutation in a 
patient with CAKUT and esophageal atresia.[52] Incidental reports by others of TE in 
syndromal patients include Thrombocytopenia- absent radius syndrome. [59-61] and a 
missense mutation in PTEN in a patient with a TEF, macrocephaly and hypoplasia of  the 
thumbs.[81] The literature search resulted in over 70 TE-associated genetic and 
environmental syndromes. Supplementary table 1 describes syndromes in which TE are an 
incidental finding and whose locus or cause are currently unknown. 
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VACTERL association and genetic syndromes 
Other VACTERL spectrum malformations are also a variable or defining feature of 
many of the genetic syndromes of which TE anomalies are a variable component. As well as 
these syndromes, there are of course syndromes with VACTERL components in which the 
esophagus is not affected, or only rarely. For instance, many patients with Alagille 
syndrome (JAG1, NOTCH2) have vertebral, cardiac and renal anomalies, while patients with 
Cornelia de Lange syndrome (NIPBL, SMC1A, SMC3) have renal and limb malformations in 
addition to their defining features.  
Since the malformations described in many genetic syndromes overlap with those 
seen in patients with TE and VACTERL association, the patients in question may have a 
much higher frequency of known syndromic cases than previously described, and would 
benefit from genetic screening based on current knowledge. As differential diagnosis can be 
challenging if it is based on phenotype alone, reverse phenotyping might provide diagnoses 
in many of these previously “unresolved” cases. For instance, a search through these 
“unresolved cases” in the our database identified one male patient with cardiac, 
genitourinary and TE anomalies as well as choanal atresia and cleft palate—who may thus 
have CHARGE syndrome. Several patients had anorectal malformations, TE, and dysplastic 
ears or microtia that would warrant SALL1 (Townes-Brocks syndrome) mutational 
screening. Interestingly, SALL1 is an interaction partner of SOX2 and Nanog[82], the 
genes affected in AEG-syndrome and involved in a recurrent TE-associated chromosomal 
anomaly in the 17q21.3-q24.2 region (NOG).[43] Our database contains 11 patients 
registered with VACTERL-associated malformations combined with hydrocephaly 
(VACTERL-H or hemifacial microsomia); similarly, a number of patients with hypospadias 
or other genitourinary malformations and two or more VACTERL component features 
could have Opitz G/ BBB syndrome. In EA/TEF patients with consanguineous parents or 
microcephaly, Fanconi anemia should be considered. 
Chromosomal anomalies, Copy Number Variations  
Tracheo-esophageal anomalies can be present in patients with whole-chromosome 
duplication syndromes such as Down syndrome (0.5-1.0%), trisomy 13 and trisomy 18, and 
Triple X syndrome.[48, 49] Since many genes are involved in these triplications, it is 
difficult to determine the causal gene. Chromosomal rearrangements and aneuploidies have 
also been described in patients with TE.[43, 83] Chromosomal studies have described 
hotspots such as deletions on chromosome 2q37, 4q35, 6q13-q15 and duplications on 3p25-
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pter and 5q34-qter.[43, 83] Chromosomal syndromes such as chromosome 10 - paternal 
disomy, chromosome 17q22-q23.2 - submicroscopic deletion, chromosome 6q27 - 
submicroscopic deletion and mosaic trisomy 16 are also described in the London 
Dysmorphology Database.[40]  
These hotspots are all de novo in origin and could harbor disease-causing genes. For 
instance, we know from animal knockout studies that loss of function of Nog and Tbx4 can 
cause TE abnormalities, and that these genes are located within the frequently deleted 
human 17q21.3-q24.2 region.[84-86] Although patients with chromosomal deletions that 
include the SHH locus have been described, only two of them have TE anomalies.[87-91] 
As new technologies such as micro-array have largely replaced GTG-band karyotyping, and 
allow us to detect small Copy Number Variations (CNV), de novo and rare recurrent CNV 
have been detected in VACTERL and TE patients.[50, 91-99] However, sequencing of 
candidate genes involved in TE anomalies through CNV Profiling or Next Generation 
Sequencing of sporadic TE cases [52, 95, 100] did not identify other patients with similar 
mutations or CNVs. These incidental findings demonstrate the wide heterogeneity of the 
underlying gene defects that cause TE and associated anomalies. 
Animal knockout models 
Animal models can be used to study the effect of gene mutation, deletion or 
knockout. They have successfully identified candidate genes involved in human disease, and 
help to characterize the genes, signaling pathways and biological processes involved in 
normal tracheo-esophageal development. In 2001, for instance, Mahlapuu et al. described the 
importance of murine Foxf1 in foregut development[101]; and in 2009 Stankiewicz et al. 
showed that FOXF1 mutations and deletions are responsible for Alveolar Capillary 
Dysplasia (ACD).[54, 102] TE phenotypes are found in animal studies in which other 
forkhead box transcription factors are targeted (Foxp1, Foxp2, Foxp4) [103], as they are in 
various other transcription factors such as homeobox (e.g. Hoxc4, MEOX2, NKX2.1).[104-
108] These genes are important in foregut development and candidate genes in human 
patients with TE-anomalies. Dorsal-ventral patterning and localization of Sox2 and Nkx2.1 
are crucial for proper foregut morphogenesis and tracheo-esophageal separation.[22] Sox2 
is involved in esophageal and eye malformations. In mice, Sox2 and Chd7 interact[78] and 
regulate genes of the Notch and SHH signaling pathway, including genes involved in 
VACTERL-like syndromes, such as Alagille syndrome (JAG1), Feingold syndrome (MYCN) 
and Pallister-Hall syndrome (GLI3).[78]  
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Other factors, such as Bone Morphogenic Proteins(Bmp7, Bmp4) and Noggin (Nog), 
are also important for dorsal-ventral patterning in the proximal foregut [24, 26]. Bmp7 and 
Nog are expressed in the dorsal endoderm and Bmp4 in the ventral mesenchyme; knockout of 
Bmp4 or Nog can disturb dorsal-ventral patterning. Noggin is an inhibitor of the Bone 
Morphogenic Proteins and over 70 percent of Nog knockout mice have EA/TEF [24, 26]. 
Although NOG mutations in humans have been described, no associations with EA/TEF 
has been reported thus far [26]; and no loss of function mutations was found after 
sequencing of NOG in EA patients [109]. Sonic Hedgehog (shh) knockout mice have 
EA/TEF, and two patients with TE anomalies and deletion of this gene have been 
described. However, mutation analysis of SHH in an EA cohort did not reveal any 
pathogenic mutations.[110]  
Another link between disturbed SHH signaling and esophageal developmental 
defects comes from the incidental finding of esophageal atresia in patients with ACD. 
(OMIM# 265380). These patients have reduced or absent expression of FOXF1 due to 
mutation/deletion of this gene [102] or a deletion of the upstream lncRNA, the intragenic 
GLI2 binding domain[54] or CTCF and CEBPB binding domains.[111] Although Foxf1 
heterozygous knockout mice often develop EA, manifestation of TE anomalies is rare in 
humans.[101]  (table2 and figure 1). Sometimes animal knockout models share the TE 
anomalies seen in their human disease counterparts, although in most models there is little 
overlap (table 3). Remarkably, the most prevalent syndromic EA/TEF conditions—such as 
ACD, CHARGE syndrome and Feingold syndrome—have an association with the SHH 
signaling pathway (see figure 3)  
Shh signaling induces Bmp4 [112] and Bmp4 knockouts do not develop a 
trachea.[113] SHH, GlI2 and GLI3 are dependent on proper cilia functioning.[114] While 
mice with loss of function or knockout mutations in genes involved in cilia function, 
formation and Hedgehog signal transduction (IFT172, Dync2h1, Fuz, Wdr35)[115-119] 
have TE in animal models, they do not (yet) have a TE defect counterpart in human disease 
(table 3). The importance of cilia formation and function, which are crucial for hedgehog 
signaling[114], is perhaps underestimated in foregut development, and new initiatives to 
establish a role for cilliopathy in VACTERL and other TE anomalies should be 
encouraged.[114] 
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 Figure 3. Schematic presentation of the Shh signaling pathway.  Hedgehog signaling enables the release of 
Smo by Ptch and its sub sequent accumulation in the primary cilium. Active Smo interacts with the Sufu 
complex, which translocates to the tip of the cilium. GLI is activated and transported back in the direction of 
the basel body of the cilium and sub sequent to the nucleus. There GLI can bind to the DNA and activate 
transcription of target genes. Figure based on [114] and [120] 
 
TE anomaly Genes 
In animal models only 
IFT172, Rarα/ Rarβ , Nkx2.1, Rab25, Hoxc4 , Chrd, Ctnnb1, Dync2h1, Efnb2, Foxp4, 
Fuz, Lec, Sox4, Wdr35, Foxp2, Foxp1 
In animal models and 
involved in human TEF 
NOG, TBX4, PCSK5, SHH, GLI2, GLI3, SOX2, SOX17, FOXF1, TBX1, MEOX2, 
RIPK4 
Involved exclusively in 
human syndromes of 
which TE is a variable 
feature 
HOXD13, CHD7, MYCN, SALL1, MID1, TRAP1, FANC-genes, ZIC3, PTEN, 
EFTUD2, NKX3.2, FBN2, RBM8A, GDF6, GDF3, TBX5, WHSC1, UBE3A, NDN, 
SNRPN, PAX2, HNF1B, DSTYK, UPK3A, ROBO2, POR, FGFR2, FGFR£, 
AXIN1, VANGL1, FGFR3, TERC, NOP10, TINF2, DKC1, ITGA6, FRAS1, 
FREM2, FLNA, AAAS, MKKS, WNT7a, WNT3, TCOF1 
 
 
 
Table 3. Animal and human genes involved in TE malformations.  
Table based on information obtained from a literature search using Pubmed 
(http://www.ncbi.nlm.nih.gov/pubmed/), the OMIM database (http://www.ncbi.nlm.nih.gov/omim) [121], 
MGD database (http://www.informatics.jax.org/)[122] and London Dysmorphology Database.[82] Database 
search was done in January 2014 
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In summary, there is a genetic contribution to EA and other TE- and VACTERL-
associated defects. As the underlying genetic defect is still unknown in a subset of patients, it 
is yet to be discovered. The phenotypical and genetic heterogeneity seen in EA/TEF 
patients is indicative of not one, but several underlying causes. New causal genetic defects 
and predisposing loci in the etiology in specific sub-populations will be identified by 
combining statistical analysis of component findings in large patient cohorts with genome 
sequencing and genome-wide association studies.  
Seemingly pathogenic chromosomal rearrangements, CNV or mutations in human 
genes that are involved in TE anomalies, identified in animal studies, and detected de novo in 
patients are also detected as events inherited from unaffected parents. For instance, the only 
person to be affected in a family with an inherited t(1;13)(p8;q12) was the patient herself. 
[121] Similarly, a chromosome 22q11 micro-duplication in another patient was inherited 
from a healthy parent.[92] But this duplication has also been described in patients as a de 
novo CNV[96] and in translocations.[122] Mutations in PCSK5 in VACTERL patients 
were also inherited from unaffected parents.[106] It is also indicated by the variable 
penetrance of the TE–anomalies in several known genetic syndromes that there is more to 
these defects than Mendelian genetics alone: low heritability and monozygotic twin 
concordance rate indicate an environmental contribution, possibly a large one. As 
discordance has been described in several syndromes in which TE- and VACTERL-
associated anomalies are variable features [123], monozygotic twin discordance is not 
unique to patients with TE-anomalies.  
Environmental and other risk factors 
Several risk and environmental factors have been associated with an increased risk 
for EA and VACTERL association (table 4). Environmental exposures can be estimated with 
questionnaires, either retrospectively during follow-up counseling visits in hospitals, or 
prospectively in a cohort of pregnant women. Several population-based studies and case-
reports have highlighted a wide variety of associated risks, ranging from excessive hot-tub 
use during pregnancy to fetal alcohol exposure. Higher paternal and maternal age and low 
parity have also been associated with an increased risk. Some case reports have linked 
maternal diabetes to congenital anomalies, including those of the VACTERL 
spectrum.[124] At least seven case reports have described children with EA who were 
exposed to Methimiazole/ Carbimazole during pregnancy .[125] Affected patients can have 
features such as facial dysmorphisms, scalp vertex cutis aplasia, choanal atresia, EA/TEF, 
25 
 General Introduction  
developmental delay, and growth retardation. Methimiazole and Carbimazole are anti-
thyroid drugs used to treat Graves’ disease, a disorder characterized by excessive thyroid 
hormone secretion and thyromegaly caused by activation of the thyroid gland by 
immunoglobulin G autoantibodies. It has been debated whether or not these abnormalities 
are caused by the use of the anti-thyroid drugs or by the hyperthyroidism itself .[126, 127] 
Another example of a teratogen is Diethylstilbestrol (DES), a synthetic estrogen 
used to prevent miscarriages. This endocrine-disrupting chemical has a trans-generational 
effect and associated congenital anomalies include genitourinary anomalies such as 
hypospadias[128, 129] and vaginal and cervical adenocarcinomas.[130, 131] Felix and 
coworkers describe nine women exposed to DES in utero who have children with 
EA/TEF.[132] Three women (2.4%) reported in utero DES exposure in an epidemiological 
study in which questionnaires were sent to parents who were contacted through a patient 
organization. Their children had trachea-esophageal anomalies as well as other congenital 
anomalies. One girl with isolated EA/TEF, a girl with meningocele and agenesis of the 
corpus callosum and a boy with EA/TEF and renal, anorectal and vertebral anomalies. 
Furthermore, Felix reported six EA/TEF children of the Erasmus MC-Sophia cohort with 
mothers exposed to DES (3.1%). These children had EA and or TEF, and four of them had 
one or more additional major anomaly, mainly of the VACTERL spectrum.[132] Although 
DES is significantly associated with EA/TEF, the exact mechanism whereby DES causes 
this anomaly in the offspring of women exposed in utero is unclear.  
DES disturbs estrogen signaling via the esr1 receptor [133], thereby inhibiting trp63 
expression.[134, 135] Interestingly, trp63 is important in esophageal development and 
epithelial morphogenesis.[24, 136] However, the EA/TEF children have never been 
exposed to DES. Conceivably, epigenetic modifications are involved in the trans-
generational effect of DES. While a pilot study in the Erasmus MC-Sophia children’s cohort 
(n=48) showed a trend towards a significant association between gardening during 
pregnancy and EA/TEF, herbicide use was not significantly associated, making it hard to 
draw conclusions from the gardening trend.[5]Although numerous targeted and induced 
animal models have examined the development of the foregut [24, 115-119, 137-139], their 
importance to our understanding of human EA is not always clear. Critical foregut 
developmental pathways can be experimentally manipulated. For instance, we know from 
animal models that maternal cadmium exposure and smoking disturb Wnt- and SHH- 
signaling in neonatal mice and chickens.[140, 141]  
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 Environmental or risk factor Association reference(s) 
Low maternal parity Associated [65, 142, 143] 
Maternal age Associated [5, 142, 144, 145] 
Paternal age Associated [146, 147] 
Ethnicity Associated [142] 
Obesity Absent [148, 149] 
Socio-economic status Uncertain [148] 
Seasonal effects Absent [150, 151] 
Maternal diabetes Associated [152-155] 
Frequent maternal use of hot tub Associated [156] 
Maternal dyspepsia Absent [157] 
Exogeneous sex hormones conflicting evidence [158-162] 
Maternal diethylstilbestrol exposure Associated [132] 
Methimazole Associated [126, 163, 164] 
Carbimazole Associated [163, 165] 
Mycophenolate Associated [166] 
Propylthiouracil conflicting evidence [163, 164] 
Herbicides or insecticides conflicting evidence [5, 167] 
Tabacco smoke Absent [5, 148, 168] 
Alcohol consumption Absent [5, 148, 168] 
Caffeine intake Associated [169] 
Twinning Associated [6, 170, 171] 
Maternal phenylketonuria Associated [172, 173] 
Infectious disease Absent [151] 
Vitamin A deprivation associated in animal model [174] 
Adriamycin antibiotic 
associated in animal model; absent in 
human 
[175-177] 
Ethylnitrosourea associated in animal model [106] 
 
 
Table 4. Associated and non-associated environmental components and risk factors described in 
tracheo-esophageal anomalies 
 
Another example is Adriamycin, which interferes with DNA replication and inhibits 
DNA and RNA synthesis.[173], and therefore affects many tissues and organ systems. 
While rodents develop esophageal atresia after prenatal exposure to Adriamycin, this has 
not been described in humans exposed to even higher dosages.[176] Neither does 
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adriamycin completely cross the placenta in humans, since only very low concentrations 
have been detected in the fetus.[176] VACTERL and non-VACTERL types of defects have 
been reported in the offspring of Adriamycin-treated rats. [178] While Adriamycin is 
known to cause apoptosis of monocytes and macrophages [179], nephropathy [180] and 
cardiomyopathy[181], Gillick and co-workers found no evidence of generalized cell death in 
the Adriamycin-induced VACTERL-association animal model.[182] Although the rodent 
Adriamycin model has been widely studied, it is unclear whether it is relevant to our 
understanding of EA/TEF. 
Even though there are many associations, it is difficult to move beyond them and 
prove causality of these environmental risk factors. Two findings may help establish a link 
between genetics (null genotype, de novo CNV) and a pathway involved in biotransformation 
of teratogens (Gluthatione transferases).[94, 183] The first is the association of a null 
genotype of Gluthatione transferase (GSTM1) in mothers of EA patients and in the patients 
themselves[183]; the second is the presence of a large de novo deletion encompassing 
another Gluthatione transferase gene (GSTP1) in a patient with TE.[94] Overall, however, 
progress has been made in gene-environment studies in general: it has become increasingly 
evident that environmental burdens can leave epigenetic marks. These marks in the fetal 
epigenome— for instance after maternal diabetes[184] or after prenatal exposure to 
cigarette smoke[185]—are detected or suspected and can lead to disturbances in key 
developmental pathways. Studying the TE patient’s epigenome may facilitate the unbiased 
measurement of prenatal environmental exposure.  
Future developments  
The wide genetic and phenotypical heterogeneity of TE defects indicate a 
multifactorial etiology. Next-Generation Sequencing and high resolution SNP arrays now 
enable us to detect smaller and smaller de novo CNV and mutations. Their use in the few 
familial cases and phenotypically clustered groups of sporadic patients may identify new 
genetic syndromes. Such new syndromes will explain an increasing part of the etiology in 
patients currently diagnosed with EA/TEF and VACTERL-associated malformations. 
Describing patient phenotypes uniformly will help to categorize this heterogeneous patient 
population prior to investigating genetic or environmental associations. 
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To date, the majority of EA/TEF and VACTERL-association patients have been 
sporadic, many of them caused by private de novo CNV or mutations. Improved surgical 
treatment has increased patient survival. Now that they are at an age when they may wish to 
have children, these patients may be at risk of transmitting their de novo mutations to the 
next generation in an autosomal dominant manner. Genetic counseling and genome 
profiling of families with recurrence using techniques that were unavailable at their time of 
their birth may be an important instrument not only for identifying genes involved in 
disease etiology, but also for predicting future high-risk pregnancies.  
However, such developments will be very unlikely to explain the entire EA/TEF and 
VACTERL-association etiology. If association studies are to detect rare and low-effect loci, 
large patient and control cohorts are necessary, which will only be possible by combining 
patient cohorts. The effect of multiple rare or private inherited variants detected with NGS 
and studied with a burden test, also need large sample sizes.  Uniform parental 
questionnaires should be used in multicenter studies, possibly in combination with one 
specific type of high-density SNP array or sequencing pipeline, thus enabling 
epidemiological and Genome Wide Association Studies in large cohorts.  
The greatest challenge in elucidating EA/TEF and VACTERL association etiology 
will be to categorize the non-genetic contribution to their etiology. While the use of uniform 
questionnaires will lead to new associations, proving the causality of these associations will 
be much more difficult. It may be best first to focus on the effect of known mutations and 
teratogenic risk factors, possibly by using functional tests to study suspected biological 
pathways or processes. Patient specific genetic and environmental causality presents 
challenges with regard to counseling and informing parents on recurrence risk and future 
co-morbidity, and also the risk of familial recurrence. Greater knowledge of environmental 
risk factors, genetic predisposition and causal genetic syndromes may even produce 
preventive strategies and the ability to predict co-morbidity. 
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 Aim and outline of this thesis 
 
 
 
 
 
Aim and outline of this thesis 
In chapter 1 of this thesis, a general introduction, the current knowledge on the 
etiology of esophageal atresia and tracheo-esophageal fistula is reviewed. EA/TEF is a 
clinical heterogeneous condition and has a heterogeneous etiology. Tracheo-esophageal 
anomalies are a variable feature in over 70 genetic syndromes. Moreover, chromosomal 
anomalies, single base pair mutations and Copy Number Variations have been described in 
sporadic patients, a causal genetic aberration can be identified in 11-12% of patients.  
EA/TEF is mostly a sporadic finding. As this suggests that epigenetic and environmental 
factors also contribute to the disease, non-syndromic EA/TEF is generally believed to be a 
multifactorial condition. Indeed several population-based studies and case reports describe a 
wide range of associated risks, including age, diabetes, drug use, herbicides, smoking and 
fetal alcohol exposure.  
In chapter 2, Copy Number Variations in patients with EA or VACTERL spectrum 
malformations, we address chromosomal anomalies and CNV in these patients.  We have 
reviewed the literature for de novo CNV and describe the recurrent inherited and de novo 
CNV in the Erasmus University MC-Sophia Children’s hospital TE- cohort. We show that 
although described in literature and present in our cohort, de novo CNV is rare in these 
patients. Furthermore, we hypothesize about the role of rare an private recurrent CNV in 
these patients which, although inherited, could point to mechanisms or biological processes 
contributing to this constellation of developmental defects.  
In chapter 3, Genetic studies in discordant monozygotic twins, we describe why twin 
studies can be a valuable asset in the geneticists’ toolbox.  Also, we discuss the pitfalls e.g. 
caution has to be taken by the interpretation of these twin-study results since environmental 
and genetic components are not always exactly identical in monozygous twins. We compare 
the DNA of discordant monozygotic twins using SNP-array and Whole-Exome sequencing 
in order to identify somatic changes, either Copy Number Variations, small 
insertions/deletions or single nucleotide changes,  that could explain the twin discordance.  
Chapter 4, Next generation sequencing in familial and consanguineous patients, describes 
two other methods we used to determine underlying genetic factors in EA/TEF and renal 
agenesis/hypoplasia, one of the VACTERL spectrum associated malformations. With 
genetic studies in families with multiple affected members and with studies in 
consanguineous patients we aim to identify the causal genetic variants in these patients. TE 
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and VACTERL association familial recurrence rate is low (1-3%). We describe two genetic 
studies, one in 5 familial cases and the other study in 3 consanguineous patients with TE 
anomalies and a family with two siblings with renal anomalies.  
In chapter five, the General discussion, we discuss the results of our experiments and 
address the prospects and challenges of our and future research. We highlight the 
phenotypical and genetic heterogeneity in EA/TEF patients, indicating not one underlying 
cause, but several causal and contributing factors. This wide genetic and phenotypical 
heterogeneity of TE defects indicate a multifactorial etiology. We give recommendations for 
further research, stressing the importance of international collaboration and joining of large 
cohorts of patients. With joint efforts we will be able to speed up the process of identifying 
new causal and predisposing, genetic and environmental, factors in EA/TEF etiology.  
Next-Generation Sequencing and high resolution SNP arrays now enable us to detect 
smaller and smaller de novo CNV and mutations: their use in the few familial cases and 
phenotypically clustered groups of sporadic patients will reveal causal genetic variation and 
may identify new genetic syndromes. Such new syndromes will explain an increasing part of 
the etiology in patients currently diagnosed with EA/TEF and VACTERL-associated 
malformations. Describing patient phenotypes uniformly will help to categorize the 
heterogeneous patient population prior to genetic or environmental associations. 
To date, the majority of EA/TEF and VACTERL-association patients have been 
sporadic, many of them caused by private de novo CNV or mutations. Improved surgical 
treatment has increased patient survival. Now they are at an age when they may wish get 
pregnant, these patients are at risk of transmitting their de novo mutations to the next 
generations in an autosomal dominant manner. Genetic counseling and genome profiling of 
young adults using techniques that were unavailable at their time of their birth may be an 
important instrument not only for identifying genes involved in disease etiology, but also for 
predicting high-risk pregnancies. However, such developments will be very unlikely to 
explain the entire EA/TEF and VACTERL-association etiology. If association studies are 
to detect rare and low-effect loci, large patient and control cohorts are necessary, which will 
only be possible by combining patient cohorts. Uniform parental questionnaires should be 
used in multicenter studies, possibly in combination with one specific type of high-density 
SNP array, thus enabling epidemiological and Genome Wide Association Studies in large 
cohorts. After all, our main goal in these type of patient based studies is to gain more 
knowledge of risk factors in order to improve parental counseling, and perhaps predict and 
prevent co-morbidity. 
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Abstract 
Copy number variations (CNVs), either DNA gains or losses, have been found at 
common regions throughout the human genome. Most CNVs neither have a pathogenic 
significance nor result in disease related phenotypes but, instead, reflect the normal 
population variance. However, larger CNVs, which often arise de novo, are frequently 
associated with human disease. A genetic contribution has long been suspected in 
VACTERL (Vertebral, Anal, Cardiac, TracheoEsophageal fistula, Renal and Limb 
anomalies) association. The anomalies observed in this association overlap with several 
monogenetic conditions associated with mutations in specific genes, e.g. Townes Brocks 
(SALL1),Feingold syndrome (MYCN) or Fanconi anemia. So far VACTERL association is 
typically considered a diagnosis of exclusion.  Identifying recurrent or de novo genomic 
variations in individuals with VACTERL association could make it easier to distinguish 
VACTERL association from other syndromes and could provide insight into disease 
mechanisms.  
Sporadically, de novo CNVs associated with VACTERL are described in literature. 
In addition to this literature review of genomic variation in published VACTERL 
association patients we describe CNVs present in 68 VACTERL association patients 
collected in our institution. De novo variations (>30kb) are absent in our VACTERL 
association cohort. However, we identified recurrent rare CNVs which, although inherited, 
could point to mechanisms or biological processes contributing to this constellation of 
developmental defects.  
  
44 
Chapter 2.1 
Introduction 
Copy number analysis has proven to be a powerful tool for identifying genes and 
genomic regions that contribute to the occurrence of congenital malformations. Common 
copy number variations (CNVs), regions of variable DNA gains or losses, account for a 
significant proportion of the healthy human genome. [1, 2] Most CNVs are inherited 
polymorphisms that have no appreciable effect on health.  However, there are many 
examples of de novo or rare CNVs that have clearly been associated with human diseases, 
e.g. Wolf-Hirschhorn syndrome (OMIM #194190) and 22q11.2 deletion syndrome (OMIM 
#192430).[3] Pathologic CNVs are often larger (>500kb) in size and are usually not 
inherited from an unaffected parent.[4] 
Implementation of new molecular cytogenetic techniques, such as microarray-based 
comparative genomic hybridization and single nucleotide polymorphism arrays, has revealed 
previously unidentified genotypic aberrations which can now be correlated with phenotypic 
anomalies. As a result, numerous publications have implicated specific pathogenic CNVs in 
intellectual disability, congenital anomalies like cleft lip, microcephaly , renal malformations 
[5], and neurological conditions including autism and schizophrenia[3]It may very well be 
that, like in other congenital anomalies, there is role for pathogenic CNVs in VACTERL 
association (OMIM #192350) etiology.  VACTERL association is a heterogeneous condition 
defined by six core structural defects (Vertebral, Anal, Cardiac, Trachea-Esophageal fistula, 
Renal and Limb anomalies) which occur together more commonly than would be expected 
by chance alone. 
These defects are also observed in several other monogenetic conditions caused by 
intragenic mutations, e.g. Townes-Brocks syndrome (OMIM #107480; SALL1)—whose 
features include imperforate anus, cardiac defects, renal anomalies and hand defects, most 
often affecting the thumb—and Feingold syndrome (OMIM #164280; MYCN)—whse 
features can include esophageal atresia, cardiac anomalies, renal anomalies and abnormalities 
of the hand and fingers. [6]) In addition to gene mutations, CNVs have been described as 
causal factor in several VACTERL-like syndromes. These include Goldenhar/OAVS 
(OMIM #141400[7], Townes-Brocks syndrome [8], X-linked VACTERL-H (OMIM 
#314390) [9], MURCS association (OMIM #601076) [10], OEIS complex (OMIM 
#258040) [11, 12], TAR syndrome (OMIM #274000) [13], 13q32 deletion syndrome 
[14]and 22q11.2 deletion syndrome.[15]  Due to the abundance of overlapping defects in 
various organs, the scarcity of known causal factors and its heterogeneous phenotype, 
VACTERL association is typically considered a diagnosis of exclusion.  In general the 
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diagnosis is made when at least three of the six associated core defects are present and all 
other phenotypical overlapping syndromes have been excluded. [16] 
The role of genetics in VACTERL association has long been suspected. VACTERL 
is usually a sporadic finding, but familial cases do exist. [17] Moreover, in about 9% of 
VACTERL patients one of the relatives has one of the six core VACTERL features.[18]In 
some rare cases a genetic defects have been described such as a polyalanine expansion[19], 
nuclear [20-22] or mtDNA [23, 24] mutations and numerical or structural chromosome 
aberrations. [25-27] The resolution to detect these chromosomal anomalies has increased 
significantly with the introduction of micro-array technology; as current technologies allow 
detection of genomic imbalances down to only a few kb in size.  Although the role of CNV 
and chromosomal aberrations in congenital anomalies is well established, little is known of 
their role in VACTERL association etiology.  It is possible that recurrent or de novo 
genomic variations contribute to the development of some cases of VACTERL association.  
Identifying such changes could make it easier to distinguish VACTERL association from 
other syndromes and other potentially-related conditions, and could provide insight into 
disease mechanisms 
Materials and Methods 
Literature Review 
We reviewed the literature to identify both numerical or structural chromosomal 
anomalies and copy number variations described in individuals with VACTERL association. 
We followed the inclusion criteria for VACTERL association (three or more of the core 
VACTERL elements, Figure 1) and excluded the patients with a confirmed genetic 
syndrome.  
Study Population 
Since 1988, the Erasmus MC - Sophia Children’s Hospital Department of Pediatric 
Surgery unit has been collecting clinical data and, when possible, DNA, from VACTERL 
patients. This cohort is part of a larger EA/TEF cohort (n=567) in which patient sampling 
and registration are based on the existence of either Esophageal Atresia and/or 
TracheoEsophageal fistula regardless of additional anomalies. Patients were selected using 
the same criteria as for the literature review. In total, DNA from 68 out of 121 VACTERL 
patients was analyzed for copy number variations.  
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Analysis of copy number variation 
Copy number variation analysis was performed using Illumine 12-HumanCytoSNP, 
Human 610-Quad or Omni Express Bead Chips (Illumina, Inc., San Diego, USA) according 
to manufacturer’s instructions. Arrays are processed according to their manufacturer’s 
standard protocol.  Normalized output was generated with Illumina’s Genome Studio 
program (Illumina, San Diego, CA, USA) and copy number variation was visualized in 
Nexus CN6.1.  (Biodiscovery Inc, El Segundo, CA, USA) Inheritance of CNVs was 
determined only if they were larger than 30kb, contained genes and were either unique or 
had a low frequency in the general population.  
 
Figure 1. Inclusion criteria. (A) In total  45% of the EA/TEF cohort had 1 core component (TEF) and 27% 
had one additional core element.  163 patients out of 567 (21%) entries in the Rotterdam EA/TEF cohort met 
the criteria for VACTERL association. (B) 42 Patients had a confirmed genetic syndrome (7%) and were 
excluded from the VACTERL cohort.  
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Results and Discussion 
Published CNVs identified in patients with VACTERL association 
No large studies looking for CNVs in individuals with VACTERL association have 
been published.  However, several case reports have been published that describe 
chromosomal anomalies and recurrent and de novo CNVs in VACTERL patients (Table 1).  
Most of the published de novo genetic anomalies that have been identified in individuals 
with VACTERL association are unique.  However, some changes are recurrent and have 
been identified in more than one VACTERL patient.  
The first is on chromosome 17 where two overlapping deletions have been reported 
affecting chromosome band 17q23 in both patients. This region contains many genes, but 
includes 2 candidate genes, TBX2and TBX4, which encode T-box transcription factors. 
Heterozygous loss of function mutations in TBX4 have been shown to cause small patella 
syndrome (OMIM #147891) an autosomal dominant skeletal dysplasia characterized by 
patellar aplasia or hypoplasia and by anomalies of the pelvis and feet [28].  TBX2 has not 
been implicated in human disease but homozygous Tbx2knockout mice are embryonic lethal 
and have cardiac anomalies and polydactyly.[29] The second shared locus is chromosomal 
band 8q24.3 which is duplicated in two individuals with VACTERL. This locus harbours 
many genes including GLI4 that encodes a member of the krueppel C2H2-type zinc-finger 
protein family.  Although the exact function of GLI4 has not been determined, we note that 
Gli2-/- and Gli3-/- mice have a VACTERL phenotype [30].  Therefore we consider GLI4 to 
be an excellent candidate gene.  
CNVs identified in the Rotterdam VACTERL cohort 
In the Rotterdam VACTERL cohort, we did not observe any clearly de novo CNVs.  
However, one VACTERL patient with trachea agenesis had a maternally inherited 488 kb 
16p12.1 deletion and a 3.7MB deletion on chromosome 5q11.2[31]The 5q11.2 deletion was 
not inherited from the mother. There was no DNA available from the unknown sperm 
donor. Several genes are located in this large deletion. Among the top ranked genes by the 
Endeavour gene prioritization tool are ITGA1, which regulates mesenchymal stem cell 
proliferation [32]and FST, an activin binding protein. Although de novo CNVs were not 
identified, all of the patients in this cohort had one or more large (>100kb) CNVs (Figure 2).  
Most of these CNVs were known polymorphisms whose frequencies in normal controls 
make them unlikely to contribute to VACTERL association.   
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 Figure 2. CNVs in the Rotterdam Cohort and recurring published CNV and structural chromosomal 
anomalies. In this karyogram our institution’s unique and rare (underlined) gain (blue) and loss (red) are 
depicted alongside the chromosomal bands in which they are located. Common polymorphisms are not 
visualised. At three loci, recurrent gains either from literature (8q24.3), in our cohort (10q25.3) or both (22q11) 
(blue regions on ideogram). Two published recurrent chromosomal anomalies lead to a deletion of band 17q23 
(red region on ideogram). With arrows, de novo CNV are depicted. 
However, we observed 3 regions with CNVs which are rarely seen in the general 
population but were shared by more than one of our VACTERL patients (Table 1). These 
recurring variations can point to pathways or mechanisms involved in disease etiology, 
especially when they have an extremely low frequency in the general population.   
The first of these rare recurrent CNV in our cohort consisted of maternally inherited 
300kb duplications in band 10q25.3.  This region contains the actin binding LIM protein 
family member 1 gene (ABLIM1) which encodes a protein that may play a role in binding 
cytoplasmatic proteins to the actin cytoskeleton.[33] Interestingly, Arrington et al. found a 
451 kb interstitial deletion on chromosome 3q28 involving only the LIM domain containing 
preferred translocation partner in lipoma (LPP) gene in an individual with esophageal 
atresia with tracheoesophageal fistula, hypospadia, cardiac-, renal- and rib 
anomalies.[34]This change was not found in the individual’s mother but a paternal sample 
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was not available, making it impossible to determine if this was a de novo change or was 
inherited from an unaffected family member. In our cohort, no CNVs affecting LPP were 
identified [35] but the presence of deletions affecting both ABLIM1 and LPP in some 
VACTERL association patients (e.g. esophageal atresia with tracheoesophageal fistula, 
hypospadia, horseshoe kidneys, hemivertebrae and urinary reflux) suggests that 
disturbances of the cytoskeleton may contribute to VACTERL phenotypes.  
The second recurring CNV was a duplication affecting chromosome 22q11.2. The 
patient, with all of the 6 core VACTERL features affected and her mother had a 22q11.2 
micro duplication overlapping 1.4 Mb of the de novo duplication in a VACTERL patient 
described by Schramm and colleagues.[36]This patient had vertebral fusion, anal atresia, 
right sided duplicated kidney and additional non-VACTERL deformations. 
The third recurring CNV involves a gain of the Short stature HOmeoboX-containing 
gene (SHOX), which plays an important role in limb development. [37] Duplications 
involving SHOX were identified in two VACTERL patients, both of whom had limb 
anomalies and esophageal atresia with tracheoesophageal fistula. [38]) Moreover, one of the 
two patients had horseshoe kidneys, hypospadia and dysmorphic features and the second 
patient an atrial septum defect. The duplications were inherited, one from the patient’s 
mother and the other from the patient’s father.  
CNVs inherited from an unaffected parent are often considered to be non-pathogenic. 
[39] However, the absence of a phenotype in the parent does not exclude a causal 
relationship.  Differences in phenotypes seen in individuals carrying the same CNV can be 
due to several mechanisms, i.e. differences in environmental exposures; the combination of 
two recessive alleles in the affected individual, variable expressivity, incomplete penetrance, 
skewed X-inactivation or a two-hit CNV model. In this last model, it is postulated that 
second hits, or alterations in another genomic region, can affect the same biological process 
and that the additive effects of these changes result in a particular phenotype.[40, 41]Large 
CNVs with low population frequencies are excellent candidates for a two hit model.  
Due to the scarcity of published de novo CNVs and absence of such changes in our 
cohort, we believe that relatively large de novo copy number variations are not a common 
cause of VACTERL association.  Furthermore, we cannot exclude the possibility that 
smaller, inherited CNVs can contribute to the development of VACTERL phenotypes. We 
did observe several small unique and rare inherited CNVs in our cohort, which on their own 
are likely benign but could contribute to VACTERL association in a two hit model. The 
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latest high resolution arrays contain millions of probes and can detect CNVs as small as 2kb. 
If we want to progress our knowledge about the role of small CNV in VACTERL 
association etiology, we must know more about frequency and distribution of these small 
variants in large normal control populations.   
To summarize, we believe that copy number variations can play a role in VACTERL 
association by shifting the balance from normal to abnormal development in combination 
with other genetic, environmental, and/or stochastic factors. These changes may also focus 
attention on genes, pathways, or processes that are frequently affected, by mutations or 
CNVs, in individuals with VACTERL association.  By studying larger cohorts it may be 
possible to identify additional recurrent CNVs that contribute to VACTERL phenotypes 
which could, in turn, provide insight into the etiology of VACTERL association. 
Chromosome Type Remarks (hg18) Inheritance Ref 
1q41 Gain chr1: 215 945 774–216 077 064 de novo [42] 
2q37.3 Gain chr2: 241 202 666–241 227 781 de novo [42] 
2q22-q24.2 Deletion del(2) (q22q24.2) de novo [43] 
3q28 Loss chr3:189395885-189951376 de novo [34] 
5q11 Loss chr5:51,185,650-55,001,348 ICSI; father NA [31] 
6q25.3-q27 Loss #1 NA - 
6q13-q15 Deletion (6)(q13-q15) de novo [44] 
7 Duplication trisomy 7 de novo [45] 
8q24.22-q24.3 Gain #1 NA - 
8q24.3 Gain chr8: 145 012 210–145 132 100 de novo [42] 
10q22-qter Duplication dup(10)(q22-qter) de novo [46] 
10q25.3 Gain chr10:116,250,268-116,546,953 Inherited-Mat  
10q25.3 Gain chr10:116,261,258-116,515,586 Inherited-Mat  
11q23-qter Duplication 47,XY+der(22)t(11;22)(q23;q11.2) de novo [47] 
12 Duplication r(12) de novo [48] 
13,r(13) Duplication trisomy 13 de novo [26, 49] 
16p12.1 Loss chr16: 21,854,140-22,342,140 Inherited-Mat [31] 
16q24.1 Loss chr16:82908199–86405076 de novo [50] 
17q23-2q24.3 Deletion del (17) (q23.2q24.3) de novo [51] 
17q22-q23.3 Deletion del (17)(q22q23.3) de novo [52] 
18q12.1 Loss #1 NA - 
18q22.2-qter Deletion 18q22.2-->qter de novo [53] 
18,r(18) Duplication trisomy 18 de novo [26, 54] 
21 Duplication trisomy 21 de novo [26] 
22q11.2 Gain chr22:17,281,004-19,792,353 de novo [36] 
22q11.2 Gain chr22:17,017,139-18,665,833 Inherited-Mat  
22pter-q11.2 Duplication 47,XY+der(22)t(11;22)(q23;q11.2) de novo [47] 
X Duplication Triple X de novo [38] 
Xp22.3 Gain chrX:242,432-1,318,727 Inherited-Pat [38] 
Xp22.3 Gain chrX:327,015-1,889,115 Inherited-Mat [38] 
 
Table 1 Chromosomal anomalies, recurring and de novo CNVs seen in VACTERL patients . #1 abstract 
Shin et al American Society of Human Genetics 2011,  NA data not available; Mat (maternal) and Pat 
(paternal); recurrent CNV in bold; ICSI (Intracytoplasmic sperm injection) 
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Abstract 
Esophageal Atresia (EA) with or without TracheoEsophageal Fistula (TEF) are 
common congenital anomalies whose cause is unknown in over 90% of affected patients. 
EA/TEF can either be present as an isolated defect or in association with other 
developmental defects: e.g. as one of the core features of the VACTERL (Vertebral, Anal, 
Cardiac, Tracheo-esophageal fistula, Renal and Limb anomalies) association. The hypothesis 
that genetic defects contribute to both EA/TEF and VACTERL etiology is supported by 
the fact that EA/TEF is a variable feature of several known monogenetic syndromes. 
Among these possible defects are Copy Number Variations (CNVs). As de novo CNVs can 
help to identify causal genes or affected biological pathways, the recurrence of unique and 
rare inherited CNVs may, in combination with other factors, predispose for the development 
of EA/TEF and other features of the VACTERL association.  
We therefore profiled 268 affected individuals with micro-array. All had one or more 
relatively large (≥ 30kb) CNV, most of them known polymorphisms. However, sixteen loci 
contained putative de novo CNVs, most of which were seen only once in our patient cohort. 
These (putative) de novo variants were observed at two previously published (5q11 and 
16q24.1), four loci affecting genes of known syndromes (4p16.3, 4q21, 7p14.1, 7q36) and  
twelve new loci: i.e.  4q35, 6q23.2, 7p22, 8p22, 8q13.1, 11p14, 15q21, 13q12.11, 16p13.11, 
21q22, Xp21.  We also identified 295 inherited CNVs which were either absent or rare in 
published cohorts of control individuals and our in-house control database. Interestingly, 26 
of these inherited variants were recurrent in our patient cohort. Using our genome-wide 
multiplatform approach we identified several loci that may interfere with biological 
pathways disturbed in EA/TEF or VACTERL association patients.  
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Introduction 
Foregut-related anomalies are complex diseases believed to be caused by multiple 
genetic and environmental factors.[1, 2] With a prevalence of 2-3 in 10,000 live births [3] 
Esophageal Atresia (EA) with or without Tracheo-Esophageal fistula (TEF) is one of the 
more common foregut-related anomalies.  Although over half of these patients have EA/ 
TEF as an isolated defect, many also have additional congenital malformations; 23% of them 
have at least two other of the six core defects of VACTERL (Vertebral, Anal, Cardiac, 
Tracheo-Esophageal fistula, Renal, Limb anomalies) association.[4] 
Chromosomal anomalies, including aneuploidies as trisomy 13, 18 and 21, can be 
identified in 6-10% of patients.[2, 5, 6] These aneuploidies and other genetic disorders 
represent the 9-10% of  EA/TEF patients with a confirmed genetic syndrome[7, 8], and 
there is a strong suspicion that genetic factors are involved in the remainder. One of the 
reasons for this is that EA/TEF is a variable feature of many monogenetic syndromes 
associated with single base-pair mutations. Other VACTERL-associated anomalies have a 
large overlap with these syndromes, e.g. Feingold syndrome (MYCN), CHARGE syndrome 
(CHD7), Anophthalmia-Esophageal-Genital (AEG) syndrome (SOX2) and Fanconi anemia. 
[2, 9] Non-syndromic TE is usually a sporadic findings, although there are reports 
describing familial recurrence.[10-12] 
Few studies describe genetic aberrations in EA/TEF and VACTERL association. 
[13, 14] EA/TEF is reported in patients with aneuploidy, structural chromosomal 
anomalies, single-nucleotide mutations and de novo Copy Number Variations (CNV).[5, 15] 
These CNV, which are detected with microarray technology, have a well-established role in 
congenital anomalies: this technique has identified many genes or loci involved in 
developmental defects.[16-18] CNV can contribute to disease etiology in several genetic 
syndromes which have TE anomalies as a variable feature such as Feingold syndrome[19], 
22q11 deletion syndrome, Fanconi anemia[20], CHARGE syndrome[21], alveolar capillary 
dysplasia[22] and mandibulofacial dysostosis.[23] Despite sporadic evidence that de novo 
CNV can play a role in non-syndromic EA/TEF and the VACTERL association[24]  no 
frequently recurring risk loci have yet been identified.  
  
57 
  Recurrent CNV in EA/TEF 
We hypothesize that de novo genomic and inherited rare recurrent CNV could 
predispose to EA/TEF and VACTERL association. These CNV harbor one or more disease-
related genes or phenotype-modifying factors. We describe the variation detected in our 
cohort (n=268) enabling us to identify several rare recurring and de novo CNV. Our 
multiplatform array screening provides insight into the biological pathways and disease 
mechanisms involved.  
Methods 
Study design 
Candidate genes for rare genetic conditions are usually identified using 
homozygosity mapping or linkage analysis (and subsequent sequencing of these loci) in 
large families with several affected and unaffected relatives. Unfortunately, because familial 
recurrence is extremely low in EA/TEF [25, 26] we had to use a different strategy to test 
our hypothesis. Our strategy was based on three assumptions: (1) CNV are usually 
considered to be causal for the abnormal phenotype in congenital anomalies if this CNV is 
absent in the parents of the affected individual and if it targets relevant genes. (2) Copy 
number variation recurrent in single cases could indicate loci harboring genes mutated or 
otherwise affected in larger disease cohorts. (3) Although a CNV is inherited, it could act as 
a modifier or in a multiple hit model if it has an extremely low population frequency and is 
also seen more than once in patients with a rare disease.  
Patient cohort 
This research was approved by the Medical Ethical Review Boards of Erasmus MC - 
Sophia Children’s Hospital (Rotterdam, NL) and  Baylor College of Medicine (Houston, 
USA). Patients with EA/TEF and VACTERL associated anomalies were identified from the 
medical records and/or referral to clinical geneticists. We reviewed these records;  patients 
with a confirmed genetic syndrome or chromosomal aberration, were excluded from further 
analysis. After retrieval of parental informed consent, blood was drawn from 268 patient and 
their parents. Two hundred and thirty nine patients were treated in the Erasmus MC- 
Sophia, twenty eight in the Baylor College of Medicine. The major abnormalities of each 
patient are available on request, the phenotypes of patients with de novo CNV (table 2) and 
the patients with overlapping CNV and phenotypes are described in supplementary table 2. 
VACTERL patients were defined as those with three or more anomalies of the VACTERL 
core components with the diagnostic criteria described earlier [7], and absence of a 
confirmed genetic syndrome.[27]  
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DNA isolation  
DNA for genomic analysis was extracted from peripheral blood and fibroblast cells 
with the Puregene DNA purification kit (Gentra Systems, USA) or QIAamp DNA Blood 
Midi Kit. (Qiagen, Inc., Hilden, Germany) DNA was extracted from Formalin Fixed Paraffin 
Embedded (FFPE) samples (thymus tissue) as instructed by the supplier of the microarrays 
(Agilent Inc., San Diego, CA, USA). DNA quality was evaluated with the Thermo Scientific 
Nano Drop 2000 (Thermo Fisher Scientific Inc., Waltham, USA), and dsDNA quantity with 
the Quant-iT™ PicoGreen ® dsDNA kit. (Invitrogen, Carlsbad, CA, USA). A total of 200 
ng dsDNA was used as input for microarray analysis.  
Detection of genomic variation 
Karyotyping was done according to standard analytical methods. All DNA was 
tested for subtelomeric aberrations with Multiplex ligation-dependent probe amplification 
analysis, using the P036E1 and P070A2 Salsa telomere kits (MRC Holland, Amsterdam, the 
Netherlands) as published previously. [28] 
High-resolution analyses were performed using single-nucleotide polymorphism 
(SNP) microarrays (Illumina Inc., San Diego, CA, USA and Affymetrix Inc. Santa Clara, CA, 
USA) and CGH (Agilent Inc., San Diego, CA, USA ) oligonucleotide-based arrays using 
standard protocols. Micro-array analysis was initially performed using three types of array 
chips  (GeneChip Human Mapping 250K Nsp, 12-HumanCytoSNP DNA Analysis 
BeadChips v1-v2.1, and Agilent Human Genome CGH 105K and 244K), later on these were 
replaced by chips with a higher resolution (Illumina Human 610-Quad Beadchip and 
Illumina HumanOmniExpress BeadChip, Illumina Infinium CytoSNP-850k BeadChip and 
Agilent SurePrint G3 Human CGH 1M Oligo Microarray Kits G4411B/G4447). Most of 
the patients were screened with more than one array chip type.  
We generated normalized output with Feature Extraction software (version 9.1), 
with CGH analytics software (version 3.3.28), with Affymetrix GTYPE v4.1 (Affymetrix, 
Santa Clara, CA) or with Illumina Genomestudio version 2011.1, depending on chip type.  
(Illumina, San Diego, CA, USA)   CNVs in patient samples were visualized as log2-Ratios 
(Log2R) detected through comparison of patient probe intensity data with those of a virtual 
reference set of 400 female CEU samples (SNP-array) or by comparison with sex matched 
controls of unaffected, unrelated individuals or reference DNA. (Promega Corporation, 
Madison, WI) 
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Analysis settings 
We visualized SNP-array Copy Number State (Log2R) and allelic ratio (B-Allele 
Frequency, BAF) in Biodiscovery Nexus CN7.5  (Biodiscovery inc, Hawthorne, CA, USA) 
This program estimates SNP array copy number state using the SNP-FASST2 
Segmentation algorithm, a Hidden-Markov-Model -based segmentation algorithm that uses 
a combination of the BAF and LogR states to determine copy number and allelic segments.  
Segmentation significance threshold was set at 5.0E-7 with a minimum of 5 probes per 
segment and a maximum probe spacing of 1000kb.  The log2R-ratio thresholds were set at 
+0.18 (single copy gain), -0.18 (single copy loss), 0.4 (two or more copy gain) and -1.1 
(homozygous loss). The Homozygous Frequency/ Homozygous Value/ Heterozygous 
Imbalance Threshold were set at 0.95/0.8/ 0.4. The minimum LOH length was set at 100kb 
and minimum SNP probe density, at 10 probes/Mb.  Gender correction was used with a 3:1 
sex chromosome gain threshold of 1.2 and a 4:1 sex chromosome gain threshold of 1.7. 
Log2R ratios of CGH-array results were determined with the ADM2 algorithm with 
filtering options of a minimum of 3 probes and abs. (log2Ratio) >0.3. Each segment 
deviating from the normal situation was reviewed by visual inspection in Nexus CN 7.5. 
During the course of this study, the genome build switched from build hg18 to hg19. Not all 
arrays-chips could be re-processed or re-analyzed in the new genome build. Detected 
regions were transformed using the UCSC lift-over tool. Re-analysis of SNP-array in the 
new genome build, improved segmentation and waving correction algorithms resulted in the 
loss of several low confidence CNV calls.  
Validation of microarray results 
The frequency of each individual CNV in our cohort was compared with CNV 
frequency at that locus in the Toronto Database of Genomic Variants [29],  the Copy 
Number Variation project at the Children's Hospital of Philadelphia [30] and an in-house 
control database of common copy number variations found in unaffected individuals. 
Genomic changes were considered to be a private CNV if similar changes were absent, and to 
be a rare CNV if their frequency was less than 0,25% in these databases. All CNV above this 
last threshold were considered to be common polymorphisms.  
We used different array chips in this experiment, each with different marker spacing, 
distribution and content.  Therefore, we set a size CNV restriction threshold of minimum 
30kb for single events and 10-30kb, depending on array type and probe content and spacing, 
if there were multiple CNVs affecting the same locus in our patient cohort. We only 
confirmed CN state and inheritance pattern of unique and rare CNV if their size exceeded 
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the restrictions thresholds and contained genes. Similar to the size settings, if a CNV did not 
contained genes it was only further examined when there were multiple CNVs affecting the 
same locus.  
To confirm the de novo results, patient and parental CN quantification was done by 
either additional SNP array, Real Time Quantitative PCR, Fluorescence In Situ 
Hybridization (FISH) and/or Multiplex Amplicon Quantification (Multiplicon N.V., Gent, 
Belgium). Two Primer pairs for qPCR were designed within the possible CNVs using 
Primer Express Software v2.0 (Applied Biosystems, Foster City, CA, USA), absence of SNPs 
in primer sequences confirmed in dbSNP (build 135) and specificity of amplified region 
determined with the University of Santa Cruz (UCSC) in sillco PCR and melting-curve 
analysis. Primer pairs with repeats in their resulting amplicon, according to CENSOR repeat 
masker[31] were excluded. QPCR experiments were performed using a Lightcycler 1.5 
instrument and LightCycler FastStart DNA Master SYBER Green I kit with C14ORF145 
as a control locus. (Roche Molecular Diagnostics, Indianapolis, IN, USA) Each sample, 
including the no-template control (NTC) and control DNA, was run in triplicate. Locus 
exon 4 of the KIAA1279-gene was used as a control.[11] Cut-off values of <0.7 were used 
for deletions and values of >1.3  for duplications. For FISH confirmation, BAC-clones were 
selected from the UCSC genome browser and ordered from BACPAC Resources. After 
isolation of the BAC-DNA, the probes were amplified, labeled and used for FISH, according 
to standard protocols and described earlier.[32] 
The MAQ assay is a PCR-based-amplification method which uses 6 primer pairs on 
different loci for sample-internal copy number normalization, maximal 5 CNV specific 
primer pairs developed with the manufacturers’ software package, and one type of FAM 
labeled primer specific to the sequence-tagged forward primers to amplify 20ng of dsDNA 
input. The DNA of 4 unaffected, unrelated individuals is used as sample-external copy 
number normalization. We amplified the DNA according to the manufacturer’s protocol in a 
thermocycler with a heated lid, and analysed the resulting Fam-labelled amplicons of 
patient, parental and CEU controls on an automated sequencer (ABI 3730XL, Applied 
Biosystems, Foster City, CA, USA). This capillary electrophoresis step separates fragments 
on the basis of their length, these differences in amplicon length make multiplexing possible. 
The differences in fluorescence intensity reflect copy number state and are visualized in the 
MAQ-S analysis tool (Multiplicom Inc., Niel, Belgium) which compares amplicon size to the 
Genescan LIZ 500 size standard and normalizes copy number state to the internal amplicons 
and 4 external references.   
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Results 
Patient cohort 
In this study we determined the copy number profile of 268 patients of the Erasmus 
MC Rotterdam and Houston Baylor College of Medicine cohorts of Esophageal Atresia 
patients. Supplementary table 2 describes the patients’ phenotypes, which have recurrent 
CNV. We performed CNV profiling on 268 out of 583 patients of the combined cohorts. A 
total of 60 had EA/TEF as an isolated defect, 86 had one other additional major VACTERL 
associated defect, and 122 patients fulfilled all of the criteria or VACTERL association.  This 
means that 77.6 % of patients had additional, predominantly VACTERL associated, major 
congenital anomalies.   
Screening our large cohort with high-resolution oligonucleotide and SNP 
microarrays led to the identification of many copy number polymorphisms already described 
in unaffected individuals (data not shown).[29, 30, 33] Comparison of the recorded de novo 
CNV data with known EA/TEF loci from animal models or syndromic EA/TEF yielded 
five loci of interest. One de novo CNV covering FRAS1, a small intronic GLI3  deletion, a 
WHSC1 deletion, and two previously described FOXF1 regulatory site deletions.[22] 
We observed 295 rare and private inherited CNV (~1 per patient), widely distributed 
over the genome. Interestingly, our analysis identified 26 rare CNV observed in multiple 
patients, 14 patients had de novo CNV of which three patients had more than one de novo 
CNV.  Several, not all, of these loci affect genes with a possible role in the abnormal 
phenotype. Table 1 depicts the de novo CNV seen in the Erasmus MC-Sophia and Baylor 
College of Medicine TE-cohorts.  Three examples of de novo CNV are depicted in figure 1, 2 
and 3. Recurrent CNV are visualized in figure 4 and described in online supplementary table 
1, single rare and private CNV regions are available on request. In addition to the current 
described genomic aberration, two patients have a chromosomal anomaly, twenty-two 
patients have a whole chromosome duplications: three have Triple X syndrome, 11 have 
Down syndrome, seven have trisomy 13 and one has trisomy 18.[34]  
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 Figure 1. De novo deletion on chromosome 13q21. Note the loss (red dots) in the patients logR track and 
the loss of Heterozygosity (yellow dots) in the patients B-allele frequency (BAF) plot.  
 
Figure 2. De novo duplication on chromosome 8p22. Note the gain (blue dots/arrow) in the patients logR 
track and allelic imbalance (purple dots/arrow) in the patients B-allele frequency (BAF) plot.  
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 Figure 3. De novo deletion ranging from chromosomal band 7q35 to 7q36.3. Note the loss (red) in the 
patients logR track and the loss of Heterozygosity (yellow) in the patients B-allele frequency (BAF) plot. 
Lower panel depicts the de novo 16p13.11 duplication in the same patient. Note the gain (blue) in the patients 
logR track and allelic imbalance (purple) in the patients B-allele frequency (BAF) 
  
Figure 4 Overview of de novo deletions (red arrows), de novo duplications (blue arrows) and recurrent 
inherited losses (red colored chromosomal bands) and gains (blue) in the Erasmus MC-Sophia and Baylor 
College of Medicine TE cohorts.
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Type Cytoband Chromosome Region Length (Candidate) genes Reference 
Gain 
Gain 
1q41 
8q24.3 
chr1:217879151-218010441* 
chr8:144940222-145060112* 
131290 
119890 
SPATA17 
PLEC-1, PARP10 [35] 
Loss 2q33.2q35 chr2:204,394,564–219,189,331 14794767 MAP2 [36] 
Loss 3q28 chr3:187913191-188468682* 555491 LPP [37] 
Loss 4p16.3 chr4:1889113-1966468 77355 WHSC1 This manuscript 
Gain 
Gain 
4q21.1q21.21 
21q22.2 
chr4:78968955-78988693 
chr21:40100880-40154748 
19738 
53868 
FRAS1 
LINC00114 This manuscript 
Loss 4q35.2 chr4:189025846-189042743 16897 TRIML2 This manuscript 
Loss 5q11 chr5:51149893-54965591* 3815698 Multiple [38] 
Loss 6q23.2 chr6:134730991-135020544* 289553 AJ606330, LOC154092, LINC01010, AJ606331 This manuscript 
Loss 7p22 chr7:6123758-6139997* 16239 Distal to USP42 This manuscript 
Loss 7p14.1 chr7:42125411-42131780 6369 GLI3-intronic This manuscript 
Loss 
Gain 
7q35q36.3 
16p13.11 chr7:143,839,360-159,138,663 15299304 Multiple incl. SHH, MNX1 This manuscript 
Loss 7q35q36 chr7:147683847-159088636* 11404789 SHH, MNX1 [39, 40] 
Gain 
Loss 
Loss 
8p22 
11p14.3 
15q21.3 
chr8:17625479-17813225 
chr11:21853276-22016176 
chr15:53994879-54022499 
187746 
162900 
27620 
FGL1, LFIRE1, MTUS1, PCM1 
. 
WDR72 
This manuscript 
Gain 8q13.1 chr8:66955527-66980813* 25286 DNAJC5B This manuscript 
Loss 11q13.1q13.2 chr11:65508902-67473140* 1964238 GSTP1 [41] 
Loss 13q12.11 chr13:22688792-22981935 293143 AK054845, LINC00540 This manuscript 
Loss 16q24.1 chr16:85979509-86361236* 381727 LINC01082, LINC01081 [22] 
Loss 16q24.1 chr16:86202409-86286888* 84479 LINC01082, LINC01081 [22] 
Gain 17q12 chr17:34727386-36297053** 1569667 AATF, TADA2L, HNF1B [42] 
Loss 20q13.33 chr20:60238426-60895697* 657271 GTPBP5 [43] 
Null# Xp21.11 chrX:22961251-23106879 145628 DDX53, LOC100873065 This manuscript 
 
Table 1. De novo CNV in the Erasmus MC-Sophia and Baylor College of Medicine TE cohorts and de novo CNV described in literature. *Region from hg18-hg19 
liftover, ** Region from hg17-hg19 liftover, #nullizygous
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Discussion 
We hypothesized that both de novo genomic and inherited rare recurrent CNV could 
predispose to, or modify the phenotype of, EA/TEF and VACTERL association patients. 
We indeed identified several de novo, unique and rare recurring CNV with this multiplatform 
micro-array cohort screening. Genes affected by these CNV could help to give insight in 
disease mechanisms and biological pathways involved in EA/TEF and VACTERL 
association disease etiology. CNVs larger than 500 kb are not frequent in our genome, in the 
general population ~ 9% of individuals have a CNV larger than 500kb of which only 3% is 
larger than 1 Mb. The  de novo rate of these large CNV is estimated at 1.2 x 10-2 per 
generation.[44, 45] We identified 295 rare and private inherited CNV larger than 30kb (~1 
per patient), widely distributed over the genome. Interestingly, our analysis identified 26 of 
those rare CNV in multiple patients. Fifteen patients had de novo CNV, two patients had 
multiple putative de novo CNV. All de novo CNV was non-recurrent, except two previously 
published deletions on chromosome 16q24.1[22] However, de novo CNV had overlap with 
structural chromosomal anomalies previously described in EA/TEF.[5, 15]   
Aneuploidies and structural chromosomal anomalies 
These  chromosomal anomalies and aneuploidies are however, not frequent observed 
phenomena, except for  those seen in genetic syndromes such as trisomy 13, 18 or 21. Some 
of the recurrent structural chromosomal anomalies have overlap with the de novo CNV seen 
in our study. For instance, 46,XY,der(4)t(3;4)(p25;q35)mat[46] has overlap with the 4q35 
deletion and 46,XX,-13,+der(18)t(13;18)(q12;p11.2)[47] has overlap with the 13q12 
deletion. Genes in these overlapping regions could have impact on EA/TEF aetiology.  
Unfortunately, little is known about the genes within the smallest region of overlap  For 
instance, the tripartite motif family-like 2 gene (TRIML2), the only gene affected by the 
4q35 de novo deletion is expressed in whole brain and in lymphoblast B-cells. These type of 
B-box and SPRY domain containing proteins might play a role in early embryonic 
development[48], but the exact role or mechanism is unknown. 
Balanced structural chromosomal anomalies are not detected by micro-array and, 
since this technology has replaced high resolution GTG-banded karyotyping as a first tier 
diagnostic procedure[49], these will not be detected as much as in the past.  Inherited, 
balanced translocations are seen in EA/TEF patients. For example, Cetinkaya and co-
workers [50] describe a familial translocation (1;13)(p8;q12) in a patient with esophageal 
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atresia and a translocation 46,XY,t(5;10)(q13;q23)pat, inherited from an unaffected father 
was described by Felix and co-workers.[5]  
Rare recurrent inherited CNV 
Inheritance of a single CNV from a healthy parent is generally regarded as a benign 
variant. These rare and private are proposed to arise after replication errors.[16] These 
CNV have such a low population frequency that they have either arisen recently and have no 
biological meaning or are somehow detrimental and are virtually extinct from the 
population. Interpretation of these CNV is difficult, for instance they can be ancestry 
specific[51] or have only modifying role, like the 1q21 deletion in TAR syndrome [52] or 
the 16p21.1 micro-deletion in patients with developmental delay.[53] Other factors 
complicating interpretation of rare and private inherited CNV are variable gene 
expressivity, incomplete penetrance, skewed X-inactivation and/or mutations elsewhere in 
the genome.[16]  
Recurrent inherited rare or private CNV and an overlapping patient phenotype 
extending trachea-esophageal anomalies are 2p16 gain (patients have EA/TEF and 
anorectal malformations), 3q21.1 gain (patients have EA/TEF and cardiac anomalies), 7p21 
loss, (patients have EA/TEF and cardiac anomalies), 8p22 gain (patients have EA/TEF and 
vertebral anomalies), 11q21 loss (patients have EA/TEF, anorectal and genitourinary 
anomalies), a 22q11 duplication (patients have EA/TEF, renal anomalies) and PAR1 
duplication (patients have EA/TEF, thumb anomalies). Previously we have described these 
last two patients with inherited duplications of Short stature HOmeoboX-containing gene 
(SHOX) within the X/Yp PAR1 region.[34] We proposed that these CNV contributed to 
the patients’phenotypes and might be a determinant in the secondary phenotypical 
anomalies.  
Reduced penetrance of these CNV is also described in patients with EA. Since the 
introduction of micro-array technology reports describing chromosomal rearrangements, of 
which detection is often dependent on karyotyping,  are less frequent.  Cetinkaya describes 
an inherited translocation involving chromosome 1 and 13, t(1;13)(p8;q12), in a patient with 
esophageal atresia. [50] His translocation was inherited from a healthy parent. We also 
observed incomplete penetrance in our cohort:  one patient with an inherited 22q11 
microduplication syndrome had a severe phenotype; all 6 VACTERL features were present. 
In contrast her mother, with similar 22q11 duplication, had only mild dysmorphic features. 
An overlapping duplication has also been described as a de novo micro duplication [54] and 
67 
  Recurrent CNV in EA/TEF 
in a translocation.[55] This regions overlaps the TBX1 gene, , a dosage sensitive gene, 
responsible for the phenotype in DiGeorge syndrome [MIM 188400][56] the associated 
gene in the 22q11 deletion syndrome. Deletions of this region have been observed in 
patients with trachea-esophageal anomalies.[57, 58] 
Yet another, explanations for an absence of phenotypical characteristics is variable 
expressivity. For instance, while a part of their phenotype overlaps, Faguer describes 
differences in expression of a micro-duplication. [59] Faguer reports a father with bilateral 
vesico-ureteric reflux and renal hypodysplasia and his child with left multicystic 
hypodysplastic kidney with megaureter, vesico-ureteric reflux and bladder diverticulae and 
esophageal atresia, both having a duplication harboring the HNF1B gene mutated in one 
fifth of patients with hypodysplastic kidneys.[59] 
Rare and private CNV could have a subclinical phenotype in the patients parents. Or 
on their own they are not enough to disturb normal development, but act in a so-called two-
‘hit’ model. Two factors, genetic or non-genetic, tilt the balance from normal to abnormal 
development.  This two hit hypothesis, first proposed by Knudson in tumor genesis[60], 
states that multiple factors disturb a similar biological process. The co-occurrence of these 
rare CNV in a cohort of a rare, heterogeneous, developmental defects as EA/TEF could be a 
chance effect, representing the increased screening of patients compared to unaffected 
individuals. Although their virtual absence in large cohorts such as the database of genomic 
variants suggests otherwise. Proving polygenetic inheritance is difficult. Recently Chan and 
co-workers describe this phenomenon in schizophrenia and diabetes[61], but they also point 
out false positive results in GWAS association studies. 
If these rare CNV are modifiers and second, genetic, hits are present than these will 
most likely be gene mutations. Tracheo-esophageal anomalies are frequent in single gene 
disorders and perhaps diagnosis of these disorders is difficult due to the changed 
phenotypical characteristics of patients carrying both the modyfing factor and the gene 
mutation. Duplications might be rescue mechanisms in which a normal copy is duplicated to 
balance out a copy affected by a mutation, resulting in increased gene expression[62] or 
deletions might worsen an otherwise less severe condition.  
De novo CNV in this study cohort 
A CNV is most likely to be pathogenic if it is absent in both unaffected parents and 
affects meaningful genes.  These (putative) de novo variants were observed at two 
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previously published (5q11[38] and 16q24.1[22]), four loci affecting genes of known 
syndromes (4p16.3, 4q21, 7p14.1, 7q36) and  twelve new loci: i.e.  4q35, 6q23.2, 7p22, 8p22, 
8q13.1, 11p14, 15q21, 13q12.11, 16p13.11, 21q22, Xp21.  Excluding aneuploidies and 
confirmed genetic syndromes this would total the frequency of patients with de novo CNV at 
5.2% and the de novo rate of rare and private CNV at 6.1%. Although this de novo rate is 
increased compared to the general population, we describe much smaller CNV.   Assuming 
variation increases with decreasing variation size, these numbers are not as different from 
the population background as seen in Congenital Diaphragmatic Hernia[63] or intellectual 
disability.[64] Moreover, the de novo CNV seen in EA/TEF is in general non-recurrent and 
does not always affect genes with clear association to abnormalities seen in patients. 
Therefore, these de novo CNV could very well be non-causal. 
Two de novo deletions involve twin pregnancies. The first, male patient SKZ_2038, 
born 2nd from a monochorionic diamniotic pregnancy,  with reduced hearing, duodenal and 
esophageal atresia and trachea-esophageal fistula. SALL1 mutation screening was negative. 
Wolf-Hirschhorn syndrome patients have seizures, typical craniofacial malformations and 
facial dysmorphisms. It is a contiguous gene syndrome, with variable deletion sizes. The 
characteristic facial features are not always present in patients with smaller deletions.[65] 
In patient SKZ_2038 only the WHSC1 gene was deleted. Many syndromes have TE 
anomalies as an incidental finding[4]  and now this syndrome can be added to the list. His 
brother did not have trachea-esophageal anomalies, but will be screened for Wolf-Hirschorn 
features  later in life. The twin of patient SKZ_1662 patient, with a 13q12.11 de novo deletion 
died in utero. No information was available regarding observed congenital anomalies. The 
female index patient has EA/TEF, tracheal stenosis, a sacral abnormality and her left kidney 
was abnormaly positioned in the midline. Within this region one transcribed mRNA 
(AK054845) and one lncRNA (LINC00540) are located. No information was available on 
their biological role. At approximately 500kb distance the FGF9 gene is located. Mice fgf9 
knockouts can have a wide variety of abnormalities, including developmental problems of 
the skeletal, respiratory and the gastrointestinal system.[66] Perhaps a FGF9 regulatory 
region is affected by the de novo deletion.  
The DNA of female patient SKZ_1307 was previously analyzed on a low-resolution 
beadchip. reanalysis, transformation to genome build hg19 and comparison to high 
resolution SNP-array data of his parents hinted at the presence of a putative de novo FRAS1 
deletion.  Patients with Fraser syndrome can have VACTERL associated anomalies [27] 
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and homozygous recessive or compound heterozygous FRAS1 mutations are characterized 
by cardiac, renal and genitourinary malformations as well as crypophthalmos and 
syndactyly.  This patient has long fingers and toes, anal atresia and EA/TEF, none of the 
typical Fraser syndrome associated anomalies.  However, this patient has a de novo 
duplication, which could be a contributing factor in this uncharacteristic phenotype. 
Moreover, an additional putative de novo gain in copy number is present in this patient 
which affected a long non-coding RNA, LINC00114,  on chromosome 21.  
The importance and biological impact of most detected de novo deletions is uncertain. 
For instance, the de novo 7p22 deletion does not affect genes. It is located distal to the 
USP42 gene, which might involve in p53 stability.[67] A 6q23.2 deletion in a patient with 
dysmorphic features and a ventricular septal defect also did not involve any genes. However 
several transcribed noncoding RNAs are affected and these might influence the expression 
of important genes. For instance, at 300 kb distance the TCF21 gene is located, a gene that 
interacts with TBX1.[68] Yet another, de novo DNAJC5B duplication, also observed three 
additional times as an inherited duplication in this cohort, has no evident relationship with 
the patients’ phenotype.  Female patient SKZ_416 has EA/TEF, hydronephrosis, large ears, 
palpebral fissures slant down, thin fingers and long phalanges. The patients with an 
inherited deletion had EA/TEF and cranial malformations (SKZ_641) or isolated EA/TEF 
(SKZ_1510 and 1560). In general, DNAJ proteins are involved in protein folding. There is 
no information about the specific role of DNAJC5B in embryonic development.  
TE and de novo CNV described in literature 
Not many de novo CNV, either micro deletions or micro duplications, are described 
in patients with nonsyndromic EA/TEF. Van Binsbergen et al describes a patient with brain 
malformations, micrognathia, esophageal atresia, laryngeal stenosis and intrauterine growth 
retardation [36]This patient has an interstitial  deletion in chromosomal bands 2q33q35 
and propose that the microtubule associated protein 2 (MAP2) as a candidate gene for the 
brain malformations. Other de novo micro deletions described in literature are a 20q13.33 
micro deletion in a boy with EA/TEF, cardiac and genital anomalies[43], a 11q13.1q13.2 
micro deletion in a boy with EA/TEF, developmental delay and minor facial dysmorphisms 
[41] and a deletion of the long arm of chromosome 7q, including SHH, in a patient with 
multiple congenital anomalies including esophageal stenosis.[39]  
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LIM domain containing preferred translocation partner in lipoma (LPP) is deleted in 
an patient with esophageal atresia with tracheoesophageal fistula, hypospadia, cardiac-, 
renal- and rib anomalies.[37]  Screening our cohort for abnormalities in this gene did not 
result in additional cases.[69]  
Micro duplications have also been described. Recently Smigiel et al describe a 17q12 
duplication in a boy with EA/TEF, anal atresia, sacral bone defect and cryptorchidism. 
Hilger and coworkers describe two micro duplications; one at 1q41 in a male with vertebral, 
anorectal, cardiac, trachea-esophageal and renal malformations and the other at 8q24.3 in a 
boy with vertebral, anorectal, trachea-esophageal, renal and genitourinary 
malformations.[35]   
Concluding remarks 
The micro-arrays used in these experiments increased in resolution over the years. 
Not all samples are analysed at the same resolution. We can conclude that relatively large  ≥ 
30- 50kb de novo CNV do not play a major role in EA/TEF disease etiology. New platforms 
with higher resolutions, such as the Affymetrix HD GeneChip have resolutions up to 2kb. 
Whole genome sequencing will, eventually, bring down the resolution to the base pair level.  
Re-evaluating our cohort with these techniques could increase the level of detected de novo 
variation. Large cohorts of unaffected individuals will need to be screened with these 
techniques in order to have a clear picture about the pathogenic nature of small CNV. Also a 
better understanding of the impact of (small) CNV on regulatory elements, insulators and 
other untranscribed DNA segments is necessary. As previously shown with the lncRNA 
deletions in patients with EA/TEF alveolar capillary dysplasia[22] these CNV can have a 
severe impact. A better understanding of where and how much variation is tolerated in our 
genomes (without an immediate pathogenic impact on developmental) is necessary because 
else an increase in resolution to detect CNV may lead to data interpretation problems, such 
high false positive rates and the discovery of smaller CNVs of unknown clinical significance. 
[70] Perhaps we should even first focus on those parts of healthy genomes that are never 
affected by CNV.[71]  
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Although we screened a large number of patients of our cohorts, the number 
represented approximately half. Isolated EA, although present in half of patients, was 
severly underrepresented in this screening. Also, as time progressed (we have collected data 
since 1988) more and more genetic syndromes were discovered. Screening our and other 
“historical” cohorts may be necessary to determine the exact impact of genetic factors. If 
such an endeavor is undertaken, it may be wise to use (the same) high density SNP-arrays or 
perform whole genome sequencing. Using genotyping information, genome wide association 
studies (GWAS) and homozygosity mapping in outbred individuals has proven to be 
successful in other congenital anomalies.[72-74] GWAS and homozygosity mapping 
require large sample sizes to obtain sufficient statistical power especially in heterogeneous 
conditions as VACTERL association.  
We hypothesized that de novo genomic and inherited rare recurrent CNV could cause 
or predispose to EA/TEF.  The data presented in this study provides limited evidence for a 
moderate impact of de novo CNVs in EA/TEF and VACTERL disease etiology, ~5%.  
Although we found several de novo and rare recurring changes, they do not point to one 
specific pathway or biological process. In addition comparison of the recorded overlapping 
CNV data with known EA/TEF loci from animal models or recorded chromosomal 
anomalies yielded no new candidates. Although predisposing loci are present (e.g. SHOX, 
22q11dup) and probably influence or modify patient phenotype in sporadic occasions, their 
individual impact on patient population phenotype is moderate.  
To conclude, there is a contribution of genetic factors to EA/TEF and the 
VACTERL association etiology. With aneuploidy and structural chromosomal anomalies 
(~4%), single base pair mutations (~6 %) now Copy Number Variation (~5 %) totals the 
genetic contribution to about ~15%. Whole genome and whole Exome DNA sequencing 
large patient cohorts will reveal new DNA variations increasing the contribution of genetics 
and our knowledge of EA/TEF and VACTERL disease etiology.  
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Casenr Gender Major anomalies 
148-04-01 NA NA 
148-09-01 NA NA 
148-10-01 NA NA 
SKZ_0060 M EA/TEF, upper limb anomalies, dysmorphisms 
SKZ_0282 M EA/TEF, renal anomalies 
SKZ_0374 M EA/TEF, cardiac anomalies, renal anomalies, upper limb anomalies, genital anomalies 
SKZ_0399 M EA/TEF, anal anomalies, upper limb anomalies, genital anomalies, dysmorphisms 
SKZ_0416 F EA/TEF, renal anomalies, dysmorphisms 
SKZ_0641 M EA/TEF, cranial abnormalities, deafness 
SKZ_0671 F EA/TEF, vertebral anomalies, cranial anomalies, dysmorphisms 
SKZ_0708 F EA/TEF, vertebral anomalies, renal anomalies, ureteral atresia, genital anomalies 
SKZ_0744 F EA/TEF, vertebral anomalies 
SKZ_0773 F EA/TEF, vertebral anomalies, anal , genital and ear anomalies, renal anomalies, upper limb anomalies, cleft lip+jaw+palate, duodenal atresia,  
SKZ_0796  EA/TEF, pyloric stenosis 
SKZ_0832 M EA/TEF, vertebral anomalies, anal anomalies, renal anomalies, genital anomalies, lower limb anomalies 
SKZ_0856 M EA/TEF, anal anomalies, cardiac anomalies,vertebral anomalies, dysmorphisms 
SKZ_1032 M EA/TEF, cardiac anomalies 
SKZ_1035 F EA/TEF, cardiac anomalies, brain anomalies, cranial anomalies, dysmorphisms 
SKZ_1150 F EA/TEF + cardiac anomalies 
SKZ_1307 F EA/TEF, anal anomalies, upper limb anomalies 
SKZ_1415 M EA/TEF, cardiac anomalies, upper limb anomalies, duodenal atresia, dysmorphisms, spleen anomalies, pancreas  andgenital anomalies 
SKZ_1432 M EA/TEF, anal anomalies, renal anomalies, urethral fistula and atresia, genital anomalies 
SKZ_1497 M EA/TEF, cardiac anomalies 
SKZ_1508 M EA/TEF, upper limb anomalies, cardiac anomalies, dysmorphisms 
SKZ_1516 F EA/TEF, cardiac anomalies 
SKZ_1550 M EA/TEF, anal anomalies, renal anomalies, urethral anomalies 
SKZ_1730 M EA/TEF, anal anomalies, cardiac anomalies, upper limb anomalies, cranial anomalies, genital anomalies 
SKZ_1780 M EA/TEF, vertebral anomalies, anal anomalies, cardiac anomalies, renal anomalies, upper+lower limb anomalies 
SKZ_1790 F EA/TEF, cardiac anomalies, anal atresia,  
SKZ_1810 M EA/TEF, vertebral anomalies, cardiac anomalies, renal anomalies, upper limb anomalies, brain anomalies 
SKZ_1821 M EA/TEF, cardiac anomalies, genital anomalies, ear anomalies 
SKZ_1825 M EA/TEF, cranial anomalies 
SKZ_1900 M TEF, lung hypoplasia/agenesis 
SKZ_1910 M EA/TEF, cardiac anomalies 
SKZ_1988 F EA/TEF, anal anomalies 
SKZ_2010 M EA, ACD 
SKZ_2035 F EA/TEF, anal anomalies, renal anomalies 
SKZ_2041 M EA/TEF, cardiac anomalies, renal anomalies 
SKZ_2064 M TEF, cardiac anomalies 
Supplementary table 2 Major affected organ systems in patients with recurring CNV. Not depicted patients have isolated EA 
and/ or TEF 
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  2.3
Structural and numerical 
changes of chromosome X in 
patients with esophageal 
 atresia 
 
 
 
 
Adapted from: 
Structural and numerical changes of chromosome X in patients with esophageal atresia.  
Erwin Brosens, Elisabeth M. de Jong, Tahsin Stefan Barakat, Bert H Eussen, Barbara D’haene4, Elfride de 
Baere, Hannah Verdin, P, Pino P Poddighe, Robert-Jan Galjaard, Joost Gribnau,  Alice S Brooks, Dick Tibboel, 
and Annelies de Klein. Eur J Hum Genet. 2014 Jan 8; Epub ahead of print 
 
Abstract 
Esophageal atresia with or without tracheo-esophageal fistula (EA/TEF) is a 
relatively common birth defect often associated with additional congenital anomalies 
as vertebral, anal, cardiovascular, renal and limb defects: the so-called VACTERL 
association. Little is known about causal genetic factors. Rare case- reports of gastro-
intestinal anomalies in children with triple X syndrome prompted us to survey the 
incidence of structural and numerical changes of chromosome X in patients with 
EA/TEF. 
All available (n= 269) karyotypes of our large (321) EA/TEF patient cohort 
were evaluated for X-chromosome anomalies.  If sufficient DNA material was 
available,  we determined genome-wide copy number profiles with SNP-array and 
identified subtelomeric aberrations on the difficult to profile PAR1 region using  
telomere-MLPA. Additionally we investigated X-chromosome inactivation (XCI) 
patterns and mode of inheritance of detected aberrations in selected patients. 
Three EA/TEF patients had an additional, maternally inherited X 
chromosome. These three females had normal random XCI patterns. Two male 
EA/TEF patients had small inherited duplications of the XY-linked SHOX  locus. 
Patients were small for gestational age at birth (<P5) and had additional, mostly 
VACTERL associated,  anomalies. 
Triple X syndrome is rarely described in patients with EA/TEF and no 
duplications of the SHOX gene were reported so far in these patients. Since normal 
patterns of XCI were seen, over-expression of X-linked genes that escape XCI, such as 
the SHOX gene, could be pathogenic by disturbing developmental pathways. 
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Introduction 
Esophageal atresia (EA) with or without tracheo-esophageal fistula (TEF) is a 
relatively common birth defect affecting approximately 1:3500 newborns. These 
newborns can have a heterogeneous phenotype, some have EA and/or TEF as an 
isolated defect and others have more anomalies, predominantly VACTERL (Vertebral, 
Anal, Cardiovascular, Tracheo-Esophageal, Renal and Limb) associated. [1]  
EA/TEF is a variable feature in several genetic syndromes e.g. Feingold 
(MYCN), CHARGE (CHD7), Anophthalmia-Esophageal-Genital (AEG) syndrome 
(SOX2) and Fanconi anemia. [2] In addition the genetic defects in these syndromes, 
other putative causal genetic aberrations are described in EA/TEF patients. Although 
there are chromosomal hotspots, these aberrations are mostly scattered across the 
genome.[2] 
Structural and numerical chromosome abnormalities affecting sex 
chromosomes have been described in patients with congenital malformations. [3-5] 
These defects are rare in patients with EA/TEF, although EA/TEF is a variable 
feature in patients with Opitz G syndrome (MID1) and VACTERL association with 
hydrocephalus (FANCB)[1, 2] There are several reports describing X-chromosome 
duplication in association with gastro-intestinal anomalies.[6] This prompted us to 
retrospectively evaluate the cytogenetic results in our EA/TEF cohort.  
We identified three patients with a triple X karyotype, strengthening the 
relationship of gastrointestinal anomalies and X-chromosome triplication. In addition 
to classical karyotyping, we examined patient DNA with telomere-multiplex ligation-
dependent probe amplification (MLPA) and micro arrays for structural X-chromosome 
abnormalities. These molecular-genetic studies revealed Short stature HOmeoboX-
containing gene (SHOX) duplications in two additional patients with esophageal 
atresia, tracheo-esophageal fistula and limb anomalies.   
We hypothesize that genes on X and/or genes that escape X chromosome 
inactivation could influence essential developmental pathways in limb and foregut 
development.  
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Patients and Methods 
Patient population 
This study was approved by the Medical Ethical Review Board of Erasmus MC 
- Sophia Children’s Hospital. After retrieving (parental) informed consent, 321 patients 
with EA/TEF, admitted to the department of Paediatric Surgery were included. 
Pregnancy, clinical and follow-up data were extracted from medical charts. Available 
DNA and cell lines of patients (n=180) and parents were collected and used for genetic 
analysis. Patients with a previous confirmed genetic syndrome, known chromosomal 
anomaly and/or pathogenic point mutation were excluded from further molecular-
genetic evaluation. There is weak evidence for an association of EA/TEF with certain 
environmental components [7], however we did not exclude any of the patients in our 
cohort based on these risk factors.  
The database (>100.000 patients) of prenatal and postnatal diagnostics of our 
department of Clinical Genetics  was searched for triple X karyotypes and confirmed 
SHOX duplications. 
Cytogenetic evaluation 
Karyotyping was performed according to standard protocols on either 
lymphocytes from peripheral blood cultures or after amniocentesis.  Karyotyping had 
been performed for 269 of the 321 patients of our cohort, as systematic cytogenetic 
follow-up of patients with congenital anomalies was not done before 1998.  
Multiplex ligation-dependent probe amplification (MLPA) and quantitative PCR 
Not all array chips used had sufficient marker density in the PAR1 region. 
Therefore, we additionally screened for copy number variations in this region with 
MLPA, using the P036E1 and P070A2 Salsa telomere kit (MRC Holland, Amsterdam, 
the Netherlands) as previously described.[8] Genemarker 1.6 (SoftGenetics, LLC, 
State College, PA, USA) was used for data analysis. If duplications of the PAR1 region 
were detected, copy number profiling of the SHOX region was confirmed with a newly 
developed qPCR assay, with 11 amplicons within SHOX and the PAR1 region.[9]  
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Fluorescent in situ hybridization (FISH) 
The target BAC clone for Xp22 (RP11-800K15) and control probes on Xq25 
(RP11-49N19) and 8p12 (RP11-489E7) were selected from the University of Santa 
Cruz (UCSC) genome browser (UC Santa Cruz, CA, USA, assembly march 2006) and 
ordered from BACPAC Resources. (Oakland, CA, USA) After isolation of the BAC 
DNA, the probes were labelled and used for FISH on chromosome preparations from 
patients and parents, according to standard protocols.[10] 
RNA-FISH analysis and immunocytochemistry of human cell lines  
RNA-FISH and immunocytochemistry were performed on fibroblast cell lines 
(>90% confluence) and EBV-transformed lymphocytes, as previously described by 
Jonkers et al [11, 12] using a 16.4 kb plasmid covering the complete XIST RNA 
sequence as described previously. [13, 14] 
HUMARA analysis 
To determine the parental origin and the methylation status of the additional 
X-chromosome, we used the HUMARA assay (Human Methylation of the Androgen 
Receptor Assay) using 40ng of genomic DNA input for the digestion reaction and gel 
electrophoresis to separate PCR products.[15] 
Microarrays 
The genome wide copy number profile of all patients (n=180) was determined 
using either Affymetrix GeneChip Human Mapping 250K NSP1 (Affymetrix, Santa 
Clara, CA), HumanQ610, HumanCytoSNP-12v1 to 2.1 or HumanOmniExpress 
(Illumina, San Diego, CA).  We generated Affymetrix CEL files with the Affymetrix 
genotype command console v3.2 software. The HumanCytoSNP-12v2.1 chip 
(Illumina®, San Diego, CA, USA) was used in the cases with SHOX duplications and 
their parents, for better coverage of the PAR1 region. All procedures were done 
according to the manufacturer’s protocol as previously described.[16]  
SALL1 mutation analysis 
“Sequencing of the coding region of the SALL1 gene, including the splice sites, 
was done as described previously. [17] Primer sequences are available on request. We 
did not have sufficient DNA of Triple X patient 3 to perform additional Sanger 
sequencing” 
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Statistical analysis 
Differences in two proportions were tested with the Pearson's chi-square (χ2) 
test, reported with a 95% confidence interval (CI), performed in SPSS 15.0. 
Results 
Patient characteristics 
Patients included in the Erasmus MC - Sophia Children’s Hospital EA/TEF 
cohort can be subdivided into four categories: isolated EA and/or TEF (45%) , patients 
with one additional core VACTERL component (27%), VACTERL association e.g. 
three or more of the VACTERL core components(21%) and patients with a diagnosed 
genetic syndrome (7%) . [18, 19] 
Triple X syndrome 
A triple X karyotype (see supplementary figure 1) was identified in three 
EA/TEF patients resulting in an odds ratio for triple X syndrome of 11.3, (95% CI= 
3.6 to 35.2). All three were small for gestational age at birth (<5th percentile) with 
maternal ages ranging from almost 26 to 28. The first patient had all VACTERL 
anomalies and additional genito-urinary anomalies. The second patient had TEF and 
mild dysmorphic features and the third patient had EA/TEF, ventricular septal defect 
and thin fingers (patients 1-3, Table 1).  SNP array analysis performed to exclude copy 
number variations elsewhere in the genome, did not reveal additional possible 
pathogenic copy number variations in any of the three triple X patients.  
Searching the database of our department of Clinical Genetics, yielded 59 non-
mosaic 47,XXX karyotypes since 1988; 29 had been detected prenatally and 30 
postnatal (apart from the above three patients). Indications (not mutually exclusive) 
for prenatal karyotyping were: maternal age >35 years (n=25), congenital 
malformations on ultrasound (n=4), increased risk for Down syndrome on first 
trimester screening ultrasound (n=2), increased echogenicity of the foetal bowel on 
ultrasound (n=1), and congenital anomalies in an earlier pregnancy (n=3). One 
screening, with an increased maternal age indication, concerned a twin pregnancy of 
which one sib had a 47,XXX karyotype. Postnatal patients were karyotyped based on 
the following indications: suspicion of Fragile X syndrome (n=5), mental retardation 
(n=5), multiple congenital anomalies (n=4), combined mental retardation and multiple 
congenital anomalies (n=3), repeating spontaneous abortions in the index (n=4), 
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failure to thrive (n=4), a chromosomal abnormality in the family (n=3), suspicion of 
trisomy 21 (n=1), and a possible chromosomal aberration in juvenile systemic lupus 
erythematosus (n=1). 
Postnatal follow-up of thirteen pregnancies was not documented. Seven 
pregnancies were terminated, in one case because the foetus showed anencephaly. 
Congenital malformations had been documented for three of the nine births; a neural 
tube defect, hygroma colli with generalized edema, and osteogenesis imperfecta, 
respectively. A review of the medical charts of the postnatal diagnosed patients 
identified at least four patients with congenital heart defects.  
X inactivation studies 
Previous studies have indicated that only one X chromosome remains active in 
somatic cells of 47,XXX patients. RNA-FISH and immunocytochemistry were 
performed to assess the X inactivation status in cell lines derived from the 47,XXX 
patients of our cohort. RNA-FISH analysis revealed two XIST clouds in almost every 
fibroblast and lymphocyte cell (>95% of the nuclei), co-localizing with an area of low 
level COT-1 expression (figure 2A). Immunocytochemistry of 47,XXX fibroblasts 
detected enrichment of the facultative heterochromatin markers H3K27me3 and 
MacroH2A1 on two X-chromosomes, co-localizing with the DAPI-dense Barr-bodies 
(Figure 2B). HUMARA analysis confirmed a maternal origin of the additional X-
chromosome in all three patients. In all these patients and their mothers random XCI 
was observed, with no skewed preference of inactivation of a particular X-chromosome 
(supplementary figure 3)  
SHOX duplications  
Enrichment of the triple X karyotype in our EA/TEF cohort prompted us to 
look further in our cohort for sex- chromosome aberrations with micro-array and 
telomere-MLPA. These results indicated inherited SHOX duplications in two boys: 
patient 4 with an paternal inherited partial PAR1 duplication and patient 5 with an 
partial PAR1 duplication inherited from his mother. Duplication of the SHOX gene is 
a rare event, it is present only 2 times in the database of genomic variation.  Both 
SHOX duplications were confirmed with a SHOX-specific qPCR [9] (figure 1A, 
supplementary figure 2). 
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To exclude additional potential pathogenic copy number variations in other 
regions in the genome of both patients and their parents, we analysed their genome-
wide copy number profile.  These results revealed multiple copy number variations in 
both the patients and their parents. However, upon closer examination of these regions 
in the database of genomic variation, all of them were common polymorphisms. Given 
their relative high population frequency they were not considered as potential 
pathogenic copy number variations in a relatively rare condition as EA/TEF or 
VACTERL association. 
Patient 4’s twin sib was spontaneously aborted in the third month of gestation. 
His mother was diagnosed with Goldenhar syndrome. She has right-sided hemifacial 
microsomia, anotia, deafness, paresis of the pallatum molle and facial dysmorphisms. 
Two relatives on the mother’s side have thumb anomalies. EA/TEF or other major 
anomalies were absent in the father. The boy was small for gestational age at birth 
(<2SD) and had associated cardiovascular, renal, limb and genital anomalies (Table 1).  
 
SHOX-specific qPCR confirmed the duplication of the SHOX gene (amplicon 
1-13) in the PAR1 region in patient 4 and his father. Cultured lymphocytes of proband 
or parents for FISH validation or to localize the duplication were not available. The 
981Kb duplicated segment, corresponds to the PAR1 region on chromosome X and 
both SHOX variants, SHOXA g1-292dup and SHOXB g1-225dup are completely 
duplicated in patient 4, including all of its regulatory sequences.[20, 24, 25]. (arr 
[hg18] Xp22 or Yp11(248,968 _1,229,976)x3) (Figure 1A, 1B, supplementary fig. 4).  
Patient 5, with apparently healthy parents, was also small for gestational age at 
birth and had cardiac and limb anomalies. He inherited a PAR1 duplication/suspected 
rearrangement from his mother overlapping the SHOX gene (arr [hg18] Xp22 
(325941_593267)x3) and separated by a region with normal copy numbers a second 
Xp22 duplicated segment containing 7 other genes. (IL3RA, SLC25A6, ASMTL, 
PP1164, P2RY8, SFRS17A and ASMT) (arr [hg18 ] Xp22(1428051_1891174)x3, 
supplementary figure 5). SHOX-specific qPCR (duplication of amplicon 2-8) confirmed 
the SHOX gene duplication in patient 5 and his mother. Moreover, FISH (BAC clone 
RP11-800K15) confirmed the location of the duplication at chromosome band Xp22. 
The direction of the inserted duplicated segment was not determined 
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 Figure 1 Triple X syndrome and SHOX aberrations in patients with OA/TOF. 1A. The 
HumanCytoSNP-12 chip (Illumina®, San Diego, CA, USA) showing an interstitial duplication of the 
PAR1 region (base pair position chrX:248,968-1,229,976), including the SHOX gene in patient 4. The 
elevated log2 ratio indicates the duplicated segment (green bar) 1B.The HumanCytoSNP-12 chip result 
visualized in Biodiscovery Nexus CN6.1. The B-allele frequency of patient 4 is indicated in the enlarged 
right panel (purple bar,  arrow). The shift from a heterozygous state (gray dots, 0.5) to a 0.33/0.66 
frequency (purple dots) is indicative for a copy number change. Together with the raise in the logR this 
state is indicative for a copy number gain. 1C.Schematic presentation of  the SHOX A and B transcripts 
in dark blue and brown, the conserved non-coding elements (blue) [20], SHOX gene exons (green), 
SHOX qPCR (red) [9]and SHOX regulatory elements described in literature (dark-red), the SHOX 
duplications in patient 4 and 5 and their position compared the duplications observed in patients 1-4 in 
Thomas et al. [21], Roos et al. [22], the database of genomic variation and the duplication in 
LWD/ISS patients described by Benito-Sanz et al. [23].  The red lines indicate the length of the 
duplications, with a larger duplication in patient 4 (amplicon 1-13) and a SHOX duplication in patient 5 
(amplicons 2-8). (supplementary fig. 2) Both MLPA probes (orange) were duplicated in patient 4 and 5. 
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Pt no Karyotype MLPA results Maternal age Clinical features 
1 47,XXX X/Yp SHOX enh 
 
25.9 Absent sacrum  
Anal atresia 
Pulmonary stenosis 
EA + TEF 
Vesico-urethral reflux; urethral atresia 
Absent thumbs 
Cloacal malformation: abnormal labia, hydrometrocolpos 
2 47,XXX X/Yp SHOX enh 
 
28.2 TEF 
Dysmorphic features 
3 47,XXX X/Yp SHOX enh 
 
26.1 EA + TEF 
Ventricular septum defect 
Thin fingers 
4 46,XY X/Yp SHOX enh 
paternal inheritance 
31.5 Aberrant subclavian artery 
EA + TEF  
Horseshoe kidneys 
Adducted thumbs; left thumb smaller than right 
Hypospadias 
Frontal bossing 
Dysmorphic features 
5 46,XY X/Yp SHOX enh 
maternal inheritance 
34.3 Atrial septum defect (type II) 
EA + TEF 
Proximal placement of thumbs 
     
Table 1 Congenital anomalies of EA/TEF patients with X-chromosome anomaly, EA; esophageal atresia; TEF: tracheo-esophageal fistula; enh, enhanced 
signal with MLPA kits P036E1 and P070A2 
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 N genital urinary gastrointestinal anomalies V A C TE R L Other anomalies Reference 
3 + + cloacal extrophy incl. imperforate anus, 
esophageal atresia + TEF 
+ + + +   + dysmorphic features present 
study 
1     jejunal atresia               [26] 
1     duodenal atresia               [27] 
1   duodenal atresia *   +     [6] 
1     omphalocele             Beckwith-Wiedemann syndrome [28] 
1     omphalocele         +      [29] 
1 + +           +   pulmonary hypoplasia, laryngeal 
atresia, craniofacial anomalies 
[30] 
1   ectopic anus  +    + clinodactyly, inferior coloboma, 
clinodactyly, dysmorphic features 
[31] 
1 + + cloacal extrophy incl. imperforate anus   +           [32] 
1 + + cloacal extrophy incl. imperforate anus and 
rectoperineal fistula, colonic atresia, 
omphalocele 
  +     +     [33] 
1 + + imperforate anus, esophageal atresia + 
TEF 
+ +   + +   pulmonary hypoplasia, agenesis 
of gallbladder 
[34] 
            
 
Table 2 Congenital malformations of the gastro-intestinal tract and/or foregut-related structures in triple X syndrome N; number of patients, TEF; 
tracheo-oesophageal fistula, GI; gastro-intestinal malformations; V, vertebral defects; A; anorectal malformations; C, cardiovascular anomalies; TE, esophageal 
atresia and/or tracheo-esophageal fistula; R, renal anomalies; L, limb malformations; *, duodenal atresia due to annular pancreas
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 Figure 2. X-Chromosome inactivation studies in triple X patients. 2A. RNA-FISH analysis 
detecting XIST and COT-1 RNA. XIST RNA was detected using a digeoxin-labelled cDNA probe [12, 
14] (FITC, green), and a biotin-labelled COT-1 DNA probe detected expression of repetitive sequences 
(Rhodamine, red). Characteristic for an inactive X-chromosome is the presence of XIST RNA 
accumulation and absence of COT-1 RNA. In 47, XXX patient cells two XIST clouds and COT-1 holes 
were detected in the majority of the cells (> 95% of the nuclei, n >100). Nuclei were counterstained with 
DAPI. 2B. Immunocytochemistry detecting H3K27me3 (Rhodamine, red) and MacroH2A1 (FITC, 
green). Enrichment of H3K27me3 and MacroH2A1 was found on two X-chromosomes in 47, XXX 
fibroblast cell lines, co-localizing with DAPI-dense Barr bodies, indicative of two inactive X-
chromosomes. Nuclei are counterstained with DAPI. 
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SALL1 mutation analysis 
Mutation analysis of the SALL1 coding region only identified common variants 
e.g. two missense variants, one in all patients and a control (rs4614723; minor allele 
frequency is 1.514%) and one in patient 4 (rs13336129; minor allele frequency is 
6.651%). We also identified one intronic variant in patient 4 (rs13336129; minor allele 
frequency is 45.545%) and two synonymous variants in triple X patient 1 and a control 
(rs11645288; minor allele frequency is 17,816% and rs1965024; minor allele frequency 
is 49,216%)” 
Discussion 
Triple X syndrome and Gastro-intestinal anomalies 
Congenital malformations and mental retardation syndromes have been linked 
to the X-chromosome. Our search for genes or loci involved in EA/TEF or other 
foregut-related anomalies identified five patients in our cohort with chromosome 
X/Yp aberrations; three with triple X syndrome and two with inherited PAR1 
duplications.  
A large proportion of triple X females have a subclinical phenotype, therefore a 
triple X karyotype is usually a random finding in prenatal screening or  cytogenetic 
follow-up of pregnancies. Most 47,XXX females remain undiagnosed, therefore triple 
X syndrome has an estimated incidence rate of 0.10% with an average maternal age of 
33.[4] Affected girls have a lower birth weight, more accelerated growth until 
puberty, long legs and an increase in behavioural problems and psychiatric disorder 
prevalence.[4] In 90% of patients, the additional X-chromosome is the result of a 
maternal meiotic I error and the incidence of non-disjunction errors increases with 
maternal age.[35]  
Sex chromosome triploidies (47,XXX/ 47,XXY/ 47,XYY) are a rare (0.42%) 
finding in a large (n=4282) prenatal cohort analysed with karyotyping and micro-
array.[36] Haverty et al. calculate the incidence rate in females and to be 0.17%.[32] 
In a recent European study of the EUROCAT working group 0.054 triple X 
patients/1000 births are observed. [37] In our EA/TEF cohort the incidence rate of 
triple X syndrome is 1.12 % with an average maternal age of 30.8, 11 times higher 
than that in the estimated general population and 6.5 times higher than in the 
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calculated incidence rate by Haverty et. al. Guichet et al. reviewed prenatally and 
postnatally diagnosed 47,XXX karyotypes from 18 laboratories.[38]  
Mental retardation or congenital malformations were described in over one 
third of the 190 patients reported. In all cases, weight-for-gestational-age at birth was 
under the 25th percentile. Congenital anomalies associated with the triple X syndrome 
described in case reports include anomalies of the urinary tract, genital anomalies and 
craniofacial anomalies, specifically a reduced head circumference and/or decreased 
brain volume.[4, 39, 40]  Genito-urinary malformations are well-described in triple X 
patients. Since genito-urinary malformations often are associated with lower gastro-
intestinal tractanomalies, perhaps a cloacal septation problem gives rise to the higher 
incidence of these types of malformations. Gastro-intestinal anomalies, including 
atresia of the esophagus, duodenum and jejunum, as well as omphalocele and anorectal 
malformations, have been reported sporadically.[6, 26-29, 31-34] All thirteen reported 
patients with gastro-intestinal and/or foregut-related anomalies are reviewed in Table 
2. The patient described by Hoang et al. shows a similar phenotype compared to our 
patients; higher mesodermal defects (esophageal atresia) and lower mesodermal defects 
(anal atresia, genito-urinary defects).[34]   
X inactivation patterns 
The HUMARA assay demonstrated the maternal origin of the supernumerary 
X-chromosome and the absence of skewed preference for a particular X-chromosome 
in our triple X patients. RNA-FISH analysis and immunocytochemistry demonstrated 
inactivation of two out of three X-chromosomes  
Overexpression of genes escaping X-inactivation could be responsible for the 
phenotypical abnormalities observed in our three EA/TEF patients and the gastro-
intestinal patients described in literature. Ten percent of genes have a variable pattern 
of gene X-inactivation and expression.[41] The extent of this escape is tissue specific, 
and often results in variable or lower levels of expression from the inactive X 
chromosome compared to the active X chromosome.[42, 43] Why and how certain 
genes escape XCI, especially in humans, is still unknown.[44] Female ‘escapees’ may 
have a dosage-sensitive function, which would explain the phenotype in patients with 
sex chromosome anomalies, such as Turner and Klinefelter syndrome. The 
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observation that 47,XXX females also have decreased brain volume in the presence of 
normal pubertal maturation, suggests a possible direct dosage effect of X-
chromosomal genes.[45] Two esophageal atresia candidate genes, MID1 and FANCB 
do not escape X-inactivation, although there is a X-inactivation preference for the X-
chromosome that contains the mutated allele in Fanconi anemia.[36] Other genes that 
escape XCI could perhaps cause the gastro-intestinal anomalies found in our cohort. 
SHOX duplications  
One of those escapees, located in the PAR1 region, is SHOX. This gene has 2 
isoforms; SHOXA and SHOXB which are surrounded by several conserved non coding 
regulators. [20]  SHOX encodes a cell-specific homeodomain protein and isoform a 
plays an important role during human embryonic bone and limb development. [46]  
Two patients in our EA/TEF cohort have a duplication in the PAR1 region, the only 
overlapping duplicated gene is SHOX. The co-occurrence of SHOX duplication in a 
small cohort of a rare disease as esophageal atresia is intriguing, but we cannot 
exclude a chance finding. Large PAR1 duplications are relatively rare in the database 
of genomic variation (http://dgv.tcag.ca/), a database of “healthy” individuals and only 
2 duplications of SHOX are described. In the ISCA consortium patient database  
(www.iscaconsortium.org) duplications of SHOX are more prevalent (92 in total) and 
generally classified as uncertain.   
However, we observed a SHOX duplication in two EA/TEF patients and in 
both these patients limb development is disturbed. The limb anomalies, growth 
anomalies of the thump, are different from the wrist deformity usually associated with 
SHOX deletions and duplications. [23, 47] Furthermore, SHOX duplications are also 
associated with limb anomalies e.g. in Mayer-Rokitansky-Küster-Hauser (MRKH) 
syndrome type 1[48], Idiopathic Short Stature [49] or Leri-Weill Dyschondrosteosis. 
[23]  
The healthy carriers of the transmitted SHOX duplications in patient 4 and 5 
seem to have the exact same duplication/rearrangement as their offspring. Absence of 
a phenotype in healthy parents could be caused by incomplete penetrance or variable 
expressivity as described for other microdeletion/ duplication syndromes.[50] 
Thomas et al. and Roos et al. describe five families with inherited SHOX 
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duplications.[21, 22] The duplication was associated with cleft palate in two cases and 
one patient had a Madelung deformity.  These, and the SHOX duplications described 
by Benito-Sanz [21-23] are often inherited from an unaffected parent. However, it is 
important to know the exact location of the SHOX duplication since insertion of the 
duplicated segment could result in haploinsufficiency of SHOX by affecting the normal 
copy of the gene or its regulatory elements. It would certainly be beneficial to 
determine RNA and protein expression in e.g. esophageal or bone tissue, however no 
biopsies of affected and corresponding normal tissues are available at this moment 
The mouse homologue of SHOX, Shox2 is involved in limb development [51] 
and in human SHOX enhancers are active in developing limbs.[52] Sall1 and hoxd 
mutant mice with limb anomalies quit similar to those observed in our patients have 
overexpression of shox2. [53, 54]  SALL1 is mutated in Townes-Brocks syndrome, 
patients suffering from this syndrome often have anal, renal and thump anomalies and 
esophageal atresia is a variable feature in this syndrome. Sequencing revealed no 
pathogenic SALL1 mutations in the SHOX duplication patients.  
We could speculate that SHOX duplication is the second hit in a two hit model 
modulating, not causing, the abnormal development in these patients.  
SHOX duplication and other rare inherited Copy Number Variations could be 
modifying factors explaining responsible for the broad phenotypical spectrum 
characteristic of the EA/TEF patient population. [19] 
  Genetic aberration e.g. pathogenic mutations, aneuploidies and structural 
chromosomal changes like translocations, inversions or Copy Number Variations have 
previously been detected in ~12.5% of patients in our cohort. This number will 
steadily increase, since it is expected that screening previously unresolved cases with 
whole exome sequencing or improved high-resolution micro-array will identify both 
known and new causal genetic defects.  Screening large patient cohorts for genetic 
defects can delineate new genetic syndromes when genotypes and phenotypes overlap, 
like recently published for the EFTUD2 gene. [55] 
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In conclusion, we describe five patients with sex chromosomal aberrations and 
EA/TEF. All five patients had duplicated loci of pseudoautosomal genes, including 
SHOX,  that escape X-inactivation and are candidates for a gene dosage effect. As a 
consequence of the additional X-chromosome, triple X females express more 
transcripts from genes that escape XCI. The expression of one or several of these 
genes could contribute to the phenotype. Overexpression of XCI escapees could shift 
the balance from normal to abnormal development in a small percentage of triple X 
patients. The expression levels of escaping genes on the inactive X-chromosomes may 
vary between individuals and different tissues.[56] As previously described the 
phenotypic variability of triple X syndrome ranges widely, from subclinical 
phenotypes to mental retardation and congenital malformations. [4] 
 
The incidence of triple X syndrome in our EA/TEF cohort is 6.5-11 times 
higher than expected. Overexpression of XCI-escapees, SHOX or other X-linked genes 
could be responsible for or modulate the phenotype of EA/TEF patients.  
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To the editor: 
 Esophageal atresia (EA) and tracheoesophageal fistula (TEF) are common life-
threatening birth defects that affect approximately 1 in 3,500 births [1].  Approximately 
10% of individuals with EA/TEF also meet criteria for VACTERL association which 
requires the presence of three or more of the following non-randomly associated birth 
defects: Vertebral anomalies, Anal anomalies, Cardiac defects, TracheoEsophageal fistula 
and/or esophageal atresia, Renal anomalies and Limb.[2] The genetic factors that 
contribute to the development of most cases of TEF and VACTERL association have yet to 
be identified.    
 The LIM domain containing preferred translocation partner in lipoma (LPP) gene 
has recently been proposed as a candidate gene that may contribute to the development of 
EA/TEF, or phenotypes associated with VACTERL association [3].  LPP localizes in focal 
adhesions as well as in cell-to-cell contacts and binds to VASP, a protein implicated in the 
control of actin organization.  This suggests that LPP has a structural role at sites of cell 
adhesion in maintaining cell shape and motility. [4, 5] LPP is also transiently located in the 
nucleus where it can activate transcription.[5]  
The bulk of evidence for LPP’s role in EA/TEF and VACTERL association comes 
from a report by Arrington et al. in which they described a 451 kb interstitial deletion 
involving only the LPP gene in an individual diagnosed with EA/TEF and VACTERL 
association [3].  They also described an intronic deletion in LPP associated with reduced 
LPP expression levels that segregated with TOF in three individuals in a small nuclear 
family—a father and two children.  However, in both cases, a lack of DNA from family 
members made it impossible to determine if the changes arose de novo or were inherited from 
an unaffected family member.  Deletions affecting multiple exons of LPP have also been 
reported in 5 out of 2906 unselected adults (0.17%) from the island of Kosrae, Micronesia 
but the phenotype of these individuals was not reported, making it impossible to draw any 
conclusions about their effects.[6] 
In an effort to clarify LPP’s role in the development of EA/TEF and VACTERL 
association, we looked for genomic alterations and deleterious sequence changes in the LPP 
gene in individuals with these diagnoses.  First, we screened for genomic alterations in a 
convenience cohort of 195 patients with these diagnoses based on a review of their medical 
records.  This cohort consisted of 48 individuals with isolated EA/TEF, 77 with EA/TEF 
and additional findings, 64 with non-isolated EA/TEF who met criteria for VACTERL 
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association, and 6 with VACTERL association in whom EA/TEF was not a feature.  After 
obtaining informed consent, DNA samples were screened for genomic alterations using an 
array comparative genomic hybridization or SNP-based copy number detection platform.  
Although each of these platforms contained a minimum of 40 probes within the LPP gene, 
no copy number variations or regions of absence of heterozygosity (AOH) >1 Mb—which 
could be associated with consanguinity and the possible inheritance of a recessive inherited 
deleterious allele—affecting the LPP gene were detected in this cohort.    
If we assume that these array-based copy number detection techniques can detect 
90% of deleterious copy number changes, then screening 195 individuals would have a 
greater than 97% chance of identifying at least one copy number change in the LPP gene if 
such changes were present in at least 2% of a similarly affected cohort.   The absence of LPP 
copy number changes in our cohort suggests that such changes are not a common cause of 
EA/TEF or VACTERL association. 
 To determine if deleterious sequence changes in LPP are a common cause of 
EA/TEF or VACTERL association, we screened for such changes in a partially overlapping 
cohort of 75 patients—21 with isolated EA/TEF, 18 with EA/TEF and additional findings, 
27 with non-isolated EA/TEF who met criteria for VACTERL association, and 9 patients 
with VACTERL association in whom EA/TEF was not a feature.  PCR amplification and 
sequencing of the LPP coding region and intervening introns (Supplemental Online 
Material) revealed four non-synonymous changes—pSer144Thr (S144T), p.Ser246Leu 
(S246L), p.Tyr346His (Y346H), and p.Arg388Cys (R388C).   
These changes were identified in a total of seven patients whose clinical findings are 
summarized in Table I.  The S246L, Y346H and R388C changes have been previously 
reported in the SNP database (dbSNP) and the Y346H, and R388C changes have also been 
seen in individuals sequenced as part of the 1000 Genomes project.  Three publicly available 
on-line programs — the HumVar model of PolyPhen2 
(http://genetics.bwh.harvard.edu/pph2/), SIFT (http://sift.jcvi.org/) and SNPs3D 
(http://www.snps3d.org/) —were used to predict the effects of non-synonymous changes in 
the LPP gene on protein function.  These results are shown in Table II.  
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 Patient ID Clinical Synopsis a Non-Synonymous Change (Inheritance b) 
TX-11 VACTERL association with TEF, 
vertebral, and cardiac anomalies 
Het Y346H  
(Parental samples not available) 
TX-22 VACTERL association with vertebral, 
renal, and limb anomalies 
Homo Y346H  
(Inherited from heterozygous parents) 
Het R388C 
(Maternal) 
N-A12 EA/TEF and cardiac anomalies Het Y346H 
(Both parents are heterozygous) 
N-A13 EA/TEF, cardiac Het S246L  
(Maternal) 
N-A15 EA/TEF, limb anomalies Het S246L  
(Maternal) 
N-A24 EA/TEF Het S144T  
(Paternal) 
N-A42 EA/TEF, upper limb, and genital 
anomalies 
Homo Y346H 
(Paternal, maternal sample  not available) 
 
Table I. Clinical and molecular synopsis of individuals with non-synonymous changes in LPP. 
Het = individuals were heterozygous for the change; Homo = individuals were homozygous for the change.  a 
Phenotype based on an analysis of the medical record. b Parents were reported to be unaffected but no 
radiological evaluations were obtained to rule out subtle changes that may have eluded detection.   
 
 Although the S144T change is rare, it is unlikely to contribute to the phenotype of 
the patient in which it was found since it was inherited from a self-reportedly unaffected 
father and was predicted to be benign by all three of the prediction programs.  The Y346H 
allele was predicted to be possibly damaging by one prediction program but benign by the 
other two— calling into question its effect on LPP function.  The c.1036T>C change 
associated with the Y346H allele is also a relatively common variant with a reported minor 
allele frequency of 0.2099 in dbSNP.  Based on Hardy-Weinberg equilibrium, the Y346H 
allele is expected to be found in the homozygous state in 4.4% of the population, a level that 
would make it unlikely to strongly contribute to the development of EA/TEF or 
VACTERL association even in the homozygous state.     
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In contrast to the Y346H change, both the S246L change that was seen in two 
patients and the R388C change seen in one patient are relatively rare.  The S246L change 
was predicted to be deleterious by one of the three prediction programs and the R388C 
change was predicted to be deleterious by all three prediction programs.  However, in all 
cases, these changes were inherited from self-reportedly unaffected parents.  The R388C 
change was also seen in 1 out of 78 African American controls from the Baylor 
Polymorphism Resource—a collection of anonymous control samples from major ethnic and 
racial backgrounds.  Although the anonymous nature of this resource makes it impossible to 
determine the phenotype of the individual carrying the R388C change, the presence of this 
change in these control individuals suggests that this allele may be seen more commonly in 
this ethnic group.  
Taken together, these results suggest that genomic alterations and clearly 
deleterious sequence changes in the LPP gene are not a common cause of EA/TEF or 
VACTERL association.  This makes it unlikely that clinical screening of the LPP gene 
would prove to be cost effective in individuals with EA/TEF or VACTERL association.  
Our data also suggests that if the non-synonymous LPP sequence changes identified in this 
study contribute to the development of these phenotypes, they are likely to have a relatively 
mild effect and to do so in combination with other genetic, environmental and/or stochastic 
factors.   
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Observed 
Change 
Number of Patients  Present in dbSNP? Present in 1000 Genomes? Predicted Effect (PolyPhen 2) Predicted Effect (SIFT) Predicted Effect (SNPs3D) 
Nonsynonymous Changes 
c.431G>C 
p.Ser144Thr 
S144T 
1 Het No No Benign Tolerated Non-Deleterious 
c.737C>T 
p.Ser246Leu 
S246L 
2 Het  Yes 
 
No Benign Deleterious Non-Deleterious 
c.1036T>C 
p.Tyr346His 
Y346H 
3 Het 
1 Homo 
Yes Yes Probably Damaging Tolerated Non-Deleterious 
c.1162C>T 
p.Arg388Cys 
R388C 
1 Het 
 
Yes Yes Possibly Damaging Deleterious Deleterious 
Synonymous Changes 
c.942C>T 
p.Asp314= 
D314D 
24 Homo 
34 Het 
Yes Yes N/A N/A N/A 
c.1605A>G 
p.Cys536= 
C536C 
22 Homo 33 Het  No No N/A N/A N/A 
c.1143G>A 
p.Ser382= 
S382S 
1 Het No No N/A N/A N/A 
c.1395C>T 
p.Glu466= 
E466E 
2 Het No No N/A N/A N/A 
       
Table II.  Evaluation of changes in the LPP gene identified in patients with EA/TEF and VACTERL association. Het = individuals were heterozygous for the 
change; Homo = individuals were homozygous for the change; N/A = not applicable 
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Materials and Methods 
Patient accrual and preparation of DNA 
 Informed consent was obtained from a convenience sample of patients with EA/TEF 
or a diagnosis of VACTERL association based on the presence of three or more of the 
following birth defects: Vertebral anomalies, Anal anomalies, Cardiac defects, 
TracheoEsophageal fistula or esophageal atresia, Renal anomalies and Limb defects.  When 
possible, the parents of these individuals were similarly accrued.  DNA was extracted from 
whole blood or immortalized lymphoblastic cultures.  dsDNA extracted from whole blood or 
immortalized lymphoblastic cultures using a QIAamp DNA Blood Midi Kit (Qiagen Inc., 
Hilden, Germany) or a Qiagen Puregene Blood Kit (Qiagen Sciences, MD, USA) was 
quantified using a Quant-iT™ PicoGreen ® dsDNA kit (Invitrogen, CA, USA) or a 
NanoDrop ND-1000 spectrophotometer  (NanoDrop Technologies Inc., DE, USA) . 
 In cases where the amount of genomic DNA available was limiting, ~10 ng of DNA 
was amplified using a GenomiPhi DNA (GE Healthcare Life Sciences, NJ, USA) 
amplification kit according to manufacturer’s instructions.  This amplified DNA was then 
used as a template for PCR amplification and sequencing but not for array studies. 
  African American control samples were obtained from the Baylor Polymorphism 
Resource, a collection of anonymous control samples from major ethnic and racial 
backgrounds. 
Array comparative genomic hybridization and SNP-based copy number analyses 
A screen for copy number changes involving LPP was carried out by array 
comparative genomic hybridization (aCGH) or SNP-based copy number analysis enabling 
both copy number and absence of heterozygosity (AOH) detection.  
 aCGH experiments were performed using Agilent Human Genome CGH 244K or 
SurePrint G3 Human CGH 1M Oligo Microarray Kits (G4411B, G4447, Agilent 
Technologies, CA, USA) as previously described [7]These arrays have a minimum of 82 
probes that span the length of the LPP gene.  Controls consisted of DNA from sex matched 
individuals with no personal or family history of EA/TEF or VACTERL association.   
 SNP-based analyses of copy number and AOH detection, were performed using 
either Affymetrix GeneChip Human Mapping 250K NSP1 (Affymetrix, CA, USA), 
HumanQ610, HumanCytoSNP-12v2.1 or HumanOmniExpress (Illumina, CA, USA) 
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platforms.  Depending on array type, a minimum of 40 markers within the LPP gene allow 
for copy number and/or AOH detection.  Information within the array allow for self-
normalization of image intensities.  We generated Affymetrix CEL files with the Affymetrix 
genotype command console v3.2 software or Illumina Final Reports with Illumina’s Genome 
Studio. We analyzed the SNP arrays in Biodiscovery Nexus CN5.1 using Illumina’s 
SNPFASST2 algorithm to call segments consisting of a minimum of 3 markers.  SNP array 
data were compared to a virtual reference array.  This virtual array was composed of a large 
pool of array specific CEU HapMap control samples.  The copy number was considered 
abnormal if both logR and B-allele frequency were either above (gain) or below (loss) normal 
values (logR values between -0.18 and +0.18 and B-allele frequencies ranging from 0.45 to 
0.55).   
Sequencing of LPP and analysis of variants 
 The coding region and intervening exon/intron boundaries of LPP were amplified 
by PCR using previously published primers [Arrington et al., 2010].  Sequence changes in 
PCR amplified products were identified by comparison with control DNA sequences using 
Sequencher 4.7 software (Gene Codes Corporation).   
 Three publicly available on-line programs—the HumVar model of PolyPhen2 
(http://genetics.bwh.harvard.edu/pph2/), SIFT (http://sift.jcvi.org/) and SNPs3D 
(http://www.snps3d.org/)—were used to predict the effects of non-synonymous changes in 
the LPP gene on protein function. 
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Abstract 
An unanticipated and tremendous amount of the non-coding sequences of the human 
genome are transcribed. Long non-coding RNAs (lncRNAs) constitute a significant fraction 
of non-protein coding transcripts; however, their functions remain enigmatic.  
We demonstrate that deletions of a small non-coding differentially-methylated 
region at 16q24.1, including lncRNA genes, cause a lethal lung developmental disorder, 
Alveolar Capillary Dysplasia with Misalignment of Pulmonary Veins (ACD/MPV), with 
parent of origin effects. We identify overlapping deletions 250 kb upstream to FOXF1 in 
nine patients with ACD/MPV that arose de novo specifically on the maternally inherited 
chromosome and delete two lung-specific lncRNA genes. These deletions define a distant 
cis-regulatory region that harbors, besides lncRNA genes, also a differentially methylated 
CpG island, binds GLI2 depending on the methylation status of this CpG island, and 
physically interacts with and up-regulates the FOXF1 promoter.  
We suggest that lung-transcribed 16q24.1 lncRNAs may contribute to long-range 
regulation of FOXF1 by GLI and other transcription factors. Perturbation of lncRNA-
mediated chromatin interactions may, in general, be responsible for position effect 
phenomenon and potentially cause many disorders of human development. 
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Introduction 
Mammalian regulatory elements, including enhancers, repressors, and insulators are 
usually contained in regions that lack protein-coding genes, and can be located hundreds of 
kb from genes that they regulate[1]. High-throughput analysis of the human transcriptome 
revealed that the majority of noncoding portion of the genome is transcribed as regulatory 
RNAs [2, 3] Long non-coding RNAs (lncRNAs) are non-protein coding transcripts longer 
than 200 nucleotides, distinguished from small regulatory RNAs such as microRNAs, 
siRNAs, piwiRNAs, and snoRNAs. Little is known about the function of lncRNAs in 
humans with XIST being the earliest identified and best characterized to date human 
lncRNA. Recently, lncRNAs have been implicated in imprinting and long-range gene 
regulation with functional properties of enhancers [2-4]. Here, we demonstrate that loss of 
a distant enhancer region in a coding-gene desert at 16q24.1, that includes lung-expressed 
lncRNA genes, leads to Alveolar Capillary Dysplasia with Misalignment of Pulmonary 
Veins (ACD/MPV) (MIM 265380).  
ACD/MPV is a rare neonatally lethal developmental disorder of the lungs defined by 
malposition of pulmonary veins adjacent to small pulmonary arteries, medial thickening of 
small pulmonary arteries, deficient lobular development, a paucity of alveolar wall 
capillaries, and occasional lymphangiectasis[5, 6]. A few familial ACD/MPV cases have 
been described ([7, 8]. During the last 10 years, we ascertained ACD/MPV samples (mainly 
formalin-fixed paraffin-embedded lung tissues) from over 90 families. In 2009, we reported 
genomic deletions and inactivating point mutations in the FOXF1 gene in chromosome 
16q24.1 in unrelated patients with sporadic histopathologically-verified ACD/MPV [9].  
FOXF1 (Forkhead box protein F1) is a member of the FOX transcription factor 
family sharing a winged helix/forkhead DNA-binding domain [10-12]. FOXF1 and its 
mouse orthologue are predominantly expressed in sub-epithelial mesenchymal tissues of 
developing lung and foregut[4, 13-15] (. Homozygous mice deficient for Foxf1 die in utero 
by E10 due to defects in mesodermal differentiation and cell adhesion [16]. Interestingly, 
approximately 50% of Foxf1+/- mice die from pulmonary hemorrhage and show severe 
defects in alveolarization and vasculogenesis[16, 17], partially recapitulating 
histopathological pulmonary defects in infants with ACD/MPV, whereas the remainder 
appears normal.  
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Both in vitro and in vivo studies in mice have shown that none of the in silico-
predicted transcription factor binding sites located within the Foxf1 promoter confer its 
tissue specificity [4, 18], suggesting that the promoter is regulated by tissue specific distant 
regulatory elements. Also, deletions upstream to FOXF1, leaving FOXF1 intact, have been 
described in two patients with ACD/MPV, suggesting the presence of distant regulatory 
elements for FOXF1 [9]. In addition, FOXF1 has been bioinformatically predicted to be 
paternally imprinted [19] and other studies have supported this prediction[9, 20].  
We now report novel overlaping de novo non-coding deletion copy-number variants 
(CNVs) located 96-257 kb upstream to FOXF1 in seven patients with ACD/MPV, who all 
died in the first month of life with severe respiratory distress and pulmonary hypertension. 
Based on extensive experimental characterization of the microdeletion-defined upstream 
regulatory region, SDR, we propose that paternally incompletely imprinted FOXF1 is 
regulated in cis by an interplay between chromatin looping, possibly with contribution of 
lncRNAs, and methylation-controlled GLI2-binding. 
Results 
Non-coding deletion CNVs upstream to FOXF1  
 DNA samples from nine patients with ACD/MPV, negative for point mutations 
within the FOXF1 coding exons, were analyzed by array comparative genomic 
hybridization (aCGH) for the presence of CNVs in 16q24.1. In sample 59.4, aCGH revealed a 
15 kb deletion of the entire FOXF1 and its promoter. Studies of the remaining eight cases 
identified CNVs that left the FOXF1 coding region intact. In patient 41.4, a ~ 11 kb 
deletion, mapping 2.6 kb upstream to FOXF1, removed one copy of the distal portion of the 
FOXF1 promoter, corresponding to Foxf1 promoter region II in mice (Kim et al. 2005) and 
overlapping with a portion of the lncRNA gene LOC400550 (FOXF1-AS1, Ota et al. 2004; 
lncFOXF1, Khalil et al. 2009). We show by RT-PCR and DNA sequencing that lncFOXF1 is 
expressed in normal newborn lungs (Supplemental Fig. S1). In the remaining seven patients, 
overlapping deletions, ranging in size from 140 kb to 2,625 kb, mapped 96-257 kb upstream 
to FOXF1 (Fig. 1; Supplemental Table S1). 
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Figure. 1. Nine (two published D9, D10, and seven novel) ACD/MPV-causing microdeletions share a 75 kb 
putative regulatory region (SDR), mapping 257 kb upstream to FOXF1 (16q24.1). Array CGH plots of two 
deletions defining SDR are shown.  
  
To better estimate the recurrence risk for these deletions, we mapped and sequenced 
the deletion breakpoints of six of the upstream microdeletions (patients 57.3, 60.4, 64.5, 77.3, 
95.3, and 96.3) (Supplemental Fig. S2; Supplemental Table S1) and the microdeletion that 
included the FOXF1 gene (patient 59.4) (Supplemental Fig. S2). Microhomology was 
identified in five of seven breakpoint junctions (patients 57.3, 60.4, 64.5, 77.3, and 95.3) 
consistent with the deletions arising by a template switching replicative mechanism such as 
FoSTeS/MMBIR [21, 22]. In three of these five cases, both deletion breakpoints mapped 
within Alu elements (Supplemental Table S1). The probability of finding both breakpoints in 
Alu elements by chance was estimated at less than 0.0066 (Supplemental Fig. S3), thus being 
much lower than the observed frequency of finding breakpoints of ACD/MPV 
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microdeletions in Alu repetitive elements. This finding suggests a mechanistic link between 
Alu sequences and the location of microdeletion breakpoints.  
 Interestingly, in patients 64.5 and 95.3, the distal breakpoints were located within 
the same copy of an AluSx element (about 100 bp apart), thus defining a potential breakage-
prone hotspot. In patient 59.4, the breakpoints occurred within highly homologous regions 
of the low complexity/GC rich repeats and SINE/MIR repeats. We did not find any 
evidence for low-level somatic mosaicism in parental blood samples using PCR for patient-
specific junction fragments; all microdeletions appear to have occurred de novo 
(Supplemental Fig. S4).   
Regulatory region upstream to FOXF1  
Sequence alignments of the seven distant microdeletions showed that they share a 75 
kb region 257 kb upstream to FOXF1 (chr16:86,212,040-86,287,054) (Shared Deletion 
Region, SDR) (Fig. 1; Supplemental Table S1). We found that this, deletion-defined SDR 
represents a protein-gene desert (http://genome.ucsc.edu). Nevertheless, this genomic 
region harbors DNA segments that are evolutionarily conserved among land vertebrates 
and have high 7x regulatory potential (Fig. 2A). Hence, we hypothesized that the SDR may 
contain regulatory site(s) controlling the FOXF1 promoter.  
Interestingly, we also found that the SDR encompasses one locus (chr16:86,223,827-
86,234,547) and part of another locus (chr16:86,254,429-86,338,058), encoding differentially-
spliced putative lncRNAs exhibiting increased expression in the lungs 
(http://genome.ucsc.edu). The 43.5 kb EST CR737045 (chr16:86,259,186-86,302,689), part 
of the 79-kb lncRNA TCONS_00024764, is specifically expressed in fetal lungs (SOURCE 
at http://source.stanford.edu). We show, by RT-PCR and sequencing, that 
TCONS_00024764 lncRNAs is also expressed in normal newborn lung at much higher level 
than in HEK293 kidney cells and lymphoblasts (Supplemental Fig. S1).We further narrowed 
SDR to ~ 10 kb Segment 1 of the highest 7x regulatory potential and sequence conservation 
(Fig. 2A), containing a cluster of GLI-binding sites overlapping with CpG island (Fragment 
1a) (Fig. 2B; Supplemental Fig. S5), and ~ 8 kb Segment 2 with multiple binding sites for 
other transcription regulators, and highest potential for histone methylation and acetylation. 
Both segments encode lncRNAs expressed in the lungs (Fig. 2A). 
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Figure. 2. Characterization of the SDR. (A) Segment 1 (~ 10 kb, black rectangle), and Segment 2 (~ 8 kb, red 
rectangle), harboring, among others, transcription factor binding sites and a part of the fetal lung-expressed 
lncRNA, are shown. The figure is drawn according to the 2009 human reference sequence (GRCh37/hg19). (B) 
Insight into the ~ 1.5 kb Fragment 1a showing (from top to bottom): bisulfite sequenced region, methylation 
array oligo probes that indicated differential methylation, differentially-methylated CpG island, ChIP-chip 
GLI2-binding region, 7x regulatory potential, mammalian evolutionary conservation, and CG content. 
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 GLI2 binds within the upstream regulatory region  
Sonic hedgehog (Shh) signaling targets a GLI2 transcription factor and is crucial for 
early lung development in mice [23]) and humans [24]. GLI1-3 have been shown to be 
expressed in human lung mesenchymal tissues, including endothelial cells [14]. Moreover, 
studies in mice have shown that Gli2 regulates Foxf1 expression in the developing stomach 
and intestine [25], which, together with airway and alveolar tissues, are of endodermal 
origin. To determine whether in silico identified GLI-binding sites in the SDR bind GLI2 in 
vivo, we screened the SDR for the GLI2-binding using a ChIP-chip assay. We detected 
strong binding of GLI2 to SDR in the cultured human pulmonary microvascular endothelial 
cells (HPMEC) (p=0.007, n=2) at a region including several in silico-predicted GLI-binding 
sites (chr16:86,232,498-86,232,882) (Supplemental Fig. S5,S6). Although only one of the 
GLI-binding sites of SDR perfectly matches the consensus sequence, the clustering of nine 
of these sites within a 0.2 kb segment of the Fragment 1a may have synergistic effect on 
GLI2 binding. Given that HPMEC express both FOXF1 and GLI2 (Supplemental Fig. S7), 
we hypothesized that GLI2 binding at SDR may regulate FOXF1 transcription. 
GLI2-binding to the distant enhancer regulates FOXF1 promoter  
 To this end, we performed a secreted alkaline phosphatase (SEAP) reporter assay in 
HPMEC (Fig. 3A,B). We prepared plasmid constructs that allow for transient expression of 
the SEAP reporter gene under the control of the FOXF1 promoter and its putative 
regulatory sites. The upstream putative regulatory sequences were then tested both in cis 
(inserted into a vector upstream to the FOXF1 promoter) and in trans (placed on another 
plasmid used in the co-transfection of HPMEC with the FOXF1 promoter-containing 
reporter vector). The -5.5 kb FOXF1 promoter region includes two intervals that remain 
highly conserved between mice and humans (Kim et al. 2005), and contains the RNA PolII 
binding site (chr16:86,543,198-86,543,374) and multiple transcription factor binding sites 
(httm://genome.ucsc.edu). When placed upstream to the promoterless SEAP, the -5.5 kb 
promoter region activated SEAP transcription 11 to 20 fold, this range depended on 
whether the cells were additionally co-transfected with a pCS2Gli2 vector, constitutively 
expressing GLI2 (P<0.0001) (Fig. 3A).  
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Figure. 3. Distant regulatory region, SDR, controls the activity of FOXF1 promoter. (A, B) Results of the 
reporter assay experiments showing regulation of the FOXF1 promoter in HPMEC by fragments of Segments 
1 and 2 of the SDR. Abbreviations: FOXF1p, FOXF1 promoter (0 to 5.5 kb upstream to ATG codon) cloned in 
pSEAP2Basic; 41.4delp, truncated FOXF1 promoter (0 to -3.0 kb, ACD case 41.4) cloned in pSEAP2Basic; 
Seg1FOXF1p, distant upstream GLI-binding region (part of Fragment 1a) and FOXF1 promoter cloned in 
pSEAP2Basic; Seg2>FOXF1p, Segment 2 putative enhancer and FOXF1 promoter cloned in pSEAP2Basic; 
Seg2<FOXF1p, same enhancer in reverse orientation and FOXF1 promoter cloned in pSEAP2Basic; vect, 
pGEM-T Easy vector; Seg1, GLI-binding region of Fragment 1a cloned in pGEM-T Easy; Seg2, putative 
enhancer of Segment 2 cloned in pGEM-T Easy. The presence of additional GLI2 constitutively expressed 
from pCS2Gli2 vector is denoted by + GLI2. The GLI-binding region of Fragment 1a stimulates activity of 
FOXF1 promoter in cis (A) and in trans (B) settings. (C) Results of the 4C experiment revealing long-range 
physical interaction between the FOXF1 promoter and SDR. Coordinates of the SDR region interacting with 
the FOXF1 promoter (SDR-promoter interaction peaks) in HPMEC are (from top): 86,246,725-86,246,982 
(0.05<FDR≤0.1) and 86,246,125-86,246,982 (0.1<FDR≤0.2). The two HPMEC panels represent results of 
independent experiments. No SDR-FOXF1 promoter interaction peak was detected in lymphoblasts, which do 
not express FOXF1.  
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Madison et al. [25] demonstrated that the FOXF1 promoter harbors the 
evolutionarily conserved (identical among mammalian, bird, fish, and amphibian species) 
consensus GLI binding site (chr16:86,539,377-86,539,385) that is deleted in patient 41.4 
(Fig. 1). As expected, the truncated version of the FOXF1 promoter, missing this GLI-
binding site, showed weaker SEAP expression in comparison with the intact promoter, 
especially in the excess of GLI2 (P=0.038) (Fig. 3A). Of note, several variant GLI-binding 
sites are still present in the residual truncated promoter region from case 41.4, potentially 
explaining why it responded, although weakly, to excess of GLI2 (Fig. 3A). Placement of the 
0.6 kb part of the Fragment 1a of the SDR (containing GLI-binding sites) upstream to the 
FOXF1 promoter increased SEAP expression from the FOXF1 promoter two-fold 
(P<0.0016). Activation of the promoter by the SDR GLI-binding sites in trans also increased 
reporter expression (P=0.027) (Fig. 3B), further suggesting that these GLI-binding sites can 
regulate FOXF1 transcription from a distant location, likely through chromatin looping that 
juxtaposes FOXF1 promoter and SDR. Moreover, co-transfection of HPMEC with the 
plasmid pCS2Gli2, constitutively expressing GLI2 protein, increased expression of the 
SEAP reporter from the FOXF1 promoter in all construct combinations that we tested (Fig. 
3A,B), further indicating that FOXF1 can be regulated in lung endothelial cells by a GLI2 
transcription factor. The increase of FOXF1 transcription from -5.5 kb FOXF1 promoter 
alone, in response to the extra GLI2 synthesis, most likely results from binding of GLI2 to 
the mentioned consensus GLI-binding site or any of several GLI-binding site variants 
located within 5.5 kb upstream to FOXF1.  
Using the SEAP reporter assay, we also tested an in silico identified putative 
regulatory Segment 2, located ~ 16 kb distally to the Segment 1 (Fig. 2A). This region was 
indicated by ChIP-seq assay to bind CTCF insulators, enhancer-binding protein CEBPB,  
and several transcription factors other than GLI, including STAT3, c-Jun, p300 (N-15), 
JunD, KAP1, TBP, and AP-2 gamma (http://genome.ucsc.edu). In the presence or absence 
of the excess of GLI2, a 1.4 kb fragment (chr16:86,256,619-86,258,038) of the Segment 2 
appeared to have no effect on the SEAP expression from the FOXF1 promoter when 
subcloned next to the FOXF1 promoter in the same orientation as the promoter, but 
increased the promoter activity five-fold when placed in the opposite orientation (p<0.0001) 
(Fig. 3A). When tested in trans, the 1.4 kb fragment of Segment 2 did not significantly affect 
the FOXF1 promoter activity (Fig. 3B). Thus, in contrast to the GLI-binding sites of the 
Fragment 1a, the tested fragment of Segment 2 seems less likely to contribute to the long-
range control of the FOXF1 expression.   
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SDR-FOXF1 promoter chromatin looping  
To determine whether there is a physical interaction between the FOXF1 promoter 
and the SDR that would juxtapose distant GLI-binding sites and the FOXF1 promoter, we 
performed a chromosome conformation capture-on-chip (4C) analysis. We detected 
interactions between the FOXF1 promoter region and regions located upstream to it, 
including the 75 kb SDR (Fig. 3C). Using two independently prepared 4C libraries from 
HPMEC, we identified overlapping fragments (chr16:86,246,725-86,246,982 and 
86,246,125-86,246,982) interacting with the FOXF1 promoter around the PolII-binding site 
that were not detected in the 4C library prepared from control lymphoblasts (Fig. 3C). 
These fragments map 12 kb distal to the Segment 1. Chromatine looping between SDR and 
FOXF1 promoter could occure with a contribution of lncRNAs[2, 26-28] including any of 
those encoded within SDR. Moreover, CTCF binding within the SDR (Supplemental Fig. 
S8) also might contribute to the formation of looping architecture[29]. Since we did not 
detect interactions between SDR and the FOXF1 promoter in lymphoblasts, we propose 
that chromatin looping between SDR and the FOXF1 promoter (Supplemental Fig. S9) 
allows GLI2 to increase FOXF1 activity specifically in lung endothelium.  
Maternal origin of ACD/MPV microdeletions  
We have determined parental origin for seven out of eight upstream microdeletions 
(patients 57.3, 60.4, 64.5, 77.3, 81.3, 95.3, and 96.3) and for one microdeletion (59.4) that 
included the entire FOXF1. Interestingly, all these microdeletions arose de novo on the 
maternal chromosome (Supplemental Table S1,S2). Six published de novo microdeletions that 
included FOXF1 (D1, D3, D4, and D8) or mapped upstream to FOXF1 (D9 and D10) also 
arose de novo on the maternal chromosome [9]. Moreover, in recently published unique 
familial case of ACD/MPV, with missense mutations in FOXF1 affecting five subjects, the 
mutation was inherited from heterozygous healthy mother, in whom the mutation arose de 
novo on her paternal chromosome [20]. In aggregate, these findings strongly suggest a 
parental origin bias of FOXF1-associated CNVs (P<0.001, n=14).  
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Differential expression of FOXF1 parental alleles 
To further test whether FOXF1 is imprinted, we compared FOXF1 expression levels 
from both parental chromosomes using two sets of semi-quantitative RT-PCRs with 
primers designed to differentiate between the two parental chromosomes. We found that 
whereas both primer sets amplified equal amounts of FOXF1 from genomic DNA, their 
amplification from cDNA differed significantly (P=0.011, n=3) (Supplemental Fig. S10). 
Thus, our data indicate that FOXF1 expression from the maternal chromosome is not equal 
to its expression from the paternal chromosome, further indicating that FOXF1 is imprinted 
in humans albeit incompletely. 
Differentially methylated CpG site within SDR  
Genomic imprinting can be caused by differential methylation of CpG islands, 
histone modification, or interactions with lncRNAs [30]. Here, we have investigated in 
detail CpG methylation as one of the potential mechanisms of FOXF1 imprinting. The 
FOXF1 promoter resides within a large CpG island [31]. We have bisulfite sequenced this 
region of DNA from normal lung and have found that the FOXF1 promoter is not 
methylated. Previous studies using immortalized normal cells and mammary organoids have 
also shown that the FOXF1 promoter is not methylated [31]. Interestingly, the part of the 
FOXF1 CpG island that is included in the FOXF1 first exon is extensively methylated (Fig. 
4A); however, the functional significance of this methylation remains unknown. We also 
analyzed the results of the methylation studies using Infinium 450K methylation arrays on 
39 brain DNA samples from normal individuals (courtesy of Dr. A.L. Beaudet). One of the 
13 potentially differentially methylated regions upstream to FOXF1 encompassed three 
probes located within the SDR Fragment 1a in the vicinity of a cluster of GLI2-binding sites 
(Fig. 2B, Supplemental Fig. S5, Supplemental Table S3) identified in the ChIP-chip 
experiment, and functionally verified in the reporter assay. Bisulfite sequencing of the SDR 
0.2 kb CpG island closest to the consensus GLI2-binding site and overlaping with several 
GLI-binding site variants confirmed that it is differentially methylated in DNA of normal 
fetal lung (Fig. 4A).  
Methylation of CpG island regulates GLI-binding sites  
We were interested to know whether methylation of the CpG island, including and 
neighboring the GLI-binding sites, interferes with the ability of these sites to regulate 
FOXF1 expression. To this end, we have methylated (in vitro) half of the C residues of this 
CpG island in a 0.6 kb portion (chr16:86,232,261-86,232,908) of the Fragment 1a. We then 
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co-transfected the methylated construct with a FOXF1 promoter-harboring reporter 
plasmid. We observed a reduction in the ability of the Fragment 1a GLI-binding sites to 
activate the FOXF1 promoter, following partial methylation of the CpG island (P=0.015) 
(Fig. 4B). The function of the methylated GLI-binding region did not significantly increase 
in the presence of the excess of GLI2 following the co-transfection of HPMEC with 
pCS2Gli2 (Fig. 4B).  
Discussion 
We identified overlapping deletions, located upstream to FOXF1 in seven unrelated 
patients with ACD/MPV, defining a putative distant regulatory region (SDR) for FOXF1. 
This region, located 257 kb 5` to FOXF1, is 75 kb in size and contains two smaller segments 
that are distinguished by high evolutionary conservation among land vertebrates and high 
7x regulatory potential (Fig. 2). The ~ 1.5 kb part of Segment 1 (Fragment 1a) encompasses 
several GLI-binding sites (Supplemental Fig. S5).  GLI2 is essential for lung development in 
humans and mice[14, 23-25] (. Using ChIP-chip assay, we have confirmed binding of GLI2 
to the Fragment 1a in HPMEC (Supplemental Fig. S6). The 0.6 kb GLI2-binding portion of 
Fragment 1a significantly increased transcription from the FOXF1 promoter in our reporter 
assay, further indicating that it may regulate FOXF1 in vivo (Fig. 3A,B). The increase of 
FOXF1 transcription occurred not only in cis but also in trans, suggesting that this 
activation could occur in vivo through chromatin looping that juxtaposes the FOXF1 
promoter and SDR. The CTCF binding within the SDR (Supplemental Fig. S8) may 
contribute to the formation of this looping architecture[29]. Both cis and trans activations of 
the FOXF1 promoter seem to be specific, since (1) substitution of the 0.6 kb sequence from 
the 1.5 kb Fragment 1a with a 1.4 kb fragment of Segment 2, harboring sites for 
transcription factors other than GLI, in trans or in cis in its original genomic orientation had 
no effect on the promoter activity, and (2) the 3 kb empty vector pGEM-T Easy did not 
activate the FOXF1 promoter. 
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Figure. 4. Methylation of SDR CpG island decreases SDR potential to activate the FOXF1 promoter. The 
presence of additional GLI2, constitutively expressed from pCS2Gli2 vector, is denoted as + GLI2. (A) 
Methylation status of the FOXF1 promoter and SDR CpG island in normal fetal lung (similar CpG 
methylation pattern was observed in DNA isolated from blood). Each lane represents a separate clone. (●) 
Methylated CpGs, (○) unmethylated CpGs. Location of a cluster of GLI-binding site variants is higlighted in 
pink. Position of the consensus “core” GLI-binding site is shown in red. Genomic coordinates of the bisulfite 
sequenced regions are: SDR CpG island: chr16:86,232,367-86,232,979, FOXF1 promoter 2: chr16:86,542,223-
86,542,807 and promoter 1: chr16:86,543,777-86,543,907, FOXF1 exon 1: chr16:6,544,458-86,545,037. (B) 
Methylation of the SDR CpG island overlaping with GLI-binding sites dramatically decreases the ability of 
this regulatory region to activate the FOXF1 promoter. The presence of additional GLI2 constitutively 
expressed from pCS2Gli2 vector is denoted by + GLI2. Abbreviations: FOXF1p, FOXF1 promoter cloned in 
pSEAP2Basic; vect, pGEM-T Easy; Seg1, GLI-binding region (Fragment 1a) cloned in pGEM-T Easy; Seg1*, 
mock control for mSeg1; mSeg1, GLI-binding region of Fragment 1a with in vitro methylated CpG island 
cloned in pGEM-T Easy. 
 
We supported the chromatin looping hypothesis via 4C studies, in which we 
identified physical interaction of the SDR with the FOXF1 promoter around the PolII 
binding site (Fig. 3C). This interaction brings the distant GLI2-binding sites to the 
proximity of the FOXF1 promoter. Although only one of the distant GLI-binding sites of 
SDR perfectly matches the consensus “core” sequence, the clustering of nine of these sites 
within this segment may have synergistic effects on GLI2 binding. Moreover, the variant 
GLI-binding sites with relatively low affinity have been recently shown to strongly induce 
transcription when present in native promoters [32]. Since we did not detect interactions 
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between SDR and the FOXF1 promoter in lymphoblasts, where FOXF1 is not expressed, 
we propose that chromatin looping between SDR and FOXF1 allows GLI2 to increase 
FOXF1 activity specifically in lung endothelium.  
Importantly, we have also identified putative lncRNA genes within the SDR region 
(Fig. 2A). LncRNAs play a crucial role in embryonic development [33]. Moreover, lncRNAs 
have been proposed to play a role in imprinting and both in cis and trans regulating gene 
expression by acting as scaffolds for chromatin-modifying complexes and nuclear bodies, as 
enhancers as well as mediators of long-range chromatin interactions[2, 26, 28, 34, 35]. 
Thus, it seems tempting to speculate that some of the lung-expressed lncRNAs may be 
needed for tissue-specific interaction of the FOXF1 promoter with the distant regulatory 
regions. LncRNAs can also guide chromatin-modifying complexes to specific genomic loci to 
regulate gene expression [2]. For instance, Khalil et al. [3] showed that a 34 kb lncRNA 
TCONS_00024240 (mRNA AK091834), mapping 1.7 kb upstream to FOXF1, binds the 
polycomb repressive complex PRC2. Of note, this lncRNA has the highest expression in 
human lungs (http://genome.ucsc.edu) (see also Supplemental Fig. S1), partially overlaps 
with the FOXF1 promoter, and its locus is largely deleted in the ACD/MPV case 41.4. Our 
preliminary experiments on lncFOXF1 knock-down using siRNAs showed that ~50% 
decrease of lncFOXF1 expression in HPMEC resulted in a weak increase of FOXF1 
transcription (Supplemental Fig. S1), supporting its suggested function as a transcriptional 
repressor [3]. However, in case 41.4, in addition to lncFOXF1 gene, also a GLI-binding 
consensus sequence is deleted, likely leading to a net decrease of FOXF1 expression.  
 Intriguingly, all of the deletions for which we were able to determine the parental 
chromosome origin arose on maternal chromosome 16, strongly suggesting that FOXF1 
could be paternally imprinted (p<0.001, n=14). The paternal imprinting of FOXF1 has been 
also predicted bioinformatically [19]. Even so, any paternal imprinting is probably 
incomplete, because paternal uniparental disomy of chromosome 16 (UPD16pat) has been 
reported in a child with only pre- and postnatal growth retardation [36]. Our data showing 
differential expression of FOXF1 in the lungs supports partial imprinting hypothesis 
(Supplemental Fig. S10). We also reported a paternally inherited no-stop mutation (last 
codon) in FOXF1 in a patient with ACD/MPV [9]. We hypothesize that the extended 
FOXF1 RNA transcript might have escaped nonsense mediated decay and negatively 
interacted with the wild-type copy, resulting in ACD/MPV.   
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We have investigated in detail CpG methylation as a potential mechanism of FOXF1 
imprinting. The FOXF1 promoter resides within a large CpG island (Lo et al. 2010), which 
is not methylated in normal lung tissue (Fig. 4A). Using genome-wide differential 
methylation array hybridization and bisulfate sequencing, we found that a small CpG island, 
located within the Fragment 1a of SDR and overlaping with GLI-binding sites, is 
differentially methylated. Using in vitro methylation and reporter assays, we showed that the 
methylation of this distant CpG island compromises the ability of its GLI-binding region to 
activate the FOXF1 promoter in vitro (Fig. 4B). Although only two of the GLI-binding site 
variants include CpGs within their sequence, and thus can be directly affected by CpG 
methylation, it is likely that methylation of the CpG island changes the local DNA 
environment, and hence affinity of its GLI-binding sites for GLI2. Interestingly, 
methylation of CpGs has been also shown to inhibit interaction of the GLI-type zinc-finger 
factor YYI with its own binding sites [37].  
Position effect or cis-ruption disorders are defined as conditions arising due to 
disruption of the cis regulatory genomic architecture of a disease gene locus [38, 39]. To 
date, this phenomenon has been reported for over 40 gene loci; however, the underlying 
mechanism remains unknown. Of interest, a 7.4 kb cis-regulatory deletion disrupting 
conserved non-coding sequences and their interaction with the promoter of another FOX 
gene, FOXL2, mapping over 280 kb apart, has been described as pathogenic for 
blepharophimosis, ptosis, and epicanthus inversus (BPES, OMIM 110100) [40]. Recently, 
Guttman et al. [41] successfully knocked-down genome-wide 147 (out of 226) lncRNAs 
using shRNAs and observed gene dysregulation both in trans and cis, with cis effects ranging 
up to 300 kb. Our findings further suggest that lncRNA-based chromatin interactions could 
be responsible for the position effect phenomenon in humans and potentially cause many 
other disorders of development. 
In summary, we propose a model of long-range regulation of FOXF1 expression in 
the lungs that includes CpG methylation-controlled GLI2 binding at a distant tissue-specific 
enhancer, whereby chromosomal looping, likely utilizing lncRNAs and CTCF, juxtapose 
this enhancer and the FOXF1 promoter.  
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Methods 
Subject recruitment 
DNA samples were collected from nine unrelated probands clinically and 
histopathologically diagnosed with ACD/MPV. All patients died from severe pulmonary 
insufficiency and hypertension in the first month of life.  
DNA and RNA isolation, and DNA sequencing  
Peripheral blood DNA was extracted using Gentra Puregene Blood Kit (Qiagen). 
DNA from frozen lung tissues was extracted using DNeasy Blood & Tissue Kit (Qiagen). 
DNA from FFPE lung tissues was isolated following manufacturer’s protocol (Agilent 
Technologies). RNA from cultured HPMEC was extracted using RNeasy Protect Mini Kit 
(Invitrogen). Lung RNA was isolated from frozen tissues using Illustra TriplePrep Kit (GE 
Healthcare). 
 PCR products and plasmid DNA were sequenced by the dye-terminator cycle 
sequencing method (Lone Star Labs). Before cycle sequencing, PCR products were treated 
with ExoSAP-IT (USB) to remove unincorporated nucleotides and primers. 
DNA sequence analysis 
Reference sequences were downloaded from the UCSC Genome Browser (NCBI 
build 37/hg19, http://.genome.ucsc.edu). DNA sequence similarities were analyzed using 
BLAT (http://genome.ucsc.edu). Evolutionary conservation and regulatory potential of the 
analyzed sequences were assessed using the UCSC “Conservation” and “7x Reg potential” 
tracks, respectively. The 7x regulatory potential scores are computed from alignments of 
human, chimpanzee, macaque, mouse, rat, dog, and cow genomes using log-ratios of 
transition probabilities from two variable order Markov models[42, 43]. Sequences were 
assembled using Sequencher v4.8 (GeneCodes). Repetitive sequences were identified using 
RepeatMasker (http://repeatmasker.org). GC content was determined using CpGPlot 
(http://ebi.ac.uk/Tools/emboss/cpgplot). CTCF-binding hot spots were identified using 
the University of Washington CTCF binding site track from the UCSC genome browser 
(ChIP-Seq determined) using a threshold value of 500. P-values of finding microdeletion 
with both breakpoints in Alu family repetitive elements by chance were calculated using an 
approach similar to the one presented by de Smith et al. [44](see also Supplemental 
Methods). 
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Screening FOXF1 for mutations 
The entire coding region of FOXF1 (two exons) and its splicing sites were amplified 
for each patient in partially overlapping fragments using GoTaq Flexi DNA Polymerase 
(Promega) in the presence of 8% DMSO. PCR conditions were: 25 cycles of incubation at 
94°C for 30 sec, 56°C for 30 sec, and 72°C for 30 sec. Following purification, PCR products 
were directly sequenced. DNA sequences were then compared with the FOXF1 reference 
sequence (NM_001451.2). 
Genomic copy-number analysis 
CNVs were identified by aCGH with either custom-designed 16q24.1 region-specific 
(1 Mb flanking FOXF1) 180K oligonucleotide microarrays (Agilent Technologies) or 4.2M 
genome-wide oligonucleotide microarrays (Roche-NimbleGen). 4x180 microarrays were 
scanned using Agilent DNA Microarray Scanner, and the data were analyzed using an 
Agilent Genomic Workbench software. 4.2M microarrays were scanned on a Roche-
NimbleGen MS 200 Microarray Scanner. Scanned images of the arrays were processed 
using NimbleScan v2.5 (Roche NimbleGen) and analyzed using SignalMap v1.9 (Roche 
NimbleGen).   
Amplification and sequencing of microdeletion breakpoints 
PCR primers flanking each microdeletion were designed using Primer3 v0.4.0 
software (Supplemental Table S4). Amplification of a 5-12 kb junction fragments for 
sequencing was performed using LA Taq polymerase (TaKaRa Bio USA).  
Parental origin of microdeletions  
Parental origin of microdeletions was determined following identification of 
informative SNPs in parental and patients’ chromosomes. Regions containing the potentially 
informative SNPs were amplified by PCR and directly sequenced. Primers used in this 
analysis were designed based on the location of known SNPs. 
ChIP-chip analysis 
Chromatin immunoprecipitation with anti-GLI2 antibody was conducted in HPMEC 
(ScienCell Research Laboratories). Expression of FOXF1 and GLI2 in these cells was 
confirmed by RT-PCR using SuperScript One-Step RT-PCR Kit (Invitrogen) (Supplemental 
Fig. S7, Supplemental Table S5). The reference DNA was extracted from skin fibroblasts 
that do not express FOXF1. HPMEC were cultured to confluence in EMS medium 
supplemented with 10% FBS, ECGS and 1% penicillin-streptomycin (ScienCell Research 
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Laboratories) at 37°C with 5% CO2. Fibroblasts were cultured in DMEM medium 
(Invitrogen), supplemented with 10% FBS and 1% penicillin-streptomycin, at 37°C with 10% 
CO2. Because of low levels of endogenous GLI2 expression, cells were transfected, 24 hrs 
before the assay, with GLI2 expressing plasmid pCS2Gli2 [45](Addgene) (1µg of DNA/60 
mm plate) using Lipofectamine LTX and Plus Reagent (Invitrogen). Protein-chromatin 
interactions were captured by incubating cells with 1% formaldehyde for 10 min at room 
temperature. Cells were then lysed in SDS lysis buffer and sonicated. Fragmentation of the 
DNA to ∼ 1 kb fragments was verified by agarose gel electrophoresis. Immunoprecipitation 
was performed using EZ ChIP kit (Millipore) and anti-GLI2 antibody (R&D Systems). 5µl 
of the anti-GLI-2 antibody was added to 1 ml of the sample and the GLI2-DNA complex 
was immunoprecipitated overnight at 4°C. 20 µl of Normal Sheep IgG (R&D Systems) was 
used as a negative control. Anti-mono/di/tri methyl-histone H3 (lys4) clone AW304, rabbit 
monoclonal IgG (Upstate) was used as a positive control. MinElute PCR Purification Kit 
(Qiagen) was used to purify and concentrate DNA to final volume of 10 µl. 
Immunoprecipitated DNA was then amplified using GenomePlex Complete Whole Genome 
Amplification Kit (Sigma-Aldrich). After amplification, samples were labeled with Cyanine 
dUTP (Agilent Technologies) using Agilent Genomic DNA Enzymatic Labeling Kit and 
used for array hybridization at 65°C for 24 hrs on custom-designed 16q24.1 region-specific 
4x180K oligonucleotide microarray (Agilent Technologies). 
Reporter assay constructs 
The -5.5 kb FOXF1 promoter region (chr16: 86,538,679-86,544,175), directly 
upstream to the FOXF1’s AUG initiation codon, was amplified by PCR from genomic DNA 
isolated from the blood sample of a normal control individual. This region contained a 43 
bp-long 5’-untranslated part of the FOXF1 first exon. Primers used for the amplification 
were Foxp2F2: 5`CTAGCTAGCACATTTCCTCATATTCTGTGTAGAGAGCACCT3` 
and FoxAUG2R: 5`TTGCGCCGATTCGAACGGGTGGCTGCTG3`, and included 
restrictions sites for NheI and BstBI, respectively. PCR was done using LA Taq DNA 
polymerase (TaKaRa Bio) in the presence of 6% DMSO, applying 25 cycles of 94°C for 30 
sec and 68°C for 5 min. Following digestion with NheI and BstBI (NEB), the PCR product 
was cloned between NheI and BstBI sites of multiple cloning site of the promoterless SEAP 
reporter vector, pSEAP-Basic (Clontech), generating a plasmid p5.5FoxSEAP. The 
pSEAP2-Control vector, containing the constitutive SV40 early promoter with its enhancer, 
was used as a positive control in the assay. The plasmid p41.4Δ4, containing the truncated 
version of the 5.5 kb FOXF1 promoter region (devoid of its 5’ portion deleted in an 
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ACD/MPV case 41.4) was constructed by digesting the p5.5FoxSEAP with KpnI and 
religating the remaining portion of the vector. A 0.6 kb portion of the Segment 1a 
(chr16:86,232,261-86,232,908), bearing CpG island and GLI2-binding sites, was amplified 
from genomic DNA of normal control individual using Taq DNA polymerase (Invitrogen) 
and the following primers upsdelCGliF: 
5`GTGCTAGCATGGTGTAAATCACCCTGACAGTAAACACT3` and upsdelCGliR1: 
`GTGCTAGCGATCTATTCTGCTATCTACCCTCTGCTTTTCC3`, both encompassing 
the NheI site. PCR conditions were 25 cycles of 94°C for 30 sec, 58°C for 30 sec and 72°C for 
1 min. This 0.6 kb fragment was then cloned both into pGEM-T Easy (Promega) by T-
vector cloning to create pGliTEasy, and, following digestion with NheI, into the NheI site of 
p5.5FoxSEAP, upstream to the 5.5 kb FOXF1 promoter region, generating pGli-
5.5FoxSEAP. The 1.4 kb putative enhancer region of the Segment 2 (chr16:86,256,619-
86,258,038) was amplified by PCR using Pfu Ultra DNA polymerase (Stratagene) with the 
primers upsdelEnhF: 5`AAACTTCATCTCTCCCTGCAGCTTCTCTGT3` and 
upsdelEnhR: 5`GTTGGACTCTGAAATCAGTGCCTTCAACAT3`. The blunt-ended PCR 
product was A-tailed using GoTaq Flexi DNA polymerase and cloned in pGEM-T Easy 
vector to generate plasmid pEnhTEasy. This new vector was then cut with NheI and the 
putative enhancer-containing fragment was subcloned in NheI site of p5.5FoxSEAP, 
generating a plasmid pEnh5.5FoxSEAP.   
Cell transfection and reporter assay  
The HPMEC were cultured as described above. Transient transfection of HPMEC 
with reporter gene constructs was done by electroporation using the NEON transfection 
system (Invitrogen). The electroporation parameters were as follow: pulse voltage, 1,350 V; 
pulse width, 30 ms; pulse number, 1; cell density, 1.0x107 cells/ml. The transfection 
efficiency was between 20% and 30%. 0.5 µg of pSEAP2Basic (no promoter), 
pSEAP2Control (Clontech), pEnhTEasy, pUpstdelGliTEasy, or 1 µg of p5.5FoxSEAP, 
pGli5.5FoxSEAP, or pEnh5.5FoxSEAP were co-transfected with 0.1 µg of pMetLuc-
Control (Clontech) (internal control for transfection efficiency) and with or without 0.4 µg of 
pCS2Gli2.  
In an in vitro methylation experiment, 3 µg of linearized, methylated, or 
nonmethylated pUpstdelGliTEasy vector were co-transfected with p5.5FoxSEAP and 
pMetLucControl. One set of transfections included also pCS2Gli2. Each well of 24-well 
plates was seeded with 1.5x105 cells. Activities of SEAP and Metridia luciferase (MetLuc) 
were measured 55 hrs later by a luminescence assays using Ready-to-Glow Dual Secreted 
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Reporter System (Clontech) according to manufacturer’s protocol. Luminescence was 
recorded using microplate LUMIstar Omega luminometer (BMG Labtech, Durham, NC). 
SEAP activities of individual transfections were normalized for Metridia luciferase activities. 
Results are shown as the mean of three independent experiments. Statistical significance of 
the observed differences was estimated applying unpaired t test. 
4C analysis 
3C libraries were generated according to the protocol described by Dostie and 
Dekker [46] using 1x107 HPMEC or lymphoblasts. Crosslinked DNA was digested with 
EcoRI overnight, and religated with T4 ligase for 4 hrs at 16°C at low DNA concentration. 
The 3C library was then processed according to the procedure described by Simonis et al. 
[47]. The ligation junctions were trimmed by digestion of 3C library with TaqaI overnight, 
followed by phenol/chloroform extraction, religation at low DNA concentration for 4 hrs at 
16°C, and DNA linearization with HindIII at 37°C overnight. The 4C template was created 
by linear amplification of DNA using the Expand Long Template PCR System (Roche 
Applied Science). 200 ng of 4C template was amplified per reaction. Primers used for 
amplification were: 5`GGCAGGAAGTTTACAGGGTTTAACG3` and 
5`TGTGTGTGCTAATGTGTGGACAAGA3`. The primers were designed within the 
EcoRI-TaqaI fragment, containing PolII binding site. PCR cycling conditions were: 94°C for 
30 sec, 55°C for 1 min, and 68°C for 3 min. Sixteen reactions were conducted for each 
template. Pooled PCR products were purified using Qiagen PCR cleanup kit (Qiagen).As a 
reference DNA for hybridization, we used uncrosslinked DNA isolated from HPMEC or 
lymphoblasts with Puregene Blood Core Kit A, and digested overnight with EcoRI and 
TaqaI. 
 Custom designed 720K microarrays covering 2 Mb regions flanking FOXF1 were 
designed and produced by Roche-NimbleGen. Labeling and hybridization of 4C DNA 
libraries was done according to manufacturer’s instructions (Roche-NimbleGen). The arrays 
were scanned on NimbleGen 200 Microarray Scanner, and the data were analyzed using 
NimbleScan v2.5 and SignalMap v1.9. The 4C peak data were generated from the scaled log2 
ratio data. Peaks were detected by searching four or more probes whose signals are above 
the specified cutoff values, using a 500 bp sliding window. Each peak was assigned a false 
discovery rate (FDR) score. Scores ≤0.2 are indicative of an interaction site. 
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Bisulfite sequencing  
Bisulfite modification of lung and blood DNA for sequencing was performed using 
EpiTect Bisulfite Kit (Qiagen). Primers for methylation PCR were designed using 
MethPrimer software (Li and Dahiya 2002) (http://urogene.org/methprimer/index1.html) 
(Supplemental Table S6). PCR was performed in 25 µl reaction mixture containing 200 ng of 
bisulfite-treated DNA, 0.5 nmol of each primer, and 1.25 U of HotStarTaq polymerase 
(Qiagen). Cycling conditions were 95°C for 1 min, 50°C to 62°C for 30 sec, and 72°C for 1 
min. PCR products, ranging from 0.2 to 0.6 kb were purified from unincorporated primers 
and nucleotides using QIAquick PCR Purification Kit (Qiagen), and T-vector cloned in 
DH5α cells using pGEM-T Easy Vector System. Plasmid minipreps were prepared from 25 
randomly selected transformant colonies using Perfectprep Plasmid Mini kit (Eppendorf) 
and sequenced using T7 and SP6 promoter universal primers.  
In vitro methylation of CpG island  
For the in vitro methylation assay, the pUpstdelGliTEasy vector was first linearized 
using SphI restriction enzyme (NEB), and then treated with HpaII methyltransferase (NEB) 
that methylates the internal C residue of the sequence CCGG. The 25 µl reaction mixture 
contained 1 µg of the DNA, 1 U HpaII methylase, 50 mM Tris-HCl, pH 7.5, 10 mM EDTA, 
5 mM 2-mercaptoethanol, and 80 µM S-adenosylmethinine. Methylation was performed at 
37°C for 1 hr. In the mock-methylation reaction, S-adenosylmethinine was omitted. Plasmid 
DNA was subsequently extracted with phenol/chlorophorm, precipitated with isopropanol 
and analyzed for the degree of methylation by digestion with HpaII restriction nuclease 
(NEB). Completely methylated plasmid DNA was then used for transfections with an 
unmethylated DNA used as a control. The stability of methylation following transfection of 
the methylated construct was demonstrated recently in the similar experiments reported by 
Ilan and Katzav (2012) and Matousková et al. (2012).  
 
Analysis of FOXF1 expression from individual parental chromosomes 
To determine whether there is a difference in FOXF1 expression from maternal 
versus paternal chromosomes, we first looked for heterozygous SNPs in FOXF1 exons in 
genomic DNA extracted from normal newborn lung tissue, from which we also extracted 
RNA. We identified heterologous SNP G>G/A (chr16:86,547,496) within FOXF1 exon 2. 
We then performed two sets of RT-PCR, using RNA with reverse primer in one setting 
ending in G nucleotide (FoxE2RnaRG: CAGAAAGTTTACAGTAGAGGTTGGG) and, in 
the other setting, in A nucleotide (FoxE2RnaRA: 
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CAGAAAGTTTACAGTAGAGGTTGGA). The forward primer was the same in both 
settings (FoxE2RnaF1: GTCTCCCTTTAGAGCCGTCTTTTG). Both pairs of primers 
were checked for their equal efficiency in priming PCR using genomic DNA. Semi-
quantitative RT-PCR was done using SuperScript One-Step RT-PCR Kit. cDNA was 
synthesized at 50°C for 30 min. Temperature profile of PCR was: 19 cycles of 30 s at 94°C, 
45 s at 56°C, and 45 s at 72°C, and final extension for 5 min at 72°C. 
Data access 
The aCGH, ChIP-chip, and 4C data sets can be accessed through the NCBI Gene 
Expression Omnibus (GEO) (http://www.ncbi.nih.gov/geo/) under accession number 
GSE39258. 
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Abstract 
Since the end of the 19th century twin studies have successfully been used to 
determine the contribution of environmental and genetic factors in traits and diseases.  
Several methods exist to study the genetic component or heritability of any given trait or 
disease. One approach is a Genome-Wide Association Study (GWAS), a method which can 
link human diseases and traits to specific haplotypes using Single Nucleotide 
Polymorphisms (SNP). In GWAS large groups of cases are compared to large groups of 
controls. With a similar approach, using the same genotyping platforms, traits and diseases 
can be associated with large DNA gains or losses.  
Comparing genetics and phenotypes of concordant and discordant twins can be a 
powerful addition to standard association studies. Nowadays, large twin registries exist, 
enabling follow-up of phenotype development over time. Recent advantages in genetic 
technology allow for screening of almost the entire human genome. Comparing the DNA of 
twins is now possible up to the base pair level and allows for mapping of disease genes in 
cohorts of concordant and discordant monozygotic and dizygotic twins, and intra-twin 
comparisons in concordant and discordant monozygotic twins. The genetic contribution of a 
trait or disease can subsequently be inferred by comparing the genetic variance with the 
environmental variance; in monozygous twins any phenotypical discordance should be 
attributed to an environmental exposure later in life.  
Caution has to be taken by the interpretation of these twin-study results since 
environmental and genetic components are not always exactly identical in monozygous 
twins. Maternal blood, including nutrients, oxygen, CO2, metabolites and stem cells can be 
transferred from one twin to the other via placental anastomoses. Unequal access these 
factors exposure to waste products can result in environmental exposure differences. 
Moreover, DNA changes can occur de novo at any time during human life span. These 
somatic changes can be either absent or present in a different frequency in monozygotic 
twins and even in individual tissues depending on the timing of twin separation and 
mutation during pregnancy. It is important to keep in mind that these somatic changes 
could not only explain twin discordance, but also highlight the importance of screening for 
genetic aberrations in different tissues.  
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Introduction 
Micro-array technology in GWAS and Copy Number Variations  
Genome-wide association studies (GWAS) are used to associate human disease and 
traits with a certain chromosomal locus or loci. This is done by whole genome genotyping of 
many cases and controls using so-called tag-SNP probes containing a relative common SNP 
associated with a region in linkage disequilibrium. If a certain tag-SNP has a statistical 
significant higher frequency in cases compared to controls, the studied trait or disease is said 
to be associated with that specific locus. This method has proven to be successful in many 
occasions [1, 2] and has increased our knowledge of disease etiology and human 
development significantly. Genotyping has mainly been done using micro-arrays with up to 
several millions allele specific oligo-probes. These micro-arrays contain information on the 
relative amount of DNA at a given locus. Using both genotype and quantitative information 
these SNP based GWAS studies can be extended to include DNA gains or losses. These 
segmental variations in DNA copy number can arise de novo or be inherited in a Mendelian 
matter. Many of the characteristics of other types of genomic variation are shared: they can 
be ancestry specific, are driven by selection pressure and can influence the expression of 
genes by altering their copy number or affecting gene regulatory regions.[3, 4] Losses can 
result in haploinsufficiency of one or several genes or truncated proteins whilst gains can 
increase gene expression or can also lead to altered protein structure, reduced protein levels 
or function.  
Copy Number Variation; common, rare and de novo 
Many gains and losses are rather common and most likely represent the normal 
population variance.[4, 5] These recurrent DNA variations have an allele frequency of over 
1% and are called common Copy Number Polymorphisms (CNPs). CNPs account for a 
significant proportion of the healthy human genome.[6, 7] They often arise after non-allelic 
homologous recombination of misaligned DNA segments due to the presence of low copy 
repeats.[5] In general, common CNV are not associated with severe congenital anomalies 
but could influence human traits like height [8], aging[9] or age of menarche[10] and raise 
disease susceptibility for a limited number of complex diseases as age related macular 
degeneration [11], Crohns disease[12] , obesity [13], diabetes and rheumatoid 
arthritis[14]. If recurrent gains and losses have an allele frequency under <1%, they are 
called rare Copy Number Variations (CNVs). [15] These CNV are proposed to arise after 
replication errors e.g. non-homologues end joining, fork stalling and template switching or 
micro homology mediated break induced replication.[5] These low population frequency 
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CNVs can contribute to a wide range of diseases for instance in congenital heart disease.[16, 
17] Interpretation of the significance of a rare CNV can sometimes be difficult since CNV 
can be ancestry specific.[18] 
Common CNPs and rare CNVs can be used in genome wide association studies [19] 
and could explain some of the heritability of common diseases or traits.[20] However it has 
to be expected that many associated loci are likely to have been previously detected by tag-
SNPs from “regular” GWAS studies.[14]  In contrast, often large (>500kb) de novo CNV, 
affecting many genes and regulatory sites, are related to pathogenic conditions. For instance 
in congenital anomalies as Congenital Diaphragmatic Hernia [21, 22] Sotos syndrome, 
craniosynostosis and congenital anomalies of the kidney and urinary tract [23],tumor 
genesis[24] autism [25] and intellectual disability. [26] It can be difficult to pinpoint the 
causal gene in these large de novo CNVs since many sites are affected. However, overlapping 
CNVs in similar patients can result in a reduction of the “region of interest”. It can be 
difficult to pinpoint the causal gene in these large de novo CNVs since many sites are 
affected. However, overlapping CNVs in similar patients can result in a reduction of the 
“region of interest”. Summarizing, CNPs are usually associated with traits and not to severe 
early onset diseases. Rare inherited CNVs can be associated with traits, common and rare 
diseases with differences in timing and penetrance in individuals. Finally, large de novo CNV 
can be causal in both early and late onset diseases, congenital anomalies and tumorgenesis. 
(figure 1)  
The prevalence of spontaneous multiple offspring in a single gravidity, twinning, is 
about 1 in 40 pregnancies, although large regional differences are present.[27] The 
incidence of twin pregnancies has increased in the developed world due to the increasing use 
of fertility treatments, increased maternal age, weight and height.[28-30] More congenital 
anomalies are observed in twin pregnancies. Twins can originate either from one oocyte 
(also called monozygous, ~30%) or from multiple oocytes (di- or polyzygotic, ~70%).[31]. 
The fetal placental membrane, the chorion, starts to develop around day 3-4 and the amnion 
forms between day 6 to 8.[27] Depending on time of separation, monozygous twins either 
have independent amnions, chorions and placentas or share one or more of these 
structures.[31] In almost all dizygotic pregnancies each embryo develops an individual 
amnion, chorion and placenta.  
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Figure 1 Copy Number Variation frequency and association to traits and their diseases. DNA gains and 
losses affect large parts of the otherwise diploid human genome. Variation recurring with a population 
frequency over 1% are called common Copy Number Polymorphisms usually have little impact on health but 
could influence human traits.  Copy Number Variations have an allele frequency under <1 and could raise 
disease susceptibility for a limited number of sporadic or common complex diseases. Congenital anomalies are 
mostly associated with de novo CNV, although again rare CNV could contribute often in a multifactorial 
disease model.  
 
There are however, rare incidences of other mechanisms.[32] Dichorionic 
diamnionic monozygous (DCDA)  twins separate before day three, have two placentas and 
represent about 20-30% of monozygous twins. Monochorionic diamniotic (70-75%) twins 
are roughly thought to separate between day 5 and 7 after fertilization. In contrast, 
monochorionic monoamniotic twins (1-2%) have one placenta and separate after day 8 whilst 
division at or after day 13 results in conjoined twins.[27, 33] These placenta’s can be joined 
or connected via vascular anastomoses, just as this can happen in dizygotic twins.[27] 
Genetic factors, in vitro fertilization and increased concentrations of follicle stimulating 
hormone are factors associated with dizygous twinning, whilst monozygous twinning 
etiology is less clear. It has been suggested that inner cell mass damage, breaks in the zona 
pelucida, genetic factors or skewed X-inactivation could be mechanisms resulting in 
monozygous twinning.[27] Ultrasonographic assessment of chorionicity is optimally 
performed in the first or early second trimester.[34, 35] 
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Classical twin design; nature vs. nurture 
Using cohorts of concordant and discordant monozygotic and dizygotic twins 
researchers are able to determine the impact of environment and genetic factors in traits and 
common or complex diseases.[36] Two advantages of twin-studies are that twins share an 
intra-uterine environment and are perfect age-matched controls. Moreover, the genetic 
contribution of a trait or disease can be inferred by comparing the genetic variance with the 
environmental difference. Since monozygotic twins are (mostly) genetically identical any 
phenotypical discordance should be attributed to an environmental exposure in-utero or 
later in life-span. Dizygotic twins only share on average half of their DNA, i.e. like common 
siblings, and a greater variance between dizygotic versus monozygotic twins is supportive of 
an increased genetic contribution. Comparing the DNA of twins is now possible up to the 
base pair level and allow for the mapping of disease genes in dizygotic twins and intra-twin 
comparisons in monozygotic twins.[37]  
 
 CNP-inherited events 
CNV-rare or private, 
inherited from 
affected parent 
CNV-rare or private, 
inherited from unaffected 
parents 
CNV-rare or private,   
de novo 
Population 
frequency high low or even absent low or even absent low or even absent 
Disease or trait 
May be associated to common 
late onset diseases (-
susceptibility) and traits 
May be associated in 
rare diseases if relevant 
genes are affected 
Possible modifying or 
predisposing factors in rare 
diseases 
Likely causal in rare 
diseases if relevant genes 
are affected 
In Case-
Control studies 
Enrichment in case-control 
studies Associated with disease 
Almost absent in controls 
and enriched in cases; 
absolute frequency is low 
Virtually absent in 
controls and enriched in 
cases; absolute frequency 
is low 
MZ twin 
phenotype is 
concordant 
Associated if parent with CNP 
has trait or disease (-
susceptibility) is detected in 
case-control studies 
Associated if 
monozygous twins are 
both affected 
Possible modifying or 
predisposing factors in rare 
diseases 
Likely causal in rare 
diseases if relevant genes 
are affected 
MZ twin 
phenotype is 
discordant 
CNP not associated with trait 
or disease (-susceptibility) and 
traits 
Possible role in 
multifactorial etiology 
with reduced 
penetrancea 
Possible role in 
multifactorial etiology with 
reduced penetrance if 
enriched in cases. a 
Possible role in 
multifactorial etiology 
with reduced penetrancea 
 
Table 1 Copy Number alterations in traits and disease. CNP; Copy Number Polymorphism, CNV; Copy 
Number Variation; a additional functional studies are necessary to prove or exclude causality. Partly adapted 
from [15] 
 
Associations of CNV and traits or diseases 
Enrichment of CNVs in classical case-control studies can result in a statistical 
significant association to a given phenotype. There is a huge increase in the number of 
publications of GWAS studies establishing associations of CNV with a specific disease or 
trait, e.g. in osteoporotic fractures[38], colorectal cancer[39], short stature[40], congenital 
heart disease [16], age of menarche [10], alcohol dependence [41] and schizophrenia.[42] 
In these studies CNV profiles of cases were compared with those of controls. Enrichment of 
phenotypical concordance in monozygotic twin cohorts compared to their dizygotic 
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counterparts hints to a more genetic background. Moreover, genetic discordance in 
discordant monozygotic twins can give strong clues about genetic background. (as depicted 
in table 1) The identification of specific CNV more prevalent in affected monozygous twins 
and their virtual absence in unaffected dizygous twins could identify causal CNV in traits or 
diseases. CNV-twin studies can be either additive to “regular” GWAS or “classical” twin 
studies, or used as an independent study protocol. Therefore, monozygotic twins, either 
concordant or discordant for a given phenotype or trait can be very helpful in these CNV 
association studies. 
Similar as in these studies, enrichment of phenotypical concordance in monozygotic 
twin cohorts compared to their dizygotic counterparts hints to a more genetic background. 
Moreover, genetic discordance in phenotypical discordant monozygotic twins can give 
strong clues about genetic background. (table 1) Specific CNV more prevalent in affected 
monozygous twins and their virtual absence in unaffected dizygous twins could identify 
causal CNV in traits or diseases. CNV-twin studies can be either additive to “regular” 
GWAS or “classical” twin studies, or used as an independent study protocol. Therefore, 
monozygotic twins, either concordant or discordant for a given phenotype or trait, can be 
very helpful in these CNV association studies. 
Surprisingly, CNV-association studies in twins are even rarer than regular CNV-
GWAS studies. Few studies focus on single genes or locus e.g. CES1 gene duplication with 
susceptibility to type 2 diabetes.[43] In this study mRNA expression levels and CES1 gene 
copy number of 295 monozygous and 170 dizygous twins discordant for obesity were 
compared. A positive association was found between CES1 mRNA levels and body mass 
index, insulin resistance, insulin levels, fasting glucose levels and triglyceride levels. 
Moreover, gene duplication was associated with insulin sensitivity, glucose tolerance and 
negatively associated with insulin resistance. Interestingly, CES1 mRNA levels were not 
associated with CES1 Copy Number; most likely other factors also contribute to the 
associations found in this study.  
In a Genome-wide CNV association study [44], the copy number profiles of 20 
sporadic patients with type 1 diabetes was compared with 20 healthy controls. The resulting 
39 CNVs were subsequent validated in a discordant monozygous twin pair cohort (n=10). 
Five of these CNV, enriched in the twin cohort, pointed to susceptibility loci for type 1 
diabetes. Nag and co-workers studied intra-ocular pressure in 992 twins enlisted in the UK 
twin registry and replicated their findings in two independent twin cohorts (n=467 and 
139 
  CNV in twins 
n=1620). They found an association with a CNV on chromosome 5q21.[45] With a CNV 
burden test associations were obtained between specific CNV and attention deficit disorder. 
Although Ehli and co-workers detected two de novo CNV; these were concordant in the 
monozygous twins.[46] However, CNV burden in patients was significantly higher and the 
affected individuals had larger, more often rare and de novo, CNVs compared to unaffected 
individuals. These rare CNVs could contribute to the attention deficit disorder. This is in 
line with the “common disease, rare variant” hypothesis or rare allele model, in which 
recently emerged (in the population) rare alleles have a large effect on disease etiology. In 
this model penetrance may be influenced by other factors.[47-49]  
Identical twins; exceptions to the dogma 
There are some exceptions to consider before interpreting twin study results. First of 
all, the intra-uterine environmental conditions are not always equal. For example, twin-to-
twin transfusion syndrome (TTTS), one of the most serious complications of monochorionic 
multiple gestations, can occur. TTTS develops as discordant loss of arteriovenous 
anastomoses resulting in asymmetrical flow resistance.[50]  In monozygotic twins often the 
placenta is shared. Blood including nutrients, oxygen, CO2, metabolites and stem cells can 
be transferred from one twin to the other via placental anastomoses due to increasing 
hydrostatic and osmotic forces; the resulting disproportional blood supply causes 
developmental delay and decreased urinary output in the “donor” twin (and 
oligohydramnion) and increased urinary output and resulting polyhydramnios in the 
“recipient” twin. The increased blood flow can result in cardiac anomalies in the later twin. 
The unequal access to maternal blood, transfusion and waste of nutrients, and 
oligohydramnios and polyhydramnios result in differences in environmental exposure. 
TTTS develops in 10 to 15 percent of monochorionic twins and is associated with several 
congenital anomalies. For instance, TTTS and undiagnosed loss of a twin fetus in early 
stage of pregnancy could be a substantial factor contributing to congenital anomalies as 
VACTERL association or gastro-intestinal atresia.[33, 51]  
Second, DNA changes, mutations or Copy Number Variations, can arise de novo at 
any time during the human life span. Somatic DNA variations, occurring early in 
development or later in life can be either absent or present in a different frequency in 
monozygotic twins depending on the timing of egg division and mutation. (figure 2) Clear 
examples are those CNV that are involved in tumorgenesis [52] although these DNA 
changes can occur much earlier and be responsible for less dramatic somatic differences 
between newborns.[53]  
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It has even been proposed that DNA mutations cause cells in the blastocyst to 
recognize each other as foreign resulting in separation of these cells and causing the 
twinning process.[27] 
Current twin study design and discordant twin studies 
Improvements in genetic and epidemiological insights enable researchers to go 
beyond the classical twin design. The genomes of parents, mono- and dizygous twins are 
characterized and very large twin registries enable us to follow the phenotype of interest 
over time. Several experimental set-ups are now possible. For instance, the DNA of 
phenotypical discordant monozygotic twins can now be compared and any discrepancy could 
point to disease causing mutations. Subsequent screening of large cohorts of cases and 
controls could confirm the impact of this mutation on disease etiology. In a classical twin 
design the concordance rate of monozygotic and dizygotic twins is compared. Another 
approach could be to compare CNV burden of affected concordant monozygous twins and 
compare this to cohorts of affected concordant dizygotic twins. (figure 2) If a specific type of 
CNV is more present in the monozygous cohort it is likely to be associated with the trait or 
disease studied.  An essential aspect of twin studies, which is independent of study design, is 
the need for proper zygosity determination. 
Experimental procedures 
Determination of zygosity 
Zygosity can be determined in a number of ways, with variable accuracy in different 
study populations e.g. blood group, gender, chorionicity, dermatoglyphics and phenotypical 
appearances. Selection of same-sex pairs combined with questionnaires could be accurate 
enough in adult twin studies. Although relatively reliably in adults, zygosity typing based 
on gender, chronicity and appearances alone is not so reliable in newborns. For instance, 
Mono-chorionicity does not always mean that twins are monozygous [54], same-sex pairs 
are not always monozygous [55] nor does having an opposite gender confirms 
dizygosity.[56] DNA based test give an almost hundred percent certainty e.g. comparing 
the length of several polymorphic tetra-nucleotide short tandem repeat loci, using several 
SNPs (not in linkage disequilibrium) or genome-wide SNP-arrays.[52, 55, 57]  
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Figure 2 Examples of experimental set-ups to determine the genetic basis or contribution of a disease 
or trait A. With Genome Wide Association Studies in sporadic cases enrichment of a DNA variant in cases 
(right) and a significant over-representation of a trait or disease in these cases (and) compared to controls 
(left, � and ) points to a genetic contribution of a specific locus. B If the concordance rate in monozygotic 
twins is higher compared to dizygous twins it is likely that genetic factors contribute to the trait or disease. C 
A trait or disease can be hereditary. Pedigree and linkage analysis can pinpoint inheritance pattern and locus of 
the contributing or causal genetic factor.  D Comparing the genomes of monozygotic twins can aid in finding 
the causal genetic factor of a trait or disease. In discordant monozygous twins (left) finding a discordant 
genetic variant would provide first evidence of this causal factor. Finding de novo variants in concordant 
monozygous twin with healthy parents could also provide this evidence. Finding variants that disturb protein 
function, structure or expression level in several independent families or twin-parent combinations strengthens 
this evidence for a causal gene; subsequent functional studies would prove causality. 
 
Copy Number Variation profiling 
Determining the genome wide segmental copy number can be done with DNA-array 
using Single Nucleotide Polymorphism (SNP) based probes or by using oligonucleotides in a 
comparative genomic hybridization (CGH) experiment. SNP based micro-array has the 
advantage that they rely on two types of information; allelic and segmental copy number 
state. Therefore, these kinds of arrays are less influenced by DNA input variations. Most 
laboratories use SNP-array for genotyping and GWAS, homozygosity mapping and CNV 
analysis. Using these types of arrays there is also no need for zygosity testing in twin births 
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since zygosity and gender can easily be determined within the genotyping analysis. CNV 
size and number are dependent on platform used, amount and spacing of probes, analysis 
settings and CNV calling algorithms and software. [58-60] Throughout the years the 
resolution to distinguish copy number variation from background noise has increased 
significantly: current micro-array technologies allow detecting of genomic imbalances down 
to only a few Kb in size.   
Figure 3 Two examples of concordant copy number variations in discordant twin-pairs. A1-A2 On the 
left the SNP array results, visualized with Nexus Copy Number v7 (Biodiscovery inc., Hawthorne,CA,USA), of 
a monozygotic twin pair discordant for esophageal atresia. Both the affected (upper panel A1 and lower panel 
A1) and healthy twin (upper panel A2 and lower panel A2) have a 201kb gain affecting exon 2 of the PARK2 
gene. In the upper panel the log2R ratio, representing the copy number status, shows a raise (blue dots) of 
several probes. This raise is accompanied by a shift in allelic frequency (B-allele frequency, lower panel) 
indicative for the over-representation of one allele over the other. The combination of raise in log2R ratio and 
shift in B-allele frequency of several allele specific SNP-probes is indicative for a gain in DNA quantity of that 
specific locus. Both twins have exactly the same gain and this gain was inherited maternally, which was 
confirmed with qPCR. B1-B2 On the right the SNP array results of a monozygous twin pair discordant for 
Congenital Diaphragmatic Hernia. The affected twin (upper panel B1 and lower panel B1) and unaffected sib 
(upper panel B2 and lower panel B2) both have a 474kb deletion deleting several exons of the ARHGAP24 
gene. The drop in log2R ratio (upper panel, red dots) and loss of one allele type (yellow dots, lower panel) are 
indicative of a loss of one copy of DNA at that locus.  qPCR confirmed that both twins had the same deletion 
and that this deletion was inherited maternally. [55] 
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Confirmation of results with a second technique 
It is always advisable to confirm Copy Number events of interest with a second 
technique, preferably as dissimilar to the initial technique as possible. For instance, using 
Fluorescence in situ hybridization (FISH) and counting signals on metaphase slides, melting 
curve analysis or quantitative PCR. Ideally, the effect of the discordant chromosomal 
aberration is measured e.g. with RNA or protein expression based studies in relevant tissues. 
The need for validation has several reasons: 1) determination of CNV using micro-array is a 
relative new technique, each platform has its own sensitivity and specificity. 2) With micro-
array the relative copy number is determined i.e. compared to one or more reference samples 
or to a large reference cohort. 3) Moreover, it determines the average amount of DNA at 
each segment, gains and losses at the same locus result in a diploid copy number and 4) 
micro-array gives limited information on the location or orientation of a given CNV.  5) Also 
technical variation can influence experimental outcome e.g. micro-array relies on 
amplification of DNA and measurements using (fluorescence) intensity. 
Considerations in monozygous twins 
In general, monozygous twins with a concordant pathogenic genetic aberration have 
a concordant phenotype. The presence of a newly associated pathogenic CNV in both twins 
strengthens the implication of the CNV pathogenicity. For instance, two monozygous twin 
boys with autism both had the newly identified pathogenic 16p11 micro duplication.[61] 
Surprisingly, monozygous twins with concordant chromosomal anomalies, pathogenic CNV 
or mutations can also have a discordant phenotype. Even monozygous twins with known 
genetic syndromes can have a highly variable phenotype.[62] For instance the phenotypical 
spectrum of the 22q11.2 deletion syndrome [63, 64] is extremely variable. One of the 
proposed explanations for the discordance is an undetected difference in deletion size.[65] 
Others could be epigenetic differences, differences in blood perfusion, somatic changes, 
single nucleotide changes and other genetic abnormalities below the detection threshold on 
the other allele. Phenotypical discordant monozygous twin studies are an excellent model 
for studying the phenotypical spectrum of known genetic diseases.[62] Critical to consider 
in some, often late onset, diseases is that initial phenotypical discordant twins can become 
concordant e.g. in familial amyloidotic polyneuropathy type 1 [66], schizophrenia [67] or 
spinocerebellar ataxia.[67] Various factors could contribute to these age of onset 
differences. For instance, environmental components were suspected to modulate the 
penetrance of a concordant repeat expansion in a monozygotic twin pair with Huntington 
Disease.[68] 
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Timing matters; twin separation and mutation 
Phenotypical discordance between monozygotic twins at birth can have several 
reasons i.e. differences in epigenetic modifications, environmental exposure, stochastic 
factors but also genetic differences. Here we would like to discuss these DNA differences. 
This sounds a bit counter-intuitive since by definition the DNA of monozygous twins is the 
same as they originate from a single zygote. However, there is increasing evidence that 
there are exceptions and several studies have undertaken the endeavor of comparing their 
genomes. The rationale behind these types of studies is that discordant somatic mutations 
arisen during development or lifespan are responsible for the phenotypical discordance. 
These discordant twin studies are performed at different resolutions. Karyotyping (see Table 
2) is able to detect numerical and large structural chromosomal anomalies. CNV analysis 
(see Table 3) is able to detect DNA gains and losses around the gene level resolution. 
Finally, whole genome Next Generation Sequencing (NGS) which can not only measure 
SNPs and small DNA gains and losses called Insertion/ Deletions (InDel) but also CNV at 
the exon level, inversions and translocations. Moreover, this genome wide screening is not 
dependent on platform design as is the case with array technology. Here, we will discuss two 
types of copy number discordance; hetero-karyotypical discordance and Copy Number 
Variation.  
Mutations or non-disjunction during meiosis or early mitosis can lead to either 
complete concordant mutated genomic DNA or, via unequal distribution and sub-sequent 
rescue mechanisms, to differences in somatic mosaicism in monozygotic twins. Post-zygotic 
DNA mutations will lead to somatic mosaicism if the cells survive the damage and the 
mutations is not repaired. These mutations can either be single base-pair changes, deletions 
and insertions of several bases or CNVs ranging from dozens of base-pairs to gains and 
losses of several megabases in length. Depending on the developmental stage and cell types 
affected, CNV can be present throughout the body, or be present at certain frequencies in 
specific tissues. If germ cells are affected, the mutation can be transmitted to subsequent 
generations.  Differences in timing of separation and mutation result in differences in genetic 
manifestations; depending on the number of cells with and without the mutation and their 
distribution across the twins, tissue specific somatic mosaicism can vary accordingly. 
Therefore, it is advisable to test different tissues for the presence of a genetic aberration e.g. 
to search for placental mosaicism or the presence of low-grade mosaicism in dermal 
fibroblasts.  
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A source of false positive results when testing for genetic defects in blood or saliva 
immediately after birth are those differences caused by transfer of lymphocytes via twin-to-
twin transfusion. After several weeks each twin has their ”own” lymphocytes in its 
circulation, although transfer of hematopoietic stem cells can’t be excluded.[69]  
Germline non-disjunction, aneuploidy and somatic mosaicsm 
For example, karyotyping of cultured cells derived after amniocentesis of two 
monochorionic diamniotic twin boys revealed discordance for trisomy 18. Both twins had 
trisomy 18 mosaicism of blood and buccal smear samples after birth. However, the placenta 
turned out to be mosaic for trisomy 18, indicative for a mosaicism in the early zygote. 
Further testing revealed only a low grade (5%) mosaicism in skin fibroblasts in one of the 
sibs.[70] Therefore, most likely non-disjunction during meiosis II followed by an unequal 
distribution of normal /affected cells to the twin sibs led to this discordant karyotype. 
Analysis of the placenta of MCDA twins, in which one had a non-mosaic deletion of the 
short arm of chromosome X and the other twin had non-mosaic Turner syndrome, revealed 
a 45,X/46,X, del(X)(p11.1) karyotype in the placenta. [71] Loss of the p-arm of the X-
chromosome has led to complete loss of the aberrant X chromosome during early mitotic 
events.   
Aneuploidy prior to conception, i.e. in the germ cells, can result in hetero-
karyotypical discordance between monozygotic twins.  During meiosis or early post-zygotic 
mitosis, non-disjunction of sister-chromatids (meiosis II or mitosis) or homologues 
chromosomes (meiosis I) can lead to an unequal distribution of chromosomes; the resulting 
cells have either 0 or 2 copies (meiosis I and II nondisjunction) or 1 and 3 copies (mitotic 
non-disjunction error). Depending on timing of the twin separation and division of cell 
lineages the monozygous twins can be complete discordant for the aneuploidy or have a 
certain discordant somatic mosaicism. For example, karyotypes from blood derived of a 
MCDA twin pregnancy hinted at mosaicism for trisomy 21 in both sibs. However, cheek and 
skin biopsies revealed two distinct karyotypes; 46, XY in the healthy sib and 47, XY, +21 in 
the affected sib.[72] This a clear example of the effect of TTTS responsible for the 
admixture of 47,XY,+21 cells of the affected to the healthy twin. Also, since both twins were 
mosaic in blood, there was blood flow from the healthy twin to the affected twin effectively 
diluting the 47,XY,+21 cells with 46,XY cells. Since the trisomy was present in skin and 
blood, non-disjunction during meiosis is a plausible cause of this discordant aneuploidy. 
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Genetic 
abnormality 
location Tested for 
monozygosity 
Technique Confirmation 
method 
Discordant phenotype Ref. 
Trisomy  13 Short tandem 
repeat profiling 
with 7 markers 
and one gender 
marker 
Quantitative 
PCR 
karyotyping NA; radiofrequency 
ablation of affected twin 
at 18 weeks of gestation 
[73] 
Trisomy  18 Chorionicity 
(MCDA) and 
Short tandem 
repeat 
Karyotyping 
after 
amniocentesis of 
both sacs 
Karyotyping of 
fibroblasts and 
chorionic villi taken 
from different sites 
of placenta 
MCA, 47,XY,+18 
versus healthy twin 
with low grade (5%) 
+18 mosaicism in 
fibroblasts 
[70] 
Trisomy  21 Chorionicity and 
gender 
MSS in 1th 
trimester and 
nuchal 
translucency 
scan 
Karyotyping in one 
case; others not 
described 
21 cases discordant for 
Down syndrome 
[72] 
Trisomy  21 Chorionicity and 
short tandem 
repeat profiling 
with 10 markers 
Karyotyping 
amniotic fluid 
cells 
Short tandem repeat 
with 7 STR markers 
on Chr. 21 
Placenta was mosaic 
trisomy 21; 46,XY sib 
spontaneous aborted. 
Termination of 
pregnancy of affected 
fetus. Twins discordant 
for Down syndrome 
[74] 
Monosomy X Chorionicity and 
short tandem 
repeat profiling 
with 11 markers  
Karyotyping 
amniotic fluid 
cells 
Affected twin 45,X 
[24] and  healthy 
twin low grade 
mosaic 45,X [1]/46, 
XY [29] in 
fibroblast cultures 
Termination of 
pregnancy; discordant 
for Turner syndrome ; 
placenta was mosaic 
45,X/46,XY 
[74] 
Monosomy X Chorionicity Karyotyping 
and 
Quantitative 
PCR 
Fluorescence in Situ 
Hybridization; 
karyotyping of 
fibroblasts 
45,X in one and 46,X, 
del(X)(p11.1)  
[71] 
Mosaic XY X, Y SNP-array SNP-array Fluorescence in Situ 
Hybridization 
45,X/46,XX in one and 
45,X/46,XX, 46, XY in 
the other twin 
[56] 
 
Table 2. Examples of hetero-karyotypic twinning in discordant monozygotic twins. MSS; Maternal 
serum screening: β-Human Chorionic Gonadotropin (β-HCH) and pregnancy associated plasma protein A 
levels in first trimester screening and β-HCH , unconjugated oestriol (µE3, Alpha FetoProtein (AFP) and 
Inhibin-A levels in the second trimester screening 
 
Genetic discordance; somatic mosaicism and de novo CNV 
Another source of genetic discordance are de novo CNVs. Such CNV could arise 
during meiosis in the parental germ cells, during early zygotic mitotic divisions or later in 
life. Therefore, it is recommendable to compare the CNV profiles of twins to that of their 
parents and siblings in addition to the comparison with the traditional cohorts of ancestry 
matched affected and non-affected individuals. The de novo CNV rate per generation is much 
higher than the mutation rate; estimates for CNV are 100-10.000 times higher than the 
single base-pair mutation rate per generation i.e. ~ 2 x 10-8 versus ~1-2 10-6 to 10-4. [4] 
Ehli et al. describe 26 de novo CNV, measured with SNP-micro-array, in 25 attention 
deficient concordant and discordant monozygous twin pairs.[46]  Some of these de novo 
CNVs were recurrent; there were 18 unique targets for a validation experiment. 
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Quantitative PCR primers could be developed on 11 of these target regions. Two out of 17 
tested de novo CNVs could be validated with qPCR and one could not be proven nor 
excluded i.e. 13 seemingly de novo CNV were in fact inherited from one of the parents. One 
of the de novo CNV that was present was duplication in chromosomal band 15q11. This 
duplication was present in a male concordant unaffected twin-pair and was a pre-twinning 
event. The other, a post-twinning, de novo CNV was a large 1.3 Mb deletion located on band 
4q35 and only observed in the oldest sib of a male concordant affected twin pair. The 
genotype-phenotype correlation in both instances is difficult since both unaffected twins had 
a de novo duplication and only one of the affected twins had a de novo deletion. Somatic 
mosaicism could not be excluded nor confirmed since only buccal swab derived DNA was 
available.   
Congenital anomalies are a major contributor to prenatal and postnatal mortality and 
childhood morbidity. Although some of these anomalies can be completely explained by 
chromosomal anomalies, other genetic defects, teratogens or malnutrition, the majority of 
patients still have an unknown disease etiology. Several explanations have been put forward 
for these unknown etiologies e.g. yet undiscovered genetic or epigenetic changes, 
environmental or nutritional factors, disturbances in biological processes, mechanical 
explanations or otherwise and the lack of systematic data collection of the affected child and 
the parents. Twin studies can help in assessing the contribution of environmental and 
genetic factors in many of these congenital anomalies.  
Several studies specifically searched for differences in DNA copy number between 
discordant monozygous twins with congenital anomalies. Breckpot et al compared the copy 
number profiles of six monozygous twin pairs discordant for congenital heart defects. In 
female twin pair 1 a 186 Kb large duplication was identified in the affected sib. In male pair 3 
two small 2kb losses were detected at chromosomal loci 1p33 and 6p25 in the unaffected sib 
(all false positive differences) and in a male twin pair 6 three confirmed and three false 
positive CNVs were detected in the affected male sib; the 4kb gain on chromosomal 12p13, a 
gain on Xp11.23 and a gain on Xq28 were confirmed with qPCR. [75] In a monozygous 
twin pair discordant for cleft lip and palate and growth restriction Array-CGH on DNA 
derived from uncultured amniocytes revealed a terminal deletion of chromosome 18q in the 
affected sib of a MCDA female twin-pair. Subsequent FISH confirmation on cultured cells 
confirmed a non-mosaic 46, XX, del(18)(q21qter) karyotype in the affected twin while all 
cells from the healthy sib were normal. However, fetal blood, skin, tendons and lung biopsies 
were mosaic for the chromosome 18q deletion in varying frequencies in both twins.[53] 
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Both fetal blood samples had a 25% mosaicism whilst skin, tendon and lung were low grade 
mosaic in one twin and high grade mosaic in the other. Unequal distribution of affected cells 
prior to twin separation had resulted in tissue specific differences in mosaic frequency. Twin-
to-twin transfusion resulted in mixture of normal and affected cells in both twins; it diluted 
the 18q21 deletion with normal cells in one and transferred affected cells to the other twin. 
An intriguing example of somatic copy number variation mosaicism was published 
recently. Rio and coworkers [76] describe two DCDA monozygous twin sisters in which 
one girl has facial dysmorphisms, delay in fine motor skills,  language skills and mental 
development. Her sister did not have facial dysmorphisms and only has delayed speech and 
unilateral single palmar crease. In the more severely affected twin a de novo non-mosaic 
deletion in chromosomal band 2p23 was detected with array-CGH and confirmed with locus 
specific FISH while in the mildly affected twin normal cells, 2p25 deletion and 2p25 
duplication cells were detected using FISH only. Array-CGH in the latter was normal since 
it is an average of all cells, the 2p25 duplicated balanced the signal of the 2p25 deleted cells 
to a seemingly 2n state. Post zygotic non-allelic recombination has led to these three 
distinct cell populations; normal 46,XX cells, 46,XX dup(2)(p25.3) and 46,XX, del(2)(p25.3) 
cells. This post zygotic event had to be prior to separation making the drastic differential 
distribution of three cell lineages possible. Although several studies report on CNV 
differences in monozygotic twins discordant for specific congenital anomalies [53, 75, 76] 
others have not found these differences. [55, 77, 78]  In our study the DNA of phenotypical 
discordant twins for esophageal atresia (seven pairs) and congenital diaphragmatic hernia 
(four pairs) were compared using SNP-array. Genotyping differences were validated with 
Sanger sequencing and CNVs confirmed with qPCR. No SNP nor (mosaic) CNV differences 
were present in these twins.[55] Several concordant CNPs and CNVs were observed. 
Although no shared rare inherited CNV were observed in this limited number of patients, 
few inherited CNV could be modulators or predisposing factors which, in combination with 
other factors, could have relevance to the disease phenotype. For instance the duplication 
observed in both sibs of an esophageal atresia discordant monozygotic twin pair affects the 
PARK2 gene, this gene is also duplicated in patients with low-grade dysplasia of the 
esophagus.[79] The deletion of (part of) the ARHGAP24 gene in both the affected and 
unaffected members of a monozygous twin pair discordant for congenital diaphragmatic 
hernia by disturbing normal angiogenesis.[55] Baudisch and coworkers performed a similar 
experiment in four monozygous twins discordant for urorectal malformations. They also did 
not find CNV differences between twins nor did they find de novo CNV in both twins.[77]  
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Genetic 
abnormality 
Location Tested for 
monozygosity 
Technique Confirmation 
method 
Discordance Reference 
  
CNV difference detected  
  
CNV 12p13; 
Xp11 and 
Xq28 
Same sex pairs; 
determination of 
zygosity not 
described 
Array-CGH qPCR CHD discordance [75] 
Mosaic CNV 
(mosaic; 
deletion) 
11q and 4q  SNP-test BAC and 
SNP-array 
Melting curve 
analysis and 
PCR based 
array 
CLL discordance [52] a 
CNV 2q SNP-array BAC and 
SNP-array 
Melting curve 
analysis and 
PCR based 
array 
Both sibs were healthy [52] a 
Mosaic CNV 
(mosaic; 
deletion) 
18q21.2qter  STR-profiling 
with 8 markers  
Array-CGH FISH Discordant for Cleft lip and palate 
phenotype; 18q21-qter mosaicism 
in both twins with different 
frequencies 
[53] 
CNV 
(mosaic; 
deletion) 
2p25.3 STR-profiling 
with 25markers 
Array-CGH FISH Mosaicism; 
del(2)(p25.3)/dup92)(p25.3) and 
normal cells (1:1:1) in mildly 
affected  sib; only deleted cells in 
severely affected sib 
[76] 
CNV 
 
multiple SNP-array SNP-array qPCR* Discordant for Schizophrenia [80] 
CNV 
 
multiple SNP-array SNP-array -b Discordant for amyotrophic 
lateral  sclerosis 
[81] 
CNV  
(loss-de novo) 
19p13.3 SNP-array Array-CGH Custom high 
density CGH-
array 
Discordant for Multiple System 
Atrophy 
[82] 
CNV  
(loss-de novo) 
22q11 SNP-array? SNP-array; 
FISH 
- Discordant 22q11 phenotype 
deletion size 
[65] 
       
no CNV difference detected 
 
CNV NA STR-profiling 
with 16 markers 
and SNP-array 
SNP-array qPCR Discordant for urorectal 
malformations 
[77] 
CNV NA - BAC -array -b Discordant for cono-truncal 
malformations 
[83] 
CNV NA SNP-test Array-CGH qPCR Discordant for Schizophrenia or 
bipolar disorder 
[84] 
CNV 22q11 Red cell antigens; 
STR-profiling 
FISH - Twin A; anal atresia, tetralogy of 
Fallot, pulmonary  atresia and 
characteristic facial features; twin 
B only characteristic facial 
features 
[63] 
CNV NA SNP-genotyping SNP and 
CGH-array  
DNA-
sequencing 
Discordant for cleft lip and/or 
palate 
[78] 
CNV NA SNP-array SNP-array qPCR, DNA-
sequencing 
Discordant for schizophrenia [85] 
CNV NA STR-profiling 
with 16 markers 
and SNP-array 
SNP-array; 
NGS-
Exome CN 
qPCR, FISH Discordant for CDH or  EA/TEF [55] 
 
 
Table 3. Examples of Copy Number variation measurements in discordant monozygotic twins. CNV; 
Copy Number Variation, STR; Short Tandem Repeat, CGH; Comparative Genomic Hybridization;, FISH; 
Fluorescence In Situ Hybridization, CDH; Congenital Diaphragmatic Hernia, EA; Esophageal Atresia, CHD; 
Congenital Heart Defect, SNP; Single Nucleotide Polymorphism. a Bruder at al. [52] describes several more 
somatic differences detected with both 32K BAC-array and 300K SNP-array. However, these were not 
described to be validated with a second technique. bno validation experiments addressed in article 
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Post twinning mutation and tissue specific somatic mosaicism 
Somatic changes can be responsible for slight genomic differences between 
monozygotic twins but also result in differences within different body tissues of the same 
individual. For instance, Liang et al. analyzed the genomes of clones from mouse embryonic 
stem cells and measured differences in copy number at several loci in those clones. These 
CNV arose during the mitotic cell divisions. If similar events take place in human stem cells 
we could have many somatic CNV mosaicism in our tissues.[86] There can be accumulation 
of somatic CNV in the adult with an increased incidence over time. In a large cohort of 
monozygotic twins, Forsberg could detect mosaicism for megabase size CNV in 3.4% of 
individuals of 60 years and older whilst these were absent in the younger study cohort (33-
55 years).[87] Five of these, monozygous twin pairs the CNV profiles were determined over 
time; a 5q deletion increased in frequency in female MZ sib with dysthymic disorder, 
cholelithiasis and cerebral infarction. In other, unrelated, patients with several forms of 
malignancies specific CNV accumulation was present. In fact, in two of these patients the 
CNV were indicative of, but at that time not yet diagnosed, myelodysplastic syndrome. In an 
apparently healthy individual Piotrowski and co-workers describe somatic CNV differences 
between cardiac and cerebellar cortex tissue derived DNA.[88] In fact, human neuronal 
cells can differ greatly in DNA content [89] and discordant CNVs are measured in single 
cell assays.[90] Accumulation of these genomic imbalances could be an underlying 
mechanism of late onset neuropathies.[89, 90] Perhaps it is advisable to screen individuals 
not only several times during their life, but also to evaluate multiple tissues. 
CNVs that arise after the separation of the monozygous twins are completely 
discordant between those twins. After zygosity testing, Bruder et al compared the genome of 
nine Parkinson or Parkinson-like discordant monozygotic twins and ten healthy 
monozygotic twins.[52] They found (and confirmed with additional techniques) three 
somatic intra-twin differences. In an 80 year old male twin pair, in the sib with Parkinson, 
an approximately 20% mosaicism was detected for two large deletions; one chromosome 11q 
and the other on chromosome 4q. This aberration is often seen in patients with chronic 
lymphocytic leukemia and this Parkinson patient was previously diagnosed with this 
condition. In addition to these tumorgenesis related CNVs another discordant CNV was 
detected in a concordant healthy 60 year old female monozygous twin pair. This CNV, a 
70%-80% mosaic deletion of chromosome 2p23 was only present in one of the sisters and 
was confirmed with high-resolution melting curve analysis and pyro-sequencing 
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Sasaki compared the CNV profile of a 67 year old monozygotic twin pair.[82]  The 
affected sib was diagnosed with Multiple System Atrophy (MSA) at the age of 57 years; 
atrophy of the brainstem and cerebellum was confirmed by MRI. His brother did not have 
MSA symptoms. Three discordant CNVs, present in the affected twin only, were identified 
with array-CGH: loss in chromosomal bands 2p25, loss on 4q35 and a loss on 19p13. Two 
independent array experiments (SNP-array and a custom CGH-array) confirmed the 
presence of the 19p13 loss in 10 additional MSA patients. This loss was absent in 125 
controls. These authors used successfully a twin-CNV discordance experiment to find a 
possible disease associated CNV and confirmed the pathogenicity of this CNV with a burden 
test in a case control-study.  
CNV profiling in both concordant and discordant monozygotic twins can be a used to 
identify causal or contributing genetic factors to specific traits and diseases, although 
caution has to be taken by the interpretation of these twin-study results.  Twin pregnancy 
may not be representative of a singleton pregnancy[27] and environmental and genetic 
components are not always exactly identical in monozygous twins.  TTTS can cause intra-
uterine environmental differences; somatic mutations can lead to genetic mosaicism in 
different tissues within one individual and between twins. It is advisable to screen for 
genetic abnormalities at several time-point during a person’s life-span and in different 
tissues. Accumulation of somatic changes could be responsible for a significant proportion of 
human disease. Moreover, determining the zygosity status in all pregnancies is advisable. 
Undiagnosed “vanishing” twins and TTTS could cause congenital malformations, but MZ 
twin pregnancies could also result in masking genetic aberrations in blood cells. Comparing 
different tissues, if possible, could be crucial in determining genetic aberrations in congenital 
anomalies. Comparing the genomes of large cohorts of twins and their parents may reveal 
not only de novo genetic changes but perhaps also shed light on predisposing factors 
modulating penetrance in traits and diseases in combination with environmental or other 
factors.  
Future prospects 
Epigenetic studies in discordant monozygotic twins 
Epigenetic mechanisms like X-inactivation, DNA-methylation, histone modifications 
or other mechanisms influence chromatin structure, maintenance or remodeling and by so 
influence the expression of genes. These epigenetic signatures can be heritable, vary over 
time and are responsive to environmental cues.[91] Although these epigenetic signatures in 
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monozygous twins are mostly very similar, they can differ between monozygous twins. For 
example, DNA methylation differences can develop over time in monozygous twins, possible 
caused by environmental influences. [92] Humans exposed peri-conceptional, not late 
gestational, to malnutrition conditions during the Dutch “hunger winter” in World War II 
had decreased methylation of the IGF2 gene 60 years later in life. IGF2 is maternally 
imprinted and a key factor in growth and development. Hypomethylation will lead to bi-
allelic expression of IGF2.[93] These epigenetic changes have been studied in twins and 
differences in epigenetic signature have been observed in phenotypical discordant 
monozygous twin pairs. Examples are monozygous twins discordant for systemic lupus 
erythematosus [94],  RETT syndrome (cerebroatrophic hyperammonemia) [95] and 
Beckwith-Wiedeman syndrome.[96]  
Monozygous twins with the same de novo pathogenic frame shift mutation on the 
paternal derived chromosome X in the MECP2 gene were discordant for RETT 
syndrome.[95] Weksberg et al describes differences in methylation in monozygous twins 
discordant for Beckwith-Wiedeman syndrome.[96]  There was no skewed X-inactivation, 
whole genome sequencing revealed no SNP, InDel nor CNV differences. There were no 
MECP2 expression or methylation differences in fibroblasts. However, a genome wide 
methylation survey revealed several differentially methylated regions and the corresponding 
genes were differentially expressed. Although the MECP2 locus was unaffected it is perhaps 
the combined effect, altered expression of a set of genes and the pathogenic MECP2 
mutation that result in RETT syndrome in one of the sibs. Linkage analysis in Beckwith 
Wiedeman syndrome families points to chromosome band 11p15. In this region sporadic 
cases of translocations or CNV are described. 20% of patients have uniparental disomy and it 
is known that genes in this region have maternal or paternal specific expression. [96, 97] 
Weksberg et al describes differences in methylation in monozygous twins discordant for 
Beckwith-Wiedeman syndrome. Genetically, this syndrome is characterized by altered 
expression of imprinted genes on chromosome locus 11p15.5. This expression can be altered 
by several mechanisms. In th monozygous twins studied, hypomethylation of CpG island 
KvDMR1 located within the KCNQ1 gene in the affected twin resulted in bi-allelic 
expression of the KCNQ1OT1 ncRNA.[96]   
It has been proposed that epigenetic changes could be a major contributor to 
monozygotic twin discordance [98] and studying these epigenetic differences in 
monozygotic twins could bridge the gap between environment and our genome.[99] Large 
scale studies in discordant monozygous twins could be a successful strategy to identify 
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epigenetic variation responsible complex traits and diseases.[100] Technically, epigenetic 
profiling is, like copy number measurements, in transition from single gene and genome-
wide array based techniques to high throughput techniques based on NGS.[101] So many 
more examples of discordant methylation patterns will follow in the near future. 
Next Generation sequencing based Copy Number profiling and GWAS 
Using whole genome NGS data both copy number and nucleotide sequence can be 
determined. Currently, whole genome sequencing is relatively expensive. In the near future, 
when prices will drop, large cohorts of sequenced cases can probably be compared to 
sequenced controls. GWAS on both SNP and CNV data could be performed on this data and 
not the associated but the responsible genetic variant could be identified. Whilst variant calling 
on nucleotide resolution has seen tremendous progress, InDel and CNV calling are still in 
their infancy. Current NGS based methods use read depth, the number of unique reads that 
map to a given locus in the genome, to determine the Copy Number Status at that locus. 
Comparing the read counts of individual reference samples (paired analysis) or using a 
normalized cohort of reference samples and compare this with patient samples will give a 
fairly good estimate of the relative copy number. This information can be combined with 
allelic frequency data obtained from the variant files, much like it is done with SNP-array 
analysis. Several tools exist, each with its advantages and disadvantages such as reliability to 
accurately detect relative gains or losses.[102-104] Challenges in accurately detecting copy 
number from sequencing data are aligning sequence reads in repeat region and issues that 
arise from capturing segments of the DNA during exome-NGS. [105] It is likely that SNP-
array based GWAS studies will be replaced by NGS based methods in the upcoming years. 
Although GWAS have proven their value in medical research, publications in CNV based 
association studies in twins are relatively scarce. Burden studies in monozygous twins; both 
concordant and discordant for a given phenotype could prove to be a valuable addition to the 
phenotype-genotype toolset. Tissue specific whole genome and epigenome profiling in large 
cohorts of concordant and discordant monozygous twins could be a promising key to 
unraveling the impact of gene, environment and gene-environment interactions. CNP and 
CNV affect much more our genome than SNPs do and could perhaps explain much of the 
“missing heritability” observed in traits and disease. CNP and CNV affect much more our 
genome than SNPs do and could perhaps explain much of the “missing heritability” observed 
in traits and disease.  
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Abstract 
The occurrence of phenotypic differences between monozygotic twins is commonly 
attributed to environmental factors, assuming that monozygotic twins have a complete 
identical genetic make-up. Yet, recently several lines of evidence showed that both genetic 
and epigenetic factors could play a role in phenotypic discordance after all. A high 
occurrence of copy number variation differences was observed within monozygotic twin 
pairs discordant for Parkinson disease, thereby stressing on the importance of post-zygotic 
mutations as disease-predisposing events.  
In this study, the prevalence of discrepant copy number variations was analysed in 
discordant monozygotic twins of the Esophageal Atresia and Congenital Diaphragmatic 
Hernia cohort in the Netherlands. Blood-derived DNA from 11 pairs (seven Esophageal 
Atresia and four Congenital Diaphragmatic Hernia) was screened using high-resolution 
SNP arrays.  
Results showed an identical copy number profile in each twin pair. Mosaic 
chromosome gain or losses could not be detected either with a detection threshold of twenty 
percent. Some of the germ-line structural events demonstrated in five out of eleven twin 
pairs could function as a susceptible genetic background. For example, the 177Kb loss of 
chromosome 10q26 in CDH pair-3 harbours the TCF7L2 gene (Tcf4 protein), which is 
implicated in the regulation of muscle fiber type development and maturation. 
In conclusion, discrepant copy number variations are not a common cause of twin 
discordancy in these investigated congenital anomaly cohorts.  
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Introduction 
Monozygotic (MZ) twin comparisons have been used for many decades to specify 
contributions of both nature (heredity) and nurture (environment)[1]. Normally the study 
design is based on the presumption that monozygotic twins come from one fertilized egg 
and therefore have complete identical genetic make-ups. Yet, recently several lines of 
evidence suggested that genetic and epigenetic factors could play a role in MZ phenotypic 
variances after all [2-6]. Using a BAC array platform, Bruder et al.[6] demonstrated that 
discordance in their monozygotic Parkinson’s disease (PD) twin cohort of nine individuals 
could be the result of Copy Number Variation (CNV) differences. However, Baranzini et al. 
[7] could not reproduce this high intra-twin pair variability of structural variants using 
both array and next-generation sequencing in three twin pairs discordant for Multiple 
Sclerosis. We investigated whether discrepant CNVs could cause discordance in MZ twin 
pairs of the Dutch Esophageal Atresia (EA [MIM 189960]) and Congenital Diaphragmatic 
Hernia (CDH [MIM 142340]) cohort. Blood-derived DNA from 11 (7 EA and 4 CDH) pairs 
of MZ twins was screened using high-resolution SNP arrays.  
EA generally presents at birth with a defective formation of the esophagus with or 
without a fistulous tract to the trachea. Although not lethal in most cases, long-term 
morbidity plays a significant role in these patients. CDH is a more severe birth defect 
characterised by defective formation of the diaphragm, lung hypoplasia and pulmonary 
hypertension. Despite medical advances mortality for isolated cases is 20% and for none-
isolated cases up to 60%. Both EA and CDH are presumed to have a multifactorial etiology 
and the identification of chromosomal aberrations and knockout animal models provide 
strong evidence for a genetic component [8]. In contrast, both anomalies present with low 
twin concordance rates, 10.7% and 15.6% for EA and CDH respectively, and sibling 
recurrence rates are low (1-2%) as well.  
Shaw-Smith [9] already pointed out that the incidence of twinning in EA is 2.6 times 
higher than statistically expected. 206 pairs are described in literature up until now, 
however information on zygosity is less thorough [9-16]. Orford et al.[15] stated that at 
least 80% of reported EA twins are same-sex pairs. In total, 22 out of these 206 twin pairs 
are concordant for the EA phenotype. In literature, 77 twin pairs have been described for 
CDH of which 53 were recognized as monozygotic [17-20]. 12 pairs were concordant for 
the CDH phenotype. 
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The rationale of this study was to investigate whether CNVs in the affected twin 
sibling could account for phenotypic discordance of either Esophageal Atresia or Congenital 
Diaphragmatic Hernia MZ twin siblings. Although results showed no such proof, germ-line 
structural events were detected and these could represent a susceptible genetic background 
as seen in other genetic anomalies. Results are discussed in the context of earlier MZ twin 
reports. 
Materials and methods 
Ethics statement 
Research involving human participants has been approved by the “Medical Ethical 
Committee (METC) at Erasmus-MC, which specifically approved for blood withdrawal of 
both twins and their parents. Informed consent forms were obtained for the index case and 
his/her parents at once and for the healthy twin separately.   
Patients  
The 11 affected twin samples were collected from the congenital anomaly cohort in 
Rotterdam (Erasmus MC Sophia’s Hospital, the Netherlands) in which 541 EA- and 626 
CDH- patients are currently registered. Of these, 22 CDH patients (14 dizygotic, five MZ, 
three not tested) and 35 EA patients (six dizygotic, nine MZ, 20 not tested) were the result 
of a twin pregnancy. Included were those twin samples with a written parental informed 
consent, quality material of both siblings and confirmed monozygosity by STR profiling 
(AmpFISTR identifiler PCR amplification kit, Applied Biosystems, Foster City, CA). 
Another exclusion criterion was the identification of a genetic abnormality, most commonly 
an aneuploidy.  
DNA isolation  
Automated DNA extraction from peripheral blood (or skin fibroblasts in case of two 
affected CDH twins) was performed using local standard protocols. DNA quality and 
concentration were checked with the Quant-iT™ PicoGreen ® dsDNA Kit (Invitrogen 
Corporation, Carlsbad, California, USA).  
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Whole-genome high-resolution SNP array 
SNP analysis was carried out using the Illumina HumanCytoSNP-12 bead chip 
version 2.2 (Illumina, San Diego, CA, USA). This chip includes 220.000 of the most 
informative SNPs en markers with a median physical distance of 6.2 Kb. DNA samples were 
processed according to the manufacturer’s protocol. The call rate of this array batch was 
above 0.98, except for 1 sample.   
SNP array analysis 
Data for each bead chip were self-normalized in Genomestudio GT® (Illumina, San 
Diego, CA, USA) using information contained within the array. Copy number estimates for 
each individual sample were determined by comparison to a common reference set of 200 
CEU samples from the HapMAP project [www.hapmap.org/downloads/raw_data] 
(supplied by Illumina, manifest files) and visualized in the Nexus software program (version 
five, Biodiscovery, El Segundo, CA, USA) as log2 ratios. Analysis settings were as follow: 
both SNP-FASST and SNP-Rank segmentation methods were executed independently with 
significance thresholds ranging from 1x10-4 to 1x10-6 and log-ratio thresholds of 0.18 and -
0.18 for duplication and deletions respectively. The max contiguous probe spacing was 1000 
Kbp and the minimum number of probes per segment was set to three, limiting CNV 
detection to sizes above 18.6 Kb. Subsequently, only CNVs above 50 Kb were validated. 
Paired analysis for deletions and duplications was performed in each affected twin versus its 
healthy co-twin.  
As described recently high-resolution (SNP) arrays are suitable for detection of both 
germ-line and mosaic CNVs [21-25]. Mosaic copy number aberrations are hallmarked by a 
concomitant change of log2 intensity signal and a shift in b-allele frequency. The detection 
limit (sensitivity) of the Nexus SNP-FASST algorithm for mosaic CNVs is 20 percent using 
a heterozygous imbalance threshold of 0.45 [22]. To review functionality of each putative 
CNV at once, occurrence frequencies in a qualified normal pediatric cohort of 2026 
individuals[26] (CHOP [http://cnv.chop.edu/]) and in the DGV [http://www.tcag.ca] 
were uploaded in the Nexus program as well. Since these populations display various ethnic 
backgrounds, comparison to an in-house normal reference set was performed as well. 
Additionally, possible intra-twin pair genotype differences (with respect to all SNP-markers 
presented on the array) were evaluated in Genomestudio GT® using the paired analysis 
settings. 
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 Table 1A. Clinical features EA Cohort. The following abbreviations are used: ASD; Atrial Septal defect,  EA; esophageal 
atresia, GA; Gestational Age, IUGR; Intra Uterine growth Retardation, VSD; Ventrical Septal Defect. Unfortunately, for a 
few EA subjects detailed clinical data is unavailable 
 
Table 1B. Clinical features CDH Cohort. The following abbreviations are used: ASD; Atrial Septal defect,  CDH; 
Congenital Diaphragmatic Hernia, GA; Gestational Age, IUGR; Intra Uterine growth Retardation, VSD; Ventrical Septal 
Defect. 
Pair GA Birth order Obstetric history EA Fistel Type of additional 
EA (wks) (Patient) (twin-sib)    anomalies 
EA1 37,3 1 2 Breech presentation + + Dysmorphic 
       Auricular tags, Cleft uvula 
       Abnormal dermatoglyphics 
       Heart 
       ASD 
       Lung 
       Lunghypoplasia right 
       Neurologic/skeletal 
       Scoliosis 
       Fusion of vertebrae 
       Hemivertebrae 
       IUGR 
EA2 36 2 1 Breech presentation + + Heart 
    Maternal medication:   VSD 
    sintrom   Lung 
       Lunghypoplasia  
EA3 NA NA NA NA + + Heart 
       cardiac situs 
       Dextrocardia healthy twin  
EA4 NA NA NA NA + - - 
EA5 33,5 1 2 Breech presentation + + Dysmorphic 
    Fever durante partu   Triangular face, Deep set eyes, 
       Palpebral fissures slant down 
       Small mandible 
       Thin fingers,hypoplastic thumbs 
       Proximal placement of thumb 
       Hypoplastic or absent radii 
       Sacral hemangioma healthy twin 
EA6 34, 4 NA NA Polyhydramnion + + Heart 
    Maternal medication:   VSD 
    corticosteroids   Tricuspid incompetence 
EA7  NA NA - +  + - 
 
Pair GA Birth order Obstetric history CDH Type of additional 
CDH (wks) (Patient) (Healthy twin)   anomalies 
CDH1 35,3 2 1 Sectio Caesarea left - 
    Breech presentation   
CDH2 33,4 1 2 Sectio Caesarea left - 
    >24hrs ruptured membrane   
CDH3 38,5 2 1 - right Urogenital 
      Inguinal hernia 
      Hydrocele testis 
CDH4 34,1 2 1 Sectio Caesarea left Dysmorphic 
      Small mandibula 
      IUGR 
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Validation using Fluorescent In-Situ Hybridization and relative-quantitative PCR analysis 
Confirmation of each CNV with quantitative real time PCR and/or FISH was 
executed in the twin-siblings and their parents according to local standard protocols with 
minor modifications [22, 27]. For FISH, BAC clones were selected from the UCSC genome 
browser [http://genome.ucsc.edu/], purchased at BACPAC resources centre (Oakland, 
California, USA) and labelled (Random Prime labelling system Invitrogen Corporation, 
Carlsbad, California, USA)) with Bio-16-dUTP or Dig-11-dUTP (Roche applied science, 
Indianapolis, USA). After validation on control metaphases, the chromosome 22 BAC clones 
RP11-62K15 and RP1-66M5 were used for confirmation in EA-pair-I. 
Primer pairs for quantitative real-time PCR were designed from unique sequences 
within the minimal deleted or duplicated regions of each copy number change using Primer 
Express software v2.0 (Applied Biosystems, Carlsbad, California, USA). The nucleotide-
nucleotide BLAST algorithm at NCBI [http://www.ncbi.nlm.nih.gov/BLAST/] was used 
to confirm that each PCR amplification product was unique. Quantitative PCR analyses were 
performed using an ABI7300 Real-time PCR system in combination with KAPA-SYBR fast 
master mix (KapaBiosystems, Woburn, MA, USA). Experiments were designed with a 
region of the C14ORF145 gene serving as a control locus as previously described [27]. 
Results 
Clinical characterization and monozygosity screening of twin pairs  
Clinical features of each twin pair are summarized in Table 1. Briefly, seven out of 
11 pairs were discordant for the phenotype of EA (Table1A) and four out of 11 for CDH  
(Table 1B). Four out of eleven EA-affected patients harbored (major) additional anomalies. 
Considering CDH; there is a variable expression of left and right CDH with all persons (as 
expected) featuring lung hypoplasia. We are dealing with an isolated CDH cohort since 
most anomalies in pairs 3 and 4 are minor. Finally, zygosity status of each twin pair was 
confirmed (data not shown) by STR profiling using the commercially available STR 
identifiler kits of Applied Biosystems. 
Paired CNV analysis of discordant monozygotic twins 
Results of the paired CNV analysis of each MZ twin couple are summarized in Table 
2 showing no evidence of pathogenic CNV discordance in both congenital anomaly cohorts. 
In order to detect mosaic (somatic) aberrations, specific attention was payed to b-allele 
frequency changes as well. In the EA cohort a total of ten germline CNVs were identified. 
Seven concerned common Copy Number Polymorphisms (CNP) defined by the occurrence of 
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the CNV in at least five individuals of qualified normal pediatric cohorts in literature. The 
remaining three events were present in both the twin and at least one healthy parent and are 
therefore less likely to be pathogenic as well. For example, the 666 Kb sized chromosome 
22q deletion in EA pair-1 (Figure 1) was found both in the healthy twin and his mother and 
partly overlaps with CNVs catalogued in control cohorts.   
Existence of inherited CNVs was detected in the CDH cohort as well. A total of three 
CNVs were distinguished of which two are not prevalent in normal cohorts. All three events 
were present in the healthy twin as well. Figure 2 represents the 177Kb loss of chromosome 
10q26 in CDH pair-3 and harbors the TCF7L2 gene (Tcf4 protein), which is mainly known 
for its involvement in blood glucose homeostasis as a result of Wnt signaling changes. Not 
ruled out in this study are the presence of balanced genomic alterations and small (<50kB) 
or very-low mosaic (<20%) chromosome aberrations beyond the detection level of our 
experimental approach. 
SNP genotype analysis monozygotic twin cohorts 
SNP genotype differences between the affected and unaffected twin siblings were 
evaluated for each SNP on the Illumina® bead chip. After removal of less accurately called 
SNPs, genotyping analysis showed concordance for almost all SNPs (n=299671) within each 
MZ pair. A total of five SNPs in three EA-pairs were dissimilar and three SNPs in two CDH 
pairs (Table 3). CDH pair-3 showed discrepancy for 99 SNPs, which could be attributed to 
less overall genotyping accuracy and therefore was not analyzed further. Until now, only 
rs2824374 (which is closely linked to the CXADR gene) could be associated with embryonic 
(mal) development, however literature only reports on effects to the kidneys and cochlea 
[28, 29]. None of the other identified discordant intra-twin SNP loci are directly linked to a 
phenotype.  
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Figure 1 (left panel) SNP and Fluorescent In-Situ 
Hybridization results of inherited chromosome 22-
CNV in EA pair-I  Nexus results (Top) of the 666 
Kb deletion on chromosome 22q13.3 in both 
individuals of EA pair-I showing a clear drop in 
log2 intensity signal validated by FISH (Bottom) 
on metaphase chromosomes of the affected EA 
twin-1. Probes: control: RP11-62K15 (green) and 
target: RP11-66M5 (red). Parental analysis (results 
not shown) demonstrated that this genomic event 
is inherited from the mother and therefore less 
likely pathogenic. In addition, no gene is allocated 
to this region neither are any miRNA transcripts 
hampering the identification of functional elements 
in this region as well.  
 Figure 2 (right panel) SNP and relative Q-PCR 
results of inherited chromosome 10-CNV in CDH 
pair-3. Nexus result (Top) of the chromosome 
10q26 deletion event in CDH pair-3 showing a clear 
drop in log2 intensity signal, which was confirmed 
by relative q-PCR (bottom) in the affected proband, 
the unaffected twin and the mother. 
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CDH 
pair 
Chromosomal location 
(bp) 
CNV 
(type) 
Length 
(bp) 
Gene symbols Discordant 
twin 
Normal Cohort # Validation 
1 - - - - - - - 
2 - - - - - - - 
3 chr10:114,660,279-114,838,014 CN Loss 177735 TCF7L2 [22] yes no q-PCR, inherited maternally 
4 chr4:86,595,913-87,070,050 CN Loss 474137 ARHGAP24 [23-24] yes yes (0/2026, 
0/370,  overlap 27 
DGV) 
q-PCR, inherited maternally 
 chr4:57,743,262-57,795,280 CN Gain 52018 - yes yes (2/2026, 
0/370,  overlap 15 
DGV) 
Copy Number Polymorphism 
        
Table 2. Inherited CNVs detected in MZ twins of the Rotterdam congenital anomaly cohort. The following abbreviations are used: CN; Copy Number, bp; basepairs, EA; 
Esophageal Atresia, CDH; Congenital Diaphragmatic Hernia.# Normal Cohort; CHOP [http://cnv.chop.edu/] and DGV [http://tcag.ca].& Decipher; 
[http://decipher.sanger.ac.uk/application/].Percentage of overlap with CNVs in control databases are designated if not 100% aligned.
EA 
pair 
Chromosomal location (bp) CNV 
type 
Length 
(bp) 
Gene symbols Discordant 
twin 
Normal Pediatric 
Cohort # 
Validation 
1 chr22:46,163,818-46,870,578 CN Loss 666192 FLJ46257 (hypothetical) yes yes (0/2026, 
0/370,  overlap 25 
DGV) 
FISH, inherited maternally 
2 chr7:75,420,580-75,471,147 CN Loss 50567 POR, STYXL1, TMEM120A yes yes (0/2026, 
0/370,  overlap 2 
DGV) 
q-PCR, inherited (both 
parents 
heterozygous deletion) 
3 chr6:162,638,827-162,840,229 CN Gain 201402 PARK2 yes yes: 5/2026 q-PCR, inherited maternally 
 chr17:41,522,684-41,646,903 CN Gain 124219 KIAA1267 yes yes: 69/2026 Copy Number Polymorphism 
 chr18:1,895,191-1,960,898 CN Loss 65707 - yes yes: 26/2026 Copy Number Polymorphism 
4 chr14:19,283,777-19,479,370 CN Gain 195593 OR4K1, OR4K2, OR4K5, etc yes yes: 35/2026 Copy Number Polymorphism  
5 chr12:7,892,014-8,027,862 CN gain 135848 SLC2A14,SLC2A3 yes yes: 39/2026 Copy Number Polymorphism 
6 chr12:31,146,084-31,303,651 CN gain 157567 DDX11 yes yes: 20/370 Copy Number Polymorphism 
 chr2:89,728,406-89,885,025 CN gain 156619  yes yes: 14/2026 Copy Number Polymorphism 
 chr8:2,322,561-2,577,455 CN gain 254894  yes yes: 32/2026 Copy Number Polymorphism 
7 - - - - - - - 
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 Discussion 
A high occurrence of copy number variants that differed between siblings discordant 
for Parkinson’s disease was recently suggested [6]. However, intra-twin pair variability for 
germ-line CNVs could not be detected in our subset of EA and CDH MZ twins. Within the 
limitations of the used experimental approach, structural variants in mosaic form (above 
20%) could neither be demonstrated. Application of next-generation sequencing methods 
will allow for an easier and more sensitive calling of the smallest mosaic aberrations in the 
near future and will add up to the (scarce) data generated recently on this topic by some 
other groups [30-33].  
Various causes could account for the discrepancy in CNV findings between our 
congenital anomaly twin cohort and the Parkinson cohort. First of all: an age factor. The 
rather high prevalence of mosaic CNVs in PD twins could have been generated during 
lifetime. This was suggested by a small study of the group of Dumanski et al.[34, 35], who 
identified mosaic aberrations in a wide-range of tissues of three phenotypically normal 
individuals. This hypothesis would imply that age-accumulated (tissue-specific) CNV events 
could play a role in diseases developing symptoms later in life. Consequently, they are 
expected to contribute less to congenital disorders. Secondly, differences in CNV prevalence 
between our study and the Parkinson study could be based on methodological differences 
such as choice of platform. Although Bruder et al. [6] presented confirmative evidence for a 
few of their CNVs using a different platform, detailed confirmation of most CNVs was 
lacking.  On the other hand, structural DNA variation might play a minor role in EA- and 
CDH- pathophysiology, suggesting that in these congenital cohorts the focus should be 
widened on environmental and epigenetic factors.  
Two recent studies [2, 7] revealed a (significant) proportion of epigenetic variability 
between MZ twins in investigated tissues. However, in the Multiple Sclerosis twin cohort 
study these changes could not account for disease discordance. A similar study for EA, CDH 
or other congenital anomalies is difficult to perform, since the target tissues cannot be 
obtained from the healthy co-twin for obvious reasons. Structural variations restricted to the 
affected esophagus and diaphragm tissue could represent another cause for twin 
discordancy, yet was not excluded in this monozygotic cohort due to unavailability of the 
affected material.  
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 Pair 
EA Discordant SNPs 
Chromosomal location 
(dbSNP build 130) (bp) 
Gene symbols 
1 rs11573502 chrX:24888693-24889193 POLA1 
2 - - - 
3 - - - 
4 rs10125846 chr9:2821641-2822141 KIAA0020 
 rs1744767 chr20:35200380-35200880 LOC140699 isoform 3 
 rs438895 chr1:8260692-8261192  
5 - - - 
6 - - - 
7 rs1576026 chr9:25,453,089-25,453,589 - 
    
 
Pair 
CDH Discordant SNPs 
Chromosomal location 
(dbSNP build 130) (bp) 
Gene symbols 
1 rs17730982 chr8:134851934-134852434  
 rs2824374 chr21:17879252-17879752 CXADR; possible involvement 
   kidney & cochlear development [25,26] 
2 - - - 
4 rs6571064 chr6:103400463-103400963 - 
3 Not evaluated; SNP Quality rate < 0.95 - - 
    
Table 3. Discordant SNPs in MZ twin pairs of the Rotterdam Congenital anomaly cohort. The following 
abbreviations are used:bp; basepairs, EA; Esophageal Atresia, CDH; Congenital Diaphragmatic Hernia.  
 
Finally, although our results showed no prove for CNV contribution to phenotypic 
MZ-discordance, germ-line structural events were detected in both cohorts and these events 
could represent a so-called susceptible genetic background. In five out of eleven twin pairs  
germline CNVs were identified. These were rarely detected in a specific pediatric normal 
population [26] and/or our in-house control cohort and could therefore represent an 
increased susceptibility to congenital anomalies by means of a dosage responsive- or 
position- effect. For example, the 177Kb loss of chromosome 10q26 in CDH pair-3 might be 
of functional importance. A recent report demonstrated Tcf4 (alias Tcf7l2) expression in 
connective tissue fibroblasts during development and suggested its role in the regulation of 
muscle fiber type development and maturation [36]. Additionally, certain polymorphisms 
and mutations in TCF7L2 are linked to an increased risk of type 2 diabetes37. This implies 
that loss of one functional TCF7L2 allele might be associated with (super) normal glucose 
tolerance. Indeed we observed evidence of increased serum glucose (a Glucose of 12.2 
mmol/l was identified within 24 hours postnatal) in the affected individual of twin pair 3.  
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 However, also 1 normal glucose level (Glucose 3.6 mmol/l) was determined within 
the same time window and since this patient was critically ill and died shortly thereafter no 
absolute conclusions can be drawn from these results.  The healthy twin had an 
unremarkable medical record so far. Similarly, the haploinsufficient ARHGAP24 gene in 
CDH pair-4 (encoding a vascular, cell-specific GTPase-activating protein) could confer 
genetic susceptibility for CDH by means of its function in modulating angiogenesis and 
through its interaction with filamin-A [37, 38]. Girirajan et al.[39] recently demonstrated 
that a second hit may elicit a severe phenotype in offspring of healthy CNV-carriers. 
Hypothetically this second hit can constitute another CNV in the same or associated disease 
pathway as well as a pathogenic SNP. These results underline the importance of archiving 
all genomic events (also those with a “benign” nature at first sight) in a freely accessible 
database such as initiated by the ISCA consortium [https://www.iscaconsortium.org]. 
Detailed and unbiased phenotyping is crucial for the understanding of the more complex 
genotype-phenotype correlations as well. 
In summary, we investigated whether the existence of discrepant CNVs could be 
causal to the phenotypic discordance in MZ twin pairs of the Esophageal Atresia and 
Congenital Diaphragmatic Hernia cohort in Rotterdam and found no such proof. 
Prospective collection of DNA material in various MZ twin cohorts is warranted to evaluate 
the possibility of such genetic factors contributing to human phenotypic variability in 
general and to twin-discordance specific. We feel that the use of high-resolution SNP arrays 
and sequencing based methods are more suitable in these designs than BAC arrays. Finally, 
phenotypic correlations can only be made after proper analysis in normal cohorts as well. 
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Abstract 
Congenital Hernia of the Diaphragm (CDH) and Esophageal Atresia with/or 
without Trachea-esophageal Fistula (EA/TEF) are congenital anomalies that can either be 
present as isolated anomaly or in association with other birth defects.  Both anomalies likely 
have a multifactor etiology, are associated with known (genetic) syndromes and can occur in 
combination with specific chromosomal aberrations, Copy Number Variations (CNV) or 
mutations. When evaluating the genetic component of a disease, twin studies can help to 
elucidate potential causal or predisposing genetic factors. Monozygotic (MZ) twins are 
believed to have the same genetic content and share the same environment during 
development. We hypothesize that de novo mutations arisen early in embryonic 
development could explain the phenotypical differences in discordant MZ twins.  
In total of six EA/TEF and four CDH discordant MZ twins are characterized with 
standard SNP-array, exome bead array and exome-NGS in order to detect, complete or 
mosaic, DNA discrepancies. As described previously, we could not detect any CNV 
(mosaicism) differences in these twins with micro-array.  Genotyping with SNP-array did 
not result in the detection of twin-differences. Standard exome-NGS variant calling with the 
Genome Analysis ToolKit revealed numerous discrepant SNPs and InDels. Visual 
inspection of hundreds of these events with the Broad institute’s IGV indicated that these 
discrepancies were actually false positive differences due to technical limitations, analysis 
settings (thresholding) or limitations of the variant calling. By comparing different 
alignment techniques, variant callers, statistics and analysis strategies we could reduce the 
number of likely candidate differences significantly. Interestingly, at a Bonferonni level of 
statistical significance variants were real “NGS” differences and not the result of  for 
instance thresholding or low coverage. However, we could not confirm the remaining 
differences with Sanger sequencing. With millions of measuring points, there are bound to 
be differences. These differences are in general not biological, but technical in nature. 
Differences detected in these experiments reflect the accuracy and limitations of current 
sequencing technologies and variant calling pipelines.  
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 Introduction 
About one in forty pregnancies, is a twin pregnancy and one in three of these twin 
pairs are monozygous (MZ); siblings originating from one oocyte.[1] The later implies that 
MZ twins are genetically identical. Usually monozygotic twins are also phenotypically very 
similar. However, MZ twins with concordant chromosomal anomalies, pathogenic CNV or 
mutations can have a discordant disease phenotype.[2, 3] This phenotypical discordance at 
birth could be the result of for instance differences in epigenetic modifications or, 
surprisingly, environmental exposure differences.  
However, recently it has been shown that not all MZ twins have exactly the same 
genome. For instance Bruder and co-workers identified three somatic intra-twin Copy 
Number Variation (CNV) differences in a cohort of nine Parkinson-like discordant and ten 
healthy monozygotic twins.[4] It has been suggested that DNA changes could causing 
twinning as the blastocyst recognizes these mutated cells as foreign resulting in splitting of 
the blastocyst.[1] Recently, CNV differences were also reported in monozygotic twins 
discordant for certain congenital anomalies [5-7] and both Voigt et al and Kaplan et al 
describe postzygotic somatic mosaicism in monozygotic twins discordant for 
neurofribomatosis type 1.[8, 9] However, Baranzini and coworkers could not find evidence 
for sequence differences in MZ twins discordant for Multiple Sclerosis[10], neither could 
Solomon in a twin pair discordant for VACTERL association.[11]  
Previously, we could not detect genotype or (mosaic) CNV differences in 
phenotypical discordant twins for esophageal atresia (EA) and congenital diaphragmatic 
hernia (CDH) with SNP-array[12] EA and CDH are severe developmental defects and 
patients often have additional associated anomalies.[13, 14] EA is characterized by a blind 
ending esophageal tube with often a faulty connection of the distal esophagus to the trachea, 
a trachea-esophageal fistula (TEF). The hallmark of CDH is a hole in the diaphragm and 
patients often also have lung hypoplasia and pulmonary hypertension. Both diseases are 
thought to have a multifactorial etiology. EA and CDH are variable features in many genetic 
syndromes.[13, 14]The twinning incidence is 2.6 times higher in EA pregnancies compared 
to the general background.[15] Twin concordance rates are relatively low for both 
conditions, ranging between 10-15%.[12]  
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In this current study we compare the DNA of these twins at a much higher 
resolution. Using Whole-Exome Sequencing (WES) and WES-Copy Number profiling we 
have compared the genetic sequence and Copy Number at the exon level. We hypothesize 
that discordant somatic mutations are responsible for the phenotypical discordance in these 
Congenital Diaphragmatic Hernia (CDH) and Esophageal Atresia (EA) discordant 
monozygous twin cohorts. 
Methods 
The Erasmus MC-Sophia cohort of congenital anomalies 
The Medical Ethical Review Board of Erasmus MC - Sophia Children’s Hospital 
approved this study. Parental informed consent included the genetic studies in both siblings 
and their parents. The medical charts were reviewed and clinical and and follow-up data 
registered to an interactive database. Discordant monozygotic twin were selected from the  
Erasmus University MC-Sophia TE-cohort (n=582) [14, 16]  and CDH cohort (n=703) and 
most have been described previously.[13] DNA was extracted from peripheral blood when 
the twins were at least one year of age to avoid contamination of with sibling DNA resulting 
from transfer of lymphocytes via twin-to-twin transfusion. Unfortunately, transfer of 
hematopoietic stem cells can’t be excluded.[17] We used DNA derived from skin fibroblasts 
in CDH patients CDH01 and CDH02. Mozozygosity was determined with short tandem 
repeat profiling (AmpFISTR identifiler PCR amplification kit, Applied Biosystems, Foster 
City, CA, USA) and later confirmed with SNP-array. Patients did not have confirmed 
genetic syndromes or de novo chromosomal anomalies prior to analysis.  
Copy Number Variation profiling and genotyping 
Genotyping and sub sequent Copy Number Variation profiling was done with 
Illumina HumanCytoSNP-12 version 2 or the Illumina Human Omni Express-12 version 1.0 
Bead Chips. (Illumina, San Diego, CA, USA) Additionally, all twin-pairs were genotyped 
with the Illumina Exomev1.1 genotyping chip. Arrays were processed according to their 
manufacturer’s standard protocol using Genome Studio software version 2011.1 (Illumina, 
Inc., San Diego, USA).  We used CoNVEX version 0.6 [18] and the normalized whole 
exome sequencing reads to determine exon level Copy Number. Each exon captured with 
the target enrichment kit was divided in three virtual probes. Each of these probes needed to 
be in the same segment to be called as an CNV. An “B-allele” frequency track  was made 
using the GATK unified genotyper variants. This track was used to support the loss and 
gains calls made by the segmentation algorithm in the Nexus CN7.1 software used to 
visualize CNV profiles.  (Biodiscovery Inc, El Segundo, CA, USA) Analysis settings ,CNV 
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 profiling, analysis and confirmation using Fluoresence in situ Hybridization, MAQ-assay 
(Multiplicom Inc., Niel, Belgium) and qPCR have been described previously.[19] 
Whole Exome Capture, sequencing, quality control and analysis 
Genomic DNA was fragmented (Covaris, Inc. Woburn, Massachusetts, USA) and 
yield and fragment size determined with the Bioanalyser 2100 bioanalysis chip and Agilent 
DNA 1000 Kit.(Agilent BioAnalyzer, Santa Clara, CA). We used the SureSelect Human All 
Exon 50 Mb Targeted exome enrichment kit v2 (Agilent Technologies, Inc., Santa Clara, 
California) and Illumina TruSeq version 4 paired end 2x 101 bp sequence procedure on the 
Hiseq2000 sequencer (Illumina, Inc., San Diego, USA)for all twin pairs. Sub sequent de-
multiplexing, alignment to the hg19 reference genome with Burrows-Wheeler Aligner 
version 0.6.2 [20], generation of chromosome sorted BAM-files with SAMtools version 
0.1.12a [21] and quality control is automated in the NARWHAL pipeline[22]. The quality 
control parameters include total reads, aligned reads on target, mean coverage of the target 
region, target with at least 20X coverage. These are listed in supplementary table 1.  
Genotyping and InDel calling was done with the Bayesian genotyper incorporated in 
the genome analysis toolkit version 1.2.9 [23], SAMtools mpileup, or in house developed 
callers. Variants were annotated with ANNOVAR version 2013-feb-21.[24] Moreover, raw 
sequencing read alignment, variant calling and quality control was also performed using 
CLC-bio.(Qiagen Inc., Venlo, the Netherlands) We used both variant calling methods of this 
software tool: a quality based and probabilistic method. Next the data was annotated in the 
same pipeline as GATK and (using ANNOVAR and both Refseq and ENSEMBL gene 
annotation) Variant confirmation is done using Sanger sequencing, Illumina’s Exomev1.1 
genotyping chip (Illumina, Inc., San Diego, USA) or one of the other targeted sequencing 
methods used in EA twin pair 1 and 2. Variant filtering was done with TIBCO Spotfire 
version 5.5.0.36 (TIBCO, Boston, MA, USA) and Cartagenia Bench NGS version 3.04 
(Cartagenia Inc, Boston, MA, USA)  
Whole Exome variant analysis and twin comparison 
We pair-wise compared the variants detected in the Illumina’s Exomev1.1 
genotyping chip, GATK pipeline, CLC-bio quality based and probabilistic variant calling 
pipeline and screened for variants present in one and absent in the other sibling. Moreover, 
we compared the variants of the Illumina’s Exomev1.1 genotyping with those called with 
SAMtools Mpileup and probabilistic differentiator. First, non-covered base-pairs are labeled 
with “N”. Next, using first binomial and second Fisher exact statistics, we screened the 
exome variants detected in the SAMtools Mpileup pipeline for statistical significant (p ≤ 1.0 
x 10-8) differences, taken into account coverage and variant frequency. The top ranking 
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significant differences were validated with Sanger sequencing in twins and their parents. In 
addition to a twin comparison we used two gene panels, one for trachea-esophageal 
anomalies and VACTERL associated features  and one for Congenital Diaphragmatic 
Hernia. (supplementary figure 2)  
In supplementary table 3a through 3j are the (predicted) splicing, frameshift, 
stopgain and stoploss mutations in candidate genes detected with the GATK unified 
genotyper, CLC-bio probabilistic and the CLC-bio quality based variant callers analysed 
with the Cartagenia software. Visual inspection of the discordant variants was done in the 
Broad institutes IGV. As a final step we exported all rare or private exonic variants, detected 
in the SAMtools mpileup pipeline,  with an allele frequency ≤ 0.001 in either 1000 Genomes 
and/or ESP6500 to Nexus CN to search for overlap  with the CNVs detected in both the 
WS-CN and SNP-array experiments. An example is given in figure 1. 
Results 
The Erasmus MC-Sophia cohort of congenital anomalies 
7 EA pairs (labeled EA1 to and EA 7) and 4 CDH twin pairs (labeled CDH 1 to CDH 
4) are described previously.[12] Numbering and phenotypical descriptions are kept 
consistent. We did not have enough DNA material for whole exome sequencing of twin pair 
EA4 and EA7. However, we were able to include an additional discordant EA pair, EA 8.  
Exon level  copy number comparison 
In previous experiments, we excluded large de novo CN and concluded that if a rare 
or private CNV was present in the affected twin, it was also present in the unaffected sibling 
and inherited from a healthy parent.[12] We had detected several genotyping mismatches, 
validation with Sanger sequencing confirmed that these were all technical errors and not 
actual biological differences.  SNP-array genotyping with the Illumina HumanExomev1.1 
genotyping chip -containing more than 200,000 probes specific for relatively rare variants 
selected from 12,000 sequences from several large sequencing projects- did not result in the 
detection of additional genotyping discrepancies.  
WGS-CN resulted in the detection of hundreds of small exon level copy number 
variations. Interestingly, both the overall probe level profile and normalized copy number 
profile of each twin pair was almost perfectly similar. Visual inspection of the remaining 
discrepancies of the automated pairwise comparison resulted in few variants possible 
discordant between twins. Most of this discordant variation was not present in the affected 
sib of the twins. In these instances, only the healthy twin deviated from the diploid state. 
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 Most of these regions contained segmental duplications and were known Copy Number 
Polymorphisms. (see table 2) Confirmation of the differences affecting non polymorphic 
regions; the rare and private CNV, is ongoing. 
 
Pair Gestational 
age 
Congenital anomalies in addition to EA/TEF or CDH DNA source 
EA 1-1 37.3 
Dysmorphic features, auricular tags,celft uvula,  abnormal 
dermatoglyphics, atrial septal defect, rightsided lung hypoplasia, 
neurological anomalies, scoliosis, fusion of vertebrae, 
hemivertebra, intrauterine growth restriction 
Blood/blood 
EA 2-1 36 Ventricular septal defect, lunghypoplasia Blood/blood 
EA 3-1 ? Cardiac situs inversus  Blood/blood 
EA 5-1 33.5 
Dysmorphic features, palpebral fissures slant down, deep-set 
eyes, triangular face, micrognathia, thin fingers, hypoplastic 
proximal placed thumbs, hypoplastic radii and a sacral 
hemangioma in the healthy twin 
Blood/blood 
EA 6-1 34, 4 Ventricular septal defect, tricuspid incompetence Blood/blood 
EA 8-1 ? 
Dysmorphic features, auricular tags,celft uvula,  abnormal 
dermatoglyphics, atrial septal defect, rightsided lung hypoplasia, 
neurological anomalies, scoliosis, fusion of vertebrae, 
hemivertebra, intrauterine growth restriction 
Blood/blood 
CDH 1-1 35.3 - Dermal fibroblasts/Blood 
CDH 2-1 33.4 - Blood/blood 
CDH 3-1 38.5 Urogenital malformations, ingenuil hernia and hydrocele testis Blood/blood 
CDH 4-1 34.1 Dysmorphic features, small mandibula and intraunterine growth restriction Dermal fibroblasts/Blood 
 
Table 1. Phenotype descriptions twin pairs. Affected (-1) in EA monozygous twins all have an Esophageal 
atresia as well as a tracheo-esophageal fistula. CDH affected twins all have Congenital Diaphragmatic Hernia. 
Siblings (-2) are healthy or indicated otherwise. The sib of EA 3-1 (EA 3-2) has dextrocardia. 
 
Whole Exome variant analysis and twin comparison 
Pair-wise comparison of variants detected with the GATK unified genotyper, CLC-
bio quality based and probabilistic variant callers resulted in several hundred to thousands of 
inter-twin differences. Visual inspection of hundreds of these differences in the Broad 
institute’s IGV indicated that most discrepancies were actually false positive differences. 
Most of the variation was present in both twin-sibs and did not differ much in their variant 
frequency. In other instances, the region was not (sufficiently) covered in one of the twins. 
These detected differences were a result of cut-off values in variant calling threshold 
settings, limitations of the variant calling, or sequence coverage differences.  
181 
  NGS is discordant MZ twins 
 
Figure 1. Example of combined analysis of rare loss of function mutations, SNP-array CNV profiling 
and WES-CN. In the upper panel, rare variants are depicted with specific symbols matching each variant type. 
The next two tracks, WES-CN and SNP-array CN calls depict the region in which a call is made. In the LogR 
tracks, relative copy number status of WES data (upper panel) and SNP array are depicted, In the bottom two 
panels the zygosity status is depicted as a B-allele frequency plot, with the upper panel describing the variation 
seen in the WES-variant files and the bottom panel the SNP-array genotyping results. In this example rare 
variants surround the deletion seen in both exon level WES-CN (red dots) and SNP-array (red dots). Since this 
is a deletion, the region is homozygous. This maternal inherited deletion was present in both twin-sibs and is 
described previously.[12] 
 
 
Figure 2. Examples of exon-level copy number twin differences (arrow) Depicted are the differences 
between healthy twin CDH 2-2 (loss, in red) and affected twin CDH 2-1 (diploid). Other examples are the gain 
on 1p36 seen in patient EA 6-1 (blue) and its absence in the healthy twin EA 6-2. The loss (red) on 2p23 is seen 
in healthy sib of twin pair CDH 1-2, yet absent in affected twin CDH 1-1.  
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 To circumvent this time consuming visual inspection, we mined raw sequencing 
reads, to determine read depth and allele counts at positions with a variant in each twin. 
Next, we used a statistical approach, a negative binomial model, to rank the detected 
differences. Using this approach, with a p-value cut-off of 10-8, we reduced the number of 
significant candidates differences to workable numbers for each twin-pair. (see table 3)  
 
Moreover, we detected 7 genes (ADAM3A, PGKB, EXOSC10, HOMEZ, PR2C2, 
SYN3 and TRMT44) with a discrepant variant in two twin pairs. Of these the variants seen 
in ADAM3A and HOMEZ were in the coding region. Primers were designed to determine if 
these top-ranking differences were actual genotype differences. However, almost all 
statistically significant discordant variant were located in or near a highly repetitive 
sequence. This complicated primer design. Since Sanger sequencing of candidate differences 
for which primers could be designed did not confirm the observed differences, also these 
most likely represent technical artefacts.  
Next we used a different statistical approach and filtered variant in or near repetitive 
regions. Using Fisher exact statistics and a p-value cut-off of 10-8 we reduced the number of 
candidate discordant variants and designed primers on the top-ranking variants for each 
twin pair. None of the statistical significant exonic variants with the Fisher exact test were 
shared between the twin pairs. Two exonic variants had overlap between statistical tests: a 
snp (rs1924654) in NBPF10 gene and a nonsynonymous variant in NRG3. Validation of 
these twin differences with Sangers sequencing is ongoing, although preliminary results 
indicate that also these are false positive differences.  Using the Gene panels for trachea-
esophageal anomalies and VACTERL association and the gene panel for Congenital 
Diaphragmatic Hernia we detected many loss of function mutations in candidate genes, 
visual inspection in the Broad institutes’ IGV revealed that all these were shared between 
twins. (supplementary table 3) 
Discussion 
On average 30.000 variants were detected in the targeted protein coding and ncRNA 
coding segments of the genome in each patient. We detected several loss of function 
mutations, present in both twins, even in the genes present in the candidate gene panels.  
Overall, the vast majority of variants were shared between twins, especially taken into 
account that not all of the targeted sequences are covered with the same amount of reads.  
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Twin Pair 
(-individual) 
Chromosome Region Length Event Cyto-
band 
Gene 
Count 
Gene Symbols Count of 
DGV 
Count of 
segdup 
CNV/CNP 
EA 1-2 chr2:179,516,818-179,530,927 14,109 Loss q31.2 3 MIR548N, TTN 13 2 CNV 
EA 1-2 chr22:18,671,397-21,536,612 2,865,215 Loss q11.21 1 AK129567, AK302545, GGT3P, LOC729444, USP41 129 11 CNP 
EA 1-2 chr22:24,237,925-24,399,444 161,519 Loss q11.23 18 LOC284889 – GSTTP2 519 19 CNP 
EA 2-1 chr11:433,750-455,481 21,731 Gain p15.5 3 ANO9, Metazoa_SRP, PTDSS2 19 0 CNV 
EA 3-2 chr7:63,193,176-63,224,926 31,750 Loss q11.21 2 DQ599768, DQ574660 65 22 CNP 
EA 5-1 - 0 - - - - - - - 
EA 6-1* chr1:16,883,061-16,947,163 64,102 Gain p36.13 3 AB1, NBPF1, CROCCP2 312 75 CNP 
EA 6-1* chr4:8,974,559-9,377,934 403,375 Gain p16.1 0 USP17L10 - LOC728405 7 116 CNP 
EA 6-1* chr5:34,181,127-34,206,027 24,900 Gain p13.2 4 DQ587763, DQ571461, DQ578105, DQ598168 169 45 CNP 
EA 6-1* chr10:135,376,371-135,534,747 158,376 Gain q26.3 10 SYCE1 - DUX4L6 419 63 CNP 
EA 6-2 chr13:53,100,276-53,114,495 14,219 Nullizygous q14.3 1 TPTE2P3 15 1 CNV 
EA 6-1* chr13:57,715,524-57,977,845 262,321 Gain q21.1 5 PRR20A, PRR20B, PRR20D, PRR20C, PRR20E 531 2 CNP 
EA 6-1* chr18:44,506,918-44,557,893 50,975 Gain q21.1 5 
TCEB3CL, LOC100506888, TCEB3C, TCEB3CL2, 
KATNAL2 103 2 CNP 
EA 6-1* chr20:27,500,000-29,635,688 2,135,688 Gain 
q11.1 - 
q11.21 2 Y_RNA, FRG1B 98 45 CNP 
EA 8-1 chr1:16,890,738-16,948,559 57,821 Gain p36.13 2 NBPF1, CROCCP2 313 73 CNP 
EA 8-1 chr9:140,063,526-140,066,387 2,861 Gain q34.3 2 MIR3621, LRRC26 8 0 CNV 
EA 8-1 chr17:36,263,896-36,347,903 84,007 Gain q12 8 DQ587906 - LOC440434 208 46 CNP 
          
CDH 1-2 chr10:135,475,929-135,534,747 58,818 Gain q26.3 7 DUX4L2 - DUX4L6 154 51 CNP 
CDH 1-2 chr13:57,137,164-58,048,498 911,334 Gain q21.1 5 PRR20A, PRR20B, PRR20D, PRR20C, PRR20E 566 2 CNP 
CDH 2-2 chr1:104,161,260-106,434,412 2,273,152 Loss p21.1 8 AMY2A - BC043293 1016 26 CNP 
CDH 3-2 chr1:6,268,575-6,269,853 1,278 Gain p36.31 2 RNF207, RNF207 1 0 CNV 
CDH 3-1 chr19:1,009,067-1,012,410 3,343 Loss p13.3 3 GRIN3B, FLJ00277, C19orf6 11 0 CNP 
CDH 3-2 chr8:86,651,927-86,839,906 187,979 Gain q21.2 0 - 125 72 CNP 
CDH 4-2 chr22:24,367,999-24,390,248 22,249 Gain q11.23 3 LOC391322, GSTT1, GSTTP2 168 6 CNP 
 
Table 2 WES-CN twin differences. * high signal to noise ratio resulting in waving  probe pattern, -1 = affected twin, -2= healthy twin, CNV = rare or private Copy 
Number Variation, CNP = Copy Number Polymorphism common in the general population.
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EA 01 184 978 412 14 3 
EA 02 176 2525 751 12 3 
EA 03 238 3900 816 11 14 
EA 05 705 2422 1226 296 71 
EA 06 169 3511* 5415* 5 1 
EA 08 146 634 1039 3 6 
CDH 01 284 776 1208 27 102 
CDH 02 200 419 3341 28 1 
CDH 03 117 876 1470 2 1 
CDH 04 145 612 1486 15 23 
 
Table 3 WES-variant twin differences. Twin-sib differences at ≥ 20 X coverage with at least 2 variants, 
MAF ≤ 0.001, ncRNA and exonic regions, splicing, deletions, substitutions, stopgain, stoploss and 
nonsynonymous changes. If applicable including a statistical model and a repeat filter. CLC-bio variant calling 
allowed for multiple variant types at one location. * high frequency of several different variants per specific 
location in the affected sibling. 
Visual inspection of the WES-CN profiles revealed a remarkable similarity in the 
general profile. Comparing the DNA of monozygous twins is as performing a duplicate 
experiment. With millions of measuring points, there are bound to be differences. These 
differences are in general not biological, but technical in nature. Differences detected in 
these experiments reflect the accuracy and limitations of current sequencing technologies, 
its downstream processes and variant analysis. Importantly, these experiments provide a 
better perspective regarding the strengths and limitations of this new technology.   
In general, results in genome wide association studies are only significant when 
corrected for multiple testing, often with a Bonferonni correction (p≤ 10-8). If we perform 
this statistical correction (p≤ 0.05 divided by the number of bases in the target, 50*106 ) we 
achieve the same required order of significance, 10-8. Of interest is that only when applying 
this order of significance, the discordant variants detected in high coverage, low repeat 
regions pat the visual examination of the reads in the IG viewer. The statistical difference 
test used is applicable on twins, but also on families and may be a good QC control 
parameter in NGS experiments. 
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Exon level  copy number comparison 
Using WES-CN we determined the exon level copy number profile of each 
individual. Dividing the each exon in three virtual probes decreased the noise and resulted in 
100-150 exon-level copy number variants in each twin. These events are not validated with 
additional techniques. However, visual inspection of the probe profiles, both the logR ratio 
and the B-allele frequency revealed a remarkable similarity between the two twin samples. 
Even the more noisy sample (EA 06-1) had a similar waving as its twin duplicate. Most 
differences measured within the software, were actually marginal threshold differences. Only 
a few regions seemed to be really different. Of these more than half were only present in the 
healthy twin and completely overlap common Copy Number Polymorphisms. Validation of 
the remaining five discordant Copy Number Variations is ongoing.  
Whole Exome variant analysis and twin comparison 
At 20X coverage around 2-3 percent of protein coding and  ncRNA variants are not 
measured in both twin-sibs. Marking  bases not sequenced with “N” enables differentiation 
between “base not sequenced” and “ base sequenced but equal to the reference” it can lead to 
over represention of  the number of “N” in samples of reduced quality. This is clearly the 
case in EA 6-1. Most of the observed differences are the result of limitations of the capturing 
methods, sequencing technology, thresholds settings, coverage differences and limitations of 
the variant callers. A combined statistical and filtering approaches can rank these differences 
into two categories: 1) the difference has a high chance of being an artefact, most likely due 
to limits of the technologies and algorithms used or 2 ) The differences is likely to be real. 
When we finally used additional filtering steps and another variant calling method: SAM 
tools mpileup, a probabilistic method based on the Fisher exact test which takes into account 
allelic depth and allelic frequency and sub sequent filtering of repetitive regions. This 
resulted in only a few discordant variants left. Validation of the top 10 ranking significant 
differences for each twin-pair is ongoing, preliminary results indicate that the differences 
detected with exome sequencing and exome level copy number variation profiling are 
neither de novo nor different between twins.   
Although no discordant loss of function mutations were detected using SAM tools 
mpileup, although there were numerous rare and private nonsynonymous SNV in candidate 
genes. Both CLC-bio callers detected possible discordant variants in candidate genes. 
However, visual inspection revealed that they were all present in the healthy sibling. 
Inheritance of variants from a healthy parent and the presence of these variants in the 
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 healthy sibling does not exclude their pathogenicity. As with other low penetrance diseases, 
there are monozygous twins with the same genetic syndrome, yet a discordant phenotype. 
[2] Variants could contribute in a multifactorial manner, environmental or epigenetic 
factors could tilt the balance in the affected twin from normal to abnormal development. For 
instance, EA patient 3-1 has cardiac situs inversus and trachea-esophageal anomalies. 
Interestingly, the twin-sib (3-2) has dextrocardia. It is possible that a pathogenic mutation 
causes more severe anomalies in one twin and a somewhat less complex phenotype in the 
other. EA patient five has features (thumb and limb malformations) which could fit the 
observed SALL1 mutation (Townes Brocks) and FANC mutation (Fanconi Anemia). 
Reduced penetrance and variable expressivity has been described for Fanconi anemia[25], 
although neither of the siblings has the characteristic skin pigmentations. Also Townes-
Brocks syndrome has a variable phenotype, although most patients do have anorectal 
malformations and ear anomalies.[26] Patient CDH1-1 and CDH3-1  have a mutation in the 
Slit3 gene, mutations in this gene cause congenital diaphragmatic hernia in mice.[27]  
Many variants were present multiple times in these, and other, samples. Variants in 
VANGL1, NOTCH2, FANCD2, EFTUD2 and RIPK4 were shared between EA twins and 
KIF7, PTEN and RECQL4 between CDH twins. These most likely represent technological 
artefacts as they seem NGS pipeline specific. A burden test, using similar sequencing 
technologies, read mappers and variant callers on different patient cohorts could give more 
clues about the true nature and relevance of  many pathogenic variants in candidate genes. 
Screening of large in-house cohorts of patients and healthy individuals using different 
capturing, sequencing and analysis pipelines seems a prerequisite to either filter out these 
likely technological errors in order to determine the “true” variant burden of candidate 
genes.  Previously, we could not detect differences in CNV profiles in these two cohorts of 
discordant monozygotic twins.[12] In these current experiments we detected many 
differences using whole exome sequencing and WES-CN, although to date none of them 
could be confirmed with Sanger sequencing.  Elucidating genetic factors by comparing the 
DNA of discordant monozygotic twin has proven successful in other occasions. [4, 7, 28] 
Absence of detected and validated discordant variants does not mean that they are not 
actually there. It could merely mean that we could not detect them using current 
technologies, software and experimental set-up. However, current results indicate that 
underlying etiological factors, at least in these twin pregnancies, are more likely to be non-
genetic.  
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It is known that environmental components can differ in monozygous twin 
pregnancies and that twin pregnancies are perhaps not representative of regular singleton 
growth conditions.[1] Twin-to-twin transfusion syndrome (TTTS), one of the most serious 
complications of monochorionic multiple gestations, can result in these exposure differences. 
TTTS develops in 10 to 15 percent of monochorionic twins as a disbalance in arteriovenous 
anastomoses lead to asymmetrical flow resistance.[29]  TTTS is associated with several 
congenital anomalies and can result in loss of the fetus. TTTS and undiagnosed loss of a 
twin fetus in early stage of pregnancy, a so called vanishing twin, is hypothesized to be an 
important etiological component of congenital anomalies as VACTERL association or 
gastro-intestinal atresia.[30, 31] Phenotypical descriptions of twins suffering from TTTS 
include IUGR and cardiac defects, which are present in EA01, EA08 and CDH04. TTTS is 
also described to be contributing to congenital anomalies as VACTERL association or 
gastro-intestinal atresia.[30, 31]  
Genetic factors likely contribute to congenital anomalies as esophageal atresia and 
congenital diaphragmatic hernia. However, we could not detect discordant variants between 
affected and unaffected monozygotic twins. Although other factors - the twinning process 
itself, environmental factors, TTTS, or epigenetic modifications- could be the underlying 
condition responsible for the malformations observed in these twin pregnancies, care has to 
be taken to definitively exclude DNA discrepancies. At 20X coverage only 80 percent of the 
coding region was covered and non-coding DNA variation was not taken into account in 
this targeted approach. Furthermore, determining mosaic differences with Sanger 
sequencing is difficult, if not practically impossible. If a discordant heterozygous variant is 
inherited and present in both twins, albeit in different frequencies, this mosaic difference is 
most likely an technical artefact. However, confirmation of the de novo nature of the 
mutation, absence in the parental DNA, proves the relevance of the detected difference. If a 
de novo variant is detected, further studies are needed to investigate whether, and at what 
frequency, the de novo variant is present in different tissues of both twins.  
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IJcken,  D. Tibboel, A. de Klein. Ongoing research 
 
Abstract 
Esophageal Atresia (EA) with or without Tracheo-Esophageal Fistula (TEF) is a 
relative common congenital anomaly whose cause is unknown in the majority of patients. 
These trachea-esophageal (TE) anomalies can be present either as an isolated defect or in 
association with other developmental defects: e.g. as one of the core features of the 
VACTERL (Vertebral, Anal, Cardiac, Tracheo-Esophageal, Renal and Limb anomalies) 
association. Furthermore, is TE  a variable features in several known single gene disorders.  
The hypothesis that genetic defects contribute to EA/TEF and VACTERL disease 
etiology is further supported by the high concordance rate in monozygotic twins  compared 
to dizygotic twins and murine knockout models. TE and VACTERL association are usually 
sporadic findings and the  familial recurrence rate of non-syndromic is low (1-3%).  
We have collected 5 families with 2 patients with TE anomalies and 3 
consanguineous trio’s. Evaluation of a possible phenotype genotype association in these 
families will improve our understanding of the heterogeneous TE phenotype. Using high 
density SNP-array familial relationships were confirmed and their Copy Number Variations 
profiles and Runs of Homozygosity determined.. Using first a candidate gene approach and 
second a gene discovery approach Whole Exome Sequencing (WES) and Whole Exome 
Sequencing Copy Number profiling (WES-CN) identified possible pathogenic mutations and 
several candidate genes and loci.  
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Introduction 
Esophageal Atresia (EA) with or without Tracheo-Esophageal Fistula (TEF) (MIM 
189960) is a developmental defect of the foregut. This loss of continuity of the esophagus 
and connection of the trachea to the esophagus has a prevalence ranging between 1 and 4.5 
per 10.000 live births.[1, 2] Males are more likely to be born with this condition than girls, 
this 3:2 gender disparity is hypothesized to be confounded by genetic and environmental 
factors.[3, 4] These Tracheo-Esophageal (TE) anomalies can be the sole malformation, 
although in approximately half of patients TE anomalies are associated with other 
congenital defects. Frequently the associated malformations are  those of the VACTERL 
spectrum of Vertebral, Anorectal, Cardiac, Tracheo-esophageal, Renal or urinary tract and 
Limbs malformations.[5, 6] Other anomalies are also common e.g. microcephaly, duodenal 
atresia, single umbilical artery, micrognathia, pyloric stenosis and genitourinary 
malformations.[5, 7]   
EA/TEF is variable feature in more than 70 genetic syndromes.[8] In some 
syndromes a TE defectis a frequent observed phenomenon, for instance in Microphthalmia 
and esophageal atresia syndrome (SOX2), Feingold syndrome (MYCN), CHARGE 
(Coloboma, Heart anomaly, choanal Atresia, Retardation, Genital and Ear anomalies) 
syndrome (CHD7) and in trisomy 13. However, in most syndromes, EA and or TEF are 
rather incidental findings. Further evidence for a genetic background for EA/TEF are the 
elevated probandwise concordant rate in monozygotic twins ion comparison  that of 
dizygotic twins[9], murine knockout models[10] and the presence of de novo genetic 
aberrations of variable size in sporadic EA/TEF. [10-13]  Familial recurrence rate is low 
(1-3%) and TE and VACTERL association are usually sporadic findings.[14, 15] Therefore, 
most likely dominant de novo or X-linked recessive mutations are responsible for most of the 
patients with a genetic etiology although autosomal recessive forms as Fanconi anemia 
cannot be excluded. 
In this study we aim to identify causal genetic factors in a specific subset of patients 
with TE-anomalies. By evaluating of a possible phenotype genotype association in the 
familial TE-patients and TE patients born from consanguineous marriages we hope to 
identify genes or loci to explain  the heterogeneous TE phenotype seen in these families. 
We have collected 5 families with TE anomalies and three patient-parent trio’s from 
consanguineous marriages. Using high density SNP-array familial relationships were 
confirmed and their Copy Number Variations profiles and Runs of Homozygosity (ROH) 
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determined. Homozygosity mapping is  a method which can be used to detect recessive 
mutations  in both inbred[16] and outbred[17] populations. With an online prioritarization 
tool, “the genomic oligoarray and SNP-array evaluation toolv2.0”[18], we searched for 
known autosomal recessive disorders in ROH regions. In addition we have used a Next 
generation sequencing and by  using both  a candidate gene approach or  a gene discovery 
approach we applied  Whole Exome Sequencing (WES) and Whole Exome Sequencing 
Copy Number profiling (WES-CN) to identified possible pathogenic mutations in  candidate 
genes and loci. 
Methods 
Familial and consanguineous TE-patients in the Erasmus MC-Sophia TE cohort 
This study was approved by the Medical Ethical Review Board of Erasmus MC - 
Sophia Children’s Hospital. Clinical- and follow-up data were extracted from medical charts. 
Unless otherwise indicated, none of the included patients had a previous confirmed genetic 
syndrome, known chromosomal anomaly, pathogenic point mutation nor was there evidence 
for an association with an environmental components. Since 1988 onwards, patients with TE 
are included in our Erasmus University MC-Sophia TE-cohort (n=582). An overview of this 
cohort has been described previously.[5, 8]  
In the Erasmus MC-Sophia TE cohort there are ten familial TE patients (1.9%) in 
five families (FAM1-5). Informed consent and DNA material was available for genetic 
studies of eight of these patients (see figure 2) . Here, we define “familial EA” as those 
families in which an index patient has another reported family member, either deceased or 
alive, with EA and/ or TEF. No genetic syndrome should be present, which could explain 
the phenotype segregating through the pedigree.   
Although suspected in more patients, there were six confirmed consanguineous 
patients in our cohort (1%). Informed consent and parental DNA material for genetic studies 
was available for  four patients. One consanguineous patient had Fanconi anemia, a diagnosis 
confirmed with chromosome breakage studies and mutation analysis. This patient was 
excluded from further analysis. The three remaining patients and their related parents were 
analyzed (FAM C1-3) 
Copy Number Variation profiling with SNP-array 
Using high density SNP-array genotype information familial relationships were 
confirmed and their Copy Number Variation profiles and Regions of Homozygosity (ROH) 
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determined. Micro-arrays were processed using the Illumina Human Omni Express-12 
version 1.0 Bead Chip (Illumina, Inc., San Diego, USA) according to their manufacturer’s 
standard protocol. Normalized output was generated with Illumina’s Genome Studio 
program version 2011.1 (Illumina, San Diego, CA, USA) and visualized in Nexus CN7.1 
(Biodiscovery Inc, El Segundo, CA, USA)  
In general, inheritance of CNVs was determined if they were larger than 30kb, 
contained genes and were either absent from or had a low frequency in the database of 
genomic variation.[19] Variants absent from this database were marked as “private CNV” 
and if present 5 times or less as “rare CNV”, all others as common polymorphisms. This 5 
count cut-off is indicative of an allele frequency below 0.0025. Regions were considered to be 
homozygous and marked as ROH when they contained 10 probes or more and were larger 
than 2Mb in size. If private and rare CNV were seemingly absent in the parental CNV 
profiles, they were sub sequentially validated with a second technique; either MultiPlex 
Amplicon Quantification (MAQ) or WES-CN. 
Copy Number Variation profiling with Exome-NGS 
Whole-Exome Copy Number (WES-CN) was determined using CoNVEX version 
0.6.[20] This program uses a Hidden Markov model, similar to SNP-array, to determine the 
copy cumber status from the normalized depth of coverage (DOC) relative that of a cohort of 
reference samples. Exonic DOC was sub divided in three virtual probes and segmentation 
was performed in Nexus CN7.1.  Allelic information derived from GATK-variant calling 
was transformed to a B-allele frequency track to increase reliable copy number calling. The 
Nexus CN7.1 software was used to manually compare SNP-array results with the WGS-CN 
results Moreover, we compared the WGS-CN events to the exome sequencing variants and 
searched for overlap of these events with loss of function mutations with an allele frequency 
≤ 0.001.  
MultiPlex Amplicon Quantification 
Putative de novo private and rare CNVs detected with SNP-array are validated with 
the MAQ-assay. (Multiplicom Inc., Niel, Belgium) as described before[21] With the MAQ-S 
software  the fluorescent intensities (translated into peak heights) of patient and reference 
sample are compared and visualized in dosage plots. 
Whole Exome Capture and Sequencing 
First, genomic DNA was sheared using Covaris adaptive focussed acoustic 
technology. (Covaris, Inc. Woburn, Massachusetts, USA) Fragmentation yield and fragment 
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size distributions are measured with the Bioanalyser 2100 bioanalysis chips and Agilent 
DNA 1000 Kit. (Agilent BioAnalyzer, Santa Clara, CA). The protein coding regions of the 
DNA were captured with SureSelect Human All Exon 50 Mb Targeted exome enrichment 
kit v4 (Agilent Technologies, Inc., Santa Clara, California) and sequenced using Illumina 
TruSeq version 4 paired end 2x 101 bp sequence procedure on the Hiseq2000 (Illumina, Inc., 
San Diego, USA).  
Whole exome Sequencing quality control, alignment and variant calling 
At least 5 Giga-bases of raw sequence data was mapped to the reference genome 
(hg19) using two independent methods: the NARWHAL pipeline[22] and CLC-bio 
readmapper. (Qiagen Inc., Venlo, the Netherlands) NARWHAL automates de-multiplexing, 
alignment to the hg19 reference genome with Burrows-Wheeler Aligner version 0.6.2 [23] 
and curation of low quality reads. Chromosome sorted BAM-files are generated with 
SAMtools version 0.1.12a [24] and quality control is performed on these sorted BAM files. 
The mean coverage over the target was at least 50X with over 80% of bases >20X. Most 
samples however, were >70X with >90% of target bases covered >20X.  
Genotyping was done with the Bayesian genotyper incorporated in the genome 
analysis toolkit version 1.2.9 [25] and SAMtools mpileup in combination with an inhouse 
probabilistic differentiator, variants were annotated with ANNOVAR version 2013-feb-
21.[26] In the second method, reads are aligned and quality control is performed using 
CLC-bio(Qiagen Inc., Venlo, the Netherlands). Variants are called and annotated using a 
quality based and a probabilistic method with variant callers and annotation tools 
incorporated in the CLC-bio package. Variant filtering was done with Cartagenia Bench 
NGS version 3.04 (Cartagenia Inc, Boston, MA, USA) and TIBCO Spotfire version 5.5.0.36 
(TIBCO, Boston, MA, USA). 
Whole Exome Sequencing: candidate gene approach  
First step in variant analysis is a candidate gene approach using a gene panel specific 
for  TE-anomalies and VACTERL association. Candidate genes were derived from human 
diseases, animal models and developmental pathways [27] using online databases. [28-30] 
These genes and the gene panel are described previously [8, 31] and a summary is listed in 
table 1. Variant filtering and prioritization settings are described in figure 1 and the gene 
discovery approach section.  Private or rare (At least 20X coverage, MAF≤0.001) de novo or 
X-linked protein disturbing (splicing, frameshift, stopgain or loss) variants in these 
candidate genes were evaluated. We did not evaluate other rare possible protein disturbing 
198 
Chapter 4.1 
inherited variants in candidate genes in this first phase of the analysis. These variants, if 
fitting inheritance models, would also be detected in the gene discovery approach. Rare and 
private variants in the gene panel are listed in supplementary table 4 and are available on 
request. 
 
Candidate genes Tracheo-esophageal anomalies and VACTERL association Ref 
Diagnostic set of genetic 
syndromes 
CHD7, MYCN,  SALL1,  MID1,  EFTUD2 [8, 31] 
Research Genetic 
syndromes 
Over 140 genes from genetic syndromes in which TE anomalies have 
been described or with overlap with VACTERL association (see 
supplementary figure 1) 
[8, 31] 
Animal models 
IFT172,  Rarα/ Rarβ , Nkx2.1,  Rab25,  Hoxc4 ,  Chrd, Ctnnb1, Dync2h1, 
Efnb2, Foxp4,  Fuz, Lec, Sox4,  Wdr35, Foxp2, Foxp1 
[8, 30] 
Pathways 
Bmp7, Barx1, Rhou, Wnt7b, fgf10, Bmp4, tp63, Keap1, Wny5a, Wnt11, 
Wnt2, Wnt2b 
[27] 
De novo CNV in sporadic 
patients 
LPP, GTPBP5, EPPK1, PLEC-1, PARP10, AATF, 
TADA2A,GSTP1,MAP2, HNF1B,EFNB2 
[32-39] 
 
Table 1 Candidate gene panel for Tracheo-esophageal anomalies and associated VACTERL spectrum 
anomalies 
 
Whole Exome Sequencing: gene discovery approach  
If no obvious pathogenic mutation was detected in the candidate gene panels, the 
entire exome was studied. Variant filter settings were: coverage ≥ 10X, MAF ≤ 0.1% in 
1000G or ESP6500, absence in dbSNP135, inheritance model, presence or absence in 
healthy/affected family members, possible splicing effects, exonic or ncRNA exonic variant 
location and finally the function consequence of the mutation. (ncRNA affected, 
nonsynonymous, frameshift, stopgain, stoploss) Prioritization steps include whether the  
detected variants were there present in relevant genes, absent in segmental duplications and 
their population frequency (MAF ≤ 0.001 ) We also evaluated their predicted 
deleteriousness and conservation using GERP (>3.0), PhyloP (>0.95), SIFT (>0.95), 
Polyphen2 (>0.85) and mutation taster (A or D).  
All inheritance models were performed, if multiple family members were affected, the 
variation had to be shared and had to fit logical inheritance models. Fisrt shared, loss of 
function mutations following recessive, compound heterozygous or X-linked models were 
considered. Next dominant de novo mutations in individual patients were considered. These 
variants were also compared with the exon level CNV to exclude unmasking of these 
variants. Finally, nonsynonymous variants involved in relevant biological processes were 
considered if fitting logical inheritance models. Variation was compared with animal 
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phenotypes from the MGI database, human syndromes in the OMIM database and gene 
function or presence in relevant pathways.  
De novo, homozygous recessive and X-linked rare and private variants predicted to be 
conserved are displayed in the supplementary figures. For displaying purposes only those 
compound heterozygous variants are displayed of which at least one was conserved and 
predicted to be pathogenic by all prediction tools. These in silico prediction tools were used 
to prioritize variants and not as an exclusion criterion for possible follow up analysis. A 
scheme of candidate gene and gene discovery approach is depicted in figure 1.  All 
inheritance model filtering strategies were performed on every family e.g. homozygous 
recessive and compound heterozygous mutations, all distinct de novo mutations as ‘well as 
X-linked inheritance in male patients. 
Candidate variant confirmation 
Variants of interest were confirmed  with illumina’s Exomev1.1 genotyping chip or 
Sanger sequencing. Primers were developed using the online primer3  software package, 
available on http://frodo.wi.mit.edu/.  After Touch-Down PCR the amplicons were purified 
using ExoSAP-IT (USB, Staufen, Germany) and sequenced using BigDye Terminator 
chemistry v3.1 on the ABI Prism 3130xl Genetic Analyzer (Applied Biosystems, Foster 
City, CA, USA). The resulting sequence reads were aligned to the hg19 reference sequence 
using SeqScape software version 2.6 (Applied Biosystems). Primer sequences are available 
on request. 
Results 
Familial and Consanguineous TE-patients in the Erasmus MC-Sophia TE cohort 
In the first family two brothers were born from seemingly healthy parents (Pedigrees 
are given in figure 2.). The oldest brother (patient 1) has isolated EA/TEF with and a patent 
ductus arteriosus. His more severely affected younger brother(patient 2) has in addition to 
EA/TEF, hemivertebrae, cryptorchid testes, mild ectasia pyelum, inguinal hernia, 
Ureteropelvic junction stenosis, and a sacral dimple. In family two both patients have 
EA/TEF. The nephew (patient 4)  of a girl (patient 3) with an isolated EA/TEF has 
hypoplastic proximal paced thumbs in addition to his esophageal atresia.  
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Figure 1. NGS variant analysis, filtering and prioritization scheme. 
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The patients in family three and four have deceased, more distant related, family 
member with TE anomalies. No information was currently available on congenital 
malformations other than the tracheo-esophageal anomalies. The boy(patient 5) from family 
three has EA/TEF, ventricular septal defect, an abnormal connection between the bronchus 
and his trachea, sandal gap of toes, radial deviation of his hand and hypoplastic proximal 
placed thumbs. The affected girl (patient 6) from family four has EA/TEF, a right-sided 
aortic arch and a ventricular septal defect.   
Family 5 has two affected family members: One boy (patient 7) with EA/TEF, anal 
atresia and a ventricular septal defect and his uncle (patient 8)is nephew has EA/TEF, anal 
atresia, low-set ears, hypospadias, a dislocated dysplastic hip, renal agenesis of the left 
kidney and dysplasia of the right kidney, double ureters, urinary reflux, Urethral fistulae and 
urethral stenosis. No genetic syndromes were confirmed in these patients prior to analysis. 
The 22q11 duplication in family 5 did not segregate with the Esophageal atresia phenotype.  
 
Figure 2 Pedigrees of familial EA/TEF patients 
Patient 9 is a male born from consanguineous parents and with EA/TEF, abnormal 
dermatoglyphic patterns and plantar creases, clinodactyly, hypospadias, pronounced nipples, 
hypoplastic toe nails and a short chin and neck. His parents are second degree relatives. 
Patient 10 is a boy born from consanguineous parents (2nd degree relatives) with 
hemiverteabrae, tethered cord, horshoe kidneys, atrial and ventricular septal defect. Patient 
11 is a boy and his parents have a common ancestor  5 -6 generations back. He has 
EA/TEF, anal atresia, Meckel diverticulum, an abnormal sacrum with a sacral dimple, 
coronal clefts of vertebrae, an asymmetric square shaped face, prominent forehead, 
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anomalous venous return, coarctation, patent ductus arteriosus and an abnormal arterial 
supply to his right lung. Pedigrees of these consanguineous families are given in figure 3 
  
Figure 3 Example pedigrees of a consanguineous EA/TEF patient 
Copy Number Variation profiling 
Genotyping confirmed parental relationships. Several rare and private CNV were 
identified in each familial patient using SNP array but all of these CNV .  were inherited 
from unaffected parents (see supplementary table 2). In patient 11 one private CNV covering 
a gene from the gene panel, FGFR2, was detected. This CNV was present in both his father 
and his mother. In addition to SNP-array CNV profiling, WES-CN revealed numerous 
smaller CNV events. Most events were also present in one of the parents, although 
numerous exon level events seemed de novo. None of the small seemingly de novo exon 
level WES-CN events covered genes from the candidate gene panel. WGS-CN did however 
confirm the CNVs containing genes seen in the  SNP-array. The number of these putative de 
novo events (≥ 50-100 per exome on average)  suggests that many represent background 
noise or thresholding issues. The later seems likely since, the segmentation patterns are 
very constant and also seen in other non EA affected individuals.. More experience and 
refinement of thresholds, analysis settings and perhaps ConVEX algorithm is needed to 
allow for hypothesis free exon level WES-CN analysis. Of note, a de novo polymorphism on 
chromosome 15q11 was detected in patient 9. (see figure 4) 
There were more variants detected in genes involved in  rare and private CNVs. In 
all members of family 1 a nonsynonymous  mutation was detected in exon 2 of the 
Deoxyribose-Phosphate Aldolase (DERA) gene. This gene ispredicted to have an effect on 
splicing has 9 exons. Patients 1 and 2  have a maternally inherited private loss of the loss of 
the last three exons of this gene. However, this mutation was present in a low frequency in 
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all sequenced samples and likely represents a technical artifact. Patient 3 and both her 
parents possess a rare variant in the Maestro Heat-Like Repeat Family Member 5 (MROH5) 
gene.. In patients 3, this gene is involved in a rare, maternaly inherited, gain in DNA copy 
number.  
There were no Runs of homozygosity larger than 5Mb in the familial patients. (see 
supplementary table 3) However, these ROH events were abundant in the consanguineous 
patients. No large (≥ 2 Mb) ROH was detected in patient eleven, likely reflecting the 
multiple generations to the common ancestor.  Relative large (>2Mb) runs of homozygosity 
and are depicted in supplementary table 3. The ROH regions larger than 2Mb detected with 
SNP-array were inserted genomic oligoarray and SNP-array evaluation toolv2.0[18] and 
screened for recessive candidate syndrome genes using Human Phenotype Ontology terms 
esophageal atresia or tracheo-esophageal fistula. No autosomal recessive genetic disorders 
were highlighted in patient nine, one gene was highlighted in patient ten: WNT7a on 
chromosome 3p25 associated with the autosomal recessive Al-Awadi/Raas-Rothschild 
(AARR) syndrome. (#OMIM 276820) but no disease causing variants were detected in this 
gene.  
Whole Exome Sequencing: candidate gene approach  
Interestingly, the use of two independent read-mapping methods, the NARWAL 
pipeline and CLC-bio readmapper and different variant calling algorithms (GATK Unified 
genotyper, CLC-bio®, SAMtools pileup) resulted in the detection both concordant and 
discordant cross-platform variants. Candidate variants from all pipelines were combined and 
used for further analysis. 
The candidate gene approach resulted in the identification of numerous rare and 
private putative  protein disturbing variants in these candidate genes. (listed in table 2 and 
supplementary table 4) Almost all of them were heterozygous and inherited from an 
unaffected parent. Many heterozygous variants were also present in both parents and even 
present in all samples and could reflect technical artifacts. No possible de novo or X-linked 
variants in these genes could be identified in family 1,3 or 4. In family 2, two independent 
putative de novo variants are identified. In patient 3 a nonsynonymous variant in the PAX2 
gene (NM_000278:c.A380C:p.D127A ) and in patient 4, a putative de novo variant in the 
MYCN gene. (NM_005378:c.C1177T:p.R393C).  Also for the consanguineous patients, the 
candidate gene approach also resulted in the identification of numerous rare and private 
possible protein disturbing variants in candidate genes. (listed in supplementary table 4) All 
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of them were heterozygous, mostly inherited and oftenpresent in both parents. No rare or 
private homozygous recessive WNT7A mutations were detected in patient 10. However, a 
putative de novo mutation was detected in the Fibrillin 2 (FBN2) gene 
(NM_001999:c.A8014C:p.T2672P). resequencing of patient 7 and 11 is ongoing. 
Whole Exome Sequencing: gene discovery approach  
We did not detect any homozygous recessive variants (table 4 and supplementary 
table 5) in these esophageal atresia patients, which we can associate with trachea-esophageal 
development.  Closer inspection of most detected heterozygous de novo variants in the broad 
institutes IG viewer indicated that these were in fact inherited or possible  technical 
artefacts. We did however detect rare and private heterozygous inherited variants which 
could influence the patients phenotype following compound heterozygous and X-linked 
recessive models. Little homozygous recessive candidate variants were detected in the 
consanguineous patients. After stringent filtering, only one of the homozygous recessive 
variants was in the large homozygous stretches (table 3). This was a homozygous stopgain 
mutation in the prenylcysteine oxidase 1 (PCYOX1) gene in patient 10. There was shared 
compound heterozygous variation in dynein genes DNAH2, DNAH3 and DNAH11 in 
familial patients 1 and 2, DNAH17 and DYNC2H1 in patient 5 and DNAH17 in patient 6. 
Consanguineous patients 9 (DNAH8 and9) and 10 (DRC1, DNAH1, DNAH5, DNAH9)are 
compound heterozygous for several dynein proteins. These variants did not pass the 
conservation/pathogenic prediction filter, but all had a MAF below 0.001. 
In summary, using high density SNP-array and WES-CN we detected rare or unique 
CNV in each patient.  Large ROH, absent from parental samples, was observed in the 
consanguineous patients. The candidate gene approach identified a de novo MYCN mutation 
in one of two affected family members of family 2. Moreover, many inherited, heterozygous 
rare and private nonsynonymous variants were present in genes from the candidate gene 
panel. We could at this point not identify overlap of loss of function mutations and exon 
level CNV in genes from the candidate gene panel. In general, shared compound 
heterozygous or recessive variation between the affected family members was rare. In the 
consanguineous patients homozygous candidate variants were detected, although most of 
them were located outside the large ROH regions detected with SNP-array. 
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3 PAX2 NM_000278:c.A380C:p.D127A 0 0.999084 C 1 D 0.993 D 1 D 0.999991 D 5.58 A C de novo 
3 GLI3 NM_000168:c.T2614C:p.S872P 0.04 0.997188 C 
0.958
516 NA 0.998 D 0.999999 D 0.999258 D 4.5 A G paternal 
4 MYCN NM_005378:c.C1177T:p.R393C 0 0.998798 C 1 D 1 D 1 D 0.999992 D 4.86 C T de novo 
4 FOXP4 NM_001012426:c.C76A:p.Q26K 0.09 0.998545 C 0.8 T 0.99 D 0.999948 D 0.99554 D 5 C A paternal 
4 LPP NM_001167672:c.G431C:p.S144T 0.09 0.992553 C 0.75 T 0 B 0.998635 N 0.00024 N 4.22 G C paternal 
5 FRAS1 NM_001166133:c.4566delT:p.P1522fs - - - - - - - - - - - - C - paternal 
10 FBN2 NM_001999:c.A8014C:p.T2672P 0.01 0.997812 C 0.99 D 0.966 D 0.999995 D 0.944498 D 4.69 T G de novo 
10 PARP10 NM_032789:c.C2446G:p.P816A 0 0.999308 C 0.99 D 0.6 P 0.955811 N 0.138334 N 4.27 G C maternal 
 
Table 2. Potential pathogenic variants in the candidate gene approach. Five variants were inherited from unaffected parents and two variants were de novo. All 
variants except one were nonsynonymous. (*splicing). Variants present in both parents are listed in the full table (supplementary table 4) 
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9 ELMO2 NM_182764:c.C1470A:p.N490K 0.05 0.999525 C 0.46 T 0.001 B 0.99993 D 0.978091 D 4.53 G T homozygous recessive 
9 FNIP1 NM_001008738:c.C2702G:p.T901S 0.29 0.96794 C 0.8 T 0.418689 NA 0.850073 NA 0.00002 N 3.42 G C homozygous recessive 
9 REL NM_002908:c.A206G:p.N69S 0.09 0.976613 C 0.91 T 0 B 1 N 0.846676 D 3.56 A G homozygous recessive 
10 PCYOX1* NM_016297:c.C334T:p.Q112X 0.87 0.937199 N 0.901013 NA 0.701616 NA 0.865987 N 1 A 3.89 C T homozygous recessive 
 
Table 3 . Homozygous recessive variants in consanguineous patients (gene discovery approach) All variants except one were nonsynonymous. (*splicing). Full table in 
supplementary table 5  
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3 ATP11C NM_001010986:c.G2267T:p.G756V 0 0.998709 C 1 D 0.999 D 1 D 0.999986 D 5.12 C A de novo 
3 TTC16 NM_144965:c.C1013T:p.A338V 0 0.998688 C 0.99 D 0.991 D 0.99999 D 0.634657 D 5.11 C T de novo 
4 BCL6 NM_001130845:c.T1682C:p.L561P 0 0.999115 C 1 D 0.998 D 1 D 0.999982 D 5.29 A G compound heterozygous 
4 BCL6 NM_001134738:c.A34C:p.T12P 0 0.998462 C 0.99 D 0.908 D 1 D 0.999385 D 5.26 T G compound heterozygous 
4 FHDC1 NM_033393:c.C409A:p.L137I 0 0.980859 C 0.96 D 0.993 D 1 D 0.824498 D 3.92 C A de novo 
4 HERC4 NM_015601:c.C2962T:p.R988C 0 0.999708 C 1 D 1 D 1 D 0.999999 D 5.43 G A de novo 
4 IDH3G NM_004135:c.A560G:p.E187G 0 0.998164 C 1 D 1 D 1 D 0.986759 D 5.4 T C compound heterozygous 
4 IDH3G NM_004135:c.T557G:p.V186G 0 0.998881 C 1 D 0.999 D 1 D 0.994419 D 5.4 A C compound heterozygous 
4 IDH3G NM_004135:c.T554G:p.V185G 0 0.998881 C 1 D 1 D 1 D 0.866292 D 5.4 A C compound heterozygous 
4 IDH3G NM_004135:c.C160G:p.R54G 0 0.999058 C 0.99 D 0.881 D 1 D 0.999548 D 4.56 G C compound heterozygous 
5 PPCS NM_024664:c.T110G:p.V37G 0 0.968379 C 1 D 0.988 D 0.999993 D 0.999266 D 3.92 T G compound heterozygous 
5 PPCS NM_024664:c.T113G:p.V38G 0 0.969663 C 1 D 0.967 D 0.999935 D 0.999973 D 3.93 T G compound heterozygous 
9 FOXI1 NM_012188:c.A506C:p.N169T 0 0.998242 C 1 D 0.998 D 1 D 0.999995 D 4.42 A C compound heterozygous 
9 FOXI1 NM_012188:c.T508C:p.S170P 0 0.997227 C 1 D 0.997 D 1 D 0.999994 D 4.42 T C compound heterozygous 
9 PLXNA2 NM_025179:c.T2494G:p.C832G 0.01 0.998588 C 1 D 1 D 1 D 0.999919 D 5.17 A C compound heterozygous 
9 PLXNA2 NM_025179:c.T2476G:p.C826G 0 0.998588 C 1 D 1 D 1 D 0.999914 D 5.17 A C compound heterozygous 
9 PLXNA2 NM_025179:c.T1609G:p.C537G 0 0.996938 C 1 D 1 D 1 D 0.999978 D 3.88 A C compound heterozygous 
9 SGSH NM_000199:c.A685C:p.T229P 0.01 0.995812 C 0.99 D 0.995 D 1 D 0.999247 D 4.01 T G compound heterozygous 
9 SGSH NM_000199:c.A146C:p.H49P 0.04 0.989649 C 0.96 D 0.998 D 0.999993 D 0.993561 D 3.59 T G compound heterozygous 
9 SRPX NM_001170750:c.C409T:p.R137W 0 0.96319 C 0.99 D 0.986 D 0.999949 D 0.997251 D 3.29 G A X-linked 
9 WDFY3 NM_014991:c.A2759C:p.H920P 0 0.99849 C 0.96 D 0.999 D 1 D 0.999915 D 5.6 T G compound heterozygous 
9 WDFY3 NM_014991:c.A2750C:p.H917P 0 0.99849 C 1 D 0.999 D 1 D 0.999987 D 5.6 T G compound heterozygous 
10 GRAMD4 NM_015124:c.T1412C:p.L471P 0 0.994126 C 1 D 0.996 D 0.999963 D 0.969509 D 4.18 T C de novo 
10 SLC18A1 NM_003053:c.G59T:p.R20L 0 0.982259 C 0.99 D 0.972 D 0.999999 D 0.972412 D 3.93 C A de novo 
Table 4 . Variants, predicted in conserved loci and predicted to be pathogenic by all prediction tools.  (gene discovery approach) Full table in supplementary table 5 
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Figure 2. One polymorphism , in the 15q11 region was detected with WES-CN.  In the upper panel red dots indicate loss, two MAQ assay probes (red arrow) inside the 
deleted region, confirm this loss. SNP-array resolution was not enough to call this loss. One rare variant (brown dot, lower panel) is present in this loss, however it is 
present in all samples.  
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Discussion 
Candidate gene approach  
The candidate gene approach, using a gene panel containing the genes from  
syndromes with TE features and knockout models is a first tier approach to identify variants 
that are most likely involved in the disease phenotype. This  approach resulted in the 
identification of numerous rare and private possible protein disturbing variants in candidate 
genes (see table 2 and supplementary table 4). We started with validating the most 
intriguing genes and these genes and CNVs  will be discussed below, further validation is 
ongoing)  
All except the putative de novo  PAX2, MYCN and FBN2 mutations are inherited, 
nonsynonymous, heterozygous and often predicted to be deleterious. Although patients with 
mutations in PAX2 and FBN2 can have EA/TEF[8], the EA/TEF frequency in patients 
with papillorenal syndrome, CAKUT (PAX2) or Beals syndrome (FBN2) is low .  Both 
affected members of family 2 had a putative de novo variant, albeit in a different gene from 
the candidate gene panel. Patient 3, had a de novo mutation in the paired box 2 gene (PAX2). 
PAX2 is primarily expressed in the developing nervous system and kidneys.[40] 
Heterozygous mutations in this gene can cause papillorenal syndrome or renal hypoplasia. 
This mutation is predicted to be pathogenic by all prediction tools and affects a conserved 
sequence. However, patient3 has isolated EA/TEF and no eye or renal anomalies, 
characteristic of papillorenal syndrome or renal hypoplasia. She also has a paternal inherited 
GLI3 mutation, although GLI3 is a transcriptional repressor of PAX2.[41] and most likely 
would enhance PAX2 expression and not inhibit normal expression.  
However,Q-RT PCR or other in vivo studies are needed to exclude any (synergetic) 
effect of these two mutations. Iin her nephew,  patient 4 a de novo variants was identified in 
the MYCN gene. Mutations in MYCN are known to cause the autosomal dominant Feingold 
syndrome, characterized by microcephaly, duodenal atresia, mental retardation and all 
VACTERL spectrum anomalies including esophageal atresia and hypoplastic thumbs [42] 
Two of these features are also present in patient 4r: hypoplastic proximal paced thumbs and 
trachea-esophageal malformations , which makes a Feingold diagnosis in this patient 
plausible. This MYCN mutation is not present in his niece suggesting that these two TE 
cases have no common etiology...  
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In male patient 5 an paternal inherited FRAS1 mutation was identified. This splicing 
mutation had no clinical effect in his father since only homozygous or compound 
heterozygous mutations in this gene cause Fraser syndrome. Moreover, there was little 
overlap with the typical Fraser syndrome phenotype (no eye abnormalities, syndactyly or 
genitourinary anomalies). 
Patient 7 has a maternal  inherited 22q11 microduplication. This patient has a severe 
phenotype; all 6 VACTERL anomalies were present . In contrast, his mother,  had only mild 
dysmorphic features. Adenovo 22q11 duplication as possible cause of VACTERL has been e 
described before either as a micro duplication [43] or in case with an unbalanced  
translocation.[44] An altered expression of  the TBX1 gene, responsible for the phenotype 
in DiGeorge syndrome [MIM 188400][45]  could explain the patients phenotype. 
However, this duplication does not segregate with the TE-phenotype in this family, since it 
is absent in his uncle, patient 8 . Sequenc analysis and conformation of observed common 
variant  in f this family is ongoing.  
Patient 9 is compound heterozygous for the PLEC gene. A previously reported 
patient with esophageal atresia, vertebral , anorectal, cardiac and urogenital anomalies has a 
de novo duplication of the  plectin gene region[33], an impact on trachea-esophageal 
development from these compound heterozygous mutations needs further investigation.  
In consanguineous patient 11 one private CNV involving part of the intronic region 
of  the FGFR2 gene was detected. Homozygous mutations in this gene cause autosomal 
recessive Antley-Bixler syndrome without genital anomalies or disordered steroidogenesis 
(OMIM #207410). However it has also been suggested that also heterozygous mutations 
could cause this syndrome.[46]  These patients have craniosynostosis, facial anomalies, limb 
malformations, choanal stenosis or atresia and joint contractures.[47] Incidentally, patients 
with Antley-Bixler syndrome have esophageal atresia.[48] This CNV was inherited and 
present in both parents. However, this gain was present in both the unaffected, parents. 
Sequencing is ongoing and the analysis whether this duplication causes an altered or loss of 
FGFR2 protein remains to be confirmed. One common CNV polymorphism, loss of  the 
15q11 region was detected with WES-CN.  This loss, not detected with SNP-array,  is 
implicated in patients with developmental and congenital anomalies including esophageal 
atresia and trachea-esophageal fistula.[49] This region is deleted in three additional  
esophageal atresia patients in our cohort.[8] However, it is packed with repeat elements e.g. 
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LINE, SINE and others making validation difficult  this could be like the more common 
16p13 region a recurrent CNV predisposing for developmental anomalies (ref giririja)  
Gene discovery approach 
Familial TE 
In family 1 no genes from the candidate gene panel were affected by rare or private 
variations. Since there is no information regarding other affected family members in this 
family where  both sons are affected and both parents are healthy, several inheritance models 
could be plausible. Therefore, we considered X-linked recessive, homozygous recessive and 
compound heterozygous as plausible inheritance models. One rare X-linked recessive 
variants was present, a rare nonsynonymous SNV in the retinoic acid induced 2 (RAI2) gene. 
This gene is involved in X-linked Nance-Horan syndrome. Patients affected by this 
syndrome have cataracts, dental anomalies and dysmorphic features, symptoms absent in our 
family 1  patients. In patients 5 ,  a homozygous recessive mutation in the (ATPC2C2) gene, 
and in patient 6 a compound heterozygous mutations in the Phosphopantothenoylcysteine 
Synthetase gene (PPCS) and a putative de novo mutation in the (PFAS) were identified. But 
these mutations c, could not be associated with disruptions in foregut development. Two 
separate de novo mutations were identified in family two. Moreover, there was no shared 
rare or private variation following compound heterozygous or homozygous recessive 
models.  
Consanguineous TE- patients 
Autosomal recessive diseases arise if  a detrimental mutation is inherited from both 
parents and therefore present in a homozygous state in  affected offspring. Although these 
parental mutations could have arisen independently, they are often inherited from a common 
ancestor and the parents share a haplotype in this identical by descent (IBD) region.  
Using high density SNP-array Runs of Homozygosity can be detected indicative for 
uniparental dysomy or homozygous IBD regions containing homozygous recessive 
mutations.[50] Different types of definitions exist regarding the length of ROH region to 
use in homozygosity mapping. Runs of Homozygosity are present in every human genome, 
vary in length across individuals, and can be ancestry specific. Therefore, a ROH should 
have certain characteristics to increase the probability that the ROH region studied contains 
the detrimental allele of interest. Auton and coworkers define highly homozygous regions as 
211 
NGS in familial and consanguineous esophageal atresia 
stretches of at least 50 SNPs in a 1 cM region, with SNPs having an minor allele frequency 
(MAF) of at least 5%.[51] Although heavily dependent on region specific recombination 
rate this is roughly 500kb-2000kb containing at least 50 SNPs.[52] Pemberton et al. have 
classified ROH in short (tens of kb), medium (hundreds of kb to few Mb) and long ROH 
(several Mb in length) with the medium and long ROH corresponding to shared haplotypes 
resulting from common ancestry.[53]  Szpiech and coworkers used the prediction tool 
Polyphen2[54] to classify variants found with exome sequencing in 27 individuals and find 
enrichment of variants predicted to be damaging in long Runs of Homozygosity.[55]  
Patient 9 did not have large ROH regions, absent in his parents, in which the in silico 
genomic oligo-array and SNP-array evaluation toolv2.0[18] predicted autosomal recessive 
syndromes in which patients were reported with trachea-esophageal anomalies. One 
syndrome was highlighted in the homozygosity enrichment analysis of patient 10. 
Homozygous mutations in the  WNT7a on chromosome 3p25 are associated with the 
autosomal recessive Al-awadi/Raas-Rothschild syndrome (#OMIM 276820). This 
syndrome is characterized by limb malformations, hypoplastic pelvis, Mullerian hypoplasia 
and abnormal genitalia. Esophageal atresia has been described in patients with this 
syndrome.[56] However, no rare or private homozygous recessive WNT7A mutations were 
detected in patient 10 . The only rare or private homozygous recessive variant present in in 
patent 10 was , was a stopgain mutation in the prenylcysteine oxidase 1 gene.but no link 
with foregut development could be made. 
There were no new ROH regions in patient 11. This was expected since his parents 
have a familial relationship several generations back and recombination would have caused 
heterozygosity throughout the genome. Sequencing of this patient is ongoing.  
To conclude, we identified the causal mutation in one affected family member, a 
MYCN mutation in a patient with features of Feingold syndrome. Since this mutation was de 
novo, and therefore absent in his niece, it ruled out familial TE in this family. The chance 
occurrence of two independent events leading to a similar phenotype with an incidence of 
about 2.5 in 10.000 seemed unlikely. However, it happened and gives a different perspective 
of familial TE. The absence of other Feingold specific symptoms in this patient can be due to 
variable specificity of phenotypical features. Screening patients with TE-anomalies on 
MYCN and other syndromic TE anomalies, even if only a few characteristic features are 
present, seems warranted.  
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Identifying the causal variant out of the hundreds of candidate variants is difficult in 
heterogeneous conditions as EA/TEF and VACTERL. If variant filtering was less 
stringent, excluding  conservation and prediction tools as a criterion, and only the allele 
frequency (MAF ≤ 0.001) many cilia related variants were present. There was shared 
compound heterozygous variation in dynein genes DNAH2, DNAH3,DNAH11 ,DNAH11 
and DYNC2H1 in familial patients and consanguineous patients nine and ten are compound 
heterozygous for several dynein proteins (DRC1, DNAH1, DNAH5, DNAH8, DNAH9). 
Three of these are causal genes for ciliary dyskinesia (DRC1 and DNAH5/11). Homozygous 
mutations in DRC1 , seen in patient ten, cause autosomal recessive primary ciliary 
dyskinesia[57], as do compound heterozygous or homozygous mutations in the DNAH5 
gene.[58, 59] 
These variants are intriguing since there is increasing evidence  suggesting  
ciliopathies as a causal factor in specific subsets of VACTERL patients. These include   for 
instance patients with  VACTERL-hydrocephalus type of syndrome[60] and asphyxiating 
thoracic dystrophy [61] patients with craniofacial, limb and rib defects[62, 63]. Moreover, 
compound heterozygous mutations could be responsible, as has been shown for 
Sensenbrenner syndrome.[64] Perhaps the combined effect of all variants disrupts the 
dynein complex structure or proper functioning. Testing if the cilia function properly, for 
instance measuring cilia number, length and structure[65] in dermal fibroblast could prove 
the involvement of altered cilia functioning in these patients. A word of caution however, 
there are thousands of cilia related genes and perhaps merely this number is reflected in the 
observed frequency..  
Possible pathogenic variants were detected in genes from genetic syndromes of which 
TE anomalies are a variable feature. Not all of the characteristic features of those syndromes 
are present in these patients. However, incomplete penetrance of the phenotype could mask 
the causal genetic syndrome. Screening patient cohort for pathogenic mutations in genes 
from known syndromes or genes from animal knockout models with VACTERL (-) like 
phenotypes could aid in diagnosing many of previously undiagnosed patients.  
 
Acknowledgements 
The authors would like to thank Zeliha Ozgur, M. Ploeg, D. Huigh and H.A. Nastiti 
for their technical assistance. 
  
213 
NGS in familial and consanguineous esophageal atresia 
References 
1. Oddsberg, J., Y. Lu, and J. Lagergren, Aspects of esophageal atresia in a population-based setting: incidence, 
mortality, and cancer risk. Pediatr Surg Int, 2012. 28(3): p. 249-57. 
2. Pedersen, R.N., et al., Oesophageal atresia: prevalence, prenatal diagnosis and associated anomalies in 23 
European regions. Arch Dis Child, 2012. 97(3): p. 227-32. 
3. Cui, W., et al., Sex differences in birth defects: a study of opposite-sex twins. Birth Defects Res A Clin Mol 
Teratol, 2005. 73(11): p. 876-80. 
4. Lisi, A., et al., Sex and congenital malformations: an international perspective. Am J Med Genet A, 2005. 
134a(1): p. 49-57. 
5. de Jong, E.M., et al., Non-VACTERL-type anomalies are frequent in patients with esophageal 
atresia/tracheo-esophageal fistula and full or partial VACTERL association. Birth Defects Res A Clin Mol 
Teratol, 2008. 82(2): p. 92-7. 
6. Shaw-Smith, C., Oesophageal atresia, tracheo-oesophageal fistula, and the VACTERL association: review of 
genetics and epidemiology. J Med Genet, 2006. 43(7): p. 545-54. 
7. Stoll, C., et al., Associated malformations in patients with esophageal atresia. Eur J Med Genet, 2009. 52(5): 
p. 287-90. 
8. Brosens, E., et al., Locus and phenotype heterogeneity in patients with trachea-esophageal malformations and 
associated anomalies. Journal of Medical Genetics, 2014. 
9. Schulz, A.C., et al., Nine new twin pairs with esophageal atresia: a review of the literature and performance of 
a twin study of the disorder. Birth Defects Res A Clin Mol Teratol, 2012. 94(3): p. 182-6. 
10. Felix, J.F., et al., Genetics and developmental biology of oesophageal atresia and tracheo-oesophageal fistula: 
lessons from mice relevant for paediatric surgeons. Pediatr Surg Int, 2004. 20(10): p. 731-6. 
11. de Jong, E.M., et al., Etiology of esophageal atresia and tracheoesophageal fistula: "mind the gap". Curr 
Gastroenterol Rep, 2010. 12(3): p. 215-22. 
12. Felix, J.F., D. Tibboel, and A. de Klein, Chromosomal anomalies in the aetiology of oesophageal atresia and 
tracheo-oesophageal fistula. Eur J Med Genet, 2007. 50(3): p. 163-75. 
13. Bednarczyk, D., M.M. Sasiadek, and R. Smigiel, Chromosome Aberrations And Gene Mutations In Patients 
With Esophageal Atresia. J Pediatr Gastroenterol Nutr, 2013. 
14. Choinitzki, V., et al., Second study on the recurrence risk of isolated esophageal atresia with or without 
trachea-esophageal fistula among first-degree relatives: No evidence for increased risk of recurrence of 
EA/TEF or for malformations of the VATER/VACTERL association spectrum. Birth Defects Res A Clin 
Mol Teratol, 2013. 
15. Robert, E., et al., An international collaborative study of the epidemiology of esophageal atresia or stenosis. 
Reprod Toxicol, 1993. 7(5): p. 405-21. 
16. Otto, E.A., et al., Candidate exome capture identifies mutation of SDCCAG8 as the cause of a retinal-renal 
ciliopathy. Nat Genet, 2010. 42(10): p. 840-50. 
17. Hildebrandt, F., et al., A systematic approach to mapping recessive disease genes in individuals from outbred 
populations. PLoS Genet, 2009. 5(1): p. e1000353. 
18. Wierenga, K.J., et al., A clinical evaluation tool for SNP arrays, especially for autosomal recessive conditions 
in offspring of consanguineous parents. Genet Med, 2013. 15(5): p. 354-60. 
19. Macdonald, J.R., et al., The Database of Genomic Variants: a curated collection of structural variation in the 
human genome. Nucleic Acids Res, 2014. 42(1): p. D986-92. 
20. Amarasinghe, K.C., J. Li, and S.K. Halgamuge, CoNVEX: copy number variation estimation in exome 
sequencing data using HMM. BMC Bioinformatics, 2013. 14 Suppl 2: p. S2. 
21. Fonseca, D.J., et al., A de novo 14q12q13.3 interstitial deletion in a patient affected by a severe 
neurodevelopmental disorder of unknown origin. Am J Med Genet A, 2012. 158A(3): p. 689-93. 
22. Brouwer, R.W., et al., NARWHAL, a primary analysis pipeline for NGS data. Bioinformatics, 2012. 
28(2): p. 284-5. 
23. Li, H. and R. Durbin, Fast and accurate long-read alignment with Burrows-Wheeler transform. 
Bioinformatics, 2010. 26(5): p. 589-95. 
24. Li, H., et al., The Sequence Alignment/Map format and SAMtools. Bioinformatics, 2009. 25(16): p. 2078-9. 
25. McKenna, A., et al., The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation 
DNA sequencing data. Genome Res, 2010. 20(9): p. 1297-303. 
26. Wang, K., M. Li, and H. Hakonarson, ANNOVAR: functional annotation of genetic variants from high-
throughput sequencing data. Nucleic Acids Res, 2010. 38(16): p. e164. 
27. Jacobs, I.J., W.Y. Ku, and J. Que, Genetic and cellular mechanisms regulating anterior foregut and 
esophageal development. Dev Biol, 2012. 369(1): p. 54-64. 
28. Hamosh, A., et al., Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and 
genetic disorders. Nucleic Acids Res, 2005. 33(Database issue): p. D514-7. 
214 
Chapter 4.1 
29. Guest, S.S., C.D. Evans, and R.M. Winter, The Online London Dysmorphology Database. Genet Med, 
1999. 1(5): p. 207-12. 
30. Eppig, J.T., et al., The Mouse Genome Database (MGD): comprehensive resource for genetics and genomics of 
the laboratory mouse. Nucleic Acids Res, 2012. 40(Database issue): p. D881-6. 
31. Solomon, B.D., et al., Clinical geneticists' views of VACTERL/VATER association. Am J Med Genet A, 
2012. 158a(12): p. 3087-100. 
32. Solomon, B.D., et al., De novo deletion of chromosome 20q13.33 in a patient with tracheo-esophageal fistula, 
cardiac defects and genitourinary anomalies implicates GTPBP5 as a candidate gene. Birth Defects Res A 
Clin Mol Teratol, 2011. 91(9): p. 862-5. 
33. Hilger, A., et al., De novo microduplications at 1q41, 2q37.3, and 8q24.3 in patients with 
VATER/VACTERL association. Eur J Hum Genet, 2013. 21(12): p. 1377-82. 
34. Arrington, C.B., et al., Haploinsufficiency of the LIM domain containing preferred translocation partner in 
lipoma (LPP) gene in patients with tetralogy of Fallot and VACTERL association. Am J Med Genet A, 
2010. 152a(11): p. 2919-23. 
35. Smigiel, R., et al., Oesophageal atresia with tracheoesophageal fistula and anal atresia in a patient with a de 
novo microduplication in 17q12. Eur J Med Genet, 2014. 57(1): p. 40-3. 
36. Ferreira de Almeida, T. and D.R. Bertola, Microdeletion 11q13.1.q13.2 in a patient presenting with 
developmental delay, facial dysmorphism, and esophageal atresia: possible role of the GSTP1 gene in esophagus 
malformation. Birth Defects Res A Clin Mol Teratol, 2013. 97(7): p. 463-6. 
37. van Binsbergen, E., et al., A fetus with de novo 2q33.2q35 deletion including MAP2 with brain anomalies, 
esophageal atresia, and laryngeal stenosis. Am J Med Genet A, 2014. 164a(1): p. 194-8. 
38. Faguer, S., et al., A 17q12 chromosomal duplication associated with renal disease and esophageal atresia. Eur 
J Med Genet, 2011. 54(4): p. e437-40. 
39. Dworschak, G.C., et al., De novo 13q deletions in two patients with mild anorectal malformations as part of 
VATER/VACTERL and VATER/VACTERL-like association and analysis of EFNB2 in patients with 
anorectal malformations. Am J Med Genet A, 2013. 161a(12): p. 3035-41. 
40. Heller, N. and A.W. Brandli, Xenopus Pax-2 displays multiple splice forms during embryogenesis and 
pronephric kidney development. Mech Dev, 1997. 69(1-2): p. 83-104. 
41. Hu, M.C., et al., GLI3-dependent transcriptional repression of Gli1, Gli2 and kidney patterning genes disrupts 
renal morphogenesis. Development, 2006. 133(3): p. 569-78. 
42. van Bokhoven, H., et al., MYCN haploinsufficiency is associated with reduced brain size and intestinal 
atresias in Feingold syndrome. Nat Genet, 2005. 37(5): p. 465-7. 
43. Schramm, C., et al., De novo microduplication at 22q11.21 in a patient with VACTERL association. Eur J 
Med Genet, 2011. 54(1): p. 9-13. 
44. Prieto, J.C., et al., Phenotypic expansion of the supernumerary derivative (22) chromosome syndrome: 
VACTERL and Hirschsprung's disease. J Pediatr Surg, 2007. 42(11): p. 1928-32. 
45. Shaikh, T.H., et al., Low copy repeats mediate distal chromosome 22q11.2 deletions: sequence analysis predicts 
breakpoint mechanisms. Genome Res, 2007. 17(4): p. 482-91. 
46. Chun, K., et al., FGFR2 mutation associated with clinical manifestations consistent with Antley-Bixler 
syndrome. Am J Med Genet, 1998. 77(3): p. 219-24. 
47. McGlaughlin, K.L., et al., Spectrum of Antley-Bixler syndrome. J Craniofac Surg, 2010. 21(5): p. 1560-4. 
48. Feigin, E., et al., Antley-Bixler syndrome and esophageal atresia in a patient with trisomy 21. Clin Genet, 
1995. 47(1): p. 53-5. 
49. Wong, D., et al., Expanding the BP1-BP2 15q11.2 Microdeletion Phenotype: Tracheoesophageal Fistula and 
Congenital Cataracts. Case Rep Genet, 2013. 2013: p. 801094. 
50. Kearney, H.M., J.B. Kearney, and L.K. Conlin, Diagnostic implications of excessive homozygosity detected by 
SNP-based microarrays: consanguinity, uniparental disomy, and recessive single-gene mutations. Clin Lab 
Med, 2011. 31(4): p. 595-613, ix. 
51. Auton, A., et al., Global distribution of genomic diversity underscores rich complex history of continental 
human populations. Genome Res, 2009. 19(5): p. 795-803. 
52. Yu, A., et al., Comparison of human genetic and sequence-based physical maps. Nature, 2001. 409(6822): p. 
951-3. 
53. Pemberton, T.J., et al., Genomic patterns of homozygosity in worldwide human populations. Am J Hum 
Genet, 2012. 91(2): p. 275-92. 
54. Adzhubei, I.A., et al., A method and server for predicting damaging missense mutations. Nat Methods, 2010. 
7(4): p. 248-9. 
55. Szpiech, Z.A., et al., Long runs of homozygosity are enriched for deleterious variation. Am J Hum Genet, 
2013. 93(1): p. 90-102. 
56. Lonardo, F., et al., Al-Awadi/Raas-Rothschild syndrome: two new cases and review. Am J Med Genet A, 
2007. 143a(24): p. 3169-74. 
215 
NGS in familial and consanguineous esophageal atresia 
57. Wirschell, M., et al., The nexin-dynein regulatory complex subunit DRC1 is essential for motile cilia function 
in algae and humans. Nat Genet, 2013. 45(3): p. 262-8. 
58. Olbrich, H., et al., Mutations in DNAH5 cause primary ciliary dyskinesia and randomization of left-right 
asymmetry. Nat Genet, 2002. 30(2): p. 143-4. 
59. El Zein, L., H. Omran, and P. Bouvagnet, Lateralization defects and ciliary dyskinesia: lessons from algae. 
Trends Genet, 2003. 19(3): p. 162-7. 
60. Friedland-Little, J.M., et al., A novel murine allele of Intraflagellar Transport Protein 172 causes a syndrome 
including VACTERL-like features with hydrocephalus. Hum Mol Genet, 2011. 20(19): p. 3725-37. 
61. Halbritter, J., et al., Defects in the IFT-B component IFT172 cause Jeune and Mainzer-Saldino syndromes in 
humans. Am J Hum Genet, 2013. 93(5): p. 915-25. 
62. Ashe, A., et al., Mutations in mouse Ift144 model the craniofacial, limb and rib defects in skeletal ciliopathies. 
Hum Mol Genet, 2012. 21(8): p. 1808-23. 
63. Fehrenbach, H., et al., Mutations in WDR19 encoding the intraflagellar transport component IFT144 cause 
a broad spectrum of ciliopathies. Pediatr Nephrol, 2014. 
64. Gilissen, C., et al., Exome sequencing identifies WDR35 variants involved in Sensenbrenner syndrome. Am J 
Hum Genet, 2010. 87(3): p. 418-23. 
65. Kheradmand Kia, S., et al., RTTN mutations link primary cilia function to organization of the human 
cerebral cortex. Am J Hum Genet, 2012. 91(3): p. 533-40. 
 
 
216 
Chapter 4.1 
  4.2
Whole exome resequencing 
reveals recessive mutations in 
TRAP1 in individuals with 
CAKUT and VACTERL  association 
 
 
 
 
Adapted from: 
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CAKUT and VACTERL association 
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Velibor Tasic, Tracie Pennimpede, Sivakumar Natarajan, Ethan Sperry, Danilo S. Matassa, Radovan 
Bogdanovic, Ivo de Blaauw, Carlo L.M. Marcelis, Charlotte H.W. Wijers, Enrika Bartels, Eberhard 
Schmiedeke, Dominik Schmidt, Stefanie Märzheuser, Sabine Grasshoff-Derr, Stefan Holland-Cunz, Michael 
Ludwig, Markus M. Nöthen, Markus Draaken, Erwin Brosens, Hugo Heij, Dick Tibboel, Bernhard G. 
Herrmann, Ben D. Solomon, Annelies de Klein, Iris A.L.M. van Rooij, Franca Esposito, Heiko M. Reutter, and 
Friedhelm Hildebrandt.  Kidney Int. 2013 Oct 23. ; Epub ahead of print
Abstract 
Congenital abnormalities of the kidney and urinary tract (CAKUT) account for 
approximately 50% of children with chronic kidney disease and they are the most frequent 
cause of end-stage renal disease in children in the US. However, its genetic etiology remains 
mostly elusive. VACTERL association is a rare disorder that involves multiple organs 
including the kidney and urinary tract in up to 60% of the cases.  
By homozygosity mapping and whole exome resequencing combined with high-
throughput mutation analysis by array-based multiplex PCR and next-generation 
sequencing, we identified recessive mutations in the gene TNF receptor-associated protein 1 
(TRAP1) in two families with isolated CAKUT and three families with VACTERL 
association. TRAP1 is a heat shock protein 90 (HSP90)-related mitochondrial chaperone 
possibly involved in anti-apoptotic and ER-stress signaling. Trap1 is expressed in renal 
epithelia of developing mouse kidney E13.5 and in the kidney of adult rats, most 
prominently in proximal tubules and in thick medullary ascending limbs of Henle’s loop.  
We thus identified mutations in TRAP1 as highly likely causing CAKUT or CAKUT 
in VACTERL association. 
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Introduction 
Congenital abnormalities of the kidney and urinary tract (CAKUT) occur in 3-6 per 
1,000 live births. CAKUT are the most frequent cause for chronic kidney disease in children 
(~50%)[1, 2] in the US. The acronym “CAKUT” comprises heterogeneous malformations 
involving the kidney (e.g. renal agenesis, hypodysplasia), and the urinary tract (e.g. 
vesicoureteral reflux, ureteropelvic junction obstruction)[3]. These congenital anomalies 
are related because a part of their pathogenesis is an impaired co-development of 
nephrogenic tissues derived from the metanephric mesenchyme and the ureteric bud[4]. 
Twenty monogenic causes of isolated CAKUT in humans have been published to date as 
reviewed recently by Yosypiv[5]. However, they only account for ~10% - 20% of all cases 
indicating a broad genetic heterogeneity of CAKUT. A recent study on copy number 
variations (CNVs) in a large cohort of individuals with CAKUT and two publications 
identifying novel monogenic causes of CAKUT bring further evidence that CAKUT is a 
condition of extensive genetic heterogeneity[6-8]. CAKUT most frequently occur isolated, 
but might be associated with extra-renal phenotypes, for instance with VACTERL 
association (MIM [#192350]).  
The acronym “VACTERL” describes the combination of at least three of the 
following congenital anomalies: vertebral defects (V), anorectal malformations (A), cardiac 
defects (C), tracheoesophageal fistula with or without esophageal atresia (TE), renal 
malformations (R), and limb defects (L). VACTERL association is a rare disease that occurs 
mostly sporadic in 1/10,000-40,000 live births[9]. Its etiology is enigmatic, although 
animal models suggest an involvement of Sonic hedgehog signaling[10]. In humans, ZIC3 
mutations are the cause of a closely related non-classic VACTERL condition (VACTERL-X, 
MIM [#314390])[11, 12]. Additionally, there are six case reports published of individuals 
with VACTERL association in conjunction with mitochondrial dysfunction as summarized 
recently by Siebel and Solomon[13]. In order to identify new recessive genes that cause 
isolated CAKUT or CAKUT in VACTERL association, we performed homozygosity 
mapping and whole exome resequencing in 24 affected individuals with CAKUT from 16 
families, and in 4 individuals with CAKUT in VACTERL. 
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Results 
Whole exome resequencing identifies a homozygous mutation in TRAP1 in CAKUT and in 
VACTERL association 
By homozygosity mapping in a family of two sibs (A3403) with unilateral and 
bilateral vesicoureteral reflux (VUR) III°, respectively (Figure 1A, B and Table 1), we 
identified a short 5.2 Mb segment of homozygosity on chromosome 5 (Figure 1C), 
indicating distant consanguinity of the parents. This finding suggested that in this family 
CAKUT are most likely caused by a homozygous recessive mutation in an unknown 
CAKUT gene. We performed whole exome resequencing in individual A3403-21 as 
described previously by the authors[14, 15]. In order not to miss either a homozygous 
mutation in a short run of homozygosity or a compound heterozygous mutation (which, as 
in this case, cannot be excluded a priori in families with remote consanguinity[16]), we 
considered variants not only in the homozygosity peak but within regions of genetic linkage 
for both sibs (coverage ≥ 4; minor variant frequency, MVF ≥ 0.2). Following variant 
filtering we retained 38 variants in 13 genes for Sanger confirmation and segregation 
analysis (Supplementary Table S1 online). Only a single homozygous missense mutation 
(R469H) in the gene TRAP1 on chromosome 16p13.3 survived the variant filtering process 
and segregation analysis (Figure 1D). This homozygous variant in TRAP1 in A3403-21 and 
-22 was positioned in a ~1.5 Mb run of apparent homozygosity that was not detected by 
homozygosity mapping (Figure 1C), because the threshold for detection of “homozygosity 
peaks” is 2.1 Mb[17].  
In family A4252 with CAKUT in VACTERL we performed whole exome 
resequencing in an affected individual (A4252-21). This girl was born with a right double 
kidney and duplex ureter, left VUR, esophageal atresia type IIIb, and anal atresia with a 
vestibular fistula (Figure 1E, F and Table 1). Although there was no consanguinity 
reported in this family, homozygosity mapping showed unusually broad homozygosity peaks 
on chromosome 16 on the p-terminus and q-terminus (5.5 and 9.6 Mb, respectively) (Figure 
1G). In this case, we hypothesized that CAKUT in VACTERL is caused by a homozygous 
mutation within these homozygous regions.  
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When evaluating whole exome resequencing data in this individual, the 512,733 
variants initially detected (MVF ≥ .55; coverage ≥ 2) were reduced to only 11 variants 
within the “homozygosity peaks” on chromosome 16 and 18 (Supplementary Table S2 
online). 
 
Table 1. Mutations of TRAP1 in five families with isolated CAKUT or CAKUT in VACTERL 
association Abbreviations: ASD, atrial septum defect; CAKUT, congenital abnormalities of the kidney and 
urinary tract; cDNA, complementary DNA; E. coli, Escherichia coli; EVS, Exome Variant Server; F, female; Fa, 
mutation segregating from the father; L, left; NA, not applicable; M, male; MAF, minor allele frequency; 
MCDK, multicystic dysplastic kidney; Mo, mutation segregating from the mother; MutT, MutationTaster; R, 
right; SIFT, sorting intolerant from tolerant; TRAP1, tumor necrosis factor (TNF) receptor–associated 
protein 1; VSD, ventricular septum defect; VUR-III1, vesicoureteral reflux third degree. aTRAP1 cDNA 
mutations are numbered according to human cDNA reference sequence NM_016292.2, where þ1 corresponds 
to the A of ATG start translation codon. bMutationTaster score. Range: 0–1.0, 1.0 being most deleterious. 
cPolyPhen2 (HumVar) score. Range: 0–1.0, 1.0 being most deleterious. dSIFT score. Range: 0–1.0, 0 being 
most deleterious. eMinor allele frequency in 8600 alleles of Americans of European descent. fOne individual is 
homozygous for this allele. 
 
The only variant that was confirmed by Sanger sequencing and that altered a 
conserved amino acid residue was TRAP1 R469H, the same allele as in family A3403. By 
comparison of SNPs in the affected girl and her parents, we demonstrated that partial 
maternal isodisomy of chromosome 16 with two recombinants (one located on the p-arm and 
one located on the q-arm) was the underlying cause of homozygosity for TRAP1 R469H 
(Figure 1G-J).  
 The TRAP1 allele c.1406G>A, p.R469H alters an evolutionary highly 
conserved amino acid residue and it is predicted to be deleterious for protein function by 
publically available software programs (Table 1 and Supplementary Figure S1 online). In 
the Exome Variant Server (EVS) database, R469H has a minor allele frequency (MAF) of 
0.9% in Americans of European descent. In our cohort of 675 individuals with CAKUT, 
most of them European, the MAF is 1.9%. The three affected individuals from two unrelated 
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families with homozygous TRAP1 R469H, as well as 6 additional heterozygous carriers 
share haplotypes at the TRAP1 locus (Figure S2 online) which speaks for TRAP1 R469H 
being a European founder mutation. 
Mutation analysis reveals three additional families with TRAP1 mutations 
 We subsequently analyzed the coding sequence of TRAP1 in a cohort of 675 
individuals with isolated CAKUT (Supplementary Table S3 online) and 300 individuals 
with classic VACTERL association (i.e. VACTERL-X and other related disorders have been 
excluded) using a barcoded multiplex PCR approach and consecutive next generation 
sequencing as described previously by the authors[18]. As a control group, we included 800 
individuals with the distinct renal phenotype of nephronophthisis. 
 We detected six additional recessive mutations in TRAP1 in a compound 
heterozygous state in three additional unrelated families with CAKUT or CAKUT in 
VACTERL (Table 1, Figure 1K, L, M, Supplementary Figure S1, and S3 online). In 
individual A3051-21 with a left-sided multicystic dysplatic kidney (MCDK), we found a 
maternally inherited protein-truncating frame-shift mutation (c.127_137dup, p.R46fs*75). 
This mutation abrogates the N-terminal mitochondrial targeting sequence of TRAP1, which 
makes this a null allele. The second allele was a missense mutation (c.1324G>A, p.E442K) 
which segregated from the father.  
In individual A4884-21 with CAKUT in VACTERL, including right renal agenesis, 
vertebral malformations, anal atresia with a rectoperineal fistula, atrial septum defect type 
II, esophageal atresia, and abnormal position of the thumbs  
(Table 1 and Supplementary Figure S4 online), we detected compound heterozygous 
missense mutations in TRAP1 located in the ATPase-domain (c.757A>G, p.I253V) and in 
the HSP90-domain (c.1573C>T, p.L525F) (Figure 1L). In individual EA1717 with CAKUT 
in VACTERL, including pyelectasis, left VUR, a complex anorectal malformation including 
anal atresia and persistent cloaca, esophageal atresia, cardiac defects, limb defects and, 
persistent left vena cava superior (Table 1), we detected compound heterozygous missense 
mutations which are both located in the HSP90-domain of TRAP1 (c.1330T>A, p.Y444N 
and c.1663G>A, p.V555I). 
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Figure 1 (legend on page 224) 
 
In order to exclude the presence of recessive mutations in controls, we sequenced the 
TRAP1 coding sequence in 800 individuals with the distinct renal phenotype of 
nephronophthisis (NPHP). We detected the TRAP1 allele I253V seven times (MAF 0.87%), 
T444N twice (MAF 0.25%), and R469H twice (MAF 0.025%), all of them as single 
heterozygous alleles. TRAP1 R46Sfs*75, E442K, L525F, and V555I were absent from our 
control cohort. Furthermore, no other possibly deleterious variants were present in a 
homozygous or compound heterozygous state in 800 individuals with NPHP. 
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Figure 1 | Homozygosity mapping and whole-exome resequencing identifies mutations in tumor 
necrosis factor (TNF) receptor–associated protein 1 (TRAP1) as causing congenital abnormalities of 
the kidney and urinary tract (CAKUT) or VACTERL association. (a, b) Voiding cysturethrograms 
(VCUG) of CAKUT siblings A3403-21 and A3403-22 showing unilateral vesicoureteral reflux (VUR) grade III 
and bilateral VUR, respectively (white arrow heads). (c) Nonparametric LOD (NPL) scores across the human 
genome in two affected siblings. X axis represents Affymetrix 250k StyI array single-nucleotide polymorphism 
(SNP) positions across human chromosomes concatenated from the p-terminus (left) to the q-terminus (right). 
Genetic distance is given in cM. A single peak indicates distantly related parents. (d) Chromatogram of newly 
identified homozygous missense mutation (arrow head) in the gene encoding TNF receptor–associated protein 
1 (TRAP1) over wild-type control. (e) VCUG (upper panel) and cystoscopy (lower panel) demonstrating VUR 
and a dilated ureteral orifice, respectively. (f) Chest X-ray (top panel) and esophagoscopy (bottom panel) 
showing esophageal atresia and esophagotracheal fistula in individual A4252-21 with CAKUT in VACTERL 
association. (g) NPL score in an individual A4252-21 with VACTERL association. Two maximum peaks 
indicate homozygosity at the p-terminus and q-terminus of chromosome 16. (h) Panel on the right illustrates 
maternal heterodisomy of chromosome 16 and partial uniparental isodisomy (p-ter and q-ter) of the child (Fa, 
father; Mo, mother; Ch, child). (i) Partial haplotypes of selected markers and their physical positions across 
chromosome 16 in the Fa, the Mo, and the affected Ch of CAKUT family A4252. Selected markers (biallelic 
SNPs; minor allele frequency (MAF)¼0.496–0.5) homozygous in the father are shown in green (alleles AA) and 
light green (alleles BB). The fact that for 19 of 52 alleles there is paternal noncontribution in the child strongly 
suggests maternal heterodisomy of chromosome 16. No paternal noncontribution was observed in the child on 
any other chromosome (data not shown). (j) Selected markers (biallelic SNPs; MAF¼0.497–0.5) heterozygous 
in the Mo of family A4252 are shown for alleles coded in red (AB; phase unknown). Note that in the central 
segment (b), separated by vertical lines, the Ch haplotype is identical to the mother’s haplotype. In the p-ter (a) 
and q-ter (a’) segments (a, a’), the child is homozygous, indicating maternal isodisomy in these segments. (k) 
Exon structure of human TRAP1 complementary DNA. Positions of start codon (ATG) and of stop codon 
(TGA) are indicated. (l) Domain structure of the TRAP1 protein. HSP, heat-shock protein; MTS, 
mitochondrial targeting sequence. (m) Translational changes of detected mutations are shown relative to their 
positions in TRAP1 complementary DNA (see l) and TRAP1 protein (see m) for affected individuals with 
CAKUT or CAKUT in VACTERL association with recessive TRAP1 mutations. Family numbers are shown 
in parentheses. *Denotes an individual with compound heterozygous mutations in TRAP1.  
 
Trap1 is expressed in developing and adult kidney 
In order to determine whether TRAP1 has a function during kidney development, we 
analyzed Trap1 expression in developing kidney in mouse embryos 13.5 dpc. Trap1 
expression seemed to be expressed at this stage in renal vesicles according to Trap1 
transcription assays publically available through the Gudmap project. By in-situ 
hybridization in E13.5 mouse embryos, we found Trap1 to be strongly expressed in kidney, 
adrenal gland, and gonad. Trap1 expression specifically localized to renal epithelia (Fig. 2). 
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In order to characterize TRAP1 localization in adult kidney, we performed 
immunofluorescence stainings in rat using a monoclonal TRAP1 antibody in conjunction 
with established renal markers (Figure 3). TRAP1 is present most prominently in peanut-
lectin-marked proximal tubules in the renal cortex  
(Figure 3A-B). In renal medulla, we detected TRAP1 in peanut-lectin-negative tubular 
segments and in NKCC-marked (Na+K+2Cl- co-transporter) thick ascending limbs of Henle’s 
loop (Figure 3C-D). TRAP1 co-localizes with mitochondrial marker MTCO1 in renal 
cortex and medulla. 
 
 
 
Figure 2 Trap1 is highly expressed in the renal epithelia of E13.5 mouse embryos. The upper panel 
shows a HE-stained sagittal section (a) and a Trap1-ISH (a’) in consecutive sections of a mouse embryo E13.5. 
Note the prominent Trap1 expression in the developing kidney (marked ‘Ki’ in the left panel). The lower panel 
shows higher magnifications of E13.5 mouse kidney. (b) HE staining, (b’) Trap1-ISH. The Trap1-ISH staining 
pattern is consistent with Trap1 being expressed specifically in renal epithelia (b’). Ag, adrenal gland; Go, 
gonad; HE, hematoxylineosin; ISH, in situ hybridization; Ki, kidney (i.e., metanephros); Li, liver; Lu, lung; Mg, 
midgut; Pa, pancreatic primordium; TRAP1, tumor necrosis factor (TNF) receptor–associated protein 1. 
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Figure 3 | Renal tubular segmental localization of TRAP1 by immunofluorescence microscopy in adult 
rat kidney. (a–c) Renal cortex. (a) TRAP1 (blue–green) is located in proximal tubules (marked green by 
peanut lectin) and is absent from distal convoluted tubules (DCT;marked red by NCCT-ab). (False color 
addition of blue–green and green appears as light green.) (b) TRAP1 is mostly absent from cortical thick 
ascending limb (TAL) of Henle’s loop (marked red by NKCC2-ab). (c) TRAP1 colocalizes with mitochondrial 
marker MTCO1 (marked red by MTCO1-ab) in proximal tubules. (False color addition of blue–green and red 
appears as white.) (d–f) Renal medulla. TRAP1 is absent from peanut-lectin-positive tubular segments. (d) 
TRAP1 expression is present in DCT (marked red by NCCT-ab). (e) TRAP1 is expressed in medullary thick 
ascending limb (mTAL) of Henle’s loop (marked red by NKCC2-ab). (f) TRAP1 localizes to mitochondria 
(marked red by MTCO1-ab) of peanut-lectin-negative tubular segments. Scale bar: 201 m. ab, antibody; DAPI, 
40,6-diamidino-2-phenylindole; MTCO1, mitochondrially encoded cytochrome c oxidase 1; NCCT, Naþ-Cl- co-
transporter; NKCC2, Naþ-Kþ-2Cl- co-transporter; TRAP1, tumor necrosis factor (TNF) receptor–associated 
protein 1. 
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Discussion 
 In the present study, we identified by whole exome resequencing and high-
throughput mutation analysis five unrelated families with CAKUT or CAKUT in 
VACTERL association with recessive mutations in TRAP1. Two sibs with CAKUT had a 
homozygous missense mutation (R469H), which segregated from a common ancestor of 
their parents. A girl with VACTERL association had the identical homozygous mutation 
due to maternal isodisomy of chromosome 16 p-ter and q-ter. In a cohort of 675 individuals 
with CAKUT and 300 individuals with classic VACTERL association we identified 3 
additional individuals carrying compound heterozygous mutations in TRAP1. Homozygous 
or compound heterozygous deleterious variants were absent from 800 control individuals. 
By ISH and IF, we showed that Trap1 is expressed in early mouse renal epithelia whereas 
the Trap1 protein is present only in defined segments of developed nephrons in rat.  
 In 6,500 individuals recorded in the EVS server there are several non-
synonymous variants present in TRAP1, including heterozygous truncating variants in 11 
individuals. However, deleterious alleles in recessive disease-genes, unlike in dominant 
disease-genes, do not underlie direct negative selection through evolution. Consequently the 
presence of rare deleterious variants in recessive disease genes in a large cohort is an 
expected finding. 
 The allele TRAP1 Y444N, detected as compound heterozygous mutation in 
an individual with CAKUT in VACTERL, is present homozygously in a single individual of 
the ESP cohort of 6,500 healthy Americans. However, in the context of CAKUT, this does 
not necessarily mean the variant is non-pathogenic. CAKUT frequently remain completely 
asymptomatic. For instance, a double-kidney or unilateral renal agenesis typically are an 
“accidental finding” in renal ultrasound. 
 The fact that the homozygous mutation TRAP1 R469H was found in an 
individual with CAKUT and an individual with VACTERL association is surprising. 
However, in CAKUT and in VACTERL association intra-familial phenotypic variability is 
very common[19-21]. Even in a single individual different CAKUT phenotypes may be 
present, for instance left renal agenesis and right VUR. 
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The frequencies of individuals with recessive TRAP1 mutations in our cohorts 
(0.15% in CAKUT, 0.6% in CAKUT with VACTERL) suggest that mutations in TRAP1 are 
a rare cause of these conditions. Similarly, mutations in two recently identified CAKUT-
causing genes, WNT4 and DSTYK, are rare causes of CAKUT[7, 8]. These findings in 
humans, along with numerous CAKUT-mouse models, indicate that CAKUT are a common 
clinical phenotype arising from a multitude of different single-gene causes. 
In conclusion, we propose that recessive mutations in TRAP1 are a novel rare cause 
of isolated CAKUT and the first recessive cause of the VACTERL association. 
 
Subjects and Methods 
Human subjects.  
We obtained blood samples and pedigrees following informed consent from 
individuals with CAKUT and from individuals with VACTERL association. Approval for 
human subjects research was obtained from the University of Michigan Institutional Review 
Board and other institutions involved. The diagnosis of CAKUT and VACTERL association 
was based on published clinical criteria[9]. 
Homozygosity mapping.  
We performed homozygosity mapping as described previously[17]. 
Whole exome resequencing (WER).  
Exome library preparation and massively parallel resequencing was conducted using 
the SeqCap EZ Exome v2 (Nimblegen) and Genome Analyzer II (Illumina). Subsequent 
variant detection, filtering and analysis have been described previously by the authors[14, 
15]. All detected variants were confirmed by Sanger sequencing. 
Immunofluorescence microscopy (IF).  
IF was performed as previously described by the authors[14] using a Leica SP5X 
system with an upright DM6000 compound microscope and images were processed with the 
Leica AF software suite. Antibodies used: TRAP1 (Abcam, [TRAP1-6], Cat# ab2721), 
MTCO1 (Abcam Cat# ab45918), NKCC2 (LSBio Cat# LS-C150446), NCCT (Millipore 
Cat# AB3553). Specificity of the anti-TRAP1 antibody for rat TRAP1 was confirmed in 
immunoblot (Figure S5 online). 
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In-situ hybridization (ISH).  
ISH was conducted on sections of wildtype mouse embryos with an NMRI 
background at embryonic day 13.5. Mouse embryos were dissected into ice cold phosphate 
buffered saline (PBS), fixed overnight in 4% paraformaldehyde/PBS, and then processed into 
paraffin wax. ISH was performed on paraffin sections (5µm) using antisense probes 
generated by PCR from an E11.0 total embryo cDNA library, and specific staining was 
verified using a sense probe. PCR products contained 3’ T7 and 5’ T3 RNA polymerase 
binding sites for in vitro transcription and probes were purified using G-50 sephadex 
columns (GE Healthcare). The 779bp probe for Trap1 spans exons 13-17 (Accession: 
NM_026508.2). ISH was performed according to the protocol from (Chotteau-Lelievre et al., 
2006) with minor modifications, and detection of AP activity was visualized using BM 
Purple (Roche Diagnostics). Following staining, slides were quickly dehydrated in 80% and 
then 100% ethanol, cleared twice for 1 min in xylene (Roth) and coverslips were mounted 
with Entellan mounting medium (Merck). Photographs were obtained using AxioVision 
software (Zeiss) with a Zeiss AxioCam and SteREO Discovery.V12 microscope. Three 
sections from at least 2 different embryos were analyzed. 
Bioinformatics.  
NGS reads alignment and variant detection was done with Genomics Workbench 
software (CLC Biotech). Mapping parameter: Global alignment, length fraction = 0.9, and 
similarity fraction = 0.9. Genetic location is according to the assembly of the Genome 
Reference Consortium GRCh37. 
Web Resources 
1000 Genomes Browser, http://browser.1000genomes.org; 
Ensembl Genome Browser, http://www.ensembl.org; 
Exome Variant Server, http://evs.gs.washington.edu/EVS; 
Mutation Taster, http://www.mutationtaster.org; 
Gudmap (GenitoUrinary Molecular Anatomy Project), http://www.gudmap.org; 
Online Mendelian Inheritance in Man (OMIM), http://www.omim.org; 
Polyphen2, http://genetics.bwh.harvard.edu/pph2; 
Sorting Intolerant From Tolerant (SIFT), http://sift.bii.a-star.edu.sg; 
The Human Protein Atlas, http://www.proteinatlas.org; 
UCSC Genome Browser, http://genome.ucsc.edu/cgi-bin/hgGateway. 
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General Discussion 
In the last few years genetic research has taken a significant leap forward, both in 
resolution to detect genetic variation as in our understanding of the impact of this genetic 
variation on human health and development. It has become increasingly clear that our 
genomes are packed with variation. Of all known types of DNA variation, Copy Number 
Variation (CNV) affects largest part of our genome,  Single Nucleotide Variation (SNV) is 
most abundant in total variant numbers.[1, 2] Hundreds of these variants in each genome 
are considered ”pathogenic”, private variants affecting gene splicing, causing frame shift or 
introducing stop gains or losses.[3, 4] CNV causing deletions and duplications of sometimes 
more than a MB (1000000bp), holding many genes.[5] Yet, all this variation is often 
inherited from parents not affected by the often severe conditions seen in their children. 
Discriminate the causal variant(s) in the midst of these thousands of candidate sequencing 
variants requires well planned filtering strategies, which include knowledge on inheritance 
patterns, allele frequencies in the general population, type and functional impact of the 
variation and information necessary to prioritize the affected genes. This last information 
not only includes gene specific information but also well documented and structured 
phenotype information.[6, 7]  
CNV can be inherited in a Mendelian manner and if they have an allele frequency 
under <1% in control cohorts, they are called rare Copy Number Variations (CNVs). [8] 
CNV are proposed to arise after replication errors e.g. fork stalling and template switching, 
non-homologues end joining or micro homology mediated break induced replication. [2, 5] 
Replication errors resulting in a large de novo CNV occur approximately once in a hundred 
genomes per generation.[9, 10] The majority will result in decreased fecundity and extinct, 
others have little effect and are inherited across generations. CNV are under selective 
pressure [11, 12] and could very well be one of the driving forces of human evolution. 
These large de novo CNV have frequently been associated with congenital anomalies.[13, 
14] Especially rare CNVs have shown to impact human disease in a variety of ways. For 
instance, they are involved in complex disease [15], can be the second hit unmasking a 
mutation, as has been shown for TAR syndrome [16, 17] or work in a two-hit model.[18] 
There are diagnostic guidelines for the use of micro-array [19] and CNV 
interpretation.[20] The interpretation of a rare CNV, inherited from unaffected parents, is 
difficult since the resulting phenotype can be highly variable and even a sub-clinical 
phenotype.[21, 22]  
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The impact of aneuploidies, structural chromosomal aberrations and de novo CNV 
We describe the genetic variation in our large cohort of patients. EA/TEF is a rare 
condition, with an incidence of 2.5 in 10.000 live births. Consequently, each year about 10-15 
patients are born or admitted to our hospital. We have collected patient material, clinical 
and genetic material since 1988. Our cohort currently has 600 patients, in about half of these 
patients cytogenetic studies at a 30kb resolution has been performed. Aneuploidies and 
structural chromosomal anomalies have been described at many chromosomal loci in 
patients with EA/TEF, some even recurrent such as deletions on chromosome 2q37, 4q35, 
6q13-q15 and duplications on 3p25-pter and 5q34-qter.[23, 24] There are also 
chromosomal anomalies with a link to  a syndrome in the London Dysmorphology Database, 
chromosome 10 - paternal disomy, chromosome 17q22-q23.2 - submicroscopic deletion, 
chromosome 6q27 - submicroscopic deletion and mosaic trisomy 16 all have trachea-
esophageal anomalies as variable features.[25] 
Large CNVs are rare in our genome. Approximately 9% of the individuals in control 
cohorts have a CNV larger than 500kb and 3% has a CNV larger than 1 Mb with a de novo 
rate of 1.2 x 10-2 per generation.[9, 10] Assuming variation increases with decreasing 
variation size, these numbers are somewhat larger focusing on CNV ≥ 30kb. In the Erasmus 
MC-Sophia TE-cohort on average 1 rare or private CNV larger than 30kb was present in 
each TE patient, ~6% of which de novo.   
Some of these variations affect genes with a direct link to the observed phenotype. 
Other CNV affect genes with no obvious association to foregut abnormalities and could very 
well be non-causal. Chromosomal anomalies, excluding those seen in genetic syndromes 
such as trisomy 13, 18 or 21 are  rare. Large structural events do not seem to impact 
EA/TEF and VACTERL disease burden as much as it does in other developmental 
disorders such as Congenital Diaphragmatic Hernia[26] or intellectual disability.[27] The 
de novo CNV seen in TE and VACTERL patients is also non-recurrent, with the exception of 
CNV overlapping the causative locus of a genetic syndrome.[28] It is nonetheless important 
to screen newborns with congenital anomalies, including patients with EA/TEF and 
VACTERL associated features to exclude large pathogenic variation. Mega-base 
chromosomal anomalies and aneuploidies affect hundreds of genes and the malformations 
are and will be often severe. Sub-sequent parental counseling and treatment choice can be 
more specific and better fit current and future needs. The impact of de novo CNV (6%), 
aneuploidies (3.6%) and structural chromosomal anomalies (0.3%) on the total cohort is 
limited. Yet, for an individual patient molecular karyotyping can be vital.   
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Micro-array technology has replaced high resolution GTG-banded karyotyping as a 
first tier diagnostic procedure.[29] Large, unbalanced, deletions and duplications will be 
continued to be detected. However, balanced translocations and inversions will be missed by 
micro-array, since this technique gives only information about the relative copy number, not 
the location of DNA segments. Similarly, inherited, balanced translocations will be missed 
by micro-array alone. For example, Cetinkaya and co-workers [30] describe an inherited 
(1;13)(p8;q12) translocation in a patient with esophageal atresia.  
Chromosomal anomalies can give clues to candidate genes and loci; some cover 
regions harboring candidate genes in TE; deletions on 17q21.3-q24.2 harbor Nog and Tbx4 
which cause TE anomalies in animal knockout studies[31-33]; 13q deletions are also seen as 
de novo CNV in patients with VACTERL association[34] and an unbalanced translocation 
in fact deleting chromosome 7q34qter and duplicating 8q24qter involves the SHH and 
HLXB9 loci. Deletions of SHH are rare, remarkably few reports are available describing loss 
of SHH in patients with TE anomalies.[35-39] One of the patients in the Erasmus MC-
Sophia TE-cohort has a de novo deletion of chromosome 7q36, including the SHH gene.  
Hilger and co-workers describe three de novo CNV, micro-duplications on 
chromosome 1q41, 2q37.3 and 8q24.3 in VACTERL association patients. A mutation 
screening of candidate genes in these regions did not result in additional patients with a 
shared phenotype and affected gene.[40] However, the 8q24 region is also described to be 
duplicated in two structural chromosomal aberrations and could be a susceptibility 
locus.[23] The scarce reports and presence in our cohort of de novo CNV in patients with 
TE anomalies and VACTERL association demonstrate that these factors do not have a high 
impact on TE disease burden. [39-48] 
CNV recurrence; predisposition, reduced penetrance and variable expressivity 
CNV can be inherited in a Mendelian manner and behaves much like other genetic 
variation. There are common polymorphisms and rare or private CNV, the latter likely to be 
under strong selection pressure.[1] Finding two overlapping CNV, in two unrelated 
patients in a cohort of patients with a rare disease could be indicative of a susceptibility locus 
or gene. Almost all patients in our cohort have a rare or private CNV, as does the general 
population. Recurrence of variation at a specific locus in a rare disease as EA/TEF and 
VACTERL association is likely to be more than a chance occurrence. These CNV are 
inherited and their unaffected parents usually do not report any family history of trachea-
esophageal or other VACTERL associated anomalies.  There are several reasons why this 
recurrence of are and private CNV could have an impact on foregut development. Variable 
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expressivity and reduced penetrance is seen in many of the single gene disorders with a TE 
component such as Feingold[49] and CHARGE[50], in patients with micro-deletion and -
duplication syndromes[22, 51, 52] even in patients with whole chromosome 
duplications.[53]  
It is conceivable that this variability could lead to sub-clinical anomalies in unaffected 
parents or other family members. These unaffected parents are thoroughly inspected for 
visual characteristics of the phenotype. However, they are not consistently screened for 
anomalies of the intestinal organs with MRI, X-ray or other imaging technology. Therefore, 
minor anomalies causing sub clinical phenotypes in the esophagus, heart, kidney or 
vertebrae could remain unnoticed. Current analysis strategies, mainly based on a dominant de 
novo and penetrant paradigm, of CNV in patients with congenital anomalies do not cover 
this aspect of CNV pathogenicity. Rare and private CNV, virtually absent from large control 
databases, are either new in a population and will be common polymorphisms in the future, 
or they are rare because they are under evolutionary constraint. Caution has to be taken 
when immediately considering an inherited CNV benign, further parental counseling may be 
needed. Recent publications describing tissue specific CNV justifies studying CNV in target 
tissue instead of blood derived DNA to reduce the chance of tissue specific effects. 
CNV interpretation greatly benefits from copy number profiling studies in fully 
screened healthy control populations [54-56] containing several generations of subjects. 
Inheritance of a CNV is an important exclusion for technical artefacts and a de novo CNV can 
be determined. Moreover, these cohorts should contain people from as many genetic 
backgrounds as possible, since CNV can be ancestry specific.[57]  Large cohorts of concise 
phenotyped individuals are a common in the GWAS community, therefore patient care 
would greatly benefit from the combined Copy Number and phenotype information from 
these studies. 
In a response to the discovery of single cell Copy Number Variation[58], Maosko 
and McCarrol state that perhaps these cells do not transcribe the genes underlying these 
CNV and therefore replicate these late in cell division, increasing the chance of 
mistakes.[59] Cells “know” what part of their private genome is essential for their survival 
and functioning.  They state that it is perhaps best to focus first on those parts of the 
genome that are never affected by detrimental DNA changes. Profiling these large cohorts 
could aid in describing those parts of the genome that never are affected by CNV, these 
regions likely are so crucial that disrupting them leads to a phenotype severely affecting 
fecundity. Conceivably, these regions should be enriched for loci crucial for development. A 
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recently proposed approach to prioritize candidate gens in large CNV is to look at ohnologs, 
usually dosage sensitive genes retained after ancestral whole genome duplication events 
since these genes are enriched in pathogenic CNV.[60, 61] Perhaps as important as 
discovering pathogenic variation and CNVs, is describing those that are not causative for a 
disease. Screening large cohorts of patients and controls is vital in the genome wide 
association studies (GWAS) and copy number profiling era, but will perhaps be even more 
essential in current genome and exome wide sequencing projects.   
Small Insertions/deletions and single base-pair mutations 
Gene mutations play a major role in many of the syndromes of which TE anomalies 
are a variable feature. Most syndromes are autosomal dominant in which either the 
syndrome phenotype segregates through the pedigree or occur de novo. Nine percent of 
patients from the Erasmus MC-Sophia cohort have a confirmed genetic syndrome. There are 
several reasons to suspect that the actual number is in fact higher. The first reason is that 
patients are screened for a genetic anomaly when their phenotype fits a specific genetic 
syndrome or syndromes. However, variable expressivity, reduced penetrance, modifying 
factors, skewed X-inactivation and stochastic effects could lead to difficulties recognizing a 
specific syndrome. Other reasons are more practical, not all phenotypical characteristics are 
recorded consistently, genetic analysis is sometimes not performed and registered in house 
and perhaps most important not all syndromes were known at the moment of genetic 
research. 
The discovery of these genetic syndromes has seen a steep increase in recent years. 
For instance the gene responsible for AEG-syndrome (SOX2) in 2003[62], CHARGE 
syndrome (CHD7) in 2004[63], Feingold syndrome (MYCN) has been described in 
2005[64], Alveolar capillary dysplasia in 2009[28] and EFTUD2 mutations in patients 
with mandibulofacial dysostosis and esophageal atresia in 2013.[65] We have included 
patients from 1988 onwards, and many of the more “historic” patients may have a known 
genetic syndrome based on their phenotype.[66] One of the two affected family members in 
our WES experiment had a de novo MYCN mutation, already described in literature.[49] 
His phenotype was not characteristic for Feingold syndrome, only EA/TEF and thumb 
anomalies were present. This clearly demonstrates the need for screening the entire cohort, 
regardless of associated features, for the presence of known genetic syndromes. In fact, 
research is ongoing in collaboration with the Universitätsklinikum Bonn, Radbout 
Universiteit Nijmegen, Boston Children’s hospital and the Inova Translational Medicine 
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Institute, in which the unresolved patients are being screened for the most frequent 
syndromic-TE mutations as MYCN, MID1, CHD7, SOX2 and others. 
Genetic and phenotypical heterogeneity seen in EA/TEF patients increases the need 
of large sample sizes, since we do not study one, but many separate conditions. It is now 
evident that only by combining cohorts of patients (and ideally controls) in large 
collaborative consortiums, statistical sound results can be obtained from genetic, 
environmental and other epidemiological studies. A clear consistent terminology, 
technology and experimental approach are needed to allow for the cross-institutional 
analysis of these large datasets. Collaborative studies have been initiated  to unite the 
research for certain congenital anomalies, VACTERL association included. Patients would 
benefit from these endeavors, since they are the fastest way to increase and share knowledge 
on TE-anomalies.   
Shift from coding DNA only to whole genome 
Currently, most of the research has focused on genetic factors within the coding part 
of the DNA. Recently, the ENCODE project has described numerous regions of the DNA 
which have a regulatory function. Regions in the DNA not only code for proteins, but also 
for a variety of ncRNA molecules which have the potential to regulate gene expression. We 
describe the deletion of a regulatory lncRNA in patients with TE-anomalies and Alveolar 
Capillary dysplasia.[67] This focus on the coding part of the DNA also occurs  in most of 
the current sequencing projects. Exome sequencing target enrichment kits do have some 
ncRNA molecule coverage. Genetic malformations affecting regulatory elements may 
explain more of the missing heritability seen in TE-anomalies. The deletion of certain 
specific genes could lead to in-utero death of a fetus due to the severe effect of having 
severely decreased amounts of protein, whilst less severe effects in protein level could cause 
a severe, but nowadays not lethal effect as EA and or TEF. 
The genetic contribution; re-analysis and evaluation 
With patients cohorts being screened with exome sequencing, new associated gene 
mutations will be described, some leading to new syndromes. Screening “historic” patient 
cohorts on these new, but also the already known, mutations in genes will give a clearer 
picture of the actual genetic contribution in TE patients. The same holds true for CNV-
profiling. Increasing ability of this technique in detecting smaller and smaller CNV justifies 
the re-analysis of previously patient-parent trio’s for de novo CNV.   
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Exon level copy number profiling using Next Generation Sequencing data has the 
potential to discriminate between diploid and other copy number states below the kb level.  
Combining variant level information with these CN events can potentially lead to the 
discovery of small CNV unmasking loss of function mutations.  
Rodent models have variable relevance for human foregut disease 
The responsible genes in many syndromes have previously been first identified using 
animal studies. For instance, Mahlupuu identified Foxf1 as a candidate for Alveolar capillary 
dysplasia and VACTERL association.[68, 69] and years later Stankiewicz et al. identifies 
the human disease gene FOXF1 in Alveolar Capillary Dysplasia.[28, 67] Animal models 
describing trachea-esophageal anomalies after loss of function or gene knockout are 
plentiful[66, 70] and these are increasingly associated with their human counterparts in 
disease such as in autosomal recessive Bartsocas-Papas syndrome (RIPK4)[71] short rib 
polydactyly syndrome (DYNC2H1)[72], Sensenbrenner syndrome[73] and Jeune and 
Mainzer-Saldino syndrome.[74] Currently endeavors screening patient populations of 
isolated and complex TE for gene mutations in these genes are ongoing, possibly identifying 
new genes involved in human abnormal tracheo-esophageal development. 
However, these candidate genes, although giving a clear phenotype in the rodent 
models, do not always have the same phenotype in man. For instance, mouse double 
knockouts of retinoic acid receptors Rarα and Rarβ have EA/TEF and lung hypoplasia or 
agenesis,  Nkx2-1 knockouts develop TEF, whilst no patients have been described with 
EA/TEF and defects in these genes.[75] The opposite is also true, whilst many human 
patients with defects in MYCN, MID1 and CHD7 have EA/TEF, animal models do not.[76, 
77] Animal knockouts of SHH have been described and they can have abnormal foregut 
development.[78] Deletion or mutation of the SHH gene have been described in human: 
patients with loss of function mutations often have autosomal dominant holoprosencephaly 
(OMIM#142945)[79] Only three reports describe SHH deletion in patients with TE and 
other VACTERL associated anomalies and none of the 396 patients with SHH mutations in 
a holoprosencephaly cohort had trachea-esophageal anomalies.[80]  
Gene mutations in GLI2 can also cause holoprosencephaly (#610829) [81] and in 
GLI3 Pallister Hall syndrome (#OMIM146510). [82] Tracheo-esophageal anomalies are 
only incidentally described in patients with mutations in these three genes, yet have been 
shown to be crucial in foregut development.[83]  Rodent double knockouts of Gli2 and Gli3 
can have TE-anomalies, but a knockout of only one of these genes is not sufficient to give 
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the TE phenotype.[75] Absence of a TE phenotype in most of SHH and GLI mutated 
patients could be indicative of either  in-utero death of patients carrying both a pathogenic 
mutation and having TE-anomalies, or these genes do not impact TE-disease burden as 
much as we currently believe. 
Another example is Adriamycin, a chemotherapeutic agent, interfering with DNA 
replication and inhibiting DNA and RNA synthesis.[84]  VACTERL type of anomalies, 
including EA/TEF, have been described in the offspring of Adriamycin-treated rats.[85] In 
humans adriamycin does not effectively cross the placenta in humans[86] and no EA/TEF 
has been described in exposed fetuses. These teratogenic or genetic altered animal models 
may have tissue specific protein expression and timing differences compared to humans. In 
mice, at around day 9 the foregut has formed after which lung bud morphogenesis starts. 
Human development has a different pace; it reaches the same developmental stage around 
day 20-22, thus much earlier in embryogenesis.. The esophagus in mice is, compared to 
humans,  relatively shorter, does not have columnar glandular epithelium in the fore 
stomach, the epithelium is less thick, has a keratin layer and the type of musculature 
surrounding the esophagus differs.[77]  
Therefore it seems evident that not all data from animal models are of relevance for 
the human situation. Genetic, transcriptomic and protein studies in human patients and 
controls around week four of development is impossible. A alternative approach 
circumventing this unavailability of human foregut cells is the use of human induced 
pluripotent stem cells.[87] An approach proven to be applicable for human anterior 
foregut.[88, 89] Patient specific stem cells can be generated from fibroblasts by the 
pluripotency factors - Oct3/4, Sox2, c-MYC and KLF4- and transformed to definite 
endoderm by high concentrations of activin A. Subsequent removal of Activin A from 
culture resulted in an increase in CDX2 and SOX2 expression. Green and coworkers sub-
sequent tested several combinations of morphogens and inhibitors and the addition of 
Noggin in a specific time interval  resulted in foregut specific expression patterns.[88] 
Using patient and control fibroblasts and transform these with the iPS technique to an early 
foregut structure could enableus to compare not only the effect of the genetic alterations in 
individual patients, but also to compare large groups of patients and controls. Also the 
influence of teratogens and alterations of key signaling factors, cell structures (cilia) or 
biological processes can be studied in this way.  
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TE anomalies as minor and major features 
Although most frequently associated major malformations are those of the 
VACTERL spectrum of anomalies[75], others are also recurrent, such as specific 
craniofacial anomalies, eye and ear anomalies and malformations of the genitourinary, 
respiratory and gastrointestinal systems.[90-92] These malformations sometimes seem to 
cluster together and could have one specific factor as a causative mechanism. For instance, 
genes downstream of SHH and GLI, e.g. SALL1, MYCN, FOXF1 are the causal genes in 
genetic syndromes with variable TE-anomaly frequency.   
Animal models give clues about other genes or pathways involved in foregut 
development and have led to the discovery of genes mutated in patients with malformations 
of foregut-derived organs.[28, 67, 68] Animal knockout models of transcription factors, 
such as the forkheadbox (Foxf1, Foxp1, Foxp2, Foxp4) [28, 67, 93] and homeobox (e.g. 
Hoxc4, MEOX2, NKX2.1)[94-98] transcription factors give insight in the importance of 
these molecules in foregut development. Other animal models even provide clues about 
biological important structures and functioning. Loss of function or knockout models of Shh, 
Gli2, Gli3, Bmp4, Ift172, Dync2h1, Fuz and Wdr35[73, 74, 99-103] all affect cilia 
morphology, formation and SHH signal transduction.[104] These knockout and loss of 
function models can be translated to human research with relative ease; screening of patient 
populations is ongoing. Ciliopathies with Tracheo-esophageal anomalies as a variable feature 
have been discovered in human and mice.[72, 74, 101, 105]  
In fact, trachea-esophageal anomalies have been described in well over 70 genetic 
syndromes. These anomalies either are an associated feature in a genetic syndrome or occur 
sporadically in patients with a certain genetic syndrome. Of key importance here is that, not 
all patients carrying a pathogenic mutation in these genes have trachea-esophageal 
anomalies. Only in a small subset of currently identified genetic syndromes are TE-
anomalies frequently seen. In the vast remainder, these anomalies are only incidentally 
described.[66]  
Perhaps a distinction has to be made in syndromes in which TE anomalies are part of 
the characteristic features of that specific syndrome and genetic syndromes in which TE 
anomalies can occur. In this model the first type of genetic defects actively disturb foregut 
morphogenesis and the second type alter the embryonic development in such a way that also 
foregut development can be affected. The presence of a sporadic TE phenotype in these 
syndromes could be due to a variety of reasons, a chance occurrence included. We could 
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speculate that not the genetic syndrome, but having a genetic defect increases the TE-
anomaly frequency.  
General growth restrictions or other more systemic effects could set in motion a 
cascade of events leading to the shift from normal to abnormal development. As an example, 
it has been speculated that part of VACTERL association etiology is not caused by genetic 
or environmental causes but to having a twin pregnancy.[106, 107] Other more, 
mechanistically factors could also be important in foregut anomalies. In a rodent model, 
Adriamycin influences the notochord in such a way that the structure and signals from the 
notochord are altered thereby influencing foregut development.[108] 
Environmental factors in TE-anomalies 
Apart fromidentified genetic factors, associated environmental factors are divers. 
There are general risk factors, as increased maternal age and low maternal parity. There are 
also risk factors with a more environmental component as exposure to anti-thyroid drugs 
and caffeine intake.[66, 84]  As observed in the genetic component of EA/TEF, type, 
severity and frequency of congenital anomalies associated with these exposures or risk 
factors is highly variable. It is also difficult to go beyond association and prove causality due 
to the methods currently employed. Results from teratogenic animal models, as Adriamycin 
or cadmium exposed rodent models, are difficult to transform and interpret in humans. 
Questionnaires only associate, even if the outcome of well performed epidemiological 
research is highly significant. Genetic association studies need a functional test to prove 
causality; other studies associating biological outcomes with (self-) observations do so too. 
Detecting a “biological distinct fingerprint” in patients, absent in controls and show that this 
fingerprint alters crucial cellular mechanisms would greatly advance epidemiological 
studies. Nowadays, there are epigenetic biomarkers for cigarette smoke [109, 110] and it is 
known that fetal alcohol exposure alters DNA methylation and histone modifications.[111, 
112] These types of studies could give a straightforward, unbiased, answer to exposure to 
other teratogens or other factors suspected to be involved in foregut development. For 
instance, cadmium exposure can disturb Shh and Wnt signaling [113, 114] and leaves an 
epigenic recognizable mark.[115]  
Anti-thyroid drugs taken during organogenesis are associated with severe congenital 
anomalies, including VACTERL associated malformations,  in 2-3% of children.[116] Other 
risk factors for the development of congenital anomalies are maternal diabetes[117] the 
trans generation effects of maternal in utero DES exposure[118] and exposure to 
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herbicides. If these factors would leave a distinct epigenetic mark, we could measure this in 
patients (and their parents). We could determine their impact on TE-disease burden in our 
cohort and study which gene expression alterations they cause. Differences in epigenetic 
profile have been shown to exist in phenotypical discordant monozygous twin pairs. [119-
121] in which only one twin is affected. These epigenetic differences could also be present in 
our discordant twin cohort and should be further investigated. Studying epigenetic 
differences in these twins could give answers to which pathways, genes or even 
environmental components cause their phenotypical difference. 
  Combined Transcriptomic end (epi-) genetic studies could give answers to the 
impact of DNA variation and environmental components on gene expression. Yet, timing of 
measurement and tissue specificity are variables hampering precise and reliable 
transcriptomic analysis. However, it could very well be that there is nothing wrong with 
protein structure or total amount of specific proteins but that disturbances in their relative 
amount (compared to factors in their network) or local gradients of factors at crucial time 
intervals are disturbed, masking the importance of specific factors. Proper foregut 
development could be such a time dependent and precise balancing act, that deviation from 
the equilibrium at the wrong moment in development causes a cascade effect leading to the 
variety of congenital malformations seen in some of these patients.  
To conclude, the phenotypical and genetic heterogeneity seen in EA/TEF patients 
are indicative of several underlying cause(s), each contributing only in a small proportion to 
the total TE disease burden. (see figure 1) 
Future developments 
Gene panels 
Increasing evidence in patients and animal studies suggest that a wide variety of 
factors can disturb foregut development. In fact, so many individual factors can be associated 
with the development of TE-anomalies that single gene approaches are only feasible in the 
rare syndromes with a high EA/TEF frequency as Feingold or CHARGE syndrome.    
Variable expressivity, reduced penetrance and sub-clinical phenotypes can, and do, 
hamper the recognition of a genetic syndrome. Genome wide approaches give such a huge 
amount of data that, if present, the causal variant or variants are perhaps even more difficult 
to discriminate. Using first a panel of disease causing genes and only second a genome wide 
approach reduces the risk of spending many hours of work and of resources, whilst the 
causal gene could have been identified in a few minutes.  
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Figure 1. Mind map of etiological factors in trachea-esophageal anomalies and associated features.  
 
Using this candidate gene approach in a parent-child trio can quickly identify loss of 
function mutations and their inheritance pattern. Perhaps equally important as proper Next 
Generation Sequencing technology and analysis is describing the patients phenotype in an 
organized structured and detailed way.[122] Subtle differences are present between some of 
the syndromes with variable TE-frequency. Precise phenotyping of patient and parents, 
structuring this information in a way suitable for bioinformatic approaches and updating 
these phenotypes as time progresses will enhance the number of genotype-phenotype 
correlations in a significant way.  
The wide genetic and phenotypical heterogeneity of TE defects indicate a 
multifactorial etiology. Next-Generation Sequencing and high resolution SNP arrays now 
enable us to detect smaller and smaller de novo CNV and mutations. Their use in the few 
familial cases and phenotypically clustered groups of sporadic patients will reveal causal 
genetic variation and may identify new genetic syndromes.  For instance, after the 
observation that pyloric stenosis has a high frequency in EA/TEF patients, we started to 
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investigate whether or not the same genetic variant could be responsible for this 
phenotypical cluster. 
To date, the majority of EA/TEF and VACTERL-association patients have been 
sporadic; many of them caused by yet unknown private de novo CNV or mutations. Improved 
surgical treatment has increased patient survival. Now they are reaching adulthood and may 
wish to become pregnant or raise a family, these patients are at risk of transmitting their de 
novo mutations to the next generations in an autosomal dominant manner. Genetic 
counseling and genome profiling of young adults using techniques that were unavailable at 
their time of their birth may be an important instrument not only for identifying genes 
involved in disease etiology, but also for predicting high-risk pregnancies.  
Current patients might face another kind of co-morbidity. It has become increasingly 
evident that genes involved in congenital anomalies and childhood syndromes increase the 
chance of having some kind of cancer later in life.[123] TE-anomalies are seen in patients 
with Fanconi anemia (FANC-genes), loss of function mutations in SOX2 and MYCN cause 
AEG-syndrome and Feingold syndrome, whilst overexpression of these oncogenes is 
associated with tumorgenesis.[124, 125] There are reports associating SNPs to genes 
known to be important in esophageal development to the development of Barrett’s 
esophagus and adenocarcinoma.[126, 127] Patients with EA/TEF often have gastro-
esophageal reflux. This reflux and/or these SNPs could result in a predisposition to develop 
Barrett’s and sub sequent adenocarcinoma of the esophagus. Currently, we are evaluating if 
these SNPs have a higher frequency in patients with EA/TEF.  
Tracheo-esophageal anomalies can be part of a broad spectrum of associated 
anomalies from isolated atresia’s or trachea-esophageal fistulas. This heterogeneity can be 
caused by the differences in penetrance of a limited set of (epi-) genetic and/or 
environmental factors. Another explanation could be that this heterogeneity is the 
representation of many individual causes. Regardless what causes this heterogeneity, large 
patient and control cohorts are needed to associate either many loci of low effect, or to find 
the second hit of a large effect, low frequency locus. In a rare disease this will only be 
possible by combining patient cohorts. The effect of multiple rare or private inherited 
variants detected with NGS and studied with a burden test, also need large sample sizes.  
Uniform parental questionnaires should be used in multicenter studies, possibly in 
combination with one specific type of high-density SNP array or sequencing pipeline, thus 
enabling epidemiological and Genome Wide Association Studies in large cohorts.  
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The greatest challenge in elucidating EA/TEF and VACTERL association etiology 
will be to categorize the non-genetic contribution to their etiology. While the use of uniform 
questionnaires will lead to new associations, proving the causality of these associations will 
be much more difficult. It may be best first to focus on the effect of known mutations, 
teratogen and risk factors, possibly by using functional tests to study suspected biological 
pathways or processes. Patients’ various genetic and environmental causality presents 
challenges with regard to counseling and informing parents on recurrence risk and future 
co-morbidity, and also the risk of familial recurrence. Greater knowledge of environmental 
risk factors, genetic predisposition and causal genetic syndromes may even produce 
preventive strategies and the ability to predict co-morbidity. 
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Summary 
Esophageal atresia (EA) is a relatively rare congenital anomaly in which there is no 
connection between the proximal esophagus and the stomach. In more than 90% of patients, 
the distal esophagus has an abnormal connection to the trachea; this is called a trachea-
esophageal fistula (TEF).[1-3]  
The first chapter” Clinical and etiological heterogeneity in patients with tracheo-
esophageal malformations and associated anomalies” is a review of the current knowledge on 
the etiological aspects of the anomaly, with an emphasis on its phenotypical and causative 
heterogeneity. Approximately two thirds of patients also have other major malformations, 
mostly one or more of the types of defects included in the so-called VACTERL association: 
vertebral, anorectal, cardiac, tracheo-esophageal, renal or urinary tract, and limbs 
malformations).[4] EA/TEF is a multifactorial condition for which specific risk, 
environmental and genetic factors have been identified. These are described in chapter one. 
Furthermore, trachea-esophageal anomalies, including EA/TEF, are a variable feature in 
over 70 genetic syndromes.[5-7] Examples are anophthalmia-esophageal-genital (AEG) 
syndrome, Feingold syndrome, CHARGE syndrome, and trisomy 18.  
 In the Erasmus MC-Sophia cohort of trachea-esophageal anomalies (TE)  nine 
percent of patients have a known genetic syndrome and another 1-2% the condition is 
strongly associated with an environmental factor. This leaves almost 90% of TE disease 
burden unexplained. Using two relatively new techniques, SNP-array and whole exome 
sequencing we aimed to explore genetic variation in EA/TEF and VACTERL association. 
The second chapter, ”Copy Number Variations in patients with EA/TEF and VACTERL 
associated malformations” describes the chromosomal aneuploidies, structural chromosomal 
aberrations and copy number variations (CNVs) found in this cohort and described in 
literature. Trisomies13, 18 and 21 are risk factors for EA/TEF, although it is most often 
seen in people with trisomy 18. In chapter 2.3 we describe three patients with trisomy X and 
EA/TEF and exclude the role of non-random X-inactivation. The high frequency of trisomy 
X in our cohort indicates that this also could be a risk factor for gastro-intestinal anomalies, 
including EA/TEF [8, 9]  
Many structural chromosomal anomalies have been described in patients with TE, 
but these hardly contribute to the total TE burden, in our cohort up to 0.3%, not including 
the aneuploidies. In chapter 2.1 and 2.2 we describe de novo and rare recurrent inherited 
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CNVs in patients with TE anomalies and VACTERL association. Large de novo CNVs have 
been associated with syndromes with characteristic features such as EA/TEF and other 
anomalies of the VACTERL association.[10] Consistent with the literature, de novo CNVs 
in our cohort are rare and non-recurrent. Thus they do not have a high impact on total TE 
disease burden. De novo CNVs can point to candidate genes possibly mutated in other 
patients. Others have detected one of those candidate genes, LPP, in a de novo deletion.[11] 
LPP copy number changes and mutations were not found in our large cohort, which is 
indicative of the low impact of LPP gene aberrations in patients with EA/TEF or 
VACTERL.[12]  
CNVs can be inherited in a Mendelian manner and behave much like other genetic 
variation. Finding two overlapping rare CNVs in two unrelated patients in a cohort of 
patients with a rare disease can be indicative of susceptibility locus or gene. We found 23 
loci affected more than once by a CNV; all of these CNVs were inherited from unaffected 
parents. Rare CNVs sometimes affect regions of the genome devoid of genes. However, these 
regions can still be of importance as we have shown in patients with alveolar capillary 
dysplasia and VACTERL-association features, including EA/TEF.[13] Two patients in our 
cohort had an overlapping de novo deletion of the maternal copy of an FOXF1 upstream 
lncRNA affecting the expression of the paternal imprinted gene FOXF1 [13]   
In Chapter three, ”Genetic studies in discordant monozygotic twins”, we evaluate the 
value of genetic monozygotic twin studies and the presence of CNVs, insertions, deletions 
and single nucleotide variations in discordant monozygotic twins. Somatic events can result 
in differences in DNA variation between monozygotic twins [14] and may have contributed 
to the phenotypical differences in our discordant twin cohort. The detected rare and private 
CNV were present in both twins at the same frequency.[15] We also measured numerous 
DNA variation differences with whole exome sequencing (WES) and exon level copy 
number profiling. Statistical variant comparison reduced the number of putative differences 
to only a few candidates. Validation is ongoing, but preliminary results regrettably indicate 
that most of these differences are of a technical nature.  
In chapter four, “Next generation sequencing in familial and consanguineous 
patients“, we describe our ongoing efforts to discover genetic factors involved in a small 
subset of EA/TEF patients. These patients either have a family member with reported 
tracheo-esophageal anomalies or are born from consanguineous parents. By comparing the 
DNA variation of unaffected parents and affected family members with DNA of the index 
patients we identified many de novo, compound heterozygous and some X-linked and 
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homozygous recessive variation which might have an impact on patient phenotype. Further 
research is needed to evaluate their precise contribution. EA/TEF is a rare disease and is 
not likely to co-occur in a family twice just by chance. Remarkably, only one of two affected 
family members had a de novo MYCN mutation, earlier described in patients with Feingold 
syndrome.[16] Interestingly, all patients had rare and private variation in multiple genes 
from the candidate gene panel and in genes related to cilia structure and functioning. These 
inherited heterozygous variants mutations might act together in biological relevant 
processes and in doing so tip the balance from normal to abnormal development. Non-
penetrance of syndrome specific characteristics can hinder its recognition. Screening patients 
for mutations in the most frequently affected syndromal EA/TEF genes (SOX2, MYCN, 
CHD7, MID1) might be warranted. 
In chapter 4.2 we propose a valuable approach to explain previously “unsolved” 
etiology in VACTERL-association patients. Hitherto VACTERL association is a “diagnosis 
per exclusionem”, given only when no other genetic syndrome can be diagnosed. Screening 
this group of VACTERL and VACTERL-like patients when candidate genes emerge can 
result in the identification of patients with a shared genotype and phenotype. In a whole 
exome sequencing experiment in patients with congenital anomalies of the kidney and 
urinary tract a mutation in the TNF receptor-associated protein-1 gene (TRAP1) was found 
in two patients. Subsequent screening for these TRAP1 mutations in the VACTERL cohort 
revealed three compound heterozygous mutated patients, all with renal anomalies.[17]  
In the general discussion we argue that in view of the phenotypical and etiological 
heterogeneity in TE-anomalies studies in large patient and control cohorts are needed to 
elucidate factors involved and improve insight in foregut development. Since EA/TEF is 
rare, this is only feasible by collaborating in large disease consortia in which physicians, 
researchers and patients discuss their experiences, results and hypothesis and data and 
material from genetic and epidemiological studies is shared among institutions.  Knowledge 
of environmental and other risk factors, genetic predisposition and causal genetic syndromes 
would improve parental and patient counseling and may result in the ability to predict co-
morbidity and even to devise and employ preventive strategies.  
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Samenvatting 
Oesophagusatresie (OA) is een zeldzame aangeboren afwijking waarbij een 
verbinding tussen het bovenste deel van de slokdarm en de maag ontbreekt. Bovendien 
bestaat er bij meer dan 90% van de gevallen een abnormale verbinding van het onderste deel 
van de slokdarm met de luchtpijp; de tracheo-oesophageale fistel (TOF).[1-3]  
Deel een van dit proefschrift ” Klinische en etiologische heterogeniteit bij patiënten 
met tracheo-oesophageale malformaties en andere geassocieerde afwijkingen” presenteert de 
huidige kennis over de etiologische aspecten van aangeboren slokdarmafwijkingen. Het 
blijkt dat er grote verschillen zijn in oorzaken en verschijningsvormen.  Twee derde van de 
patiënten hebben ook andere afwijkingen, vaak afwijkingen die behoren tot de zogenaamde 
VACTERL-spectrum: vertebrale afwijkingen, anusatresie, cardiale afwijkingen, tracheo-
oesophageale afwijkingen, renale afwijkingen en ledemaatsafwijkingen.[4] In dit eerste 
hoofdstuk beschrijven we de verschillende risico, milieu en genetische genetische factoren 
die ten grondslag kunnen liggen aan OA/TOF. OA/TOF komt voor bij meer dan 70 
verschillende genetische syndromen, echter bij de meeste syndromen incidenteel.[5-7] 
OA/TOF wordt wel vaak gezien bij het anophthalmia-oesophageaal-genitiaal syndroom, 
Feingold syndroom, CHARGE syndroom en trisomie 18. Bij ongeveer negen procent van de 
patiënten uit het Erasmus MC-Sophia OA/TOF-cohort is een genetisch syndroom 
gediagnostiseerd. Bij 1-2 procent van de patiënten bestaat het sterke vermoeden dat de 
oorzaak bij specifieke milieufactoren moet worden gezocht. Dit betekent dat bij ongeveer 90 
procent van de patiënten de oorzaak nog onbekend is. Met behulp van twee nieuwe 
technieken, SNP-array en whole exome sequencing, hebben we vervolgens genetisch 
onderzoek gedaan bij deze laatste groep. In deel twee beschrijven we de aneuploidiëen, 
structurele chromosomale afwijkingen en zogenaamde “copy number variations” (CNV) die 
we hebben gevonden. Het bleek dat een trisomie van chromosoom 13, 18 of 21 is 
geassocieerd met een verhoogd risico op OA/TOF, maar dat de afwijking het meest werd 
gezien bij patiënten met trisomie 18. Ook patiënten met trisomie X hebben een verhoogd 
risico hebben op gastro-intestinale malformaties, met inbegrip van OA/TOF.[8, 9] We 
hebben hierbij uitgesloten dat er een X-inactivatie voorkeur was voor een specifiek 
chromosoom X. 
Chromosomale afwijkingen, aneuploidiëen niet meegeteld, kwamen voor bij slechts 
0,3% van de patiënten in ons cohort. De hoofdstukken 2.1 en 2.2 beschrijven andere typen 
DNA–afwijkingen die we hebben gevonden: zeldzame de novo CNVs en overgeërfde CNVs. 
Grote de novo CNVs zijn vaker beschreven bij patiënten met genetische syndromen waar 
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OA/TOF en andere afwijkingen uit het VACTERL spectrum deel van kunnen 
uitmaken.[10] In overeenstemming met de literatuur kwamen de novo CNVs  echter niet 
vaak voor in ons cohort. De novo CNV in ons cohort en beschreven in de literatuur, komt 
vaak maar een keer op die specifieke plaats in het DNA voor. Dit type variatie heeft derhalve 
geen grote impact heeft op het ontstaan van OA/TOF. Wel is het zo dat de novo CNVs 
kunnen wijzen op genen die gemuteerd kunnen zijn bij andere patiënten, en anderen hebben 
gevonden dat LPP een goede kandidaat is.[11] Echter, in ons grote cohort vonden we geen 
CNVs en single base pair mutaties in dit gen, en we vermoeden daarom dat dit gen slechts 
een kleine rol speelt bij het ontstaan van OA/TOF.[12]  
CNVs kunnen een Mendeliaans overervingspatroon hebben maar ook kenmerken van 
andersoortige DNA-variaties. Wanneer twee zeldzame CNVs, die niet gevonden zijn in zeer 
grote controlecohorten, meerdere keren voorkomen bij een zeldzame ziekte als OA/TOF 
kan dit wijzen op een predispositie locus of gen. Wij hebben 23 van dit soort loci gevonden 
in ons cohort, alle overgeërfd van niet aangedane ouders. Deze zeldzame CNV kunnen 
genen bevatten, maar ook regio’s in het DNA zonder genen kunnen een afwijkend aantal 
kopieën hebben. Dat deze regio’s nog steeds belangrijk kunnen zijn laten we zien in 
hoofdstuk 2.5. Twee patiënten met alveolaire capillaire dysplasie en VACTERL-spectrum 
afwijkingen hebben een overlappende de novo deletie in de maternale kopie van een regio die 
een lncRNA bevat welke de expressie van het paternaal geïmprinte gen FOXF1 reguleert. 
[13]   
In deel drie ”Genetische studies in discordante eeneiige tweelingen” evalueren we de 
waarde van genetische studies bij eeneiige tweelingen en beschrijven we onze studie naar de 
aanwezigheid van verschillen in single nucleotide variations, CNVs en insertions/deletions 
in discordante eeneiige tweelingen. Somatische DNA veranderingen kunnen resulteren in 
verschillen in de DNA-sequentie van eeneiige tweelingen[14] en het is mogelijk dat dit 
soort veranderingen bijdragen aan de fenotypische verschillen in ons discordante 
tweelingencohort. We hebben zeldzame CNVs (niet gezien in controlecohorten) gevonden, 
maar deze waren gelijkelijk aanwezig bij beide helften van een tweeling.[15] Ook hebben 
we het gehele eiwit-coderende deel van het DNA onderworpen aan “whole exome 
sequencing” en “exon level copy number profiling”. Met een nieuwe statistische methode 
konden we het aantal gevonden verschillen binnen een tweeling paar terugbrengen tot 
enkele mogelijk relevante verschillen. Deze laatste worden nu verder onderzocht, maar de 
voorlopige resultaten laten zien dat ook deze verschillen van technische aard zijn.  
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Hoofdstuk vier “Next generation sequencing bij familiale en consanguïne patiënten“ 
beschrijft ons lopende onderzoek bij twee specifieke patiëntenpopulaties. Deze patiënten 
hebben óf andere familieleden met tracheo-oesophagelae afwijkingen, óf zijn kinderen van 
bloedverwante ouders. Door nu de DNA variatie van de onaangedane ouders en aangedane 
familieleden te vergelijken met het DNA van de index patiënt denken we genetische factoren 
te kunnen identificeren die betrokken zijn bij het ontstaan van OA/TOF. We hebben 
inderdaad al bepaalde de novo, compound heterozygoot, X-linked en homozygoot recessieve 
variaties gevonden die van invloed kunnen zijn op het fenotype. Een van de patiënten had 
een de novo variant in het MYCN gen; dit is het gen dat aangedaan is bij patiënten met het 
Feingold syndroom. De gevonden variant is eenmaal eerder gezien bij een patiënt met dit 
syndroom. [16] Opmerkelijk is dat slechts een van de twee aangedane kinderen in deze 
familie deze de novo MYCN verandering had. Gezien de zeldzaamheid leek het op voorhand 
niet waarschijnlijk dat OA/TOF twee keer, onafhankelijk van elkaar, in een familie zou 
voorkomen. De verminderde penetrantie van sommige genetische syndromen kan de 
herkenning ervan hinderen. Screenen van de gehele patiëntenpopulatie op pathogene 
afwijkingen in de meest voorkomende OA/TOF genen (SOX2, MYCN, CHD7, MID1) wordt 
dan ook aanbevolen. 
Een andere interessante waarneming is het voorkomen bij iedere patiënt van 
meerdere zeldzame varianten in genen uit ons kandidaat-genenpanel en in genen gerelateerd 
aan cilia structuur en werking. Deze varianten zijn overgeërfd van onaangedane ouders, en 
doordat ze samen van invloed zijn op relevante biologische processen kunnen ze mogelijk de 
balans verstoren tussen normale en abnormale ontwikkeling. Meerdere factoren samen 
kunnen zo wellicht zorgen voor een predispositie voor voordarm aandoeningen. Hoofdstuk 
4.2 beschrijft een aanpak om de genetische oorzaak van de aangeboren afwijkingen te vinden 
bij patiënten gediagnostiseerd met “VACTERL–associatie”.  De diagnose “VACTERL 
associatie” is een “diagnosis per exclusionem”, alleen gegeven wanneer geen andere 
syndroom kan worden geïdentificeerd. Het screenen van deze patiënten op DNA-
veranderingen in relevante genen gevonden in andere studies kan resulteren in het vinden 
van meerdere patiënten met overeenkomstige aangeboren afwijkingen én met dezelfde 
genetische afwijking. Een whole exome sequencing experiment bij patiënten met 
aangeboren afwijkingen van de nieren en de urinewegen resulteerde in de identificatie van 
twee patiënten met een pathogene afwijking in de TNF receptor-associated protein-1 gene 
(TRAP1). Vervolgens werden in meerdere cohorten, waaronder het Rotterdam OA/TOF 
cohort, nog eens drie patiënten met afwijkingen in dit gen gevonden, allen met afwijkingen 
aan de nieren.[17]  
262 
 
 
In de algemene discussie “Voordarmontwikkeling, een kwestie van evenwicht” wijzen 
we er op dat onderzoek bij grotere groepen patiënten nodig is om een beter overzicht te 
krijgen van de factoren die zijn betrokken bij het ontstaan van OA/TOF. Omdat dit een 
zeldzame ziekte is, kan dit alleen verwezenlijkt worden door samen te werken in grote 
consortia waarin artsen, onderzoekers en patiënten hun ervaringen, resultaten van 
onderzoek, nieuwe hypothesen en gegevens en materiaal uit genetische en epidemiologische 
studies delen. Meer inzicht in milieu- en andere risicofactoren, genetische predispositie en 
causale genetische syndromen maakt betere begeleiding en voorlichting van ouders en 
patiënten mogelijk en kan wellicht helpen eventuele co-morbiditeit te voorspellen, of zelfs 
preventiebeleid mogelijk maken.  
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jullie ondersteuning en hulp bij de inclusie. Erik, Desiree, Daphne en Rhiana bedankt voor 
het invallen. Collega onderzoekers uit het Sophia, Bram, Marie-Chantal, Dorian, Alexandra, 
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deel van dit onderzoek. Rutger, veel dank voor je hulp en het meedenken bij de analyses. 
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vriendin, (schoon-) familie en vrienden veel dank verschuldigd. Niet alleen voor de raad en 
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Research School: MGC 
PhD period: 01/11/2010-17/06/2014 
Promotor(s): Prof. Dr. D. Tibboel 
Supervisor: Dr. A. de Klein 
1. PhD training 
 Year Workload 
(ECTS) 
General academic skills  
- Biomedical English Writing and Communication 
- Research Integrity 
- Project Management 
- Introduction to Management and Organisation 
- Guidelines and Policy of Clinical Research (“BROK” Course) 
 
2013 
2012 
2011 
2011 
2013 
 
4 
2 
4 
4 
2 
Research skills and Methodology 
- Basic Course on Statistics part A 
- Introduction Course on SPSS 
- Basic Course on R 
 
2014 
2012 
2012 
 
2 
1 
 
In-depth courses (e.g. Research school, Medical Training) 
- Cell and Developmental Biology 
- Genetics Course 
- Biochemistry and Biophysics 
- Literature Course 
- Presenting Skills 
 
2011 
2011 
2011 
2011-2012 
2012 
 
3 
3 
3 
2 
1 
Presentations 
- Wednesday morning meetings 
- Monthly Bridge Meeting 2012 
- Sophia Scientific Research foundation Grant proposal 
 (resulted in “Jan C. Molenaarprijs” for best scientific presentation) 
- Monthly KG/KC Science Meeting 
- Ledendag Vereniging Ouderen en Kinderen met Slokdarmafsluiting (poster) 
- Landelijk overleg Cytogenetica / DNA diagnostiek 
- Erasmus MC NGS workflow and analysis pipeline meeting 
 
2011-2013 
2012 
2012 
 
2013-2014 
2013 
2013 
2013 
 
1 
0.5 
0.5 
 
0.5 
0.5 
0.5 
0.5 
(Inter-)national conferences 
- Genomic Disorders  - The Genomics of Rare Diseases, Cambridge (GBR) (Poster) 
- Genetica Retraite Rolduc,Kerkrade (NLD) (Presentation) 
- European Society of Human Genetics Conference, Nurnberg (DEU) (Attendance) 
- Nederlandse Vereniging voor Humane Genetica, Arnhem (NLD) (Poster) 
- MGC PhD Workshop, Luxembourg (LUX) (Presentation) 
- European Society of Human Genetics Conference, Paris (FRA) (Poster) 
- American Society of Human Genetics Conference, Boston (USA) (Poster)  
- European Society of Human Genetics Conference, Milan (ITA) (Poster) 
 
2011 
2012-2014 
2012 
2012 
2013 
2013 
2013 
2014 
 
1 
2 
1 
1 
1 
1 
1 
1 
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 Year Workload 
(ECTS) 
Seminars and workshops 
- Safely working in the Laboratory 
- Browsing genes and genomes with ENSEMBL  
- The NEXUS training Course 
- SNP’s and Human Diseases Course VII 
- Next generation Sequencing Course  
- Molecular Diagnostics Course IV 
- Biomedical Research Techniques Course III (2011 &2008)  
- Analysis of microarray gene expression data Course 
- Development, Stem Cells and Disease 
- CLC-BIO Course 
- A first encounter with next generation sequencing data 
- EBI Road show 2012 
- NGS 2013 Oxford: Bioinformatics and Data Analysis  
- NBIC NGS resequencing course  
- Career planning course  
 
2002 
2008 
2009+2010 
2010 
2011 
2009 
2008+2011 
2010 
2011 
2012 
2012 
2012 
2013 
2013 
2014 
 
0.5 
0,5 
1 
2 
1 
1 
1,5 
1 
1 
0.5 
1 
1 
2 
1 
1 
Didactic skills 
- Training “omgaan met groepen voor tutoren” 
 
2012 
 
0.5 
Other 
- Reviewing manuscripts 
- Work and literature discussions 
- Contact and Meetings with Software developers  
 
2011-2014 
2010-2013 
2010-2013 
 
1 
0.5 
1 
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 Year Workload 
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- Tutor 1th Year medical students 
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1 
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- Member “stuurgroep Internationalisering Koers 018” 
- Member “Klankbordgroep middelbaar laboratorium onderwijs” 
- Member BSc thesis defense committee 
 
2011-2014 
2013-2014 
2012-2013 
2012-2013 
 
0.5 
0.5 
0.5 
0.5 
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Nicole WG van Beelen, Daphne S Mous, Erwin Brosens, Annelies de Klein, Cees P van de Ven, John Vlot, 
Hanneke IJsselstijn, Rene MH Wijnen; Eur J Pediatr Surg. 2014 Feb;24(1):20-4. doi: 10.1055/s-0033-1352527. 
Epub 2013 Aug 27. 
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Baere , Pino P Poddighe, Robert-Jan Galjaard, Joost Gribnau,  Alice S Brooks, Dick Tibboel, and Annelies de 
Klein; Eur J Hum Genet. 2014 Jan 8. doi: 10.1038/ejhg.2013.295. [Epub ahead of print] 
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Tibboel , Annelies de Klein, Markus M. Nöthen, Markus Draaken, Ben D. Solomon, Iris A.L.M. van Rooij, 
Franca Esposito, Heiko M. Reutter, and Friedhelm Hildebrandt; Kidney Int. 2013 Oct 23. doi: 
10.1038/ki.2013.417. [Epub ahead of print] 
 
VACTERL association aetiology:  the impact of de novo and rare Copy Number 
Variations. 
E. Brosens, H. Eussen, Y. van Bever, R. van Helm, H. IJselstijn, H.P. Zaveri, R. Wijnen, D.Scott, D. Tibboel, 
A. de Klein 
Mol Syndromol. 2013 Feb;4(1-2):20-6. doi: 10.1159/000345577. 
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Am J Med Genet A. 2012 Jul;158A(7):1785-7. doi: 10.1002/ajmg.a.35391. Epub 2012 May 25. 
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Danielle Veenma, Erwin Brosens, Elisabeth de Jong, Kees van de Ven, Conny Meeussen, Titia Cohen-
Overbeek, Marjan Boter, Hubertus Eussen, Hannie Douben, Dick Tibboel and Annelies de Klein 
Eur J Hum Genet. 2012 Mar;20(3):298-304. doi: 10.1038/ejhg.2011.194. Epub 2011 Nov 9. 
 
Small noncoding differentially methylated copy-number variants, including lncRNA 
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Przemyslaw Szafranski, Avinash V. Dharmadhikari,Erwin Brosens, Priyatansh Gurha, Katarzyna E. 
Kołodziejska,Ou Zhishuo, Piotr Dittwald, Tadeusz Majewski,K. Naga Mohan, Bo Chen, Richard E. Person, 
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Sixto F. Guiang III,Virginia A. Hustead, Jose Jessurun, Russel Hirsch,David P. Witte, Isabelle Maystadt, Neil 
Sebire, Richard Fisher,Claire Langston, Partha Sen and Paweł Stankiewicz 
Genome Res. 2013 Jan;23(1):23-33. doi: 10.1101/gr.141887.112. Epub 2012 Oct 3. 
 
Expression profiling with and without Retinoic Acid (RA) in 15q26 deleted 
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Danielle Veenma, Erwin Brosens, M.Peters, M. Jhamai, C. Wouters, M. Pescatori, R. Rottier, A. Kremer, Dick 
Tibboel and Annelies de Klein 
PhD Thesis D. Veenma; p151-168 
 
Fine mapping of structural chromosome 3 deletions in uveal melanoma cell lines  
Th. van den Bosch, E. Brosens, D. Mooijman, J. Vaarwater, M.M. Verbiest, W. van Gils, H.T. Brüggenwirth, 
E. Kiliç, D. Paridaens, A. de Klein  
PhD Thesis Th. van den Bosch; p115-135 
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D. Veenma, E. Brosens, D. Huigh, A. van Bodegom, H. Douben, B. Eussen, P.Jhamai, A.Brooks, Y.van Bever, 
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